FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Badaro, R
   Machado, BAS
   Duthie, MS
   Araujo-Neto, CA
   Pedral-Sampaio, D
   Nakatani, M
   Reed, SG
AF Badaro, Roberto
   Machado, Bruna A. S.
   Duthie, Malcolm S.
   Araujo-Neto, C. A.
   Pedral-Sampaio, D.
   Nakatani, Maria
   Reed, Steven G.
TI The single recombinantM. tuberculosisprotein DPPD provides enhanced
   performance of skin testing among HIV-infected tuberculosis patients
SO AMB EXPRESS
LA English
DT Article
DE Tuberculosis; Mycobacteria; Skin; T cell; Diagnosis
ID XPERT MTB/RIF TEST; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS;
   ACTIVE TUBERCULOSIS; RELEASE ASSAYS; DIAGNOSIS; PROTEIN; LATENT;
   POPULATION; REACTIVITY
AB Diagnostic testing forM. tuberculosisinfection has advanced with QuantiFERON and GeneXpert, but simple cost-effective alternatives for widespread TB screening has remained elusive and purified protein derivative (PPD)-based tuberculin skin testing (TST) remains the most widely used method. PPD-based tests have reduced performance, however, in BCG vaccinees and in individuals with immune deficiencies. We compared the performance of skin testing with the recombinant DPPD protein against that of a standard PPD-based skin test. Our data indicates similar performance of DPPD and PPD (r(2) = 0.7689) among HIV-negative, active TB patients, all of whom presented greater than 10 mm induration following administration. In contrast to results demonstrating that PPD induced indurations greater than 5 mm (i.e., the recommended threshold for positive results in this population) in only half (19 of 38) of the HIV positive TB patients, 89.5% (34 of 38) of these participants developed indurations greater than 5 mm when challenged with DPPD. Importantly, none of the patients that were positive following PPD administration were negative following DPPD administration, indicating markedly improved sensitivity of DPPD among HIV-infected individuals. Our data indicate that DPPD has superior performance in skin testing than the current TST standard.
C1 [Badaro, Roberto; Machado, Bruna A. S.; Araujo-Neto, C. A.; Pedral-Sampaio, D.; Nakatani, Maria] Univ Ctr SENAI CIMATEC, SENAI Inst Innovat ISI Adv Hlth Syst CIMATEC ISI, Natl Serv Ind Learning SENAI, Salvador, BA, Brazil.
   [Badaro, Roberto] Univ Fed Bahia, Dept Med, Salvador, BA, Brazil.
   [Duthie, Malcolm S.; Reed, Steven G.] HDT Bio Corp, 1616 Eastlake Ave E, Seattle, WA 98102 USA.
RP Reed, SG (corresponding author), HDT Bio Corp, 1616 Eastlake Ave E, Seattle, WA 98102 USA.
EM steven.reed@hdt.bio
FU FAPESB (Fundacao de Amparo a Pesquisa do Estado da Bahia); CNPq
   (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico)National
   Council for Scientific and Technological Development (CNPq)
FX This work was conducted with funding from FAPESB (Fundacao de Amparo a
   Pesquisa do Estado da Bahia) and CNPq (Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico).
CR [Anonymous], 2019, MMWR-MORBID MORTAL W, V68, P552, DOI 10.15585/mmwr.mm6824a4
   Miras MDA, 2013, REUMATOL CLIN, V9, P369, DOI 10.1016/j.reuma.2012.06.011
   Guillen MA, 2011, ARCH BRONCONEUMOL, V47, P521, DOI 10.1016/j.arbres.2011.06.018
   Bass JB, 2003, INFECT CONT HOSP EP, V24, P797, DOI 10.1086/502138
   Boehme CC, 2011, LANCET, V377, P1495, DOI 10.1016/S0140-6736(11)60438-8
   Borsuk S, 2009, TUBERCULOSIS, V89, P423, DOI 10.1016/j.tube.2009.07.003
   Cameron MM, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1309-8
   Campos-Neto A, 2001, TUBERCULOSIS, V81, P353, DOI 10.1054/tube.2001.0311
   Cho YS, 2012, PROTEOMICS, V12, P979, DOI 10.1002/pmic.201100544
   Coler RN, 2000, J INFECT DIS, V182, P224, DOI 10.1086/315677
   COMSTOCK GW, 1964, B WORLD HEALTH ORGAN, V31, P161
   Dacso CC, 1990, SKIN TESTING TUBERCU, V47
   Dye C, 2013, ANNU REV PUBL HEALTH, V34, P271, DOI 10.1146/annurev-publhealth-031912-114431
   Farhat M, 2006, INT J TUBERC LUNG D, V10, P1192
   Getahun H, 2015, NEW ENGL J MED, V372, P2127, DOI 10.1056/NEJMra1405427
   Gillenwater KA, 2006, AM J INFECT CONTROL, V34, P651, DOI 10.1016/j.ajic.2006.05.288
   GOLDSTEIN S, 1994, MT SINAI J MED, V61, P337
   GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369
   Horton KC, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002119
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968
   Jensen Paul A., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Jereb J, 2013, MMWR-MORBID MORTAL W, V62, P312
   JOHNSON MP, 1992, J INFECT DIS, V166, P194, DOI 10.1093/infdis/166.1.194
   Keeler Emmett, 2006, Nature, V444 Suppl 1, P49, DOI 10.1038/nature05446
   Kimura M, 2005, INT J TUBERC LUNG D, V9, P853
   LIFSON AR, 1993, J INFECT DIS, V168, P1048, DOI 10.1093/infdis/168.4.1048
   Liu C, 2004, CAN J MICROBIOL, V50, P97, DOI 10.1139/W03-109
   Lonnroth K, 2016, T ROY SOC TROP MED H, V110, P148, DOI 10.1093/trstmh/trv108
   Mamani M, 2013, IRAN RED CRESCENT ME, V15, P775, DOI 10.5812/ircmj.6283
   Mehta SR, 2009, CLIN VACCINE IMMUNOL, V16, P541, DOI 10.1128/CVI.00375-08
   Morrison J, 2008, LANCET INFECT DIS, V8, P359, DOI 10.1016/S1473-3099(08)70071-9
   Nicol MP, 2011, LANCET INFECT DIS, V11, P819, DOI 10.1016/S1473-3099(11)70167-0
   Owusu-Edusei Kwame Jr, 2017, Tuberc Res Treat, V2017, P3816432, DOI 10.1155/2017/3816432
   Pai M, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.76
   Pai M, 2014, CLIN MICROBIOL REV, V27, P3, DOI 10.1128/CMR.00034-13
   Rangaka MX, 2012, LANCET INFECT DIS, V12, P45, DOI 10.1016/S1473-3099(11)70210-9
   Rangel-Frausto MS, 2001, INFECT CONT HOSP EP, V22, P481, DOI 10.1086/501937
   ROSE DN, 1995, J GEN INTERN MED, V10, P635, DOI 10.1007/BF02602749
   SNIDER DE, 1982, AM REV RESPIR DIS, V125, P108
   Starshinova A, 2018, INT J MYCOBACT, V7, P32, DOI 10.4103/ijmy.ijmy_17_18
   Turner RE, 2013, MMWR-MORBID MORTAL W, V62, P1014
   Uplekar M, 2015, LANCET, V385, P1799, DOI 10.1016/S0140-6736(15)60570-0
   Villarino ME, 1999, JAMA-J AM MED ASSOC, V281, P169, DOI 10.1001/jama.281.2.169
   Villarino ME, 2000, AM J RESP CRIT CARE, V161, P1167, DOI 10.1164/ajrccm.161.4.9906050
   WHITTLE H, 1993, CLIN EXP IMMUNOL, V93, P45
   World Health Organization, 2018, GLOB TUB REP 2018
   World Health Organization (WHO), 2018, LAT TUB INF UPD CONS
   Yang HL, 2012, FEMS IMMUNOL MED MIC, V66, P273, DOI 10.1111/j.1574-695X.2012.01002.x
NR 48
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2191-0855
J9 AMB EXPRESS
JI AMB Express
PD JUL 31
PY 2020
VL 10
IS 1
AR 133
DI 10.1186/s13568-020-01068-6
PG 8
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA NA3ZP
UT WOS:000559753900001
PM 32737693
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Motta, D
   Santos, AAB
   Machado, BAS
   Ribeiro, OGV
   Camargo, LOA
   Valdenegro-Toro, MA
   Kirchner, F
   Badaro, R
AF Motta, Daniel
   Bandeira Santos, Alex Alisson
   Souza Machado, Bruna Aparecida
   Ribeiro-Filho, Otavio Goncalvez Vicente
   Arriaga Camargo, Luis Octavio
   Valdenegro-Toro, Matias Alejandro
   Kirchner, Frank
   Badaro, Roberto
TI Optimization of convolutional neural network hyperparameters for
   automatic classification of adult mosquitoes
SO PLOS ONE
LA English
DT Article
ID DENGUE; DISEASES; IMPACT
AB The economic and social impacts due to diseases transmitted by mosquitoes in the latest years have been significant. Currently, no specific treatment or commercial vaccine exists for the control and prevention of arboviruses, thereby making entomological characterization fundamental in combating diseases such as dengue, chikungunya, and Zika. The morphological identification of mosquitos includes a visual exam of the samples. It is time consuming and requires adequately trained professionals. Accordingly, the development of a new automated method for realizing mosquito-perception and -classification is becoming increasingly essential. Therefore, in this study, a computational model based on a convolutional neural network (CNN) was developed to extract features from the images of mosquitoes and then classify the speciesAedes aegypti,Aedes albopictus, andCulex quinquefasciatus. In addition, the model was trained to detect the mosquitoes of the genusAedes. To train CNNs to perform the automatic morphological classification of mosquitoes, a dataset, which included 7,561 images of the target mosquitoes and 1,187 images of other insects, was acquired. Various neural networks, such as Xception and DenseNet, were used for developing the automatic-classification model based on images. A structured optimization process of random search and grid search was developed to select the hyperparameters set and increase the accuracy of the model. In addition, strategies to eliminate overfitting were implemented to increase the generalization of the model. The optimized model, during the test phase, obtained the balanced accuracy (BA) of 93.5% in classifying the target mosquitoes and other insects and the BA of 97.3% in detecting the mosquitoes of the genusAedesin comparison toCulex. The results provide fundamental information for performing the automatic morphological classification of mosquito species. Using a CNN-embedded entomological tool is a valuable and accessible resource for health workers and non-taxonomists for identifying insects that can transmit infectious diseases.
C1 [Motta, Daniel; Bandeira Santos, Alex Alisson; Souza Machado, Bruna Aparecida] Univ Ctr SENAI CIMATEC, Natl Serv Ind Learning SENAI, Computat Modeling & Ind Technol, Salvador, BA, Brazil.
   [Souza Machado, Bruna Aparecida; Badaro, Roberto] Univ Ctr SENAI CIMATEC, SENAI Inst Innovat ISI Hlth Adv Syst CIMATEC ISI, Salvador, BA, Brazil.
   [Ribeiro-Filho, Otavio Goncalvez Vicente] Univ Ctr SENAI CIMATEC, High Performance Comp Ctr SENAI CIMATEC, Salvador, BA, Brazil.
   [Arriaga Camargo, Luis Octavio; Valdenegro-Toro, Matias Alejandro; Kirchner, Frank] German Res Ctr Artificial Intelligence DFKI, Bremen, Germany.
RP Machado, BAS (corresponding author), Univ Ctr SENAI CIMATEC, Natl Serv Ind Learning SENAI, Computat Modeling & Ind Technol, Salvador, BA, Brazil.; Machado, BAS (corresponding author), Univ Ctr SENAI CIMATEC, SENAI Inst Innovat ISI Hlth Adv Syst CIMATEC ISI, Salvador, BA, Brazil.
EM brunam@fieb.org.br
RI MACHADO, BRUNA/C-3130-2016
OI MACHADO, BRUNA/0000-0003-1655-0325
CR Alom M. Z., 2018, HIST BEGAN ALEXNET C
   Amraoui F, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0006997
   [Anonymous], 2019, KERAS DOCUMENTATION
   Batista G. E. A. P. A., 2011, Proceedings of the 2011 Tenth International Conference on Machine Learning and Applications (ICMLA 2011), P364, DOI 10.1109/ICMLA.2011.145
   Bergstra J, 2012, J MACH LEARN RES, V13, P281
   Canziani A, 2016, ARXIV160507678, P1, DOI DOI 10.1002/(SICI)1520-6416(199906)127:439::AID-EEJ53.0.CO;2-8
   Chin WS, 2015, LECT NOTES ARTIF INT, V9077, P442, DOI 10.1007/978-3-319-18038-0_35
   Chollet F, 2017, PROC CVPR IEEE, P1800, DOI 10.1109/CVPR.2017.195
   De Los Reyes AMM, 2016, PROCEEDINGS OF THE 2016 IEEE REGION 10 CONFERENCE (TENCON), P2342, DOI 10.1109/TENCON.2016.7848448
   Fischer P, 2015, LECT NOTES COMPUT SC, V9358, P368, DOI 10.1007/978-3-319-24947-6_30
   Fitzpatrick C, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005785
   Fuchida M, 2017, APPL SCI-BASEL, V7, DOI 10.3390/app7010051
   Goodfellow I., 2016, ADAPTIVE COMPUTATION
   Gopalan SS, 2017, HOUSEHOLD EC IMPACT
   Guo YM, 2016, NEUROCOMPUTING, V187, P27, DOI 10.1016/j.neucom.2015.09.116
   Hernandez-espinosa MFC, 2001, NEURAL NETWORKS, P119, DOI [10.1109/IJCNN.2001.939011, DOI 10.1109/IJCNN.2001.939011]
   Higuera A, 2019, ACTA TROP, V190, P99, DOI 10.1016/j.actatropica.2018.11.010
   Holland O, 2016, 2016 23RD INTERNATIONAL CONFERENCE ON TELECOMMUNICATIONS (ICT), DOI 10.1109/ICT.2016.7500442
   Huang G, 2018, ARXIV160806993V5
   Ng KC, 2018, INSECTS, V9, DOI 10.3390/insects9030098
   Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386
   Lecun Y, 1998, P IEEE, V86, P2278, DOI 10.1109/5.726791
   Liang GD, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.18
   Lorenz C, 2015, ACTA TROP, V152, P165, DOI 10.1016/j.actatropica.2015.09.011
   Madewell ZJ, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007988
   Marcos-Marcos J, 2018, INFECT DIS POVERTY, V7, DOI 10.1186/s40249-018-0464-x
   Martin E, 2019, ACTA TROP, V192, P129, DOI 10.1016/j.actatropica.2019.02.006
   Maucourant C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020131
   Mayer SV, 2017, ACTA TROP, V166, P155, DOI 10.1016/j.actatropica.2016.11.020
   Motta D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210829
   Muller F, 2019, ROU R GLOB ENVIRON G, P67
   Oliveira JF, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228347
   Ouyang TH, 2015, COMPUT ELECTRON AGR, V118, P47, DOI 10.1016/j.compag.2015.08.021
   Packierisamy PR, 2015, AM J TROP MED HYG, V93, P1020, DOI 10.4269/ajtmh.14-0667
   PAHO, 2017, TOOL DIAGN CAR PAT S
   Paixao ES, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000530
   Park SI, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157940
   Parra-Amaya Mayra Elizabeth, 2016, Diseases, V4, DOI 10.3390/diseases4020016
   Powell JR, 2018, AM J TROP MED HYG, V98, P1563, DOI 10.4269/ajtmh.17-0866
   Rather IA, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00336
   Rodriguez RC, 2019, BURDEN DENGUE ILLNES, DOI [10.5772/intechopen.79887, DOI 10.5772/INTECHOPEN.79887]
   Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y
   Ryan SJ, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007213
   Sanchez AH, 2017, P REL MAINT S
   Saxena A, 2009, INT CONF ACOUST SPEE, P713, DOI 10.1109/ICASSP.2009.4959683
   Shepard DS, 2016, LANCET INFECT DIS, V16, P935, DOI 10.1016/S1473-3099(16)00146-8
   Shepard DS, 2014, AM J TROP MED HYG, V91, P1235, DOI 10.4269/ajtmh.14-0002
   Shepard DS, 2011, AM J TROP MED HYG, V84, P200, DOI 10.4269/ajtmh.2011.10-0503
   Shwartz-Ziv R, 2017, OPENING BLACK BOX DE, P1, DOI [10.1109/TVCG.2011.48, DOI 10.1109/TVCG.2011.48]
   Silva DF, 2013, 2013 12TH INTERNATIONAL CONFERENCE ON MACHINE LEARNING AND APPLICATIONS (ICMLA 2013), VOL 1, P99, DOI 10.1109/ICMLA.2013.24
   Silva JVJ, 2018, ACTA TROP, V182, P257, DOI 10.1016/j.actatropica.2018.03.009
   Simonyan K., 2015, 14091556 ARXIV, V1409, P1556, DOI DOI 10.1016/J.INFSOF.2008.09.005
   Straube S, 2014, FRONT COMPUT NEUROSC, V8, DOI 10.3389/fncom.2014.00043
   Szegedy C., 2015, RETHINKING INCEPTION
   Szegedy C, 2015, PROC CVPR IEEE, P1, DOI 10.1109/CVPR.2015.7298594
   Tishby N., 2000, INFORM BOTTLENECK ME
   United Nations Development Programme, 2017, SOC IMP ASS ZIK VIR, DOI [10.1016/S0140-6736(83)90866-8, DOI 10.1016/S0140-6736(83)90866-8]
   Valan M, 2019, SYST BIOL, V68, P876, DOI 10.1093/sysbio/syz014
   Wang JN, 2012, KNOWL-BASED SYST, V33, P102, DOI 10.1016/j.knosys.2012.03.014
   Weaver SC, 2010, ANTIVIR RES, V85, P328, DOI 10.1016/j.antiviral.2009.10.008
   WHO, 2017, 70 SESS WORLD HLTH A, P47
   Wilder-Smith Annelies, 2017, Lancet Infect Dis, V17, pe101, DOI 10.1016/S1473-3099(16)30518-7
   World Health Organization, 2019, DENG SEV DENG
   Yang HP, 2015, SCI REP-UK, V5, DOI 10.1038/srep12786
   Yang XY, 2015, SCI REP-UK, V5, DOI 10.1038/srep10739
NR 65
TC 1
Z9 1
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 14
PY 2020
VL 15
IS 7
AR e0234959
DI 10.1371/journal.pone.0234959
PG 30
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MQ3BK
UT WOS:000552771400017
PM 32663230
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Cruz, CCP
   Mistro, S
   Mendes, CMC
   Schooley, RT
   Badaro, RJD
AF Cruz, Camille Carvalho Peixoto
   Mistro, Sostenes
   Mendes, Carlos Mauricio Cardeal
   Schooley, Robert Turner
   Badaro, Roberto Jose da Silva
TI Monitoring of Delay to Pharmacy Refill in Assessing Adherence to
   Antiretroviral Therapy
SO JOURNAL OF PHARMACY PRACTICE
LA English
DT Article
DE HIV disease; ambulatory care
ID MEDICATION ADHERENCE; POOR ADHERENCE; VIRAL-LOAD; RECORDS; INTERVENTION;
   PREDICTORS; FAILURE; AFRICA; TRIAL
AB Background:
   Adherence to antiretroviral (ARV) therapy remains a major challenge in HIV therapeutics.
   Objective:
   To assess the adherence to ARV therapy by measuring the delay in monthly refilling of ARV drugs using pharmacy records and to correlate this with HIV plasma RNA measurements and CD4(+) cell count.
   Method:
   Records of 170 HIV-positive patients were examined to identify HIV viral load (VL)/CD4(+) results and the time interval to refill ARVs at the pharmacy. The correlation between the number of days missed to refill ARVs and plasma HIV-RNA detectability/CD4(+) count was performed using the Spearman's correlation coefficient (r).
   Results:
   Fewer days missed to refill ARV was positively correlated with undetectable VL and increase in CD4(+) count (r = 0.407 and 0.237, respectively). Increase in adherence was correlated with longer retention in the cohort (r = 0.208).
   Conclusion:
   Monitoring the delay to pick up ARVs from the pharmacy can be an important and simple tool to identify patients requiring assessment of their adherence.
C1 [Cruz, Camille Carvalho Peixoto; Badaro, Roberto Jose da Silva] Univ Fed Bahia, Program Postgrad Med & Hlth, Salvador, BA, Brazil.
   [Mistro, Sostenes] Univ Fed Bahia, Program Postgrad Publ Hlth, Vitoria Da Conquista, Brazil.
   [Mendes, Carlos Mauricio Cardeal] Univ Fed Bahia, Inst Hlth Sci, Salvador, BA, Brazil.
   [Schooley, Robert Turner] Univ Calif San Diego, Div Infect Dis, San Diego, CA 92103 USA.
RP Mistro, S (corresponding author), Univ Fed Bahia, Multidisciplinary Inst Hlth, Rua Rio Contas 58, BR-45029094 Vitoria Da Conquista, BA, Brazil.
EM smistro@gmail.com
OI Mistro, Sostenes/0000-0001-5840-820X
CR Adeniyi OV, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2942-z
   Bisson GP, 2008, JAIDS-J ACQ IMM DEF, V49, P107, DOI 10.1097/QAI.0b013e3181820141
   Bisson GP, 2008, PLOS MED, V5, P777, DOI 10.1371/journal.pmed.0050109
   Cheng Y, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009495
   de Boer IM, 2010, JAIDS-J ACQ IMM DEF, V55, P635, DOI 10.1097/QAI.0b013e3181fba6ab
   Desai KR, 2018, RES SOC ADMIN PHARM, V14, P153, DOI 10.1016/j.sapharm.2017.02.005
   Dewing S, 2015, AIDS CARE, V27, P342, DOI 10.1080/09540121.2014.994471
   Enriquez M, 2011, HIV AIDS-RES PALLIAT, V3, P45, DOI 10.2147/HIV.S8993
   Garcia R, 2006, AIDS RES HUM RETROV, V22, P1248, DOI 10.1089/aid.2006.22.1248
   Gardner EM, 2006, AIDS PATIENT CARE ST, V20, P628, DOI 10.1089/apc.2006.20.628
   Gardner Edward M, 2012, J Int Assoc Physicians AIDS Care (Chic), V11, P34, DOI 10.1177/1545109711422124
   Gilbert EM, 2016, AM J HEALTH-SYST PH, V73, P757, DOI 10.2146/ajhp150701
   Grimes DE, 2013, HIV CLIN TRIALS, V14, P68, DOI 10.1310/hct1402-68
   Grossberg R, 2004, J CLIN EPIDEMIOL, V57, P1107, DOI 10.1016/j.jclinepi.2004.04.002
   Gutierrez EB, 2012, AIDS BEHAV, V16, P1482, DOI 10.1007/s10461-012-0168-3
   Harwell JI, 2003, AIDS, V17, P1990, DOI 10.1097/00002030-200309050-00021
   Kim J, 2018, SCI REP-UK, V8, DOI [10.1038/s41598-018-21081-x, 10.26700/shuri.2018.04.8.1.1]
   Lima-Dellamora ED, 2017, CAD SAUDE PUBLICA, V33, DOI [10.1590/0102-311x00136216, 10.1590/0102-311X00136216]
   Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552
   Macalino GE, 2007, AIDS, V21, P1473, DOI 10.1097/QAD.0b013e32811ebf68
   Martin D, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21405
   McMahon JH, 2011, CLIN INFECT DIS, V52, P493, DOI 10.1093/cid/ciq167
   Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679
   Nachega JB, 2006, JAIDS-J ACQ IMM DEF, V43, P78, DOI 10.1097/01.qai.0000225015.43266.46
   Ndubuka NO, 2011, INT J NURS STUD, V48, P1323, DOI 10.1016/j.ijnurstu.2011.04.006
   Rocha GM, 2011, CAD SAUDE PUBLICA, V27, pS67, DOI 10.1590/S0102-311X2011001300008
   Saberi P, 2008, AIDS CARE, V20, P741, DOI 10.1080/09540120701694006
   SHEATHER SJ, 1991, J ROY STAT SOC B MET, V53, P683
   Shubber Z, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002183
   Simoni JM, 2011, AIDS BEHAV, V15, P919, DOI 10.1007/s10461-010-9828-3
   Townsend ML, 2007, CLIN THER, V29, P711, DOI 10.1016/j.clinthera.2007.04.006
   Venkatesh KK, 2010, AIDS PATIENT CARE ST, V24, P795, DOI 10.1089/apc.2010.0153
   Walensky RP, 2010, CLIN INFECT DIS, V51, P85, DOI 10.1086/653119
   Wasti SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035547
NR 34
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0897-1900
EI 1531-1937
J9 J PHARM PRACT
JI J. Pharm. Pract.
PD APR
PY 2020
VL 33
IS 2
BP 158
EP 163
DI 10.1177/0897190018795339
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LA3FG
UT WOS:000523835700009
PM 30122111
DA 2020-12-01
ER

PT J
AU Motta, D
   Santos, AAB
   Winkler, I
   Machado, BAS
   Pereira, DADI
   Cavalcanti, AM
   Fonseca, EOL
   Kirchner, F
   Badaro, R
AF Motta, Daniel
   Bandeira Santos, Alex Alisson
   Winkler, Ingrid
   Souza Machado, Bruna Aparecida
   Dias Imperial Pereira, Daniel Andre
   Cavalcanti, Alexandre Morais
   Lins Fonseca, Eduardo Oyama
   Kirchner, Frank
   Badaro, Roberto
TI Application of convolutional neural networks for classification of adult
   mosquitoes in the field
SO PLOS ONE
LA English
DT Article
ID AEDES-AEGYPTI; SPATIAL-DISTRIBUTION; CHIKUNGUNYA VIRUS; ZIKA; DIPTERA;
   SYSTEM
AB Dengue, chikungunya and Zika are arboviruses transmitted by mosquitos of the genus Aedes and have caused several outbreaks in world over the past ten years. Morphological identification of mosquitos is currently restricted due to the small number of adequately trained professionals. We implemented a computational model based on a convolutional neural network (CNN) to extract features from mosquito images to identify adult mosquitoes from the species Aedes aegypti, Aedes albopictus and Culex quinquefasciatus. To train the CNN to perform automatic morphological classification of mosquitoes, we used a dataset that included 4,056 mosquito images. Three neural networks, including LeNet, AlexNet and GoogleNet, were used. During the validation phase, the accuracy of the mosquito classification was 57.5% using LeNet, 74.7% using AlexNet and 83.9% using GoogleNet. During the testing phase, the best result (76.2%) was obtained using GoogleNet; results of 52.4% and 51.2% were obtained using LeNet and AlexNet, respectively. Significantly, accuracies of 100% and 90% were achieved for the classification of Aedes and Culex, respectively. A classification accuracy of 82% was achieved for Aedes females. Our results provide information that is fundamental for the automatic morphological classification of adult mosquito species in field. The use of CNN's is an important method for autonomous identification and is a valuable and accessible resource for health workers and taxonomists for the identification of some insects that can transmit infectious agents to humans.
C1 [Motta, Daniel; Bandeira Santos, Alex Alisson; Winkler, Ingrid; Souza Machado, Bruna Aparecida; Dias Imperial Pereira, Daniel Andre; Cavalcanti, Alexandre Morais; Badaro, Roberto] Univ Ctr SENAI CIMATEC, Natl Serv Ind Learning SENAI, Salvador, BA, Brazil.
   [Souza Machado, Bruna Aparecida; Lins Fonseca, Eduardo Oyama; Badaro, Roberto] Hlth Inst Technol CIMATEC ITS, Natl Serv Ind Learning SENAI, Salvador, BA, Brazil.
   [Kirchner, Frank] DFKI, Res Ctr Artificial Intelligence, Bremen, Germany.
RP Machado, BAS (corresponding author), Univ Ctr SENAI CIMATEC, Natl Serv Ind Learning SENAI, Salvador, BA, Brazil.; Machado, BAS (corresponding author), Hlth Inst Technol CIMATEC ITS, Natl Serv Ind Learning SENAI, Salvador, BA, Brazil.
EM brunam@fieb.org.br
RI Machado, Bruna Aparecida Souza/C-3130-2016; Winkler,
   Ingrid/AAU-9884-2020; Santos, Alex A.B./J-4829-2012; Kirchner,
   Frank/P-6503-2016
OI Machado, Bruna Aparecida Souza/0000-0003-1655-0325; Winkler,
   Ingrid/0000-0001-6505-6636; Kirchner, Frank/0000-0002-1713-9784
CR Arthur BJ, 2014, J ACOUST SOC AM, V135, P933, DOI 10.1121/1.4861233
   Batista G. E. A. P. A., 2011, Proceedings of the 2011 Tenth International Conference on Machine Learning and Applications (ICMLA 2011), P364, DOI 10.1109/ICMLA.2011.145
   Bova J, 2016, J AM MOSQUITO CONTR, V32, P244, DOI 10.2987/15-6535.1
   Boyer S, 2018, MICROBES INFECT, V20, P646, DOI 10.1016/j.micinf.2018.01.006
   Cauchemez S, 2016, LANCET, V387, P2125, DOI 10.1016/S0140-6736(16)00651-6
   CDC C for DC and P, 2016, SURV CONTR AED AEG A, P1, DOI [10.1371/journal.pntd.0004043, DOI 10.1371/JOURNAL.PNTD.0004043]
   Cevallos V, 2018, ACTA TROP, V177, P74, DOI 10.1016/j.actatropica.2017.09.029
   de Souza VMA, 2013, 2013 BRAZILIAN CONFERENCE ON INTELLIGENT SYSTEMS (BRACIS), P76, DOI 10.1109/BRACIS.2013.21
   del Carpio-Orantes L, 2018, J ASIA-PAC BIODIVERS, V11, P317, DOI 10.1016/j.japb.2018.01.002
   Ding FY, 2018, ACTA TROP, V178, P155, DOI 10.1016/j.actatropica.2017.11.020
   Epelboin Y, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005933
   Gaburro J, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1870-1
   Goodfellow I, 2016, ADAPT COMPUT MACH LE, P1
   Guedes DRD, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.59
   Guo XX, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.102
   Henry A, 2010, INFECT GENET EVOL, V10, P207, DOI 10.1016/j.meegid.2009.12.001
   Jinbo U, 2011, ENTOMOL SCI, V14, P107, DOI 10.1111/j.1479-8298.2011.00449.x
   Karthika P, 2018, ACTA TROP, V183, P84, DOI 10.1016/j.actatropica.2018.04.006
   Kesavaraju B, 2012, J AM MOSQUITO CONTR, V28, P330, DOI 10.2987/12-6254R.1
   Kraemer MUG, 2015, ELIFE, V4, DOI 10.7554/eLife.08347
   Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386
   Kumar NP, 2007, J MED ENTOMOL, V44, P1, DOI 10.1603/0022-2585(2007)44[1:DBCDSO]2.0.CO;2
   Lecun Y, 1998, P IEEE, V86, P2278, DOI 10.1109/5.726791
   Leta S, 2018, INT J INFECT DIS, V67, P25, DOI 10.1016/j.ijid.2017.11.026
   Lorenz C, 2015, ACTA TROP, V152, P165, DOI 10.1016/j.actatropica.2015.09.011
   Main BJ, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006524
   Mewara A, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2854-0
   Mundada R., 2013, IOSR J ELECT COMMUN, V5, P57
   Musso D, 2018, LANCET INFECT DIS, V18, pE355, DOI [10.1016/S1473-3099(18)30269-X, 10.1016/s1473-3099(18)30269-x]
   Ouyang TH, 2015, COMPUT ELECTRON AGR, V118, P47, DOI 10.1016/j.compag.2015.08.021
   PAHO, 2017, TOOL DIAGN CAR PAT S
   Rezza G, 2007, LANCET, V370, P1840, DOI 10.1016/S0140-6736(07)61779-6
   Sanchez AH, 2017, P REL MAINT S
   Santos J, 2017, ACTA TROP, V168, P80, DOI 10.1016/j.actatropica.2017.01.015
   Schaper S, 2006, REV BIOL TROP, V54, P847
   Schmidhuber J, 2015, NEURAL NETWORKS, V61, P85, DOI 10.1016/j.neunet.2014.09.003
   Schneider J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162493
   Shin JW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161015
   Sifferlin A., 2018, TIME
   Silva DF, 2013, 2013 12TH INTERNATIONAL CONFERENCE ON MACHINE LEARNING AND APPLICATIONS (ICMLA 2013), VOL 1, P99, DOI 10.1109/ICMLA.2013.24
   Szegedy C, 2015, PROC CVPR IEEE, P1, DOI 10.1109/CVPR.2015.7298594
   Thangamani S, 2016, AM J TROP MED HYG, V95, P1169, DOI 10.4269/ajtmh.16-0448
   van de Vossenberg BTLH, 2015, J MED ENTOMOL, V52, P336, DOI 10.1093/jme/tjv020
   Wang JN, 2012, KNOWL-BASED SYST, V33, P102, DOI 10.1016/j.knosys.2012.03.014
   WHO, 2017, GLOBAL VECTOR CONTRO, V2030, P47
   Yang H., 2015, SCI REP, V5, P1, DOI DOI 10.1038/SREP12786
   Yao Q, 2012, J INTEGR AGR, V11, P978, DOI 10.1016/S2095-3119(12)60089-6
   Zhong YH, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18051489
NR 48
TC 8
Z9 8
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 14
PY 2019
VL 14
IS 1
AR e0210829
DI 10.1371/journal.pone.0210829
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HH5ZP
UT WOS:000455808000050
PM 30640961
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Noormahomed, EV
   Mocumbi, AO
   Ismail, M
   Carrilho, C
   Patel, S
   Nguenha, A
   Badaro, R
   Bickler, S
   Benson, CA
   Schooley, RT
AF Noormahomed, Emilia Virginia
   Mocumbi, Ana Olga
   Ismail, Mamudo
   Carrilho, Carla
   Patel, Sam
   Nguenha, Alcido
   Badaro, Roberto
   Bickler, Stephen
   Benson, Constance A.
   Schooley, Robert T.
TI The Medical Education Partnership Initiative Effect on Increasing Health
   Professions Education and Research Capacity in Mozambique
SO ANNALS OF GLOBAL HEALTH
LA English
DT Article
ID COUNTRIES; AFRICA
AB Background: Mozambique is an emerging lower income country (LIC) on the southeast coast of Africa. There are significant workforce shortages in medical and health professions in the country. Mozambique was one of 12 countries in Africa that was awarded a grant through the Medical Education Partnership Initiative (MEPI) in 2010. The overarching goal of MEPI Mozambique was to enhance the capacity of medical schools to train the medical and scientific leadership corps that the country required to facilitate the training of doctors and other health professionals, and thus to strengthen the national health system.
   Objective: The aim of this article is to provide an overview of MEPI Mozambique activities, its outcomes and successes, lessons learned, and how these have sustainably strengthened the health sector in the country.
   What Was Done: The Eduardo Mondlane University (UEM) formed a partnership with the University of California, San Diego (UCSD) to implement MEPI Mozambique, A range of activities in medical education, research capacity development, electronic connectivity and information technology, and developing relationships among medical education stakeholders, were performed.
   Outcomes and Effects: The activities and innovations introduced under MEPI became part of the daily routine in medical education in Mozambique, dramatically influencing attitudes and perceptions. Joint research with partners leveraged research capabilities. The creation of a research support center offered a mechanism to sustainably build on MEPI achievements. Scientific knowledge generated through research has been translated into practice and policy, and has improved the working environment for health professionals. The use of interactive communication technologies enabled the scaling up of training and research in sustainable ways, and created communities of practice.
   Conclusion: MEPI Mozambique developed transformational long-term partnerships between UEM, UCSD and other partners. These are changing the trajectory of medical and health professions education in Mozambique and creating sustainable capacity for research.
C1 [Noormahomed, Emilia Virginia] UEM, Fac Med, Dept Microbiol, Maputo, Mozambique.
   [Noormahomed, Emilia Virginia; Patel, Sam; Benson, Constance A.; Schooley, Robert T.] Univ Calif San Diego, Dept Med, Div Infect Dis, San Diego, CA 92103 USA.
   [Noormahomed, Emilia Virginia; Mocumbi, Ana Olga; Nguenha, Alcido] MIHER, Maputo, Mozambique.
   [Mocumbi, Ana Olga] Natl Inst Hlth, Maputo, Mozambique.
   [Ismail, Mamudo; Carrilho, Carla] UEM, Dept Pathol, Maputo, Mozambique.
   [Ismail, Mamudo; Carrilho, Carla; Patel, Sam] Maputo Cent Hosp, Maputo, Mozambique.
   [Badaro, Roberto] Fed Univ Bahia UFBA, Salvador, BA, Brazil.
   [Bickler, Stephen] Univ Calif San Diego, Rady Childrens Hosp, Div Pediat Surg, San Diego, CA 92103 USA.
RP Noormahomed, EV (corresponding author), UEM, Fac Med, Dept Microbiol, Maputo, Mozambique.; Noormahomed, EV (corresponding author), Univ Calif San Diego, Dept Med, Div Infect Dis, San Diego, CA 92103 USA.; Noormahomed, EV (corresponding author), MIHER, Maputo, Mozambique.
EM enoormahomed@gmail.com
FU US National Institutes of Health (NIH) Fogarty International
   CenterUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC);
   Health Resources and Services Administration (HRSA) under the United
   States President's Emergency Plan for AIDS Relief (PEPFAR) [R24TW008908,
   R24TW008910]; NIH Office of Research on Women's HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Office of Research on Women's Health (ORWH); Office of AIDS
   ResearchUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; FOGARTY INTERNATIONAL CENTERUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW010135,
   D43TW010135, D43TW010135, D43TW010135] Funding Source: NIH RePORTER
FX This project was supported by the US National Institutes of Health (NIH)
   Fogarty International Center and the Health Resources and Services
   Administration (HRSA) under the United States President's Emergency Plan
   for AIDS Relief (PEPFAR), grant numbers R24TW008908 and R24TW008910.
   Co-funding was received from the NIH Office of Research on Women's
   Health and the Office of AIDS Research.
CR Anderson JE, 2014, WORLD J SURG, V38, P823, DOI 10.1007/s00268-013-2366-1
   [Anonymous], 2017, STAT TIMES
   [Anonymous], 2016, MED ED PARTNERSHIP M
   [Anonymous], 2018, HUMAN DEV REPORT, P198
   [Anonymous], 2015, MOZAMBIQUE STAT YB
   [Anonymous], 2015, MOZ 2015 HLTH BUDG B
   Bickler SN, 2015, ESSENTIAL SURG DIS C, V1, DOI DOI 10.1596/978-1-4648-0346-8_CH2
   Chu KM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001612
   CLIFF J, 1993, SOC SCI MED, V36, P843, DOI 10.1016/0277-9536(93)90076-G
   CLIFF J, 1988, SOC SCI MED, V27, P717, DOI 10.1016/0277-9536(87)90331-5
   Collins FS, 2010, SCIENCE, V330, P1324, DOI 10.1126/science.1199930
   Faierman M, 2014, INT HLTH, V8, pe3121
   Ferrinho P, 2012, HUM RESOUR HEALTH, V10, DOI 10.1186/1478-4491-10-34
   Frehywot S, 2014, ACAD MED, V89, pS45, DOI 10.1097/ACM.0000000000000349
   Fronteira I, 2014, HUM RESOUR HEALTH, V12, DOI 10.1186/1478-4491-12-63
   Givens M, 2015, CYTOM PART B-CLIN CY, P27, DOI [10.1002/cyto.b.21248, DOI 10.1002/CYT0.B.21248]
   Huang B, 2013, J SURG RES, V179, P340
   Man JP, 2004, EUR J EPIDEMIOL, V19, P811
   Mocumbi AO, 2014, ACAD MED, V89, pS78, DOI 10.1097/ACM.0000000000000331
   Noormahomed AR, 1994, WHO MACROECONOMICS H, V14, P51032
   Noormahomed EV, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-252
   Noormahomed EV, 2013, HUM RESOUR HEALTH, V11, DOI 10.1186/1478-4491-11-62
   Noormahomed EV, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1272879
   Preziosi M, 2015, SAMJ, S. Afr. med. j., V105, P370, DOI [10.7196/SAMJ.8780, 10.7196/samj.8780]
   Rose John, 2015, Bull Am Coll Surg, V100, P27
   Sherr K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035840
NR 26
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2214-9996
J9 ANN GLOB HEALTH
JI Ann. Glob. Health
PY 2018
VL 84
IS 1
BP 47
EP 57
DI 10.29024/aogh.14
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA GQ0YI
UT WOS:000441346800007
PM 30873790
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-12-01
ER

PT J
AU Mistro, S
   Gomes, B
   Rosa, L
   Miranda, L
   Camargo, M
   Badaro, R
AF Mistro, Sostenes
   Gomes, Barbara
   Rosa, Lorena
   Miranda, Ligia
   Camargo, Marianne
   Badaro, Roberto
TI Cost-effectiveness of liposomal amphotericin B in hospitalised patients
   with mucocutaneous leishmaniasis
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE leishmaniasis; liposomal amphotericin B; cost-effectiveness; net
   monetary benefit; willingness-to-pay
ID INDIAN VISCERAL LEISHMANIASIS; CUTANEOUS LEISHMANIASIS; BRAZILIENSIS;
   REGIMENS; TRIAL
AB OBJECTIVE To compare the cost-effectiveness of L-AmB with that of Sb-V and AmB-D, for the treatment of mucocutaneous leishmaniasis in a hospital in north-east Brazil.
   METHODS We developed an economic model based on retrospective data of 73 hospitalised patients in 2006-2012, from hospital and public health system perspectives.
   RESULTS In the economic model, 82.2% of patients who started treatment with L-AmB had completed it after 2months, vs. 22.0% for the Sb-V and 19.9% for the AmB-D groups. After 12months of follow-up, these proportions were 100% in the L-AmB, 77.4% in the AmB-D and 72.2% in the Sb-V group. Markov chain analyses showed that the group that started therapy with Sb-V had the lowest mean total cost (US$ 3782.38), followed by AmB-D (US$ 5211.27) and L-AmB (US$ 11337.44). The incremental cost-effectiveness ratio for L-AmB was US$ 18816.23 against Sb-V and US$ 24504.65 against AmB-D. In the sensitivity analysis, the drug acquisition cost of L-AmB significantly influenced the results.
   CONCLUSIONS In the treatment of mucocutaneous leishmaniasis, L-AmB is a cost-effective alternative to Sb-V and AmB-D owing to its higher effectiveness, safety and shorter course.
C1 [Mistro, Sostenes; Rosa, Lorena; Camargo, Marianne] Univ Fed Bahia, Multidisciplinary Inst Hlth, Vitoria Da Conquista, Brazil.
   [Mistro, Sostenes; Camargo, Marianne; Badaro, Roberto] Univ Fed Bahia, Program Postgrad Med & Hlth, Salvador, BA, Brazil.
   [Gomes, Barbara; Miranda, Ligia] Univ Fed Bahia, Univ Hosp Prof Edgard Santos, Salvador, BA, Brazil.
RP Mistro, S (corresponding author), Univ Fed Bahia, Vitoria Da Conquista, Brazil.
EM smistro@gmail.com
RI Mistro, Sostenes/L-3678-2013
OI Mistro, Sostenes/0000-0001-5840-820X; Rosa, Lorena/0000-0002-0470-5636
CR [Brasil. Ministerio da Saude Agencia Nacional de Vigilancia Sanitaria], 2015, AG NAC VIG SAN
   Brasil. Ministerio da Saude, 2007, MAN VIG LEISHM TEG A
   Burgess DS, 2000, DIAGN MICR INFEC DIS, V38, P87, DOI 10.1016/S0732-8893(00)00173-5
   Chrusciak-Talhari A, 2011, AM J TROP MED HYG, V84, P255, DOI 10.4269/ajtmh.2011.10-0155
   diMartino L, 1997, J PEDIATR-US, V131, P271, DOI 10.1016/S0022-3476(97)70165-3
   Figueras Nadal M C, 2003, An Pediatr (Barc), V59, P535
   Gradoni L, 2008, TROP MED INT HEALTH, V13, P1272, DOI 10.1111/j.1365-3156.2008.02144.x
   JOHANSEN HK, 2000, COCHRANE DB SYST REV, V3
   Laguna F, 1999, AIDS, V13, P1063, DOI 10.1097/00002030-199906180-00009
   LAINSON R, 1978, NATURE, V273, P595, DOI 10.1038/273595a0
   Machado PR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000912
   Ministerio da Saude, SIST GER TAB PROC
   Mistro S, 2016, TROP MED INT HEALTH, V21, P692, DOI 10.1111/tmi.12697
   Okwor I, 2016, AM J TROP MED HYG, V94, P489, DOI 10.4269/ajtmh.15-0408
   Prentice HG, 1997, BRIT J HAEMATOL, V98, P711, DOI 10.1046/j.1365-2141.1997.2473063.x
   Solomon M, 2013, J AM ACAD DERMATOL, V68, P284, DOI 10.1016/j.jaad.2012.06.014
   Sundar S, 2004, CLIN INFECT DIS, V38, P377, DOI 10.1086/380971
   Sundar S, 2009, AM J TROP MED HYG, V80, P700, DOI 10.4269/ajtmh.2009.80.700
   Sundar S, 2010, NEW ENGL J MED, V362, P504, DOI 10.1056/NEJMoa0903627
   Thakur CP, 1996, INDIAN J MED RES, V103, P259
   Tuon FF, 2008, INT J DERMATOL, V47, P109, DOI 10.1111/j.1365-4632.2008.03417.x
   Wade RL, 2013, DIAGN MICR INFEC DIS, V76, P361, DOI 10.1016/j.diagmicrobio.2013.04.001
   Walsh TJ, 2004, NEW ENGL J MED, V351, P1391, DOI 10.1056/NEJMoa040446
   WHO, 2010, M WHO EXP COMM CONTR
NR 24
TC 1
Z9 1
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD DEC
PY 2017
VL 22
IS 12
BP 1569
EP 1578
DI 10.1111/tmi.12996
PG 10
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FO8IU
UT WOS:000417130000010
PM 29078022
OA Bronze
DA 2020-12-01
ER

PT J
AU Styczynski, AR
   Malta, JMAS
   Krow-Lucal, ER
   Percio, J
   Nobrega, ME
   Vargas, A
   Lanzieri, TM
   Leite, PL
   Staples, JE
   Fischer, MX
   Powers, AM
   Chang, GJJ
   Burns, PL
   Borland, EM
   Ledermann, JP
   Mossel, EC
   Schonberger, LB
   Belay, EB
   Salinas, JL
   Badaro, RD
   Sejvar, JJ
   Coelho, GE
AF Styczynski, Ashley R.
   Malta, Juliane M. A. S.
   Krow-Lucal, Elisabeth R.
   Percio, Jadher
   Nobrega, Martha E.
   Vargas, Alexander
   Lanzieri, Tatiana M.
   Leite, Priscila L.
   Staples, J. Erin
   Fischer, Marc X.
   Powers, Ann M.
   Chang, Gwong-Jen J.
   Burns, P. L.
   Borland, Erin M.
   Ledermann, Jeremy P.
   Mossel, Eric C.
   Schonberger, Lawrence B.
   Belay, Ermias B.
   Salinas, Jorge L.
   Badaro, Roberto D.
   Sejvar, James J.
   Coelho, Giovanini E.
TI Increased rates of Guillain-Barre A syndrome associated with Zika virus
   outbreak in the Salvador metropolitan area, Brazil
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID DENGUE VIRUSES; INFECTION; DIAGNOSIS; EPIDEMIOLOGY; TRANSMISSION;
   CHIKUNGUNYA; WORLDWIDE
AB In mid-2015, Salvador, Brazil, reported an outbreak of Guillain-Barre A syndrome (GBS), coinciding with the introduction and spread of Zika virus (ZIKV). We found that GBS incidence during April-July 2015 among those >= 12 years of age was 5.6 cases/100,000 population/year and increased markedly with increasing age to 14.7 among those >= 60 years of age. We conducted interviews with 41 case-patients and 85 neighborhood controls and found no differences in demographics or exposures prior to GBS-symptom onset. A higher proportion of case-patients (83%) compared to controls (21%) reported an antecedent illness (OR 18.1, CI 6.9-47.5), most commonly characterized by rash, headache, fever, and myalgias, within a median of 8 days prior to GBS onset. Our investigation confirmed an outbreak of GBS, particularly in older adults, that was strongly associated with Zika-like illness and geo-temporally associated with ZIKV transmission, suggesting that ZIKV may result in severe neurologic complications.
EM Yxn2@cdc.gov
RI Borland, Erin/K-6607-2019
OI Borland, Erin/0000-0001-8631-9466; PERCIO, JADHER/0000-0002-3641-8105;
   Nobrega, Martha/0000-0003-4615-2280
FU Global Disease Detection Operations Center of the Centers for Disease
   Control and Prevention; Municipal Secretary of Health of Bahia and
   Salvador
FX Funding for this investigation was provided by the Global Disease
   Detection Operations Center of the Centers for Disease Control and
   Prevention. All authors from the Centers for Disease Control and
   Prevention had direct involvement in the investigational design, data
   collection, analysis, interpretation, and writing of the report. No
   payment has been received from a pharmaceutical or other commercial
   company. ARS had full access to all the data in the study and had final
   responsibility for the decision to submit the report for publication.
   The funders provided input regarding study design but had no role in
   data collection and analysis, decision to publish, or preparation of the
   manuscript.; We are grateful to Myrian Carvalho, Raquel Miranda, Nena
   Lentini, and Aristides Barbosa who helped facilitate the logistics of
   the investigation, and we would like to thank the Municipal Secretary of
   Health of Bahia and Salvador for their support of the investigation.
   Disclaimer: The findings and conclusions in this report are those of the
   authors and do not necessarily represent the official position of the
   Centers for Disease Control and Prevention.
CR Barcellos C, 2016, EMERG INFECT DIS, V22, P1894, DOI 10.3201/eid2211.160901
   Bradley K B C, 2016, ZIKA VIRUS DIS ZIKA
   CALISHER CH, 1989, J GEN VIROL, V70, P37, DOI 10.1099/0022-1317-70-1-37
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cardoso CW, 2015, EMERG INFECT DIS, V21, P2274, DOI 10.3201/eid2112.151167
   Collins MH, 2017, EMERG INFECT DIS, V23, P773, DOI 10.3201/eid2305.161630
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Dirlikov E, 2016, MMWR-MORBID MORTAL W, V65, P910, DOI 10.15585/mmwr.mm6534e1
   dos Santos T, 2016, NEW ENGL J MED, V375, P1598, DOI 10.1056/NEJMc1609015
   Dourado ME, 2012, ACTA NEUROL SCAND, V125, P47, DOI 10.1111/j.1600-0404.2011.01503.x
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Dupont-Rouzeyrol M, 2015, EMERG INFECT DIS, V21, P381, DOI 10.3201/eid2102.141553
   FAGBAMI AH, 1979, J HYG-CAMBRIDGE, V83, P213, DOI 10.1017/S0022172400025997
   Fokke C, 2014, BRAIN, V137, P33, DOI 10.1093/brain/awt285
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Hughes RAC, 2005, LANCET, V366, P1653, DOI 10.1016/S0140-6736(05)67665-9
   HUGHES RAC, 1978, LANCET, V2, P750, DOI 10.1016/s0140-6736(78)92644-2
   Instituto Brasileiro de Geografia e Estat A o stica, 2016, POP EST 2015
   Lebrun G, 2009, EMERG INFECT DIS, V15, P495, DOI 10.3201/eid1503.071482
   Leis A Arturo, 2012, Front Neurol, V3, P37, DOI 10.3389/fneur.2012.00037
   Mallet H. P., 2016, Bulletin Epidemiologique Hebdomadaire, P367
   Martin DA, 2000, J CLIN MICROBIOL, V38, P1823, DOI 10.1128/JCM.38.5.1823-1826.2000
   McGrogan A, 2009, NEUROEPIDEMIOLOGY, V32, P150, DOI 10.1159/000184748
   Oehler E, 2013, EUROSURVEILLANCE, V2014, P19, DOI DOI 10.2807/1560-7917.ES2014.19.9.20720
   OLSON JG, 1981, T ROY SOC TROP MED H, V75, P389, DOI 10.1016/0035-9203(81)90100-0
   Pan American Health Organization, 2016, INT ZIK VIR DIS CAS
   Paploski IAD, 2016, EMERG INFECT DIS, V22, P1438, DOI 10.3201/eid2208.160496
   Paradiso G, 1999, ANN NEUROL, V46, P701, DOI 10.1002/1531-8249(199911)46:5<701::AID-ANA4>3.0.CO;2-7
   Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Rocha MSG, 2004, ARQ NEURO-PSIQUIAT, V62, P33, DOI 10.1590/S0004-282X2004000100006
   Sejvar JJ, 2011, NEUROEPIDEMIOLOGY, V36, P123, DOI 10.1159/000324710
   Sejvar JJ, 2011, VACCINE, V29, P599, DOI 10.1016/j.vaccine.2010.06.003
   SIMPSON D. I. H., 1964, TRANS ROY SOC TROP MED HYG, V58, P335, DOI 10.1016/0035-9203(64)90201-9
   Suryapranata FST, 2016, AM J TROP MED HYG, V94, P1380, DOI 10.4269/ajtmh.15-0070
   Tam CC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000344
   van den Berg B, 2014, NAT REV NEUROL, V10, P469, DOI 10.1038/nrneurol.2014.121
   van Koningsveld R, 2007, LANCET NEUROL, V6, P589, DOI 10.1016/S1474-4422(07)70130-8
   Vorou R, 2016, INT J INFECT DIS, V48, P85, DOI 10.1016/j.ijid.2016.05.014
   Wakerley BR, 2013, EXPERT REV CLIN IMMU, V9, P627, DOI 10.1586/1744666X.2013.811119
   Willison HJ, 2016, LANCET, V388, P717, DOI 10.1016/S0140-6736(16)00339-1
   Wong AHY, 2014, J NEUROL SCI, V344, P60, DOI 10.1016/j.jns.2014.06.021
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 45
TC 42
Z9 46
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD AUG
PY 2017
VL 11
IS 8
AR e0005869
DI 10.1371/journal.pntd.0005869
PG 13
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA FH3SD
UT WOS:000411068800056
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU dos Santos, T
   Rodriguez, A
   Almiron, M
   Sanhueza, A
   Ramon, P
   de Oliveira, WK
   Coelho, GE
   Badaro, R
   Cortez, J
   Ospina, M
   Pimentel, R
   Masis, R
   Hernandez, F
   Lara, B
   Montoya, R
   Jubithana, B
   Melchor, A
   Alvarez, A
   Aldighieri, S
   Dye, C
   Espinal, MA
AF dos Santos, Thais
   Rodriguez, Angel
   Almiron, Maria
   Sanhueza, Antonio
   Ramon, Pilar
   de Oliveira, Wanderson K.
   Coelho, Giovanini E.
   Badaro, Roberto
   Cortez, Juan
   Ospina, Martha
   Pimentel, Raquel
   Masis, Rolando
   Hernandez, Franklin
   Lara, Bredy
   Montoya, Romeo
   Jubithana, Beatrix
   Melchor, Angel
   Alvarez, Angel
   Aldighieri, Sylvain
   Dye, Christopher
   Espinal, Marcos A.
TI Zika Virus and the Guillain-Barre Syndrome - Case Series from Seven
   Countries
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 [dos Santos, Thais; Rodriguez, Angel; Almiron, Maria; Sanhueza, Antonio; Ramon, Pilar; Cortez, Juan; Hernandez, Franklin; Montoya, Romeo; Alvarez, Angel; Aldighieri, Sylvain; Espinal, Marcos A.] Pan Amer Hlth Org, Washington, DC 20037 USA.
   [de Oliveira, Wanderson K.; Coelho, Giovanini E.] Minist Hlth, Brasilia, DF, Brazil.
   [Badaro, Roberto] Univ Fed Bahia, Salvador, BA, Brazil.
   [Ospina, Martha] Minist Hlth, Bogota, Colombia.
   [Pimentel, Raquel] Minist Hlth, Santo Domingo, Dominican Rep.
   [Masis, Rolando] Minist Hlth, San Salvador, El Salvador.
   [Lara, Bredy] Minist Hlth, Tegucigalpa, Honduras.
   [Jubithana, Beatrix] Minist Hlth, Paramaribo, Suriname.
   [Melchor, Angel] Minist Hlth, Caracas, Venezuela.
   [Dye, Christopher] WHO, Geneva, Switzerland.
RP Espinal, MA (corresponding author), Pan Amer Hlth Org, Washington, DC 20037 USA.
EM espinalm@paho.org
RI Oliveira, Wanderson/AAF-5182-2019
OI Oliveira, Wanderson/0000-0002-9662-1930; Dye,
   Christopher/0000-0002-2957-1793
FU World Health OrganizationWorld Health Organization [001] Funding Source:
   Medline
CR Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   McGrogan A, 2009, NEUROEPIDEMIOLOGY, V32, P150, DOI 10.1159/000184748
   RAVI V, 1994, ACTA NEUROL SCAND, V90, P67
   Sejvar JJ, 2005, EMERG INFECT DIS, V11, P1021, DOI 10.3201/eid1107.040991
NR 5
TC 168
Z9 171
U1 0
U2 12
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 20
PY 2016
VL 375
IS 16
BP 1598
EP 1601
DI 10.1056/NEJMc1609015
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA EJ3HF
UT WOS:000393102500029
PM 27579558
OA Bronze
DA 2020-12-01
ER

PT J
AU Schiper, L
   Faintuch, BL
   Badaro, RJD
   de Oliveira, EA
   Chavez, VEA
   Chinen, E
   Faintuch, J
AF Schiper, Luis
   Faintuch, Bluma Linkowski
   da Silva Badaro, Roberto Jose
   de Oliveira, Erica Aparecida
   Chavez, Victor E. Arana
   Chinen, Elisangela
   Faintuch, Joel
TI Functional investigation of bone implant viability using radiotracers in
   a new model of osteonecrosis
SO CLINICS
LA English
DT Article
DE Osteonecrosis; Angiogenesis; Femur; Abdominal Pocket; Radiotracers;
   Technetium-99m; Experimental Model
ID DISEASE; CRANIOPLASTY; TURNOVER; MARKERS; FLAP; RAT
AB OBJECTIVES: Conventional imaging methods are excellent for the morphological characterization of the consequences of osteonecrosis; however, only specialized techniques have been considered useful for obtaining functional information. To explore the affinity of radiotracers for severely devascularized bone, a new mouse model of isolated femur implanted in a subcutaneous abdominal pocket was devised. To maintain animal mobility and longevity, the femur was harvested from syngeneic donors. Two technetium-99m-labeled tracers targeting angiogenesis and bone matrix were selected.
   METHODS: Medronic acid and a homodimer peptide conjugated with RGDfK were radiolabeled with technetium-99m, and biodistribution was evaluated in Swiss mice. The grafted and control femurs were evaluated after 15, 30 and 60 days, including computed tomography (CT) and histological analysis.
   RESULTS: Radiolabeling achieved high (>95%) radiochemical purity. The biodistribution confirmed good blood clearance 1 hour after administration. For Tc-99m-hydrazinonicotinic acid (HYNIC)-E-[c(RGDfK)(2), remarkable renal excretion was observed compared to Tc-99m-methylene diphosphonate (MDP), but the latter, as expected, revealed higher bone uptake. The results obtained in the control femur were equal at all time points. In the implanted femur, Tc-99m-HYNIC-E-[c(RGDfK)(2) uptake was highest after 15 days, consistent with early angiogenesis. Regarding Tc-99m-MDP in the implant, similar uptake was documented at all time points, consistent with sustained bone viability; however, the uptake was lower than that detected in the control femur, as confirmed by histology.
   CONCLUSIONS: 1) Graft viability was successfully diagnosed using radiotracers in severely ischemic bone at all time points. 2) Analogously, indirect information about angiogenesis could be gathered using Tc-999m-HYNIC-E-[c(RGDfK)(2). 3) These techniques appear promising and warrant further studies to determine their potential clinical applications.
C1 [Schiper, Luis; da Silva Badaro, Roberto Jose] Univ Fed Bahia, Fac Med, Dept Ortopedia, Salvador, BA, Brazil.
   [Faintuch, Bluma Linkowski; de Oliveira, Erica Aparecida] Ctr Radiofarm, Inst Energia & Pesquisa Nucl, Sao Paulo, SP, Brazil.
   [Chavez, Victor E. Arana; Chinen, Elisangela] Univ Sao Paulo, Fac Odontol, Dept Biomat & Biol Oral, Sao Paulo, SP, Brazil.
   [Faintuch, Joel] Univ Sao Paulo, Div Cirurgia Gastrointestinal, Hosp Clin, Fac Med, Sao Paulo, SP, Brazil.
RP Faintuch, J (corresponding author), Univ Sao Paulo, Div Cirurgia Gastrointestinal, Hosp Clin, Fac Med, Sao Paulo, SP, Brazil.
EM blfaintuch@hotmail.com
RI Faintuch, Bluma L/D-7132-2013; Oliveira, Erica A/M-6305-2015
OI Oliveira, Erica A/0000-0002-1624-4021
CR Bombardieri E, 2003, EUR J NUCL MED MOL I, V30, pBP99, DOI 10.1007/s00259-003-1347-2
   Brown JP, 2009, CLIN BIOCHEM, V42, P929, DOI 10.1016/j.clinbiochem.2009.04.001
   Delmas PD, 1999, J BONE MINER RES, V14, P66, DOI 10.1002/jbmr.5650140213
   Faintuch BL, 2008, NUCL MED BIOL, V35, P401, DOI 10.1016/j.nucmedbio.2008.02.005
   Fan M, 2011, RHEUMATOL INT, V31, P983, DOI 10.1007/s00296-011-1819-9
   Fondi C, 2007, CLIN CASES MINER BON, V4, P21
   Hamilton Alice, 1995, EXPLORING DANGEROUS
   Herring JA, 2011, J PEDIAT ORTHOP S, V31, pS37
   Jones Lynne C, 2007, Instr Course Lect, V56, P179
   Liu Z, 2013, CURR MOL MED, V13, P1487, DOI 10.2174/1566524013666131111115347
   Mahajan Madhuri Shimpi, 2013, World J Nucl Med, V12, P116, DOI 10.4103/1450-1147.136736
   Morgan EF, 2009, BONE, V44, P335, DOI 10.1016/j.bone.2008.10.039
   Morina Arsim, 2011, Surg Neurol Int, V2, P72, DOI 10.4103/2152-7806.81735
   Norman D, 1998, INT J EXP PATHOL, V79, P173
   Oliveira EA, 2012, MELANOMA RES, V22, P45, DOI 10.1097/CMR.0b013e32834e6a7e
   Pavelka K, 2000, BEST PRACT RES CL RH, V14, P399, DOI 10.1053/berh.2000.0072
   De Mattos JCP, 2012, MOLECULES, V17, P12974, DOI 10.3390/molecules171112974
   Peruchi FM, 2015, REV BRAS ORTOP, V47, P375
   Ritter L, 2014, DENTOMAXILLOFAC RAD, V43, DOI 10.1259/dmfr.20130088
   Shiguetomi MJM, 2012, REV MEX ORTOP PED, V14, P35
   Shoakazemi A, 2009, NEUROSURGERY, V65, P505, DOI 10.1227/01.NEU.0000350870.69891.86
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Singla N, 2014, ACTA NEUROCHIR, V156, P1369, DOI 10.1007/s00701-014-2071-3
   Skaggs DL, 2001, J BONE JOINT SURG AM, V83A, P1810, DOI 10.2106/00004623-200112000-00007
   Terayama H, 2011, J TISSUE ENG REGEN M, V5, P32, DOI 10.1002/term.285
   Tremoleda JL, 2011, EJNMMI RES, V1, DOI 10.1186/2191-219X-1-11
   Vanaclocha V, 1997, ACTA NEUROCHIR, V139, P970, DOI 10.1007/BF01411307
   Wang C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096361
   Wehrli FW, 2007, J MAGN RESON IMAGING, V25, P390, DOI 10.1002/jmri.20807
   Zheleznyak A, 2012, MOL IMAGING BIOL, V14, P500, DOI 10.1007/s11307-011-0512-4
NR 30
TC 1
Z9 1
U1 0
U2 2
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PD OCT
PY 2016
VL 71
IS 10
BP 617
EP 625
DI 10.6061/clinics/2016(10)11
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA EA4JW
UT WOS:000386579200011
PM 27759852
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Mistro, S
   Rosa, L
   Gomes, B
   Miranda, L
   Badaro, R
AF Mistro, Sostenes
   Rosa, Lorena
   Gomes, Barbara
   Miranda, Ligia
   Badaro, Roberto
TI Cost-effectiveness of caspofungin versus liposomal amphotericin B in the
   treatment of systemic fungal infections: a systematic review of economic
   analyses
SO EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
LA English
DT Review
DE Liposomal amphotericin B; caspofungin; cost-effectiveness;
   pharmacoeconomics; review; severely ill patients
ID EMPIRICAL ANTIFUNGAL THERAPY; INVASIVE ASPERGILLOSIS; FEBRILE
   NEUTROPENIA; FEVER; NEPHROTOXICITY; OUTCOMES; IMPACT; TRIAL
AB Introduction: The treatment of fungal infections in severely ill patients is a clinical and economic challenge worldwide. Liposomal amphotericin B and caspofungin are highly effective antifungal drugs; however, they are very expensive and health systems must select the drug that results in the best clinical outcomes and is economically feasible.Areas covered: A systematic search was conducted in PubMed, Scopus, Web of Science, Cochrane Library, Health Economic Evaluation Database, and Centre for Review and Dissemination to find complete economic evaluations that directly compared the two treatment strategies.Expert commentary: Because of the high cost, patients in developing countries experience difficulty accessing highly effective treatments. These data can subsidize a decision for an effective antifungal treatment with reduced costs from all perspectives.
C1 [Mistro, Sostenes; Rosa, Lorena] Univ Fed Bahia Ringgold, Inst Multidisciplinar Saude, Rua Rio de Contas 58, Vitoria Da Conquista, BA, Brazil.
   [Gomes, Barbara; Miranda, Ligia] Univ Fed Bahia Ringgold, Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil.
   [Badaro, Roberto] Univ Fed Bahia Ringgold, Fac Med, Salvador, BA, Brazil.
   [Mistro, Sostenes; Badaro, Roberto] Univ Fed Bahia Ringgold, Programa Posgrad Med & Saude, Salvador, BA, Brazil.
RP Mistro, S (corresponding author), Univ Fed Bahia Ringgold, Inst Multidisciplinar Saude, Rua Rio de Contas 58, Vitoria Da Conquista, BA, Brazil.
EM smistro@ufba.br
RI Mistro, Sostenes/L-3678-2013
OI Mistro, Sostenes/0000-0001-5840-820X; Rosa, Lorena/0000-0002-0470-5636
FU Brazilian National Council for Scientific and Technological
   DevelopmentNational Council for Scientific and Technological Development
   (CNPq); Foundation for Research Support of Bahia-Brazil; Federal
   University of Bahia-Brazil
FX This review was funded by the Brazilian National Council for Scientific
   and Technological Development; Foundation for Research Support of
   Bahia-Brazil; and Federal University of Bahia-Brazil. The authors have
   no other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Al-Badriyeh D, 2009, J ANTIMICROB CHEMOTH, V63, P1276, DOI 10.1093/jac/dkp119
   Alvarez-Lerma F, 2013, REV ESP QUIM, V26, P360
   Ament AJH, 2007, J ANTIMICROB CHEMOTH, V60, P385, DOI 10.1093/jac/dkm196
   [Anonymous], 2014, INFLATION GDP DEFLAT
   Ascioglu S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083658
   Ashley ED, 2012, PHARMACOTHERAPY, V32, P890, DOI 10.1002/j.1875-9114.2012.01124
   Azie N, 2012, DIAGN MICR INFEC DIS, V73, P293, DOI 10.1016/j.diagmicrobio.2012.06.012
   Bruynesteyn K, 2007, EUR J HAEMATOL, V78, P532, DOI 10.1111/j.1600-0609.2007.00850.x
   Contreras-Hernandez I, 2011, PHARMACOECONOMICS SP, V8, P16
   des Champs-Bro B, 2011, J CLIN PHARM THER, V36, P152, DOI 10.1111/j.1365-2710.2010.01166.x
   Dignani Maria Cecilia, 2014, F1000Prime Rep, V6, P81, DOI 10.12703/P6-81
   Dixon S, 2004, PHARMACOECONOMICS, V22, P421, DOI 10.2165/00019053-200422070-00002
   Ellis M, 1998, CLIN INFECT DIS, V27, P1406, DOI 10.1086/515033
   FUJII RK, 2013, VALUE HEALTH, V16, pA89
   Gamboa Garay OA, 2012, VALUE HLTH REGIONAL, V1, P201
   Ha YE, 2012, ANTIMICROB AGENTS CH, V56, P3950, DOI 10.1128/AAC.06258-11
   Hamill RJ, 2010, CLIN INFECT DIS, V51, P225, DOI 10.1086/653606
   Husereau D, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1049
   Kaskel P, 2008, ANN HEMATOL, V87, P311, DOI 10.1007/s00277-007-0382-7
   Kassamali Z, 2013, INT J INFECT DIS, V 17, pE615, DOI 10.1016/j.ijid.2013.01.015
   Kim A, 2011, MYCOSES, V54, pE301, DOI 10.1111/j.1439-0507.2010.01903.x
   Mistro S, 2012, CLIN INFECT DIS, V54, P1774, DOI 10.1093/cid/cis290
   Naik S, 2011, SCAND J INFECT DIS, V43, P504, DOI 10.3109/00365548.2011.556145
   Prentice HG, 1997, BRIT J HAEMATOL, V98, P711, DOI 10.1046/j.1365-2141.1997.2473063.x
   Roma-Sanchez E, 2008, Farm Hosp, V32, P7
   Stam WB, 2008, VALUE HEALTH, V11, P830, DOI 10.1111/j.1524-4733.2008.00324.x
   Turner SJ, 2013, INT J ANTIMICROB AG, V42, P276, DOI 10.1016/j.ijantimicag.2013.04.030
   Turner SJ, 2013, EXPERT REV PHARM OUT, V13, P227, DOI [10.1586/erp.13.3, 10.1586/ERP.13.3]
   U. S. Food and Drug Administration Center for Drug Evaluation and Research, 2001, CANC NDA 21 227 APPR
   Ullmann AJ, 2012, CLIN MICROBIOL INFEC, V18, P53, DOI 10.1111/1469-0691.12041
   Wade RL, 2013, DIAGN MICR INFEC DIS, V76, P361, DOI 10.1016/j.diagmicrobio.2013.04.001
   Walsh TJ, 2004, NEW ENGL J MED, V351, P1391, DOI 10.1056/NEJMoa040446
   Wang JL, 2010, ANTIMICROB AGENTS CH, V54, P2409, DOI 10.1128/AAC.01657-09
   Wingard JR, 2007, AM J HEALTH-SYST PH, V64, P637, DOI 10.2146/ajhp050521
   Zhang JY, 2014, CHINESE MED J-PEKING, V127, P753, DOI 10.3760/cma.j.issn.0366-6999.20132680
NR 35
TC 2
Z9 2
U1 2
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1473-7167
EI 1744-8379
J9 EXPERT REV PHARM OUT
JI Expert Rev. Pharmacoecon. Outcomes Res.
PD AUG
PY 2016
VL 16
IS 4
BP 465
EP 473
DI 10.1080/14737167.2016.1202766
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Pharmacology
   & Pharmacy
SC Health Care Sciences & Services; Pharmacology & Pharmacy
GA DV3KI
UT WOS:000382820200006
PM 27322156
DA 2020-12-01
ER

PT J
AU Leite, B
   Mistro, S
   Carvalho, C
   Mehta, SR
   Badaro, R
AF Leite, Bartyra
   Mistro, Sostenes
   Carvalho, Camile
   Mehta, Sanjay R.
   Badaro, Roberto
TI Cohort study for evaluation of dose omission without justification in a
   teaching general hospital in Bahia, Brazil
SO INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE
LA English
DT Article
DE medication error; dose omission; patient safety
ID INTENSIVE-CARE-UNIT; ADVERSE DRUG EVENTS; MEDICATION ERRORS; SYSTEM;
   INCIDENT; AUDIT
AB Objective: To evaluate the incidence of medication errors due to dose omissions and the reasons for non-administration of medications.
   Design: A cohort study blinded to the nursing staff was conducted for 5 consecutive days to evaluate administration of prescribed medications to selected inpatients.
   Setting: A major academic teaching hospital in Brazil.
   Participants: Dispensed doses to patients in medical and surgical wards.
   Main Outcome Measures: Doses returned to pharmacy were evaluated to identify the rate of dose omission without a justification for omission.
   Results: Information was collected from 117 patients in 11 wards and 1119 doses of prescribed medications were monitored. Overall, 238/1119 (21%) dispensed doses were not administered to the patients. Among these 238 doses, 138 (58%) had no justification for not being administered. Failure in the administration of at least 1 dose occurred for 58/117 (49.6%) patients. Surgical wards had significantly more missed doses than that in medical wards (P = 0.048). The daily presence of a pharmacist in the wards was significantly correlated with lower frequency of omission errors (P = 0.019). Nervous system medications were missed more significantly than other medications (P < 0.001). No difference was noted in the omission doses in terms of route of administration.
   Conclusions: High incidence of omission errors occurs in our institution. Factors such as the deficit of nursing staff and clinical pharmacists and a weak medication dispensing system, probably contributed to incidence detected. Blinding nursing staff was essential to improve the sensibility of the method for detecting omission errors.
C1 [Leite, Bartyra; Carvalho, Camile] Univ Hosp Prof Edgard Santos, Dept Pharm, Rua Augusto Viana S-N, BR-40110160 Salvador, BA, Brazil.
   [Mistro, Sostenes] Univ Fed Bahia, Multidisciplinary Inst Hlth, Salvador, BA, Brazil.
   [Mehta, Sanjay R.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
   [Badaro, Roberto] Univ Fed Bahia, Dept Med & Diagnost, Salvador, BA, Brazil.
RP Leite, B (corresponding author), Univ Hosp Prof Edgard Santos, Dept Pharm, Rua Augusto Viana S-N, BR-40110160 Salvador, BA, Brazil.
EM bartyraleite@gmail.com
RI Mistro, Sostenes/L-3678-2013
OI Mistro, Sostenes/0000-0001-5840-820X
FU University Hospital Professor Edgard Santos Institutional grant for drug
   development
FX This work was support by the University Hospital Professor Edgard Santos
   Institutional grant for drug development and approved by the Research
   Ethical Committee of the hospital under the number: 27/2010.
CR ALLAN EL, 1990, AM J HOSP PHARM, V47, P555, DOI 10.1093/ajhp/47.3.555
   Alrwisan A, 2011, EUR J CLIN PHARMACOL, V67, P527, DOI 10.1007/s00228-010-0986-z
   Alsulami Z, 2013, EUR J CLIN PHARMACOL, V69, P995, DOI 10.1007/s00228-012-1435-y
   Anselmi ML, 2007, J CLIN NURS, V16, P1839, DOI 10.1111/j.1365-2702.2007.01834.x
   Barker K. N., 1962, AM J HOSP PHARM, V19, P361
   Barker KN, 2002, ARCH INTERN MED, V162, P1897, DOI 10.1001/archinte.162.16.1897
   Silva AEBD, 2011, REV LAT-AM ENFERM, V19, P378, DOI 10.1590/S0104-11692011000200021
   Bohomol E, 2009, J ADV NURS, V65, P1259, DOI 10.1111/j.1365-2648.2009.04979.x
   BROEKEMEIER RL, 1980, AM J HOSP PHARM, V37, P85, DOI 10.1093/ajhp/37.1.85
   Chapuis C, 2010, CRIT CARE MED, V38, P2275, DOI 10.1097/CCM.0b013e3181f8569b
   Cherici C A, 1993, Hosp Pharm, V28, P193
   Cherici CA, 1993, HOSP PHARM, V28, P201
   CHERICI CA, 1993, HOSP PHARM, V28, P198
   Coleman JJ, 2013, INT J QUAL HEALTH C, V25, P564, DOI 10.1093/intqhc/mzt044
   Coleman JJ, 2012, DRUG SAFETY, V35, P677, DOI 10.2165/11630750-000000000-00000
   GILLIAND BF, 1992, AM J HOSP PHARM, V49, P860, DOI 10.1093/ajhp/49.4.860
   Goldstein M S, 1982, Hosp Pharm, V17, P310
   Graudins LV, 2015, INT J QUAL HEALTH C, V27, P67, DOI 10.1093/intqhc/mzu099
   Grech C, 2011, AUST CRIT CARE, V24, P49, DOI 10.1016/j.aucc.2010.08.004
   HYNNIMAN CE, 1970, AM J HOSP PHARM, V27, P802, DOI 10.1093/ajhp/27.10.802
   Kester L., 2003, Clinical Pulmonary Medicine, V10, P322, DOI 10.1097/01.cpm.0000097785.02653.c1
   Kitrenos J G, 1979, Hosp Pharm, V14, P652
   Kitrenos JG, 1979, HOSP PHARM, V14, P652
   Kitrenos JG, 1979, HOSP PHARM, V14, P648
   Kopp BJ, 2006, CRIT CARE MED, V34, P415, DOI 10.1097/01.CCM.0000198106.54306.D7
   Lewis PJ, 2009, DRUG SAFETY, V32, P379, DOI 10.2165/00002018-200932050-00002
   Olds DM, 2010, J SAFETY RES, V41, P153, DOI 10.1016/j.jsr.2010.02.002
   Pasto-Cardona Lourdes, 2009, Farm Hosp, V33, P257
   Tess MP., 2013, NURS FORUM, V48, P211
   Westbrook JI, 2015, INT J QUAL HEALTH C, V27, P1, DOI 10.1093/intqhc/mzu098
   Wilson A L, 1997, Pharm Pract Manag Q, V17, P17
NR 31
TC 6
Z9 7
U1 1
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1353-4505
EI 1464-3677
J9 INT J QUAL HEALTH C
JI Int. J. Qual. Health Care
PD JUN 1
PY 2016
VL 28
IS 3
BP 288
EP 293
DI 10.1093/intqhc/mzw016
PG 6
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA DR9XU
UT WOS:000380250300005
PM 26874010
DA 2020-12-01
ER

PT J
AU Mistro, S
   Rodrigues, M
   Rosa, L
   Camargo, M
   Badaro, R
AF Mistro, Sostenes
   Rodrigues, Marlon
   Rosa, Lorena
   Camargo, Marianne
   Badaro, Roberto
TI Liposomal Amphotericin B drug access for the treatment of leishmaniasis
   in Brazil
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Editorial Material
DE leishmaniasis; Brazil; liposomal amphotericin B; access to medication;
   pharmacoeconomics; developing countries
ID VISCERAL LEISHMANIASIS; COMBINATION THERAPIES; EMULSION
C1 [Mistro, Sostenes; Badaro, Roberto] Univ Fed Bahia, Program Postgrad Med & Hlth, Salvador, BA, Brazil.
   [Mistro, Sostenes; Rodrigues, Marlon; Rosa, Lorena; Camargo, Marianne] Univ Fed Bahia, Multidisciplinary Inst Hlth, Vitoria Da Conquista, BA, Brazil.
   [Badaro, Roberto] Univ Fed Bahia, Dept Med & Diag, Salvador, BA, Brazil.
RP Mistro, S (corresponding author), 58 Q 17,Blvd 58 Candeias, BR-45029094 Vitoria Da Conquista, BA, Brazil.
EM smistro@ufba.br
RI Mistro, Sostenes/L-3678-2013
OI Mistro, Sostenes/0000-0001-5840-820X; Rosa, Lorena/0000-0002-0470-5636
CR Agencia Fiocruz de Noticias BRASIL, 2015, GOV LANC EST PROD NA
   Balasegaram M, 2012, EXPERT OPIN EMERG DR, V17, P493, DOI 10.1517/14728214.2012.748036
   Croft SL, 2001, TROP MED INT HEALTH, V6, P899, DOI 10.1046/j.1365-3156.2001.00754.x
   Goswami RP, 2016, AM J TROP MED HYG, V94, P93, DOI 10.4269/ajtmh.14-0657
   Meheus F, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000818
   Mendes CS, 2013, THESIS
   Ministerio da Saude BRASIL, 2015, LEISHM
   Ministerio da Saude BRASIL, 2012, IND DAD BAS
   Mistro S, 2012, CLIN INFECT DIS, V54, P1774, DOI 10.1093/cid/cis290
   Olliaro P, 2009, TROP MED INT HEALTH, V14, P918, DOI 10.1111/j.1365-3156.2009.02306.x
   Solomon M, 2007, J AM ACAD DERMATOL, V56, P612, DOI 10.1016/j.jaad.2006.06.044
   Sundar S, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003169
NR 12
TC 5
Z9 5
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUN
PY 2016
VL 21
IS 6
BP 692
EP 693
DI 10.1111/tmi.12697
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA DP5PB
UT WOS:000378548400001
PM 27037644
OA Bronze
DA 2020-12-01
ER

PT J
AU Maia, Z
   Viana, V
   Muniz, E
   Goncalves, LO
   Mendes, CMC
   Mehta, SR
   Badaro, R
AF Maia, Zuinara
   Viana, Vivian
   Muniz, Eduardo
   Goncalves, Larissa Oliveira
   Cardeal Mendes, Carlos Mauricio
   Mehta, Sanjay R.
   Badaro, Roberto
TI Risk Factors Associated with Human Visceral Leishmaniasis in an Urban
   Area of Bahia, Brazil
SO VECTOR-BORNE AND ZOONOTIC DISEASES
LA English
DT Article
DE Reservoir host; Sand fly; Transmission; Visceral leishmaniasis
ID INFECTION; EPIDEMIOLOGY; ANTIGEN; SELECTION; SANDFLIES; OUTBREAK;
   CHAGASI; DISEASE; DEATH
AB Background: The early diagnosis of asymptomatic, acute, and subclinical Leishmania infections remains a challenge for controlling visceral leishmaniasis (VL). Individuals with acute VL represent <1% of Leishmania infections occurring in active transmission endemic areas. In this cross-sectional study with a prospective follow-up, we explored the risk factors associated with acquisition of Leishmania infection in an area with newly identified endemic VL.
   Materials and Methods: Ninety-four households were randomly selected from the study area, which included a population of 213 individuals (10% of the total population of Pe de Areia, Bahia, Brazil). Clinical and epidemiological surveys were prospectively performed to detect cases of asymptomatic infections, acute VL, and subclinical VL, using the leishmanin skin test (LST), and serological response to two Leishmania-specific antigens: rK39 and rK26.
   Results: Within the 92 households included in the study, the prevalence of Leishmania infection in individuals detected by positive serology was 91/197 (46.2%; 95% CI: 0.3937-0.5316) and by LST was 29/114 (25.4%; 95% CI: 0.1834-0.3414). Reactivity to both antigens was detected in 64/197 individuals (32.5%; 95% CI: 0.2634-0.3931). Among 89 individuals diagnosed with leishmaniasis, we found acute VL in one (1%), subclinical VL in 20 (22.5%), and asymptomatic Leishmania infection in 68 (76.4%) subjects. Use of repellents and bed nets showed no significant protection (prevalence ratio [PR] = 1.01, p = 1.0). Interestingly, individuals residing in houses with a sand backyard had significant protection against Leishmania infection (PR = 1.24, p = 0.049) compared to those with a different type or no backyard. Moreover, the presence of cat or dog at home was also not a risk factor (dog: PR = 1.14, 95% CI: 0.80-1.64; and cat: PR = 1.19, 95% CI: 0.78-1.81). We conclude that in newly discovered areas of transmission of L. infantum infection with sylvatic reservoirs, periodic surveys may be helpful in identifying risk factors for infection and optimizing prevention guidelines.
C1 [Maia, Zuinara; Viana, Vivian; Muniz, Eduardo; Goncalves, Larissa Oliveira; Badaro, Roberto] Univ Fed Bahia, Dept Med, Salvador, BA, Brazil.
   [Cardeal Mendes, Carlos Mauricio] Univ Fed Bahia, Hlth Sci Inst, Salvador, BA, Brazil.
   [Mehta, Sanjay R.] Univ Calif San Diego, Div Infect Dis, San Diego, CA 92093 USA.
RP Badaro, R (corresponding author), Univ Fed Bahia, Dept Med HUPES, Rua Augusto Vianna S-N Canela, BR-40110060 Salvador, BA, Brazil.
EM rbadaro884@gmail.com
RI Mendes, Carlos Mauricio Cardeal/AAC-1635-2019; Maia, Zuinara Pereira
   Gusmao/AAA-6737-2020; Maia, Zuinara/M-7713-2019; Mendes, Carlos Mauricio
   Cardeal/R-3688-2017
OI Mendes, Carlos Mauricio Cardeal/0000-0003-2089-5668; Maia, Zuinara
   Pereira Gusmao/0000-0003-0224-4335; Mendes, Carlos Mauricio
   Cardeal/0000-0003-2089-5668
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)
FX The team was assisted by Marcos Nogueira and his team from the
   Department of Epidemiological Surveillance Camacari-BA, Steps Sandra and
   her team at the Center for Zoonosis Control Camacari-BA, the staff at
   the Health of the town of Pede Areia-BA, the staff at the Health
   Jaua-BA, Steve Reed, Edgar Marcelino Carvalho, Andrea Santos Magalhaes,
   the Immunology Service/HUPES, and Maria Nakatani (Laboratory of Tropical
   Medicine/HUPES). Financial support: this work was supported by the
   Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB).
CR Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Sampaio MJAD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000877
   Argaw D, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002543
   Ashford DA, 1998, AM J TROP MED HYG, V59, P53, DOI 10.4269/ajtmh.1998.59.53
   BADARO R, 1986, LANCET, V1, P647
   BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   Badaro R, 1996, J INFECT DIS, V173, P758, DOI 10.1093/infdis/173.3.758
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   Belo VS, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002182
   Bern C, 2007, AM J TROP MED HYG, V76, P909
   Burza S, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002536
   Caldas AJM, 2002, T ROY SOC TROP MED H, V96, P21, DOI 10.1016/S0035-9203(02)90227-0
   Cardo LJ, 2006, TRANSFUSION, V46, P1641, DOI 10.1111/j.1537-2995.2006.00941.x
   CERF BJ, 1987, J INFECT DIS, V156, P1030, DOI 10.1093/infdis/156.6.1030
   Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748
   Cruz I, 2002, LANCET, V359, P1124, DOI 10.1016/S0140-6736(02)08160-6
   Cruz I, 2006, INDIAN J MED RES, V123, P357
   CUNHA S, 1995, T ROY SOC TROP MED H, V89, P155, DOI 10.1016/0035-9203(95)90474-3
   De ALENCAR J. E., 1958, REV ASSOC MED BRASIL, V4, P222
   Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
   Diniz SA, 2008, J INFECT DEV COUNTR, V2, P24
   Gonzalez U, 2015, COCHRANE DB SYST REV, V8
   Gramiccia M, 2005, INT J PARASITOL, V35, P1169, DOI 10.1016/j.ijpara.2005.07.001
   Herrero M, 2009, AM J TROP MED HYG, V81, P373, DOI 10.4269/ajtmh.2009.81.373
   Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2
   JERONIMO SMB, 1994, T ROY SOC TROP MED H, V88, P386, DOI 10.1016/0035-9203(94)90393-X
   LAINSON R, 1978, NATURE, V273, P595, DOI 10.1038/273595a0
   Manson-Bahr P E, 1971, Int Rev Trop Med, V4, P123
   MARINKELLE CJ, 1980, B WORLD HEALTH ORGAN, V58, P807
   Maroli M, 2007, VET PARASITOL, V145, P357, DOI 10.1016/j.vetpar.2006.11.009
   Martins-Melo FR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093770
   Meltzer Martin I, 2014, MMWR Suppl, V63, P1
   de Araujo VEM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002540
   de Araujo VEM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001511
   Albuquerque PLMM, 2009, REV PANAM SALUD PUBL, V26, P330, DOI 10.1590/S1020-49892009001000007
   Quinnell RJ, 2009, PARASITOLOGY, V136, P1915, DOI 10.1017/S0031182009991156
   Ready PD, 2014, CLIN EPIDEMIOL, V6, P147, DOI 10.2147/CLEP.S44267
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   Ryan JR, 2006, AM J TROP MED HYG, V74, P308
   Sherlock I A, 1969, Rev Bras Malariol Doencas Trop, V21, P341
   Singh SP, 2010, TROP MED INT HEALTH, V15, P29, DOI 10.1111/j.1365-3156.2010.02515.x
   Velo E, 2005, PARASITE, V12, P45, DOI 10.1051/parasite/2005121045
   WHO, 2010, WHO TECH REP SER, V949, P1
NR 44
TC 8
Z9 8
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-3667
EI 1557-7759
J9 VECTOR-BORNE ZOONOT
JI Vector-Borne Zoonotic Dis.
PD JUN
PY 2016
VL 16
IS 6
BP 368
EP 376
DI 10.1089/vbz.2015.1880
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DN4DP
UT WOS:000377013500002
PM 27074100
DA 2020-12-01
ER

PT J
AU Guimaraes, LH
   Saldanha, M
   Menezes, T
   Moreno, L
   Torres, A
   Costa, R
   Passos, S
   Badaro, R
   Arruda, S
   Carvalho, LP
AF Guimaraes, Luiz H.
   Saldanha, Maira
   Menezes, Tais
   Moreno, Lis
   Torres, Alex
   Costa, Rubia
   Passos, Sara
   Badaro, Roberto
   Arruda, Sergio
   Carvalho, Lucas P.
TI Case Report: A Potential Role for Mononuclear Phagocytes in Cutaneous
   Ulcer Development in Human Immunodeficiency Virus-Leishmania
   braziliensis Coinfection
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID CD8(+) T-CELLS; MUCOSAL LEISHMANIASIS; MONOCYTES; INFECTION;
   MATRIX-METALLOPROTEINASE-9; PATHOLOGY; GRANZYME
AB Skin ulcer development in cutaneous leishmaniasis due to Leishmania braziliensis infection is associated with a mononuclear cell infiltrate and high levels of tumor necrosis factor (TNF). Herein, we show that despite the absence of Leishmania-driven TNF, a cutaneous leishmaniasis patient with acquired immunodeficiency syndrome developed a skin ulcer. The presence of mononuclear phagocytes and high levels of TNF, chemokine (C-C motif) ligand 2 (CCL2), and metalloproteinase-9 in tissue are identified as potential contributors to immunopathology observed in L. braziliensis-infected patients.
C1 [Guimaraes, Luiz H.; Menezes, Tais; Costa, Rubia; Passos, Sara; Carvalho, Lucas P.] Univ Fed Bahia, Serv Imunol, Complexo Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil.
   INCT DT, Salvador, BA, Brazil.
   Ctr Pesquisa Goncalo Moniz, Lab Doencas Tropicais, Salvador, BA, Brazil.
   [Torres, Alex] Univ Fed Bahia, Lab Pesquisa Infectol, Salvador, BA, Brazil.
   [Saldanha, Maira; Arruda, Sergio; Carvalho, Lucas P.] Ctr Pesquisa Goncalo Moniz, Lab Avancado Saude Publ, Salvador, BA, Brazil.
   [Moreno, Lis; Badaro, Roberto] Univ Fed Bahia, Lab Doencas Tropicais, Salvador, BA, Brazil.
RP Carvalho, LP (corresponding author), C HUPES, Serv Imunol, S-N Canela, BR-40110160 Salvador, BA, Brazil.
EM luizhenriquesg@ig.com.br; mairagsaldanha@gmail.com;
   menezes.tais@gmail.com; lis.moreno@gmail.com; ajltorres@gmail.com;
   rsuelycosta@gmail.com; saratpassos@hottnail.com; badaro@ufba.br;
   arrudasm@gmail.com; carvalholp@ig.com.br
RI Henrique, Luiz/ABA-2621-2020; Carvalho, Lucas/AAP-1844-2020; Torres,
   Alex JL/Q-6186-2018
FU National Institute of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI088650]; Brazilian
   Council for research (CNPq)National Council for Scientific and
   Technological Development (CNPq); NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U01AI088650, U01AI088650,
   U01AI088650, U01AI088650, U01AI088650, U01AI088650, U01AI088650,
   U01AI088650, U01AI088650] Funding Source: NIH RePORTER
FX This work was supported by National Institute of Health (AI088650) and
   the Brazilian Council for research (CNPq).
CR Alvar J, 2008, CLIN MICROBIOL REV, V21, P334, DOI 10.1128/CMR.00061-07
   Rodrigues MZA, 2011, CLIN VACCINE IMMUNOL, V18, P1765, DOI 10.1128/CVI.00076-11
   Antonelli LRV, 2005, IMMUNOL LETT, V101, P226, DOI 10.1016/j.imlet.2005.06.004
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   Barbosa T, 2003, VACCINE, V21, P2152, DOI 10.1016/S0264-410X(02)00721-1
   Brito G, 2014, AM J TROP MED HYG, V90, P617, DOI 10.4269/ajtmh.12-0729
   Campos TM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003282
   Cardoso TM, 2015, INFECT IMMUN, V83, P898, DOI 10.1128/IAI.02404-14
   Carvalho LP, 2007, PARASITE IMMUNOL, V29, P251, DOI 10.1111/j.1365-3024.2007.00940.x
   Cordiali-Fei Paola, 2006, J Autoimmune Dis, V3, P5
   Devillers ACA, 2007, CLIN EXP DERMATOL, V32, P311, DOI 10.1111/j.1365-2230.2007.02378.x
   Erikstrup C, 2007, JAIDS-J ACQ IMM DEF, V44, P478, DOI 10.1097/QAI.0b013e318032bbcd
   Ezra N, 2010, J GLOB INFECT DIS, V2, P248, DOI 10.4103/0974-777X.68528
   Faria DR, 2009, PARASITE IMMUNOL, V31, P432, DOI 10.1111/j.1365-3024.2009.01125.x
   Giudice A, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-75
   Guimaraes LH, 2009, T ROY SOC TROP MED H, V103, P712, DOI 10.1016/j.trstmh.2009.04.019
   Maretti-Mira AC, 2011, ACTA TROP, V119, P160, DOI 10.1016/j.actatropica.2011.05.009
   Ngouateu OB, 2012, T ROY SOC TROP MED H, V106, P137, DOI 10.1016/j.trstmh.2011.10.012
   Novais FO, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003504
   Passos S, 2015, J INFECT DIS, V211, P274, DOI 10.1093/infdis/jiu439
   Santos CDS, 2013, J INVEST DERMATOL, V133, P1533, DOI 10.1038/jid.2013.4
   Unger A, 2009, AM J TROP MED HYG, V80, P574, DOI 10.4269/ajtmh.2009.80.574
   Weirather JL, 2011, J CLIN MICROBIOL, V49, P3892, DOI 10.1128/JCM.r00764-11
   Zawada AM, 2011, BLOOD, V118, pE50, DOI 10.1182/blood-2011-01-326827
NR 24
TC 0
Z9 1
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2015
VL 93
IS 6
BP 1219
EP 1223
DI 10.4269/ajtmh.14-0475
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA CY6TD
UT WOS:000366540800018
PM 26483124
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Rocha, PN
   Macedo, MN
   Kobayashi, CD
   Moreno, L
   Guimaraes, LHS
   Machado, PRL
   Badaro, R
   Carvalho, EM
   Glesby, MJ
AF Rocha, Paulo Novis
   Macedo, Michael Nascimento
   Kobayashi, Carla Dinamerica
   Moreno, Lis
   Santos Guimaraes, Luiz Henrique
   Lima Machado, Paulo Roberto
   Badaro, Roberto
   Carvalho, Edgar M.
   Glesby, Marshall Jay
TI Role of Urine Neutrophil Gelatinase-Associated Lipocalin in the Early
   Diagnosis of Amphotericin B-Induced Acute Kidney Injury
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID INDUCED NEPHROTOXICITY; RENAL-FUNCTION; BIOMARKERS; NGAL;
   VASOCONSTRICTION; NEPHROPATHY; PREDICTS; THERAPY; MARKERS
AB Determination of the neutrophil gelatinase-associated lipocalin (NGAL) level can be used to detect acute kidney injury (AKI) earlier than determination of the serum creatinine (SCr) level in settings such as cardiac surgery, contrast nephropathy, and intensive care units. We hypothesized that urine NGAL (UrNGAL) would be an early biomarker of drug nephrotoxicity. To test this, we studied hemodynamically stable patients treated with amphotericin B (AmB). We measured the SCr and UrNGAL levels at the baseline and daily after initiation of AmB up to day 14 or development of AKI by the use of the SCr criterion. AKI was defined according to a Kidney Disease: Improving Global Outcomes (KDIGO) criterion (an increase in the SCr level by >= 0.3 mg/dl within 48 h or an SCr level >= 1.5 times the baseline level within 7 days). We studied 24 patients with a mean age of 48.4 +/- 16.4 years. Most patients were male, and the patients received AmB (12 received AmB deoxycholate and 12 received liposomal AmB) for the treatment of leishmaniasis (91.7%). Overall, 17/24 patients fulfilled a KDIGO criterion for AKI. Peak UrNGAL levels were higher in patients with AKI than in patients without AKI and in recipients of AmB deoxycholate than in recipients of liposomal AmB. The diagnostic performance of the UrNGAL level on day 5 for the detection of AKI was moderate, with the area under the curve (AUC) being 0.68 (95% confidence interval [CI], 0.41 to 0.95). In the subgroup receiving AmB deoxycholate, however, the AUC rose to 0.89 (95% CI, 0.67 to 1.00). In a patient-level analysis, we found that AKI could be detected 3.2 days earlier by the use of the UrNGAL criterion than by the use of the SCr criterion (times to AKI by the UrNGAL and SCr criteria, 3.7 +/- 2.5 versus 6.9 +/- 3.3 days, respectively; P = 0.001). Future studies should evaluate if a treatment strategy oriented toward evaluation of UrNGAL levels will improve outcomes. These findings for AmB-induced AKI in leishmaniasis patients could serve as a basis for the investigation of urine biomarkers in the early detection of drug nephrotoxicity in other clinical settings.
C1 [Rocha, Paulo Novis; Kobayashi, Carla Dinamerica; Badaro, Roberto; Carvalho, Edgar M.] Univ Fed Bahia, Med Sch Bahia, Dept Med & Diagnost Support, Salvador, BA, Brazil.
   [Macedo, Michael Nascimento; Santos Guimaraes, Luiz Henrique; Lima Machado, Paulo Roberto; Carvalho, Edgar M.] Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Immunol, Salvador, BA, Brazil.
   [Moreno, Lis; Santos Guimaraes, Luiz Henrique; Badaro, Roberto] Hosp Univ Prof Edgard Santos, Div Infect Dis, Salvador, BA, Brazil.
   [Carvalho, Edgar M.] Ctr Pesquisas Goncalo Moniz Fiocruz Ba, Salvador, BA, Brazil.
   [Lima Machado, Paulo Roberto; Carvalho, Edgar M.] Natl Inst Sci & Technol Trop Dis INCT DT, Salvador, BA, Brazil.
   [Glesby, Marshall Jay] Weill Cornell Med Coll, Dept Med, New York, NY USA.
RP Rocha, PN (corresponding author), Univ Fed Bahia, Med Sch Bahia, Dept Med & Diagnost Support, Salvador, BA, Brazil.
EM paulonrocha@ufba.br
RI MACHADO, PAULO ROBERTO LIMA/AAP-2642-2020; Rocha, Paulo
   Novis/AAE-3776-2019; Henrique, Luiz/ABA-2621-2020
OI MACHADO, PAULO ROBERTO LIMA/0000-0003-1894-6171; Rocha, Paulo
   Novis/0000-0001-9598-6711; 
FU National Institutes of Health (NIH), Fogarty International CenterUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Fogarty International Center (FIC) [5 U2R
   TW006885]; Brazilian National Research Council (CNPq/MCT); NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [AI 030639]; FOGARTY INTERNATIONAL CENTERUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Fogarty International Center (FIC) [U2RTW006885,
   U2RTW006885, U2RTW006885, U2RTW006885, U2RTW006885, U2RTW006885,
   U2RTW006885, U2RTW006885, U2RTW006885, U2RTW006885] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639] Funding Source: NIH RePORTER
FX Paulo Novis Rocha conducted this project and wrote the manuscript while
   attending the Weill Cornell Graduate School of Medical Sciences' Master
   of Science Program in Clinical Epidemiology and Health Services Research
   and was supported by grant number 5 U2R TW006885 from the National
   Institutes of Health (NIH), Fogarty International Center. This study was
   supported by the Brazilian National Research Council (CNPq/MCT) and by
   NIH (grant number AI 030639).
CR Alharazy SM, 2014, ANGIOLOGY, V65, P216, DOI 10.1177/0003319712474947
   Bachorzewska-Gajewska H, 2006, AM J NEPHROL, V26, P287, DOI 10.1159/000093961
   Bagshaw SM, 2010, INTENS CARE MED, V36, P452, DOI 10.1007/s00134-009-1724-9
   Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872
   Bellomo R, 2012, LANCET, V380, P756, DOI 10.1016/S0140-6736(11)61454-2
   Burt D, 2014, DRUG CHEM TOXICOL, V37, P204, DOI 10.3109/01480545.2013.834360
   Coca SG, 2008, KIDNEY INT, V73, P1008, DOI 10.1038/sj.ki.5002729
   de Geus HRH, 2011, AM J RESP CRIT CARE, V183, P907, DOI 10.1164/rccm.200908-1214OC
   Dieterle F, 2010, NAT BIOTECHNOL, V28, P455, DOI 10.1038/nbt.1625
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Gaspari F, 2010, NEPHRON CLIN PRACT, V115, pC154, DOI 10.1159/000312879
   Ghlissi Z, 2013, RENAL FAILURE, V35, P1130, DOI 10.3109/0886022X.2013.815091
   Haase M, 2009, AM J KIDNEY DIS, V54, P1012, DOI 10.1053/j.ajkd.2009.07.020
   Han WK, 2009, CLIN J AM SOC NEPHRO, V4, P873, DOI 10.2215/CJN.04810908
   HEIDEMANN HT, 1983, N-S ARCH PHARMACOL, V324, P148, DOI 10.1007/BF00497021
   Kellum JA, 2013, CRIT CARE, V17, DOI 10.1186/cc11454
   Kondo C, 2012, J TOXICOL SCI, V37, P723, DOI 10.2131/jts.37.723
   Koyner JL, 2008, KIDNEY INT, V74, P1059, DOI 10.1038/ki.2008.341
   Kumpers P, 2010, CRIT CARE, V14, DOI 10.1186/cc8861
   Lacquaniti A, 2013, RADIOLOGY, V267, P86, DOI 10.1148/radiol.12120578
   Luo QH, 2014, MOL CELL BIOCHEM, V397, P53, DOI 10.1007/s11010-014-2171-7
   McCullough PA, 2013, CONTRIB NEPHROL, V182, P13, DOI 10.1159/000349963
   Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713
   Mishra J, 2004, AM J NEPHROL, V24, P307, DOI 10.1159/000078452
   Mishra J, 2003, J AM SOC NEPHROL, V14, P2534, DOI 10.1097/01.ASN.0000088027.54400.C6
   Mishra Jaya, 2005, Lancet, V365, P1231, DOI 10.1016/S0140-6736(05)74811-X
   Parikh CR, 2006, AM J TRANSPLANT, V6, P1639, DOI 10.1111/j.1600-6143.2006.01352.x
   Park HD, 2012, ANN CLIN LAB SCI, V42, P7
   Rocha PN, 2015, ANTIMICROB AGENTS CH, V59, P4759, DOI 10.1128/AAC.00525-15
   SABRA R, 1991, ANTIMICROB AGENTS CH, V35, P2509, DOI 10.1128/AAC.35.12.2509
   SAWAYA BP, 1991, J CLIN INVEST, V87, P2097, DOI 10.1172/JCI115240
   Schinstock CA, 2013, NEPHROL DIAL TRANSPL, V28, P1175, DOI 10.1093/ndt/gfs127
   Shaker O, 2010, ANGIOLOGY, V61, P731, DOI 10.1177/0003319710373093
   Shapiro NI, 2010, ANN EMERG MED, V56, P52, DOI 10.1016/j.annemergmed.2010.02.010
   Shavit L, 2013, CLIN NEPHROL, V80, P405, DOI 10.5414/CN107974
   Siew ED, 2011, J AM SOC NEPHROL, V22, P810, DOI 10.1681/ASN.2010080796
   Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207
   Venkataraman R, 2007, CHEST, V131, P300, DOI 10.1378/chest.06-1246
   Wagener G, 2006, ANESTHESIOLOGY, V105, P485, DOI 10.1097/00000542-200609000-00011
   Wang L, 2008, NEPHRON CLIN PRACT, V108, pC176, DOI 10.1159/000117814
   Waring WS, 2011, CLIN TOXICOL, V49, P720, DOI 10.3109/15563650.2011.615319
   Westenfelder C, 2011, KIDNEY INT, V79, P1159, DOI 10.1038/ki.2011.19
   Zappitelli M, 2007, CRIT CARE, V11, DOI 10.1186/cc6089
NR 43
TC 11
Z9 11
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD NOV
PY 2015
VL 59
IS 11
BP 6913
EP 6921
DI 10.1128/AAC.01079-15
PG 9
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA DB0ZR
UT WOS:000368238100028
PM 26303800
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Gois, L
   Badaro, R
   Schooley, R
   Grassi, MFR
AF Gois, Luana
   Badaro, Roberto
   Schooley, Robert
   Rios Grassi, Maria Fernanda
TI Immune response to Leishmania antigens in an AIDS patient with
   mucocutaneous leishmaniasis as a manifestation of immune reconstitution
   inflammatory syndrome (IRIS): a case report
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE HIV; Leishmania; IRIS; Cytokines; Immune response
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; TEGUMENTARY
   LEISHMANIASIS; CUTANEOUS LEISHMANIASIS; MUCOSAL LEISHMANIASIS; IN-SITU;
   T-CELLS; HIV; INFECTION; IMMUNOPATHOGENESIS
AB Background: After the onset of HAART, some HIV-infected individuals under treatment present a exacerbated inflammation in response to a latent or a previously treated opportunistic pathogen termed immune reconstitution inflammatory syndrome (IRIS). Few reports of tegumentary leishmaniasis have been described in association with IRIS. Moreover, the immunopathogenesis of IRIS in association with Leishmania is unclear.
   Case presentation: The present study reports on a 29-year-old HIV-infected individual who developed mucocutaneous leishmaniasis associated with immune reconstitution inflammatory syndrome (IRIS) five months following highly active antiretroviral therapy (HAART). Severe lesions resulted in the partial destruction of the nasal septum, with improvement observed 15 days after treatment with Amphotericin B and corticosteroids. The immune response of this patient was evaluated before and after the lesions healed. IRIS was diagnosed in association with high levels of TNF-alpha and IL-6. Decreased production of IFN-gamma and a low IFN-gamma/IL-10 ratio were also observed in response to Leishmania antigens. After receiving anti-leishmanial treatment, the individual's specific Th1 immune response was restored.
   Conclusion: The results suggest that the production of inflammatory cytokines by unstimulated T-lymphocytes could contribute to occurrence of leishmaniasis associated with IRIS.
C1 [Gois, Luana; Rios Grassi, Maria Fernanda] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Badaro, Roberto] Univ Fed Bahia, Hosp Prof Edgard Santos, Salvador, BA, Brazil.
   [Schooley, Robert] Univ Calif San Diego, Dept Med, San Diego, CA USA.
RP Grassi, MFR (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
EM grassi@bahia.fiocruz.br
RI Grassi, Fernanda/X-7360-2019
OI Grassi, Fernanda/0000-0002-7356-5569
FU UCSD Center for AIDS Research, NIH grant [P30AI036214]; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214] Funding Source: NIH RePORTER
FX This study was supported by the UCSD Center for AIDS Research, NIH grant
   P30AI036214.
CR Brelaz-de-Castro MCA, 2012, CELL IMMUNOL, V279, P180, DOI 10.1016/j.cellimm.2012.11.006
   Amato VS, 2003, ACTA TROP, V85, P39, DOI 10.1016/S0001-706X(02)00260-7
   Rodrigues MZA, 2011, CLIN VACCINE IMMUNOL, V18, P1765, DOI 10.1128/CVI.00076-11
   Antonelli LRV, 2010, BLOOD, V116, P3818, DOI 10.1182/blood-2010-05-285080
   Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112
   Barber DL, 2012, NAT REV MICROBIOL, V10, P150, DOI 10.1038/nrmicro2712
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   Chrusciak-Talhari A, 2009, AM J TROP MED HYG, V81, P559, DOI 10.4269/ajtmh.2009.09-0077
   Faria DR, 2005, INFECT IMMUN, V73, P7853, DOI 10.1128/IAI.73.12.7853-7859.2005
   French MA, 2009, CLIN INFECT DIS, V48, P101, DOI 10.1086/595006
   Goto H, 2010, EXPERT REV ANTI-INFE, V8, P419, DOI 10.1586/ERI.10.19
   Grant PM, 2012, J INFECT DIS, V206, P1715, DOI 10.1093/infdis/jis604
   Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321
   Lim Andrew, 2008, AIDS Res Ther, V5, P9, DOI 10.1186/1742-6405-5-9
   Lindoso JAL, 2009, BRIT J DERMATOL, V160, P311, DOI 10.1111/j.1365-2133.2008.08908.x
   Lyons A Bruce, 2004, Curr Protoc Cytom, VChapter 9, DOI 10.1002/0471142956.cy0911s27
   Machado PR, 2011, T ROY SOC TROP MED H, V105, P438, DOI 10.1016/j.trstmh.2011.05.002
   Meintjes G, 2012, AM J RESP CRIT CARE, V186, P369, DOI 10.1164/rccm.201201-0094OC
   Meintjes G, 2008, AM J RESP CRIT CARE, V178, P1083, DOI 10.1164/rccm.200806-858OC
   Morlese JF, 2003, AIDS, V17, P1411, DOI 10.1097/00002030-200306130-00025
   Murdoch David M, 2007, AIDS Res Ther, V4, P9, DOI 10.1186/1742-6405-4-9
   Nakanjako D, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-43
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508
   Posada-Vergara MP, 2005, J INFECT DIS, V192, P1819, DOI 10.1086/497338
   Santos CDS, 2013, J INVEST DERMATOL, V133, P1533, DOI 10.1038/jid.2013.4
   Shelburne SA, 2002, MEDICINE, V81, P213, DOI 10.1097/00005792-200205000-00005
   Sinha S, 2008, INT J DERMATOL, V47, P1263, DOI 10.1111/j.1365-4632.2008.03804.x
   Stone S F, 2002, HIV Med, V3, P21, DOI 10.1046/j.1464-2662.2001.00096.x
   Weirather JL, 2011, J CLIN MICROBIOL, V49, P3892, DOI 10.1128/JCM.r00764-11
   Wendland T, 1999, AIDS, V13, P1857, DOI 10.1097/00002030-199910010-00007
NR 31
TC 3
Z9 4
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD FEB 3
PY 2015
VL 15
AR 38
DI 10.1186/s12879-015-0774-6
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA CB3IB
UT WOS:000349520300002
PM 25645330
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Mocumbi, AO
   Carrilho, C
   Aronoff-Spencer, E
   Funzamo, C
   Patel, S
   Preziosi, M
   Lederer, P
   Tilghman, W
   Benson, CA
   Badaro, R
   Nguenha, A
   Schooley, RT
   Noormahomed, EV
AF Mocumbi, Ana Olga
   Carrilho, Carla
   Aronoff-Spencer, Eliah
   Funzamo, Carlos
   Patel, Sam
   Preziosi, Michael
   Lederer, Philip
   Tilghman, Winston
   Benson, Constance A.
   Badaro, Roberto
   Nguenha, A.
   Schooley, Robert T.
   Noormahomed, Emilia V.
TI Innovative Strategies for Transforming Internal Medicine Residency
   Training in Resource-Limited Settings: The Mozambique Experience
SO ACADEMIC MEDICINE
LA English
DT Editorial Material
ID CAPACITY
AB With approximately 4 physicians per 100,000 inhabitants, Mozambique faces one of the most severe health care provider shortages in Sub-Saharan Africa. The lack of sufficient well-trained medical school faculty is one of Mozambique's major barrier to producing new physicians annually. A partnership between the Universidade Eduardo Mondlane and the University of California, San Diego, has addressed this challenge with support from the Medical Education Partnership Initiative. After an initial needs assessment involving questionnaires and focus groups of residents, and working with key members from the Ministry of Health, the Medical Council, and Maputo Central Hospital, a set of interventions was designed. The hospital's internal medicine residency program was chosen as the focus for the plan. Interventions included curriculum design, new teaching methodologies, investment in an informatics infrastructure for access to digital references, building capacity to support clinical research, and providing financial incentives to retain junior faculty. The number of candidates entering the internal medicine residency program has increased, and detailed monitoring and evaluation is measuring the impact of these changes on the quality of training. These changes are expected to improve the long-term quality of postgraduate training in general through dissemination to other departments. They also have the potential to facilitate equitable distribution of specialists nationwide by expanding postgraduate training to other hospitals and universities.
C1 [Mocumbi, Ana Olga] Inst Nacl Saude, Maputo, Mozambique.
   [Mocumbi, Ana Olga] Univ Eduardo Mondlane, Fac Med, Dept Med, Maputo, Mozambique.
   [Carrilho, Carla] Univ Eduardo Mondlane, Fac Med, Dept Pathol, Maputo, Mozambique.
   [Carrilho, Carla] Hosp Cent Maputo, Maputo, Mozambique.
   [Aronoff-Spencer, Eliah] Univ Calif San Diego, Distributed Hlth Labs, San Diego, CA 92103 USA.
   [Aronoff-Spencer, Eliah] Univ Calif San Diego, Med Educ Partnership Initiat, San Diego, CA 92103 USA.
   [Aronoff-Spencer, Eliah; Patel, Sam; Preziosi, Michael; Schooley, Robert T.; Noormahomed, Emilia V.] Univ Calif San Diego, San Diego, CA 92103 USA.
   [Funzamo, Carlos] Inst Nacl Saude, Minist Saude, Maputo, Mozambique.
   [Funzamo, Carlos; Patel, Sam; Noormahomed, Emilia V.] Univ Eduardo Mondlane, Fac Med, Maputo, Mozambique.
   [Patel, Sam] Hosp Cent Maputo, Dept Med, Maputo, Mozambique.
   [Lederer, Philip] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
   [Tilghman, Winston; Schooley, Robert T.] Univ Calif San Diego, Div Infect Dis, San Diego, CA 92103 USA.
   [Benson, Constance A.] Univ Calif San Diego, Infect Dis Training Program, Div Infect Dis, San Diego, CA 92103 USA.
   [Benson, Constance A.] Univ Calif San Diego, Infect Dis Training Program, Div Global Publ Hlth, San Diego, CA 92103 USA.
   [Benson, Constance A.] Univ Calif San Diego, Antiviral Res Ctr, San Diego, CA 92103 USA.
   [Badaro, Roberto] Univ Fed Bahia, Salvador, BA, Brazil.
   [Nguenha, A.] Mozamb Inst Hlth Educ & Res, Maputo, Mozambique.
   [Noormahomed, Emilia V.] Univ Lurio Nampula, Nampula, Mozambique.
RP Mocumbi, AO (corresponding author), Inst Nacl Saude, Av Eduardo Mondlane 1008, Maputo, Mozambique.
EM amocumbi@yahoo.com
OI Mocumbi, Ana/0000-0002-9564-2860
FU Fogarty International Center, National Institutes of Health (NIH)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Fogarty International Center (FIC) [R24TW008908];
   U.S. President's Emergency Plan for AIDS ReliefUnited States Agency for
   International Development (USAID); NIH Office of Research on Women's
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Office of Research on Women's Health
   (ORWH); Office of AIDS ResearchUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA; FOGARTY
   INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [R24TW008908, R24TW008908, R24TW008908,
   R24TW008908, R24TW008908, R24TW008908, R24TW008908, R24TW008908,
   R24TW008908, R24TW008908] Funding Source: NIH RePORTER
FX This project was supported by grant number R24TW008908 from the Fogarty
   International Center, National Institutes of Health (NIH). This award is
   supported by funds provided to the NIH and the Health Resources and
   Services Administration under the U.S. President's Emergency Plan for
   AIDS Relief. Cofunding is also provided by the NIH Office of Research on
   Women's Health and the Office of AIDS Research.
CR Ahmad S, 2006, EMERG MED J, V23, P335, DOI 10.1136/emj.2005.028761
   Assembleia da Republica, 2006, BOL REP SER, V18, P135
   Collins FS, 2010, SCIENCE, V330, P1324, DOI 10.1126/science.1199930
   Connolly C, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c5461
   Governo de Transicao, 1975, BOL OF MOC SER, V8, P26
   Kirigia JM, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-89
   Noormahomed EV, 2013, HUM RESOUR HEALTH, V11, DOI 10.1186/1478-4491-11-62
   Shah SP, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-4
   Shankar PR, 2010, RURAL REMOTE HEALTH, V10
   Sherr K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035840
NR 10
TC 9
Z9 9
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-2446
EI 1938-808X
J9 ACAD MED
JI Acad. Med.
PD AUG
PY 2014
VL 89
IS 8
SU S
BP S78
EP S82
DI 10.1097/ACM.0000000000000331
PG 5
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA AN0QX
UT WOS:000340290200021
PM 25072585
OA Green Accepted, Bronze
DA 2020-12-01
ER

PT J
AU Moreno, L
   Figueredo, M
   Sadigursky, M
   Badaro, R
AF Moreno, Lis
   Figueredo, Maria
   Sadigursky, Moises
   Badaro, Roberto
TI A Man With Newly Diagnosed HIV/AIDS With Unusual Severe Opportunistic
   Infection and No AIDS-Defining Disease
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Editorial Material
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PARACOCCIDIOIDOMYCOSIS
C1 [Moreno, Lis; Figueredo, Maria; Sadigursky, Moises; Badaro, Roberto] Univ Fed Bahia, BR-40110160 Salvador, BA, Brazil.
RP Badaro, R (corresponding author), Univ Fed Bahia, Dept Infect Dis, Rua Augusto Viana S-N, BR-40110160 Salvador, BA, Brazil.
EM rbadaro884@gmail.com
CR Benard G, 2000, CLIN INFECT DIS, V31, P1032, DOI 10.1086/318146
   Colombo AL, 2011, MED MYCOL, V49, P785, DOI 10.3109/13693786.2011.577821
   Jain SB, 2011, AIDS CARE, V23, P846, DOI 10.1080/09540121.2010.542129
   Morejon KML, 2009, AM J TROP MED HYG, V80, P359, DOI 10.4269/ajtmh.2009.80.359
   Marques SA, 2012, CLIN DERMATOL, V30, P610, DOI 10.1016/j.clindermatol.2012.01.006
   RESTREPO A, 1980, ANTIMICROB AGENTS CH, V18, P190, DOI 10.1128/AAC.18.1.190
   Shikanai-Yasuda MA, 2006, REV SOC BRAS MED TRO, V39, P297, DOI 10.1590/S0037-86822006000300017
NR 7
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 15
PY 2014
VL 58
IS 10
BP 1430
EP +
DI 10.1093/cid/ciu142
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AH3RZ
UT WOS:000336044200017
PM 24777879
OA Bronze
DA 2020-12-01
ER

PT J
AU Gois, LL
   Mehta, S
   Schooley, RT
   Badaro, R
   Grassi, MFR
AF Gois, Luana Leandro
   Mehta, Sanjay
   Schooley, Robert T.
   Badaro, Roberto
   Rios Grassi, Maria Fernanda
TI Decreased memory T-cell response and function in human immunodeficiency
   virus-infected patients with tegumentary leishmaniasis
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE Leishmania; HIV; coinfection; memory CD4(+) T-cells
ID CUTANEOUS LEISHMANIASIS; VISCERAL LEISHMANIASIS; COINFECTION; HIV;
   CYTOKINES; IMMUNE; HETEROGENEITY; BRAZILIENSIS; SUBSETS; AIDS
AB The effects of human immunodeficiency virus (HIV) on the immune response in patients with cutaneous leishmaniasis have not yet been fully delineated. This study quantified and evaluated the function of memory T-cell subsets in response to soluble Leishmania antigens (SLA) from patients coinfected with HIV and Leishmania with tegumentary leishmaniasis (TL). Eight TL/HIV coinfected subjects and 10 HIV seronegative subjects with TL were evaluated. The proliferative response of CD4(+) and CD8(+) T-cells and naive, central memory (CM) and effector memory (EM) CD4(+) T-cells in response to SLA were quantified using flow cytometry. The median cell division indices for CD4(+) and CD8(+) T-cells of coinfected patients in response to SLA were significantly lower than those in patients with Leishmania monoinfection (p < 0.05). The proportions of CM and EM CD4(+) T-cells in response to SLA were similar between the coinfected patients and patients with Leishmania monoinfection. However, the median CM and EM CD4(+) T-cell counts from coinfected patients were significantly lower (p < 0.05). The reduction in the lymphoproliferative response to Leishmania antigens coincides with the decrease in the absolute numbers of both EM and CM CD4(+) T-cells in response to Leishmania antigens in patients coinfected with HIV/Leishmania.
C1 [Gois, Luana Leandro; Rios Grassi, Maria Fernanda] Fiocruz MS, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
   [Mehta, Sanjay; Schooley, Robert T.; Badaro, Roberto] Univ Calif San Diego, La Jolla, CA 92093 USA.
   [Badaro, Roberto] Univ Fed Bahia, Salvador, BA, Brazil.
RP Grassi, MFR (corresponding author), Fiocruz MS, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
EM grassi@bahia.fiocruz.br
RI Grassi, Fernanda/X-7360-2019
OI Grassi, Fernanda/0000-0002-7356-5569
FU UCSD Center for AIDS Research, NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [P30AI036214];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [K23AI093163, K23AI093163, K23AI093163, K23AI093163, K23AI093163]
   Funding Source: NIH RePORTER
FX UCSD Center for AIDS Research, NIH (P30AI036214)
CR Rodrigues MZA, 2011, CLIN VACCINE IMMUNOL, V18, P1765, DOI 10.1128/CVI.00076-11
   Moro-Garcia MA, 2012, CURR GENOMICS, V13, P589, DOI 10.2174/138920212803759749
   Bacellar O, 2000, CYTOKINE, V12, P1228, DOI 10.1006/cyto.2000.0694
   Badaro R, 1997, BRAZ J INFECT DIS, V1, P145
   Baleeiro CO, 2006, VET PARASITOL, V139, P21, DOI 10.1016/j.vetpar.2006.02.033
   Bourreau E, 2003, INFECT IMMUN, V71, P2244, DOI 10.1128/IAI.71.4.2244-2246.2003
   Carranza-Tamayo CO, 2009, T ROY SOC TROP MED H, V103, P743, DOI 10.1016/j.trstmh.2009.01.014
   Chen G, 2001, BLOOD, V98, P156, DOI 10.1182/blood.V98.1.156
   COURA J R, 1987, Memorias do Instituto Oswaldo Cruz, V82, P581, DOI 10.1590/S0074-02761987000400019
   Cruz I, 2006, INDIAN J MED RES, V123, P357
   Da-Cruz AM, 1999, MEM I OSWALDO CRUZ, V94, P537, DOI 10.1590/S0074-02761999000400020
   DACRUZ AM, 1992, T ROY SOC TROP MED H, V86, P511, DOI 10.1016/0035-9203(92)90089-U
   DACRUZ AM, 1994, INFECT IMMUN, V62, P2614, DOI 10.1128/IAI.62.6.2614-2618.1994
   De Rosa SC, 2001, NAT MED, V7, P245, DOI 10.1038/84701
   Harari A, 2005, J IMMUNOL, V174, P1037, DOI 10.4049/jimmunol.174.2.1037
   Karp CL, 2007, CLIN INFECT DIS, V45, P1208, DOI 10.1086/522181
   Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4
   Lindoso JAL, 2009, BRIT J DERMATOL, V160, P311, DOI 10.1111/j.1365-2133.2008.08908.x
   MACHADO ES, 1992, MEM I OSWALDO CRUZ, V87, P487, DOI 10.1590/S0074-02761992000400005
   Mathur P, 2006, J MED MICROBIOL, V55, P919, DOI 10.1099/jmm.0.46574-0
   MULLER I, 1994, INFECT IMMUN, V62, P2575
   Nigro L, 1999, AM J TROP MED HYG, V60, P142, DOI 10.4269/ajtmh.1999.60.142
   Pinto Lorena Ana, 2011, ISRN Oncol, V2011, P326719, DOI 10.5402/2011/326719
   Rabello A, 2003, ANN TROP MED PARASIT, V97, P17, DOI 10.1179/000349803225002507
   Roman E, 2002, J EXP MED, V196, P957, DOI 10.1084/jem.20021052
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   ter Horst R, 2008, CLIN INFECT DIS, V46, P1702, DOI 10.1086/587899
   UNAIDS, 2012, GLOB REP 2012 UNAIDS
   Wolday D, 1999, INFECT IMMUN, V67, P5258, DOI 10.1128/IAI.67.10.5258-5264.1999
   Wolday D, 2000, AIDS, V14, P921, DOI 10.1097/00002030-200005260-00003
   Wolday D, 1999, PARASITOL TODAY, V15, P182, DOI 10.1016/S0169-4758(99)01431-3
   Wolday D, 2001, MED MICROBIOL IMMUN, V190, P65, DOI 10.1007/s004300100082
   Zaph C, 2004, NAT MED, V10, P1104, DOI 10.1038/nm1108
NR 33
TC 4
Z9 4
U1 0
U2 4
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD FEB
PY 2014
VL 109
IS 1
BP 9
EP 14
DI 10.1590/0074-0276130174
PG 6
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA AD2BU
UT WOS:000333038700002
PM 24141962
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-12-01
ER

PT J
AU Mistro, S
   Schooley, RT
   Badaro, R
AF Mistro, Sostenes
   Schooley, Robert T.
   Badaro, Roberto
TI Nephrotoxicity of Different Formulations of Amphotericin B: Summarizing
   Evidence by Network Meta-analysis Reply
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
C1 [Mistro, Sostenes] Univ Fed Bahia, Multidisciplinary Inst Hlth, Vitoria Da Conquista, Brazil.
   [Schooley, Robert T.; Badaro, Roberto] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
   [Badaro, Roberto] Univ Fed Bahia, Univ Hosp Prof Edgard Santos, Salvador, BA, Brazil.
RP Badaro, R (corresponding author), Complexo Hosp Univ Prof Edgard Santos, Unidade Docente Infectol, 6 Rua Augusto Viana S-N, BR-40110160 Salvador, BA, Brazil.
EM badaro@ufba.br
RI Mistro, Sostenes/L-3678-2013
OI Mistro, Sostenes/0000-0001-5840-820X
CR Messori A, 2013, CLIN INFECT DIS, V57, P1783, DOI 10.1093/cid/cit588
   Mistro S, 2012, CLIN INFECT DIS, V54, P1774, DOI 10.1093/cid/cis290
NR 2
TC 0
Z9 0
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD DEC 15
PY 2013
VL 57
IS 12
DI 10.1093/cid/cit591
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 262FT
UT WOS:000327720400021
PM 24140973
OA Bronze
DA 2020-12-01
ER

PT J
AU Noormahomed, EV
   Mocumbi, AO
   Preziosi, M
   Damasceno, A
   Bickler, S
   Smith, DM
   Funzamo, C
   Aronoff-Spencer, E
   Badaro, R
   Mabila, F
   Bila, D
   Nguenha, A
   Do Rosario, V
   Benson, CA
   Schooley, RT
   Patel, S
   Ferrao, LJ
   Carrilho, C
AF Noormahomed, Emilia Virginia
   Mocumbi, Ana Olga
   Preziosi, Michael
   Damasceno, Albertino
   Bickler, Stephen
   Smith, David M.
   Funzamo, Carlos
   Aronoff-Spencer, Eliah
   Badaro, Roberto
   Mabila, Francisco
   Bila, David
   Nguenha, Alcido
   Do Rosario, Virgilio
   Benson, Constance A.
   Schooley, Robert T.
   Patel, Sam
   Ferrao, Luis Jorge
   Carrilho, Carla
TI Strengthening research capacity through the medical education
   partnership initiative: the Mozambique experience
SO HUMAN RESOURCES FOR HEALTH
LA English
DT Article
DE Research; Research capacity building in Mozambique; MEPI Mozambique
ID AFRICA
AB Background: Since Mozambique's independence, the major emphasis of its higher educational institutions has been on didactic education. Because of fiscal and human resource constraints, basic and applied research activities have been relatively modest in scope, and priorities have often been set primarily by external collaborators. These factors have compromised the scope and the relevance of locally conducted research and have limited the impact of Mozambique's universities as major catalysts for national development.
   Case description: We developed a multi-institutional partnership to undertake a comprehensive analysis of the research environment at Mozambique's major public universities to identify factors that have served as barriers to the development of a robust research enterprise. Based on this analysis, we developed a multifaceted plan to reduce the impact of these barriers and to enhance research capacity within Mozambique.
   Interventions: On the basis of our needs assessment, we have implemented a number of major initiatives within participating institutions to facilitate basic and applied research activities. These have included specialized training programmes, a reorganization of the research administration infrastructure, the development of multiple collaborative research projects that have emphasized local research priorities and a substantial investment in bioinformatics. We have established a research support centre that provides grant development and management services to Mozambique's public universities and have developed an independent Institutional Review Board for the review of research involving human research subjects. Multiple research projects involving both communicable and non-communicable diseases have been developed and substantial external research support has been obtained to undertake these projects. A sizable investment in biomedical informatics has enhanced both connectivity and access to digital reference material. Active engagement with relevant entities within the Government of Mozambique has aligned institutional development with national priorities.
   Conclusions: Although multiple challenges remain, over the past 3 years significant progress has been made towards establishing conditions within which a broad range of basic, translational and clinical and public health research can be undertaken. Ongoing development of this research enterprise will enhance capacity to address critical locally relevant research questions and will leverage resources to accelerate the development of Mozambique's national universities.
C1 [Noormahomed, Emilia Virginia; Mocumbi, Ana Olga; Damasceno, Albertino; Funzamo, Carlos; Mabila, Francisco; Bila, David; Patel, Sam; Carrilho, Carla] Univ Eduardo Mondlane, Maputo, Mocambique, Mozambique.
   [Noormahomed, Emilia Virginia; Preziosi, Michael; Bickler, Stephen; Smith, David M.; Aronoff-Spencer, Eliah; Benson, Constance A.; Schooley, Robert T.] Univ Calif San Diego, San Diego, CA 92093 USA.
   [Noormahomed, Emilia Virginia; Ferrao, Luis Jorge] Univ Lurio, Nampula, Mocambique, Mozambique.
   [Mocumbi, Ana Olga] Inst Nacl Saude, Maputo, Mocambique, Mozambique.
   [Damasceno, Albertino; Patel, Sam; Carrilho, Carla] Hosp Cent Maputo, Maputo, Mocambique, Mozambique.
   [Funzamo, Carlos] Minist Saude, Maputo, Mocambique, Mozambique.
   [Badaro, Roberto] Univ Fed Bahia, BR-40110060 Salvador, BA, Brazil.
   [Nguenha, Alcido] MIHER Mozamb Inst Hlth Educ & Res, Maputo, Mozambique.
   [Do Rosario, Virgilio] Univ Nova Lisboa, Inst Higiene & Med Trop, P-1349008 Lisbon, Portugal.
RP Noormahomed, EV (corresponding author), Univ Eduardo Mondlane, Av Salvador Allende 702,Caixa Postal 257, Maputo, Mocambique, Mozambique.
EM enoormahomed@gmail.com
OI Mocumbi, Ana/0000-0002-9564-2860; Smith, Davey/0000-0003-3603-1733
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [R24TW008908, R24TW008910, R24 TW008908, R24 TW008910] Funding Source:
   Medline; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [T32 AI007036] Funding Source:
   Medline; PEPFAR Funding Source: Medline; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [R24TW008908, R24TW008908, R24TW008910, R24TW008910, R24TW008908,
   R24TW008910, R24TW008910, R24TW008908, R24TW008908, R24TW008908,
   R24TW008910, R24TW008908, R24TW008908, R24TW008908, R24TW008908] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [T32AI007036, T32AI007036, T32AI007036,
   T32AI007036, T32AI007036, T32AI007036, T32AI007036, T32AI007036,
   T32AI007036, T32AI007036, T32AI007036, T32AI007036, T32AI007036,
   T32AI007036, T32AI007036, T32AI007036, T32AI007036, T32AI007036,
   T32AI007036, T32AI007036, T32AI007036, T32AI007036, T32AI007036,
   T32AI007036, T32AI007036, T32AI007036, T32AI007036, T32AI007036,
   T32AI007036, T32AI007036, T32AI007036] Funding Source: NIH RePORTER
CR [Anonymous], 2012, PREST EF SERV PUBL S
   Boletim da Republica, 2005, B REP IMPR NAC
   Cloete N., 2011, U EC DEV AFRICA
   Collins FS, 2010, SCIENCE, V330, P1324, DOI 10.1126/science.1199930
   Greysen SR, 2011, MED EDUC, V45, P973, DOI 10.1111/j.1365-2923.2011.04039.x
   Manabe YC, 2011, HEALTH RES POLICY SY, V9, DOI 10.1186/1478-4505-9-44
   Mullan F, 2011, LANCET, V377, P1113, DOI 10.1016/S0140-6736(10)61961-7
   Sherr K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035840
NR 8
TC 13
Z9 14
U1 2
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478-4491
J9 HUM RESOUR HEALTH
JI Hum. Resour. Health
PD DEC 5
PY 2013
VL 11
AR 62
DI 10.1186/1478-4491-11-62
PG 10
WC Health Policy & Services; Industrial Relations & Labor
SC Health Care Sciences & Services; Business & Economics
GA 290YW
UT WOS:000329795600001
PM 24304706
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU de Araujo, LA
   Musegante, AFD
   Damasceno, ED
   Barroso, U
   Badaro, R
AF de Araujo, Liubiana Arantes
   de Arruda Musegante, Andre Ferraz
   Damasceno, Edjane de Oliveira
   Barroso, Ubirajara, Jr.
   Badaro, Roberto
TI Investigation into neurogenic bladder in arthrogryposis multiplex
   congenita
SO JOURNAL OF PEDIATRIC UROLOGY
LA English
DT Article
DE Urinary bladder; Neurogenic; Arthrogryposis; Urodynamic; Urinary tract
   infections
ID CONTRACTURAL SYNDROME; AMYOPLASIA
AB Objective: During the follow-up of children who had been diagnosed with arthrogryposis multiplex congenita (AMC), it was noted that some were experiencing dysfunctional voiding. Further investigation into these cases led to a diagnosis of neurogenic bladder. Few studies have investigated the relationship between AMC and neurogenic bladder, this being the first to describe the clinical characteristics of neurogenic bladder among these patients.
   Methods: A series of 26 cases were obtained from the electronic medical records of patients with AMC who were admitted to Hospital Sarah in Salvador between 1994 and 2007. The patients had all been diagnosed with neurogenic bladder through clinical symptoms, lower urinary tract exams, and urodynamic findings.
   Results: There was urinary incontinence in 21 patients (81%), and 50% had a history of urinary tract infections. Renal function was altered in 4 patients (15%) and normal in 22 (85%). In the urodynamic study, 14 patients (64%) had detrusor overactivity and 6 (27%) had underactivity.
   Conclusion: Patients with AMC may show changes in the urinary tract, including neurogenic bladder. It is mandatory to study these symptomatic children with urinary disorders. (C) 2012 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.
C1 [de Araujo, Liubiana Arantes; de Arruda Musegante, Andre Ferraz; Damasceno, Edjane de Oliveira] SARAH Hosp, Ctr Childrens Rehabil, BR-41820900 Salvador, BA, Brazil.
   [Barroso, Ubirajara, Jr.] Univ Fed Bahia, Bahiana Sch Med, BR-41170290 Salvador, BA, Brazil.
   [Badaro, Roberto] Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil.
RP de Araujo, LA (corresponding author), SARAH Hosp, Ctr Childrens Rehabil Salvador, Av Tancredo Neves 2782, BR-41820900 Salvador, BA, Brazil.
EM liubiana@ig.com.br
FU SARAH Hospital Network
FX The SARAH Hospital Network supported this work.
CR Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
   BANKER BQ, 1986, HUM PATHOL, V17, P656, DOI 10.1016/S0046-8177(86)80177-0
   Bankhead RW, 2000, J CHILD NEUROL, V15, P141, DOI 10.1177/088307380001500301
   BHARUCHA EP, 1972, J NEUROL NEUROSUR PS, V35, P425, DOI 10.1136/jnnp.35.4.425
   Coelho KEFA, 2000, AM J MED GENET, V95, P297, DOI 10.1002/1096-8628(20001211)95:4<297::AID-AJMG1>3.3.CO;2-B
   Gaitanis JN, 2010, PEDIATR NEUROL, V43, P142, DOI 10.1016/j.pediatrneurol.2010.03.018
   GILL IBS, 1987, BRIT J UROL, V60, P276, DOI 10.1111/j.1464-410X.1987.tb05506.x
   Goksen D, 2006, PEDIATR DIABETES, V7, P279, DOI 10.1111/j.1399-5448.2006.00201.x
   HALL JG, 1985, CLIN ORTHOP RELAT R, P44
   Hall JG, 1997, J PEDIATR ORTHOP B, V6, P159, DOI 10.1097/01202412-199707000-00002
   HALL JG, 1983, AM J MED GENET, V15, P571, DOI 10.1002/ajmg.1320150407
   HALL JG, 1982, AM J MED GENET, V11, P185, DOI 10.1002/ajmg.1320110208
   HERVA R, 1988, AM J MED GENET, V29, P67, DOI 10.1002/ajmg.1320290109
   Landau D, 2003, AM J MED GENET A, V117A, P37, DOI 10.1002/ajmg.a.10894
   Mennen U, 2005, J HAND SURG-BRIT EUR, V30B, P468, DOI 10.1016/j.jhsb.2005.06.004
   Merenda L, 2004, J SPINAL CORD MED, V27, pS16, DOI 10.1080/10790268.2004.11753780
   Narkis G, 2007, AM J HUM GENET, V81, P589, DOI 10.1086/520770
   QUINN CM, 1991, HISTOPATHOLOGY, V19, P155, DOI 10.1111/j.1365-2559.1991.tb00006.x
   Singh SK, 2005, PEDIATR SURG INT, V21, P578, DOI 10.1007/s00383-005-1451-4
NR 19
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1477-5131
EI 1873-4898
J9 J PEDIATR UROL
JI J. Pediatr. Urol
PD DEC
PY 2013
VL 9
IS 6
BP 895
EP 899
DI 10.1016/j.jpurol.2012.12.011
PN A
PG 5
WC Pediatrics; Urology & Nephrology
SC Pediatrics; Urology & Nephrology
GA 255QH
UT WOS:000327254400043
PM 23491981
DA 2020-12-01
ER

PT J
AU Cueva, CNC
   Rocha, MD
   Mendes, CMC
   de Freitas, LAR
   Baucia, JA
   Badaro, R
AF Carrasco Cueva, Clotario Neptali
   Rocha, Maiara dos Santos
   Cardeal Mendes, Carlos Mauricio
   Rodrigues de Freitas, Luiz Antonio
   Baucia, Jose Augusto
   Badaro, Roberto
TI Clinical and ultramicroscopic myocardial randomized study of beating
   versus arrested heart for mitral surgery
SO REVISTA BRASILEIRA DE CIRURGIA CARDIOVASCULAR
LA English
DT Article
DE Heart Arrest, Induced; Myocardium; Mitral Valve, Surgery
ID BYPASS GRAFT-SURGERY; BLOOD CARDIOPLEGIA; TERM OUTCOMES; VALVE SURGERY;
   PUMP; PROTECTION; REPLACEMENT; REPERFUSION; EXPERIENCE; ISCHEMIA
AB Introduction: Beating heart surgery on normothermic bypass simulates physiologic cardiac status.
   Objectives: This study compared clinical and transmission electron microscopic aspects of myocardial protection during mitral valve replacement using warm retrograde perfusion in empty beating versus arrested heart with cold blood antero-grade cardioplegia.
   Methods: Randomized study to evaluate myocardial cellular ischemia-reperfusion of both techniques to replace the mitral valve. Thirty-four patients were randomly assigned into group A (beating heart) and group B (arrested heart). The following parameters were assessed: echocardiography, blood chemistry, hemoglobin, lactate. During the surgical procedure a total of 102 myocardial biopsies were performed for ultrastructural analysis from anterior left ventricular wall: before cardiopulmonary bypass, before aortic desclamping and 10 minutes after reperfusion.
   Results: Elevation of lactate at 3 hours during the procedure was higher in group A, but similar at the end of surgery (P=0.06). Cardioversion was necessary in 5/17 (A) vs. 13/17 (B) P=0.07. Median intraoperative systemic temperature was significantly lower in the group B compared to A (32 degrees C vs. 36 degrees C), P<0.001. There was no significant difference of the ultramicroscopic aspects of the heart biopsies before, during and after surgery in both groups. Cellular and mitochondrial transient abnormalities such as mitochondrial swelling, glycogen loss and cytosol swelling were detected independently of the moment of the biopsies.
   Conclusion: Myocardial protection and ultrastructural abnormalities were similar for both types of mitral valve replacement beating or arrested heart techniques.
C1 [Carrasco Cueva, Clotario Neptali] Univ Fed Bahia UFBA, Sch Med, Salvador, BA, Brazil.
   [Rocha, Maiara dos Santos] Univ Fed Bahia, Med Course, Salvador, BA, Brazil.
   [Cardeal Mendes, Carlos Mauricio] Postgrad Interact Proc Organs & Syst ICS UFBA, Salvador, BA, Brazil.
   [Rodrigues de Freitas, Luiz Antonio; Baucia, Jose Augusto; Badaro, Roberto] Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.
   [Rodrigues de Freitas, Luiz Antonio] Fiocruz MS, Rio De Janeiro, Brazil.
RP Cueva, CNC (corresponding author), Univ Fed Bahia, Fac Med, Disciplina Cirurgia Torac & Cardiovasc, Dept Anestesiol & Cirurgia, Av Augusto Viana S-N, BR-40110160 Salvador, BA, Brazil.
EM calvence@yahoo.com.br
RI Mendes, Carlos Mauricio Cardeal/AAC-1635-2019; Mendes, Carlos Mauricio
   Cardeal/R-3688-2017
OI Mendes, Carlos Mauricio Cardeal/0000-0003-2089-5668; Mendes, Carlos
   Mauricio Cardeal/0000-0003-2089-5668
CR Babaroglu S, 2011, INTERACT CARDIOV TH, V12, P441, DOI 10.1510/icvts.2010.255240
   Bara C, 2008, INT J CARDIOL, V126, pE61, DOI 10.1016/j.ijcard.2007.01.027
   Botta L, 2010, J CARDIAC SURG, V25, P318, DOI 10.1111/j.1540-8191.2010.00998_1.x
   Chambers DJ, 2010, PHARMACOL THERAPEUT, V127, P41, DOI 10.1016/j.pharmthera.2010.04.001
   Cressoni ES, 2008, REV BRAS CIR CARDIOV, V23, P97, DOI 10.1590/S0102-76382008000100015
   Evora P R, 1996, Arq Bras Cardiol, V66, P239
   FOLLETTE DM, 1977, SURG FORUM, V28, P281
   Gersak B, 2000, HEART SURG FORUM, V3, P232
   Hannan EL, 2007, CIRCULATION, V116, P1145, DOI 10.1161/CIRCULATIONAHA.106.675595
   IKONOMIDIS JS, 1994, J THORAC CARDIOV SUR, V107, P510, DOI 10.1016/S0022-5223(94)70097-4
   Kamlot A, 1997, ANN THORAC SURG, V63, P98
   Kaplon RJ, 2002, J CARDIAC SURG, V17, P170, DOI 10.1111/j.1540-8191.2002.tb01194.x
   Karadeniz U, 2008, J CARDIAC SURG, V23, P107, DOI 10.1111/j.1540-8191.2007.00536.x
   Karolak W, 2007, AM HEART J, V153, P689, DOI 10.1016/j.ahj.2007.01.033
   Kloner RA, 2001, CIRCULATION, V104, P2981, DOI 10.1161/hc4801.100038
   Matsumoto Y, 2002, ANN THORAC SURG, V74, P678, DOI 10.1016/S0003-4975(02)03753-0
   Mizuno T, 2006, GEN THORAC CARDIOVAS, V54, P454, DOI 10.1007/s11748-006-0031-4
   Ricci M, 2009, ANN THORAC SURG, V87, P527, DOI 10.1016/j.athoracsur.2008.10.030
   Rosner B, 2006, FUNDAMENTALS BIOSTAT
   SALERNO TA, 1991, ANN THORAC SURG, V51, P245, DOI 10.1016/0003-4975(91)90795-R
   Salerno TA, 2007, J CARDIAC SURG, V22, P459, DOI 10.1111/j.1540-8191.2007.00448.x
   Salhiyyah Kareem, 2009, Asian Cardiovasc Thorac Ann, V17, P650, DOI 10.1177/0218492309348942
   SCHAPER J, 1982, ANN THORAC SURG, V33, P116, DOI 10.1016/S0003-4975(10)61895-4
   Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232
   Shirai T, 1996, J THORAC CARDIOV SUR, V112, P787, DOI 10.1016/S0022-5223(96)70066-1
NR 25
TC 1
Z9 1
U1 0
U2 5
PU SOC BRASIL CIRURGIA CARDIOVASC
PI SAO PAULO SP
PA RUA BEIRA RIO, 45, 7 ANDAR-CJ 72 VILA OLIMPIA, SAO PAULO SP,
   CEP04548-050, BRAZIL
SN 0102-7638
J9 REV BRAS CIR CARDIOV
JI Rev. Bras. Cir. Cardiovasc.
PY 2013
VL 28
IS 2
BP 270
EP 280
DI 10.5935/1678-9741.20130038
PG 11
WC Cardiac & Cardiovascular Systems; Surgery
SC Cardiovascular System & Cardiology; Surgery
GA 187JE
UT WOS:000322112900017
PM 23939325
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Noormahomed, EV
   Orlov, M
   do Rosario, V
   Petersen, BW
   Guthrie, C
   Badaro, R
   Schooley, RT
AF Noormahomed, Emilia V.
   Orlov, Marika
   do Rosario, Virgilio
   Petersen, Brett W.
   Guthrie, Carly
   Badaro, Roberto
   Schooley, Robert T.
TI A cross-sectional study of sub-clinical Plasmodium falciparum infection
   in HIV-1 infected and uninfected populations in Mozambique,
   South-Eastern Africa
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; P. falciparum; HIV-1
ID MALARIA PARASITEMIA; PREGNANT-WOMEN; CELL COUNT; HIV; ADULTS;
   PROPHYLAXIS; COINFECTION; PREVALENCE
AB Background: Plasmodium falciparum and HIV-1 infection cause substantial morbidity and mortality in sub-Saharan Africa. Increasing evidence suggests these two pathogens interact negatively when infecting the same individual.
   Methods: A cross-sectional study among HIV-1 infected and uninfected populations was recruited in Mocuba and Maputo, Mozambique to determine the prevalence of sub-clinical malarial parasitaemia using light microscopy and a nested PCR assay.
   Results: The prevalence of sub-clinical P. falciparum parasitaemia was low in Maputo, whether determined by microscopy (0.4%) or PCR (1.9%), but substantially higher in Mocuba (7.6 and 14.7%, respectively). Nested PCR detected nearly 70% more cases of sub-clinical parasitaemia than microscopy, but differences occur by locality. HIV-1 infected persons were more likely to be sub-clinically parasitaemic than HIV-1 uninfected individuals recruited from the same geographic areas. Trimethoprim-sulphamethoxazole use did not substantially reduce sub-clinical parasitaemia.
   Conclusions: Dried blood spots are a convenient and sensitive technique for detecting sub-clinical infection with P. falciparum by nested PCR. Prevalence of P. falciparum is substantially lower in Maputo where malaria control programmes have been more active than in the rural town of Mocuba. In Mocuba, among those presenting for HIV-1 counseling and testing, the prevalence of P. falciparum is substantially higher in those who test positive for HIV-1 than those without HIV-1 infection. The clinical implications of sub-clinical P. falciparum infection among HIV-1 infected persons warrant additional study.
C1 [Noormahomed, Emilia V.] Univ Eduardo Mondlane, Dept Microbiol, Maputo, Mozambique.
   [do Rosario, Virgilio] Univ Nova Lisboa, Inst Higiene & Med Trop, P-1200 Lisbon, Portugal.
   [Badaro, Roberto] Univ Fed Bahia, Dept Med, Salvador, BA, Brazil.
   [Noormahomed, Emilia V.; Orlov, Marika; Petersen, Brett W.; Guthrie, Carly; Badaro, Roberto; Schooley, Robert T.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
RP Schooley, RT (corresponding author), Univ Calif San Diego, Div Infect Dis, Mail Stop 0711,9500 Gilman Dr, La Jolla, CA 92093 USA.
EM rschooley@ucsd.edu
OI Orlov, Marika/0000-0003-1961-0813
FU US National Institutes of Health through the UCSD Center for AIDS
   Research [5P30AI036214-15]; Gilead FoundationGilead Sciences; FOGARTY
   INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [R24TW008908, R24TW008908, R24TW008908,
   R24TW008908, R24TW008908, R24TW008908, R24TW008908, R24TW008908,
   R24TW008908, R24TW008908] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [T32GM007198,
   T32GM007198, T32GM007198, T32GM007198, T32GM007198, T32GM007198,
   T32GM007198, T32GM007198, T32GM007198, T32GM007198, T32GM007198,
   T32GM007198, T32GM007198, T32GM007198, T32GM007198, T32GM007198,
   T32GM007198, T32GM007198, T32GM007198, T32GM007198, T32GM007198,
   T32GM007198, T32GM007198, T32GM007198, T32GM007198, T32GM007198,
   T32GM007198, T32GM007198, T32GM007198, T32GM007198, T32GM007198,
   T32GM007198, T32GM007198, T32GM007198, T32GM007198, T32GM007198,
   T32GM007198, T32GM007198, T32GM007198, T32GM007198, T32GM007198] Funding
   Source: NIH RePORTER
FX We express our gratitude to all patients who contributed to this study.
   We also acknowledge to the staff of the health units where the study was
   done. Special thanks go to Drs. Carlos Funzamo and Antonio Junior for
   their contributions in organizing the logistics for patient recruitment
   and sample shipment from Mocuba to Faculty of Medicine, Eduardo Mondlane
   University, and Maputo. The study was funded by the US National
   Institutes of Health through an International Pilot Grant from the UCSD
   Center for AIDS Research, (5P30AI036214-15) and by a grant from the
   Gilead Foundation.
CR Brouwer KC, 2007, EMERG INFECT DIS, V13, P351, DOI 10.3201/eid1302.060573
   Cohen C, 2005, CLIN INFECT DIS, V41, P1631, DOI 10.1086/498023
   COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256
   Cuadros DF, 2011, INT J EPIDEMIOL, V40, P931, DOI 10.1093/ije/dyq256
   FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619
   Franke MF, 2010, AM J TROP MED HYG, V82, P556, DOI 10.4269/ajtmh.2010.09-0477
   French N, 2001, AIDS, V15, P899, DOI 10.1097/00002030-200105040-00010
   GILLES HM, 1993, BRUCECHWATTS ESSENTI, P79
   Grimwade K, 2004, AIDS, V18, P547, DOI 10.1097/00002030-200402200-00023
   Instituto Nacional de Estatistica (INE), 2011, IMP DEM HIV SIDA
   Kublin JG, 2004, LANCET, V365, P233, DOI 10.1016/S0140-6736(05)17743-5
   Malamba SS, 2006, AM J TROP MED HYG, V75, P375, DOI 10.4269/ajtmh.2006.75.375
   Martin-Blondel G, 2010, MED MALADIES INFECT, V40, P256, DOI 10.1016/j.medmal.2009.10.008
   Mermin J, 2006, JAIDS-J ACQ IMM DEF, V41, P129, DOI 10.1097/01.qai.0000179427.11789.a7
   Ministerio da Saude, 2010, REP 2010 PROGR NAC C
   Ministerio da Saude, 2012, PROGR NAC CONTR MAL
   Ministerio da Saude, 2009, REP 2009 PROGR NAC C
   Otieno RO, 2006, AIDS, V20, P275, DOI 10.1097/01.aids.0000200533.56490.b7
   Ter Kuile FO, 2004, AM J TROP MED HYG, V71, P41, DOI 10.4269/ajtmh.2004.71.41
   Thera MA, 2005, J INFECT DIS, V192, P1823, DOI 10.1086/498249
   United Nations Programme on HIV/AIDS (UNAIDS), 2010, UNAIDS REP GLOB AIDS
   Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6
   World Health Organization, 2010, WHOHTMGMP20101
NR 23
TC 7
Z9 7
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD AUG 1
PY 2012
VL 11
AR 252
DI 10.1186/1475-2875-11-252
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 019LX
UT WOS:000309742300001
PM 22853699
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Mistro, S
   Maciel, ID
   de Menezes, RG
   Maia, ZP
   Schooley, RT
   Badaro, R
AF Mistro, Sostenes
   Maciel, Isis de M.
   de Menezes, Rouseli G.
   Maia, Zuinara P.
   Schooley, Robert T.
   Badaro, Roberto
TI Does Lipid Emulsion Reduce Amphotericin B Nephrotoxicity? A Systematic
   Review and Meta-analysis
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID FAT EMULSION; TOXICITY
AB This meta-analysis of 13 studies revealed that amphotericin B delivered as a locally prepared lipid emulsion or in liposomes reduced nephrotoxicity to a similar degree, by 18.4% (relative risk [RR], 0.40 [99% confidence interval,.25-.64]; n = 459) and 18.1% (RR, 0.48 [99% CI,.36-. 64]); n = 1233), respectively.
C1 [Mistro, Sostenes; Maciel, Isis de M.; de Menezes, Rouseli G.; Maia, Zuinara P.; Badaro, Roberto] Univ Fed Bahia, Univ Hosp Prof Edgard Santos, Salvador, BA, Brazil.
   [Schooley, Robert T.; Badaro, Roberto] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
RP Mistro, S (corresponding author), Complexo Hosp Univ Prof Edgard Santos, Serv Assistancia Farmaceut, Rua Augusto Viana,S-N Canela,1 Sub Solo, BR-40110160 Salvador, BA, Brazil.
EM smistro@ufba.br
RI Maia, Zuinara/M-7713-2019; Maia, Zuinara Pereira Gusmao/AAA-6737-2020;
   Mistro, Sostenes/L-3678-2013
OI Maia, Zuinara Pereira Gusmao/0000-0003-0224-4335; Mistro,
   Sostenes/0000-0001-5840-820X
FU FAPESB (Fundacao de Amparo a Pesquisa do Estado da Bahia, Brazil)
FX This work was supported by FAPESB (Fundacao de Amparo a Pesquisa do
   Estado da Bahia, Brazil).
CR Ayestaran A, 1996, ANTIMICROB AGENTS CH, V40, P609, DOI 10.1128/AAC.40.3.609
   Bagnis Corinne Isnard, 2002, Saudi J Kidney Dis Transpl, V13, P481
   Burgess DS, 2000, DIAGN MICR INFEC DIS, V36, P13, DOI 10.1016/S0732-8893(99)00097-8
   Egito EST, 2002, J PHARM SCI-US, V91, P2354, DOI 10.1002/jps.10223
   Gaboriau F, 1997, ANTIMICROB AGENTS CH, V41, P2345, DOI 10.1128/AAC.41.11.2345
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   JOHANSEN HK, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000969
   Kleinberg M, 2006, INT J ANTIMICROB AG, V27, pS12, DOI 10.1016/j.ijantimicag.2006.03.013
   ROWLAND LP, 1965, NEW ENGL J MED, V273, P620, DOI 10.1056/NEJM196509162731202
   Sivak O, 2004, PHARM RES-DORDR, V21, P1564, DOI 10.1023/B:PHAM.0000041449.46054.b4
   Sundar S, 2009, AM J TROP MED HYG, V80, P700, DOI 10.4269/ajtmh.2009.80.700
   The Nordic Cochrane Centre The Cochrane Collaboration, 2011, REV MAN REVMAN COMP
NR 12
TC 43
Z9 43
U1 0
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 15
PY 2012
VL 54
IS 12
BP 1774
EP 1777
DI 10.1093/cid/cis290
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 948YT
UT WOS:000304541000021
PM 22491505
OA Bronze
DA 2020-12-01
ER

PT J
AU Maia, Z
   Lirio, M
   Mistro, S
   Mendes, CMC
   Mehta, SR
   Badaro, R
AF Maia, Zuinara
   Lirio, Monique
   Mistro, Sostenes
   Cardeal Mendes, Carlos Mauricio
   Mehta, Sanjay R.
   Badaro, Roberto
TI Comparative Study of rK39 Leishmania Antigen for Serodiagnosis of
   Visceral Leishmaniasis: Systematic Review with Meta-Analysis
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Review
ID DIRECT AGGLUTINATION-TEST; RAPID IMMUNOCHROMATOGRAPHIC TEST; TEST DAT;
   KALA-AZAR; LABORATORY DIAGNOSIS; STRIP-TEST; FIELD-EVALUATION; DIPSTICK
   TESTS; INFECTION; ANTIBODY
AB Background: The rK39 recombinant protein is derived from a specific antigen produced by the Leishmania donovani complex, and has been used in the last two decades for the serodiagnosis of visceral leishmaniasis. We present here a systematic review and meta-analysis of studies evaluating serologic assays to diagnose visceral leishmaniasis to determine the accuracy of rK39 antigen in comparison to the use of other antigen preparations.
   Methodology/Principal Findings: A systematic review with meta-analysis of the literature was performed to compare the rK39 strip-test and ELISA formats against serological tests using promastigote antigens derived from whole or soluble parasites for Direct Aglutination Test (DAT), Indirect Immunofluorescence test (IFAT) and ELISA with a promastigote antigen preparation (p-ELISA). Gold standard diagnosis was defined by the demonstration of amastigotes on hematological specimens. A database search was performed on Medline, Lilacs, Scopus, Isi Web of Science, and Cochrane Library. Quality of data was assessed using the QUADAS questionnaire. A search of the electronic databases found 352 papers of which only 14 fulfilled the selection criteria. Three evaluated the rK39 ELISA, while 13 evaluated the rK39 immunochromatographic strip test. The summarized sensitivity for the rK39-ELISA was 92% followed by IFAT 88% and p-ELISA 87%. The summarized specificity for the three diagnostic tests was 81%, 90%, and 77%. Studies comparing the rK39 strip test with DAT found a similar sensitivity of 94%, although the DAT had a slightly higher specificity. The rK39 strip test was more sensitive and specific than the IFAT and p-ELISA. We did not detect any difference in the sensitivity and specificity between strips produced by different manufacturers.
   Conclusions: The rK39 protein used either in a strip test or in an ELISA, and the DAT are the best choices for implementation of rapid, easy and efficient test for serodiagnosis of VL.
C1 [Maia, Zuinara; Lirio, Monique; Mistro, Sostenes; Cardeal Mendes, Carlos Mauricio; Badaro, Roberto] Fed Univ Bahia Salvador, Dept Med, Salvador, BA, Brazil.
   [Mehta, Sanjay R.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
RP Maia, Z (corresponding author), Fed Univ Bahia Salvador, Dept Med, Salvador, BA, Brazil.
EM Badaro@ufba.br
RI Mendes, Carlos Mauricio Cardeal/AAC-1635-2019; Mendes, Carlos Mauricio
   Cardeal/R-3688-2017; Maia, Zuinara Pereira Gusmao/AAA-6737-2020; Mistro,
   Sostenes/L-3678-2013; Maia, Zuinara/M-7713-2019
OI Mendes, Carlos Mauricio Cardeal/0000-0003-2089-5668; Mendes, Carlos
   Mauricio Cardeal/0000-0003-2089-5668; Maia, Zuinara Pereira
   Gusmao/0000-0003-0224-4335; Mistro, Sostenes/0000-0001-5840-820X; 
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB) in Brazil;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [K23AI093163, K23AI093163, K23AI093163, K23AI093163, K23AI093163]
   Funding Source: NIH RePORTER
FX This study was funded by the Fundacao de Amparo a Pesquisa do Estado da
   Bahia (FAPESB) in Brazil. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ABDELHAMEED AA, 1989, TROP MED PARASITOL, V40, P470
   Babiker ZOE, 2007, AM J TROP MED HYG, V76, P689, DOI 10.4269/ajtmh.2007.76.689
   Badaro R, 1996, J INFECT DIS, V173, P758, DOI 10.1093/infdis/173.3.758
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   Boelaert M, 2004, AM J TROP MED HYG, V70, P72, DOI 10.4269/ajtmh.2004.70.72
   Brandonisio O, 2002, EUR J CLIN MICROBIOL, V21, P461, DOI 10.1007/s10096-002-0739-8
   BURNS JM, 1993, P NATL ACAD SCI USA, V90, P775, DOI 10.1073/pnas.90.2.775
   Canavate C, 2011, AM J TROP MED HYG, V84, P102, DOI 10.4269/ajtmh.2011.10-0229
   Carvalho SFG, 2003, AM J TROP MED HYG, V68, P321
   Chappuis F, 2003, TROP MED INT HEALTH, V8, P277, DOI 10.1046/j.1365-3156.2003.01026.x
   Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748
   Chappuis F, 2006, BMJ-BRIT MED J, V333, P723, DOI 10.1136/bmj.38917.503056.7C
   de Assis TSM, 2011, T ROY SOC TROP MED H, V105, P81, DOI 10.1016/j.trstmh.2010.09.004
   Deeks JJ, 2001, BRIT MED J, V323, P157, DOI 10.1136/bmj.323.7305.157
   DEKORTE PM, 1990, PARASITOL RES, V76, P526, DOI 10.1007/BF00931059
   Diro E, 2007, T ROY SOC TROP MED H, V101, P908, DOI 10.1016/j.trstmh.2007.05.002
   GALVAOCASTRO B, 1984, CLIN EXP IMMUNOL, V56, P58
   Goswami R P, 2007, J Assoc Physicians India, V55, P154
   HARITH AE, 1987, T ROY SOC TROP MED H, V81, P603, DOI 10.1016/0035-9203(87)90423-8
   HARITH AE, 1986, T ROY SOC TROP MED H, V80, P583, DOI 10.1016/0035-9203(86)90149-5
   Iared W, 2009, DIAGN TRATAMENTO, V14, P85
   Iqbal J, 2002, J CLIN MICROBIOL, V40, P475, DOI 10.1128/JCM.40.3.475-479.2001
   Kalayou S, 2011, TRANSBOUND EMERG DIS, V58, P255, DOI 10.1111/j.1865-1682.2011.01209.x
   Kilic S, 2008, TURK J MED SCI, V38, P13
   Maalej IA, 2003, AM J TROP MED HYG, V68, P312, DOI 10.4269/ajtmh.2003.68.312
   de Assis TSM, 2008, EPIDEMIOL SERV SAUDE, V17, P107
   Mandal J, 2008, AM J TROP MED HYG, V79, P76, DOI 10.4269/ajtmh.2008.79.76
   Mathur P, 2005, INDIAN J MED RES, V122, P485
   Mikaeili Fattaneh, 2007, Iran J Immunol, V4, P116
   Oliveira E, 2011, T ROY SOC TROP MED H, V105, P414, DOI 10.1016/j.trstmh.2011.04.010
   Oliveira E, 2009, T ROY SOC TROP MED H, V103, P1279, DOI 10.1016/j.trstmh.2009.04.007
   Pattabhi S, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000822
   Pedras MJ, 2008, T ROY SOC TROP MED H, V102, P172, DOI 10.1016/j.trstmh.2007.11.004
   Romero HD, 2009, AM J TROP MED HYG, V81, P27
   Rouf M A, 2009, Mymensingh Med J, V18, pS1
   Saghrouni F, 2009, T ROY SOC TROP MED H, V103, P1273, DOI 10.1016/j.trstmh.2008.10.034
   Srivastava P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019304
   Srivastava P, 2011, T ROY SOC TROP MED H, V105, P1, DOI 10.1016/j.trstmh.2010.09.006
   Sundar S, 1998, LANCET, V351, P563, DOI 10.1016/S0140-6736(97)04350-X
   Sundar S, 2007, TROP MED INT HEALTH, V12, P284, DOI 10.1111/j.1356-3156.2006.01775.x
   Sundar S, 2002, CLIN DIAGN LAB IMMUN, V9, P951, DOI 10.1128/CDLI.9.5.951-958.2002
   Sundar S, 2002, ANN TROP MED PARASIT, V96, P19, DOI 10.1179/000349802125000466
   TDR, 2010, VISC LEISHM RAP DIAG
   ter Horst R, 2009, AM J TROP MED HYG, V80, P929, DOI 10.4269/ajtmh.2009.80.929
   Vaish M, 2011, CLIN MICROBIOL INFEC
   Veeken H, 2003, TROP MED INT HEALTH, V8, P164, DOI 10.1046/j.1365-3156.2003.00996.x
   Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25
   WHO, 2010, LEISHM BURD DIS SURV
   ZIJLSTRA EE, 1991, T ROY SOC TROP MED H, V85, P474, DOI 10.1016/0035-9203(91)90224-M
NR 49
TC 68
Z9 72
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JAN
PY 2012
VL 6
IS 1
AR e1484
DI 10.1371/journal.pntd.0001484
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 894GW
UT WOS:000300416100027
PM 22303488
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Rodrigues, MZA
   Grassi, MFR
   Mehta, S
   Zhang, XQ
   Gois, LL
   Schooley, RT
   Badaro, R
AF Andrade Rodrigues, Maria Zilma
   Rios Grassi, Maria Fernanda
   Mehta, Sanjay
   Zhang, Xing-Quan
   Gois, Luana Leandro
   Schooley, Robert T.
   Badaro, Roberto
TI Th1/Th2 Cytokine Profile in Patients Coinfected with HIV and Leishmania
   in Brazil
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; T-CELL RESPONSES; CUTANEOUS
   LEISHMANIASIS; TEGUMENTARY LEISHMANIASIS; INTERLEUKIN-2 PRODUCTION;
   VISCERAL LEISHMANIASIS; MUCOSAL LEISHMANIASIS; INFECTION;
   RECONSTITUTION; AIDS
AB To evaluate the effects of HIV on immune responses in cutaneous leishmaniasis (CL), we quantified cytokine levels from plasma and stimulated peripheral blood mononuclear cells (PBMCs) from individuals infected with HIV and/or CL. Gamma interferon (IFN-gamma) and interleukin 13 (IL-13) levels and the ratio of IFN-gamma to IL-10 produced in response to stimulation with soluble Leishmania antigens were significantly lower in HIV-Leishmania-coinfected patients than in CL-monoinfected patients.
C1 [Andrade Rodrigues, Maria Zilma; Badaro, Roberto] Univ Fed Bahia, Salvador, BA, Brazil.
   [Rios Grassi, Maria Fernanda; Gois, Luana Leandro] Fiocruz MS, Oswaldo Cruz Fdn, Salvador, BA, Brazil.
   [Mehta, Sanjay; Zhang, Xing-Quan; Schooley, Robert T.; Badaro, Roberto] Univ Calif San Diego, La Jolla, CA 92093 USA.
RP Badaro, R (corresponding author), Univ Fed Bahia Complexo Hosp, Edgard Santos Unidade Docente Infectol UDAI, Rua Augusto Viana S-N, BR-40110160 Salvador, BA, Brazil.
EM badaro@ufba.br
RI Grassi, Fernanda/X-7360-2019
OI Grassi, Fernanda/0000-0002-7356-5569
FU UCSD Center for AIDS Research, NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [P30AI036214];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, K23AI093163, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, K23AI093163, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, K23AI093163,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, K23AI093163, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   K23AI093163, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214] Funding Source: NIH RePORTER
FX This study was supported by the UCSD Center for AIDS Research, NIH grant
   P30AI036214.
CR Alvar J, 2008, CLIN MICROBIOL REV, V21, P334, DOI 10.1128/CMR.00061-07
   Amato VS, 2000, J ANTIMICROB CHEMOTH, V46, P341, DOI 10.1093/jac/46.2.341
   AUKRUST P, 1994, J INFECT DIS, V169, P420, DOI 10.1093/infdis/169.2.420
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   Bacellar O, 2000, CYTOKINE, V12, P1228, DOI 10.1006/cyto.2000.0694
   *BD, 2010, BD CYT BEAD ARR HUM
   Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152
   *BIOR LAB INC, 2010, 3157 BIOR LAB INC, P1
   Bourreau E, 2003, INFECT IMMUN, V71, P2244, DOI 10.1128/IAI.71.4.2244-2246.2003
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   CAUDA R, 1987, Viral Immunology, V1, P247, DOI 10.1089/vim.1987.1.247
   Cruz I, 2006, INDIAN J MED RES, V123, P357
   Gomes-Silva A, 2007, CLIN EXP IMMUNOL, V149, P440, DOI 10.1111/j.1365-2249.2007.03436.x
   Guimaraes LH, 2009, T ROY SOC TROP MED H, V103, P712, DOI 10.1016/j.trstmh.2009.04.019
   Hardy GAD, 2003, CLIN EXP IMMUNOL, V134, P98, DOI 10.1046/j.1365-2249.2003.02256.x
   HOLADAY BJ, 1993, J CLIN INVEST, V92, P2626, DOI 10.1172/JCI116878
   Imami N, 1999, AIDS RES HUM RETROV, V15, P1499, DOI 10.1089/088922299309784
   Lindoso JAL, 2009, BRIT J DERMATOL, V160, P311, DOI 10.1111/j.1365-2133.2008.08908.x
   Mattos M, 1998, J EUR ACAD DERMATOL, V10, P218, DOI 10.1016/S0926-9959(98)00012-9
   PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341
   Posada-Vergara MP, 2005, J INFECT DIS, V192, P1819, DOI 10.1086/497338
   Rabello A, 2003, ANN TROP MED PARASIT, V97, P17, DOI 10.1179/000349803225002507
   Redhu NS, 2006, AIDS, V20, P1213, DOI 10.1097/01.aids.0000226971.42622.4e
   Rosatelli JB, 1998, J EUR ACAD DERMATOL, V10, P229, DOI 10.1016/S0926-9959(98)00014-2
   Schraner C, 2005, CLIN INFECT DIS, V40, pE120, DOI 10.1086/430444
   Turgay N, 2010, AM J TROP MED HYG, V83, P822, DOI 10.4269/ajtmh.2010.09-0605
   Valdez H, 2000, AIDS, V14, P11, DOI 10.1097/00002030-200001070-00002
   Wendland T, 1999, AIDS, V13, P1857, DOI 10.1097/00002030-199910010-00007
   Wolday D, 2000, AIDS, V14, P921, DOI 10.1097/00002030-200005260-00003
   Wolday D, 1999, PARASITOL TODAY, V15, P182, DOI 10.1016/S0169-4758(99)01431-3
NR 31
TC 9
Z9 9
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD OCT
PY 2011
VL 18
IS 10
BP 1765
EP 1769
DI 10.1128/CVI.00076-11
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 826NQ
UT WOS:000295361300023
PM 21832098
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Mehta, SR
   Zhang, XQ
   Badaro, R
   Spina, C
   Day, J
   Chang, KP
   Schooley, RT
AF Mehta, Sanjay R.
   Zhang, Xing-Quan
   Badaro, Roberto
   Spina, Celsa
   Day, John
   Chang, Kwang-Poo
   Schooley, Robert T.
TI Flow cytometric screening for anti-leishmanials in a human macrophage
   cell line
SO EXPERIMENTAL PARASITOLOGY
LA English
DT Article
DE Leishmania amazonensis; Parasite; Amastigote; Drug screening; THP-1;
   Flow cytometry
ID AMPHOTERICIN-B; PHARMACOKINETICS; MILTEFOSINE; THP-1; MODEL; OLD
AB High-throughput drug screening methods against the intracellular stage of Leishmania have been facilitated by the development of in vitro models of infection. The use of cell lines rather than primary cells facilitates these methods. Peripheral blood mononuclear cell (PBMC) derived macrophages and THP-1 cells were infected with stationary phase egfp transfected Leishmania amazonensis parasites and then treated with anti-leishmanial compounds. Drug activity was measured using a flow cytometric approach, and toxicity was assessed using either the MTT assay or trypan blue dye exclusion. Calculated EC50's for amphotericin B, sodium stibogluconate, and miltefosine were 0.1445 +/- 0.0005 mu g/ml, 0.1203 +/- 0.018 mg/ml, and 26.71 mu M using THP-1 cells, and 0.179 +/- 0.035 mu g/ml, 0.1948 +/- 0.0364 mg/ml, and 13.77 +/- 10.74 mu M using PBMC derived macrophages, respectively. We conclude that a flow cytometric approach using egfp transfected Leishmania species can be used to evaluate anti-leishmanial compounds against the amastigote stage of the parasite in THP-1 cells with excellent concordance to human PBMC derived macrophages. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Mehta, Sanjay R.; Zhang, Xing-Quan; Badaro, Roberto; Spina, Celsa; Day, John; Schooley, Robert T.] Univ Calif San Diego, Div Infect Dis, La Jolla, CA 92103 USA.
   [Badaro, Roberto] Univ Fed Bahia, Div Infect Dis, BR-41170290 Salvador, BA, Brazil.
   [Chang, Kwang-Poo] Rosalind Franklin Univ, Chicago Med Sch, Dept Microbiol & Immunol, N Chicago, IL USA.
RP Mehta, SR (corresponding author), Univ Calif San Diego, Div Infect Dis, SCRB 402A,9500 Gilman Dr MC 0711, La Jolla, CA 92103 USA.
EM srmehta@ucsd.edu
FU UCSD Center for AIDS Research; NIAID Institutional Postdoctoral
   TrainingUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [5T32AI007036]; NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [AI-20486, AI-68835]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI020486, T32AI007036, R01AI020486,
   T32AI007036, T32AI007036, R01AI020486, R21AI068835, T32AI007036,
   T32AI007036, R01AI020486, T32AI007036, T32AI007036, R01AI020486,
   T32AI007036, R01AI020486, R01AI020486, T32AI007036, R21AI068835,
   R01AI020486, T32AI007036, R01AI020486, R01AI020486, T32AI007036,
   R01AI020486, R01AI020486, T32AI007036, T32AI007036, T32AI007036,
   T32AI007036, T32AI007036, T32AI007036, T32AI007036, T32AI007036,
   R01AI020486, R01AI020486, T32AI007036, T32AI007036, R01AI020486,
   T32AI007036, T32AI007036, T32AI007036, T32AI007036, T32AI007036,
   R01AI020486, R01AI020486, T32AI007036, T32AI007036, T32AI007036,
   T32AI007036, T32AI007036] Funding Source: NIH RePORTER
FX Support for this work was provided by the UCSD Center for AIDS Research
   and by NIAID Institutional Postdoctoral Training Grant #5T32AI007036.
   K.P.C. is supported by NIH AI-20486 and AI-68835.
CR AL JM, 1995, ANTIMICROBIAL AGENTS, V39, P516
   [Anonymous], 1984, World Health Organ Tech Rep Ser, V701, P1
   ATKINSON AJ, 1978, ANTIMICROB AGENTS CH, V13, P271, DOI 10.1128/AAC.13.2.271
   AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244
   Ayres DC, 2008, J PARASITOL, V94, P1415, DOI 10.1645/GE-1613.1
   CHULAY JD, 1988, T ROY SOC TROP MED H, V82, P69, DOI 10.1016/0035-9203(88)90267-2
   Dorlo TPC, 2008, ANTIMICROB AGENTS CH, V52, P2855, DOI 10.1128/AAC.00014-08
   GEBREHIWOT A, 1992, ACTA TROP, V51, P237, DOI 10.1016/0001-706X(92)90042-V
   Kawazu SI, 1997, GENE, V196, P49, DOI 10.1016/S0378-1119(97)00190-X
   Matthews JB, 2001, J MATER SCI-MATER M, V12, P249, DOI 10.1023/A:1008967200706
   OGUNKOLADE BW, 1990, ACTA TROP, V47, P171, DOI 10.1016/0001-706X(90)90023-S
   PRIETO J, 1994, CELL IMMUNOL, V156, P191, DOI 10.1006/cimm.1994.1164
   Varela RE, 2009, EXP PARASITOL, V122, P134, DOI 10.1016/j.exppara.2009.02.012
   Verma NK, 2004, ANTIMICROB AGENTS CH, V48, P3010, DOI 10.1128/AAC.48.8.3010-3015.2004
   Yardley V, 2000, INT J ANTIMICROB AG, V13, P243, DOI 10.1016/S0924-8579(99)00133-8
NR 15
TC 6
Z9 6
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4894
EI 1090-2449
J9 EXP PARASITOL
JI Exp. Parasitol.
PD DEC
PY 2010
VL 126
IS 4
BP 617
EP 620
DI 10.1016/j.exppara.2010.06.007
PG 4
WC Parasitology
SC Parasitology
GA 654IJ
UT WOS:000282161400027
PM 20540940
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Mehta, SR
   Huang, R
   Yang, M
   Zhang, XQ
   Kolli, B
   Chang, KP
   Hoffman, RM
   Goto, Y
   Badaro, R
   Schooley, RT
AF Mehta, Sanjay R.
   Huang, Robert
   Yang, Meng
   Zhang, Xing-Quan
   Kolli, Bala
   Chang, Kwang-Poo
   Hoffman, Robert M.
   Goto, Yasuyuki
   Badaro, Roberto
   Schooley, Robert T.
TI Real-Time In Vivo Green Fluorescent Protein Imaging of a Murine
   Leishmaniasis Model as a New Tool for Leishmania Vaccine and Drug
   Discovery
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID CUTANEOUS LEISHMANIASIS; AMAZONENSIS; MICE; EXPRESSION; IMMUNOTHERAPY;
   MACROPHAGES; LUCIFERASE; INFECTION; ANTIGENS; VITRO
AB Leishmania species are obligate intracellular protozoan parasites that cause a broad spectrum of clinical diseases in mammalian hosts. The most frequently used approach to quantify parasites in murine model systems is based on thickness measurements of the footpad or ear after experimental infection. To overcome the limitations of this method, we used a Leishmania mutant episomally transfected with enhanced green fluorescent protein, enabling in vivo real-time whole-body fluorescence imaging, to follow the progression of Leishmania infection in parasitized tissues. Fluorescence correlated with the number of Leishmania parasites in the tissue and demonstrated the real-time efficacy of a therapeutic vaccine. This approach provides several substantial advantages over currently available animal model systems for the in vivo study of immunopathogenesis, prevention, and therapy of leishmaniasis. These include improvements in sensitivity and the ability to acquire real-time data on progression and spread of the infection.
C1 [Mehta, Sanjay R.; Huang, Robert; Zhang, Xing-Quan; Badaro, Roberto; Schooley, Robert T.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
   [Kolli, Bala; Chang, Kwang-Poo] Rosalind Franklin Univ, Chicago Med Sch, Dept Microbiol Immunol, Chicago, IL 60637 USA.
   [Yang, Meng; Hoffman, Robert M.] AntiCancer Inc, San Diego, CA USA.
   [Hoffman, Robert M.] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA.
   [Goto, Yasuyuki] Infect Dis Res Inst, Seattle, WA USA.
   [Badaro, Roberto] Univ Fed Bahia, Salvador, BA, Brazil.
RP Schooley, RT (corresponding author), Stein Clin Res Bldg 402A,9500 Gilman Dr Box 0711, La Jolla, CA 92093 USA.
EM rschooley@ucsd.edu
RI Goto, Yasuyuki/E-9028-2011
OI Goto, Yasuyuki/0000-0002-8654-7888
FU UCSD Center for AIDS Research; NIAID Institutional Postdoctoral
   TrainingUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [5T32AI007036]; NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [AI-20486, AI-68835]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [T32AI007036, R01AI020486, R01AI020486,
   R01AI020486, T32AI007036, T32AI007036, R01AI020486, R01AI020486,
   T32AI007036, R01AI020486, R01AI020486, T32AI007036, R01AI020486,
   R01AI020486, T32AI007036, T32AI007036, T32AI007036, R21AI068835,
   T32AI007036, T32AI007036, R01AI020486, T32AI007036, T32AI007036,
   T32AI007036, T32AI007036, R01AI020486, R01AI020486, T32AI007036,
   T32AI007036, R01AI020486, R01AI020486, R21AI068835, T32AI007036,
   T32AI007036, T32AI007036, T32AI007036, T32AI007036, T32AI007036,
   T32AI007036, T32AI007036, T32AI007036, T32AI007036, T32AI007036,
   R01AI020486, R01AI020486, R01AI020486, T32AI007036, T32AI007036,
   T32AI007036, T32AI007036] Funding Source: NIH RePORTER
FX Support for the development of the model was also provided by the UCSD
   Center for AIDS Research and by NIAID Institutional Postdoctoral
   Training grant 5T32AI007036. K.P.C. and B.K. are supported by NIH
   AI-20486 and AI-68835.; We thank Steven Baird for assistance with frozen
   tissue sections; Keith Jenne for assistance with photography and animal
   care; and finally Jim Feramisco, Kersi Pestonjamasp, and the UCSD Cancer
   Center Histology Core for assistance with immunofluorescence imaging.;
   R.M.H. is president of AntiCancer, Inc. Y.G. is an employee of the
   Infectious Disease Research Institute. All other authors report no
   financial conflicts of interest.
CR Amino R, 2006, NAT MED, V12, P220, DOI 10.1038/nm1350
   Badaro R, 2006, J INFECT DIS, V194, P1151, DOI 10.1086/507708
   Calvopina M, 2006, INT J DERMATOL, V45, P116, DOI 10.1111/j.1365-4632.2004.02518.x
   Calvopina M, 2006, VACCINE, V24, P5645, DOI 10.1016/j.vaccine.2006.03.023
   Chan MMY, 2003, PARASITOL RES, V89, P266, DOI 10.1007/s00436-002-0706-4
   Coler RN, 2002, INFECT IMMUN, V70, P4215, DOI 10.1128/IAI.70.8.4215-4225.2002
   Courret N, 2003, INT J PARASITOL, V33, P1373, DOI 10.1016/S0020-7519(03)00179-6
   Dube A, 2005, PARASITOL RES, V96, P216, DOI 10.1007/s00436-005-1339-1
   Dutta S, 2005, ANTIMICROB AGENTS CH, V49, P4474, DOI 10.1128/AAC.49.11.4474-4484.2005
   Hoffman RM, 2005, NAT BIOTECHNOL, V23, P790, DOI 10.1038/nbt0705-790
   Hoffman RM, 2005, NAT REV CANCER, V5, P796, DOI 10.1038/nrc1717
   Kamau SW, 2001, ANTIMICROB AGENTS CH, V45, P3654, DOI 10.1128/AAC.45.12.3654-3656.2001
   Kawazu SI, 1997, GENE, V196, P49, DOI 10.1016/S0378-1119(97)00190-X
   Khamesipour A, 2006, INDIAN J MED RES, V123, P423
   Lang T, 2005, CELL MICROBIOL, V7, P383, DOI 10.1111/j.1462-5822.2004.00468.x
   Leifso K, 2007, MOL BIOCHEM PARASIT, V152, P35, DOI 10.1016/j.molbiopara.2006.11.009
   Louis J, 2002, EUR J DERMATOL, V12, P316
   Murray HW, 2003, ANTIMICROB AGENTS CH, V47, P2513, DOI 10.1128/AAC.47.8.2513-2517.2003
   Naumov GN, 1999, J CELL SCI, V112, P1835
   Okuno T, 2003, EXP ANIM TOKYO, V52, P109, DOI 10.1538/expanim.52.109
   Roy G, 2000, MOL BIOCHEM PARASIT, V110, P195, DOI 10.1016/S0166-6851(00)00270-X
   Sacks D, 2004, IMMUNOL REV, V201, P225, DOI 10.1111/j.0105-2896.2004.00185.x
   Singh N, 2004, AM J TROP MED HYG, V71, P400, DOI 10.4269/ajtmh.2004.71.400
   *WHO, 2002, LEISH LEISH HIV COIN
   Yamauchi K, 2006, CANCER RES, V66, P4208, DOI 10.1158/0008-5472.CAN-05-3927
   Yang M, 2000, P NATL ACAD SCI USA, V97, P1206, DOI 10.1073/pnas.97.3.1206
   Zhao M, 2005, P NATL ACAD SCI USA, V102, P755, DOI 10.1073/pnas.0408422102
NR 27
TC 40
Z9 41
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
EI 1556-679X
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD DEC
PY 2008
VL 15
IS 12
BP 1764
EP 1770
DI 10.1128/CVI.00270-08
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 379GN
UT WOS:000261384800004
PM 18945882
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Andrade, ACO
   Ladeia, AM
   Netto, EM
   Mascarenhas, A
   Cotter, B
   Benson, CA
   Badaro, R
AF Andrade, Ana Cristina O.
   Ladeia, Ana Marice
   Netto, Eduardo M.
   Mascarenhas, Amanda
   Cotter, Bruno
   Benson, Constance A.
   Badaro, Roberto
TI Cross-sectional study of endothelial function in HIV-infected patients
   in Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID PROTEASE INHIBITOR THERAPY; RISK-FACTORS; ARTERY; ATHEROSCLEROSIS;
   DYSFUNCTION; RITONAVIR; INCREASE; DISEASE; EVENTS
AB Antiretroviral therapy (ART) in HIV-infected patients has been associated with an increased risk of cardiovascular disease. This study evaluates vascular endothelial dysfunction of the peripheral circulation in Brazilian HIV-infected subjects on ART or naive to ART compared to a control group matched for age and body mass index (BMI). We performed a cross-sectional comparative study to measure postischemic peak flow-mediated dilation (FMD) of the brachial artery and the response to glyceryl trinitrate (GTN) in HIV-infected patients and healthy controls in Salvador, Bahia, Brazil. Endothelial vasomotor function was evaluated by assessing brachial artery FMD. Forty-four HIV-infected individuals (33 ARV treated and 11 ART naive) were compared to 25 healthy controls matched for age and BMI. FMD % was significantly lower for the ART-experienced patients compared to the ART-naive patients and was also significantly different from controls (ART experienced 8.2 +/- 6.0% vs. 19.3 +/- 4.8% vs. 23.3 +/- 6.1%), respectively (p < 0.0001). The cholesterol, triglyceride, and ALT levels were significantly higher in the ART-experienced group compared to the ART-naive and control subjects (p < 0.028); however, linear regression analysis revealed a statistically significant association of endothelial dysfunction as a dependent variable only with ARV treatment in HIV-infected subjects (p = 0.03). The association of endothelial dysfunction with ARV therapy in HIV-infected patients was independent of protease inhibitor-containing regimens or dyslipidemia. This dysfunction may contribute to the risk for HIV-associated atherosclerosis.
C1 [Andrade, Ana Cristina O.; Ladeia, Ana Marice; Mascarenhas, Amanda] Bahian Sch Med & Publ Hlth, Bahia Blanca, Buenos Aires, Argentina.
   [Netto, Eduardo M.; Badaro, Roberto] Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil.
   [Cotter, Bruno; Benson, Constance A.; Badaro, Roberto] Univ Calif San Diego, La Jolla, CA 92093 USA.
RP Andrade, ACO (corresponding author), ALLMED Clin Especializadas, Edificio Louis Pasteur,Complexo Odondomed Itaigar, Salvador, BA, Brazil.
EM anaandrade@terra.com.br
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761; Ladeia, Ana
   Marice/0000-0002-2235-7401
CR Andrade Ana Cristina O., 2006, Braz J Infect Dis, V10, P139, DOI 10.1590/S1413-86702006000200012
   Andre P, 1998, P NATL ACAD SCI USA, V95, P13120, DOI 10.1073/pnas.95.22.13120
   Bo J, 2006, JAIDS-J ACQ IMM DEF, V42, P391
   Bozzette SA, 2003, NEW ENGL J MED, V348, P702, DOI 10.1056/NEJMoa022048
   Chardon F, 2005, THEOR APPL GENET, V112, P1, DOI 10.1007/s00122-005-0050-z
   Corretti MC, 2002, J AM COLL CARDIOL, V39, P257, DOI 10.1016/S0735-1097(01)01746-6
   Cotter Bruno R, 2006, Curr HIV/AIDS Rep, V3, P126, DOI 10.1007/BF02696656
   Currier JS, 2005, AIDS, V19, P927, DOI 10.1097/01.aids.0000171406.53737.f9
   Depairon M, 2001, AIDS, V15, P329, DOI 10.1097/00002030-200102160-00005
   Friis-Moller N, 2003, AIDS, V17, P1179, DOI 10.1097/00002030-200305230-00010
   Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723
   Gokce N, 2003, J AM COLL CARDIOL, V41, P1769, DOI 10.1016/S0735-1097(03)00333-4
   Grinspoon S, 2005, NEW ENGL J MED, V352, P48, DOI 10.1056/NEJMra041811
   Grubb JR, 2006, J INFECT DIS, V193, P1516, DOI 10.1086/503807
   Gujuluva C, 2001, MOL MED, V7, P169, DOI 10.1007/BF03401950
   Holmberg SD, 2002, LANCET, V360, P1747, DOI 10.1016/S0140-6736(02)11672-2
   Hurlimann D, 2006, HEART, V92, P110, DOI 10.1136/hrt.2004.056523
   Klein D, 2002, J ACQ IMMUN DEF SYND, V30, P471, DOI 10.1097/00126334-200208150-00002
   Lenhard JM, 2000, ANTIVIR RES, V47, P121, DOI 10.1016/S0166-3542(00)00102-9
   Mary-Krause M, 2003, AIDS, V17, P2479, DOI 10.1097/00002030-200311210-00010
   Nguyen AT, 2000, AIDS, V14, P2467, DOI 10.1097/00002030-200011100-00007
   Nolan D, 2003, QJM-INT J MED, V96, P825, DOI 10.1093/qjmed/hcg145
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Rios Blanco JJ, 2006, J ANTIMICROB CHEMOTH, V58, P133, DOI 10.1093/jac/dkl190
   Russo G, 2002, VASC PHARMACOL, V38, P259, DOI 10.1016/S1537-1891(02)00250-1
   SCHAG CC, 1984, J CLIN ONCOL, V2, P187, DOI 10.1200/JCO.1984.2.3.187
   Seigneur M, 1997, THROMB HAEMOSTASIS, V77, P646
   Shankar SS, 2005, AM HEART J, V150, DOI 10.1016/j.ahj.2005.06.005
   Shankar Sudha S, 2004, Cardiovasc Toxicol, V4, P261, DOI 10.1385/CT:4:3:261
   Solages A, 2006, CLIN INFECT DIS, V42, P1325, DOI 10.1086/503261
   Stein JH, 2004, AM HEART J, V147, DOI 10.1016/j.ahj.2003.10.018
   Stein JH, 2001, CIRCULATION, V104, P257
   Tousoulis D, 2005, HEART, V91, P553, DOI 10.1136/hrt.2003.032847
   van Wijk JPH, 2006, J AM COLL CARDIOL, V47, P1117, DOI 10.1016/j.jacc.2005.09.073
NR 34
TC 13
Z9 14
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JAN
PY 2008
VL 24
IS 1
BP 27
EP 33
DI 10.1089/aid.2006.0281
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 254PH
UT WOS:000252598000005
PM 18275345
DA 2020-12-01
ER

PT J
AU Brennan, CA
   Brites, C
   Bodelle, P
   Golden, A
   Hackett, J
   Holzmayer, V
   Swanson, P
   Vallari, A
   Yamaguchi, J
   Devare, S
   Pedroso, C
   Ramos, A
   Badaro, R
AF Brennan, Catherine A.
   Brites, Carlos
   Bodelle, Pierre
   Golden, Alan
   Hackett, John, Jr.
   Holzmayer, Vera
   Swanson, Priscilla
   Vallari, Ana
   Yamaguchi, Julie
   Devare, Sushil
   Pedroso, Celia
   Ramos, Andre
   Badaro, Roberto
TI HIV-1 strains identified in Brazilian blood donors: Significant
   prevalence of B/F1 recombinants
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID SAO-PAULO; DRUG-RESISTANCE; INDIVIDUALS; GENE
AB In the Brazilian HIV-1 epidemic subtypes B, C, and F1 are cocirculating in the high risk population groups, and there is a high prevalence of intersubtype recombinant forms. The dynamic nature of the HIV epidemic in Brazil led us to study HIV-1 subtypes present in HIV-infected blood donations collected from 2001 to 2003. Donations from 91 seropositive donors were evaluated. Genetic subtype was obtained for 88 specimens based on sequence analysis of gag p24, pol IN, and env gp41 IDR. HIV-1 subtype B was the predominant strain present in the donor population (73.9%). A significant prevalence of intersubtype recombinants of subtypes B and F1 was found (22.7%). Subtype C (1.1%) and F1 (2.3%) were rare. None of the B/F1 recombinants is CRF28_BF or CRF29_BF. The high level of unique B/F1 recombinant strains in this population demonstrates the dynamic and complex nature of the HIV epidemic in Brazil.
C1 Abbott Diagnost, Abbott Pk, IL 60064 USA.
   Univ Fed Bahia, Fundacao Bahiana Infectol, BR-41170290 Salvador, BA, Brazil.
   Univ Calif San Diego, La Jolla, CA 92093 USA.
RP Brennan, CA (corresponding author), Abbott Diagnost, D-09NG,Bldg AP20,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.
EM catherine.brennan@abbott.com
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Barreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338
   Bello G, 2006, AIDS, V20, P763, DOI 10.1097/01.aids.0000216377.84313.52
   Brigido LFM, 2005, AIDS RES HUM RETROV, V21, P673, DOI 10.1089/aid.2005.21.673
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Couto-Fernandez JC, 1999, J ACQ IMMUN DEF SYND, V22, P288
   De Sa DJ, 2006, AIDS RES HUM RETROV, V22, P1
   FILHO DJD, 2005, AIDS RES HUM RETROV, V21, P145
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   Magiorkinis G, 2003, J GEN VIROL, V84, P2715, DOI 10.1099/vir.0.19180-0
   Quarleri JF, 2004, AIDS RES HUM RETROV, V20, P1100, DOI 10.1089/aid.2004.20.1100
   Rodrigues R, 2006, VIRUS RES, V116, P201, DOI 10.1016/j.virusres.2005.10.004
   Soares EAJM, 2003, JAIDS-J ACQ IMM DEF, V34, P520, DOI 10.1097/00126334-200312150-00012
   Swanson P, 2003, AIDS RES HUM RETROV, V19, P625, DOI 10.1089/088922203322231003
   Swanson P, 2006, J VIROL METHODS, V134, P237, DOI 10.1016/j.jviromet.2006.01.012
   Thomson MM, 2004, AIDS RES HUM RETROV, V20, P1126, DOI 10.1089/aid.2004.20.1126
   Turchi MD, 2002, J ACQ IMMUN DEF SYND, V30, P527, DOI 10.1097/00126334-200208150-00009
   VINCENTE ACP, 2000, J ACQ IMMUN DEF SYND, V23, P327
NR 17
TC 27
Z9 28
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV
PY 2007
VL 23
IS 11
BP 1434
EP 1441
DI 10.1089/aid.2007.0121
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 239SU
UT WOS:000251538800017
PM 18184087
DA 2020-12-01
ER

PT J
AU Lemos, ACM
   Coelho, JC
   Matos, ED
   Montal, G
   Aguiar, F
   Badaro, R
AF Moreira Lemos, Antonio Carlos
   Coelho, Joao Carlos
   Matos, Eliana Dias
   Montal, Guilherme
   Aguiar, Fernanda
   Badaro, Roberto
TI Paragonimiasis: First case reported in brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE paragonimiasis; tuberculosis; respiratory insufficiency; bronchiolitis
   Brazil; case report
ID DIAGNOSIS; PRAZIQUANTEL
AB The authors present a case from a 59 years old white female Brazilian patient, based in Salvador-Bahia, Brazil's northeastern side area, who experienced irritative cough and progressive dyspnea, and, after 18 months, was admitted to a hospital with respiratory insufficiency. The physical exam showed diffuse rales in both hemithoraces. Initial leukogram showed 14,400 cells/mu L with 14% of eosinophils and chest X-ray showed peribronchovascular infiltrate, predominating in the lower half of the lung fields, and small opaque nodules. The high-resolution computed tomography scan of the chest (HRCT) presented compatible pattern with airways disease, especially from the small airways, with air trapping, tree sprouting images, central lobular nodules and bronchiectasis, making the results compatible with bronchiolitis and bronchiectasis. The transbroncho biopsy unveiled granulomatous lesion with necrosis, where was noticed a structure compatible to a parasitic case, and the research of the parasite eggs in the sputum was positive to paragonimus. After the praziquantel use, the patient presented a thick ferruginous expectoration and the result for BAAR examination was positive. The PCR exam and the sputum culture confirmed M. tuberculosis, and then the treatment for M. tuberculosis was initiated. The authors warn that this infection may have been a consequence of economics globalization process, where the importation of parasitized crustaceans might be the cause. However, there is the need of an accurate examination for the possibility of paragonimus specimens in this area of Brazil.
C1 [Moreira Lemos, Antonio Carlos; Matos, Eliana Dias; Montal, Guilherme; Aguiar, Fernanda] Octavio Mangabeira Hosp, Salvador, BA, Brazil.
   [Moreira Lemos, Antonio Carlos; Badaro, Roberto] Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.
   [Coelho, Joao Carlos] Jose Silveia Fdn, Pathol Lab, Salvador, BA, Brazil.
   [Matos, Eliana Dias] Med Sch & Publ Hlth Bahia, Salvador, BA, Brazil.
   [Moreira Lemos, Antonio Carlos] Octavio Mangabeira Hosp, Ctr Pneumol Res, Salvador, BA, Brazil.
   [Montal, Guilherme; Aguiar, Fernanda] Cardio Pulmonar Inst, Salvador, BA, Brazil.
RP Lemos, ACM (corresponding author), NUPEP HEOM, S-N Pau Miudo, BR-40320350 Salvador, BA, Brazil.
EM acmlemos@uol.com.br
CR CALVOPINA H, 1994, ED MED CONTIN, V44, P17
   Choi D.W., 1990, Korean Journal of Parasitology, V28, P79, DOI 10.3347/kjp.1990.28.Suppl.79
   HARINASUTA T, 1993, INFECT DIS CLIN N AM, V7, P699
   IMAI J, 1987, T ROY SOC TROP MED H, V81, P3, DOI 10.1016/0035-9203(87)90267-7
   JOHNSON JR, 1982, CHEST, V82, P168, DOI 10.1378/chest.82.2.168
   JOHNSON R, 1980, AM REW RESP DIS, V128, P534
   JOHNSON RJ, 1985, REV INFECT DIS, V7, P200
   Kagawa F T, 1997, Semin Respir Infect, V12, P149
   KUSNER DJ, 1993, SEMIN NEUROL, V13, P201, DOI 10.1055/s-2008-1041126
   LEMOS A, 1990, JORNAL PNEUMOLOGIA
   MALEEWONG W, 1997, ASIAN J TROP MED PUB, V28, P134
   NANA A, 1991, SEMIN RESPIR MED, V12, P46, DOI 10.1055/s-2007-1006224
   PACHUCKI CT, 1984, NEW ENGL J MED, V311, P582, DOI 10.1056/NEJM198408303110906
   SWENSEN SJ, 1994, CHEST, V105, P49, DOI 10.1378/chest.105.1.49
NR 14
TC 8
Z9 9
U1 0
U2 2
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD FEB
PY 2007
VL 11
IS 1
BP 153
EP 156
DI 10.1590/S1413-86702007000100031
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA 274JM
UT WOS:000253997600031
PM 17625745
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Garcia, R
   Badaro, R
   Netto, EM
   Silva, M
   Amorin, FS
   Ramos, A
   Vaida, F
   Brites, C
   Schooley, RT
AF Garcia, Rosa
   Badaro, Roberto
   Netto, Eduardo M.
   Silva, Marcio
   Amorin, Fabio S.
   Ramos, Andre
   Vaida, Florin
   Brites, Carlos
   Schooley, Robert T.
TI Cross-sectional study to evaluate factors associated with adherence to
   antiretroviral therapy by Brazilian HIV-infected patients
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID SELF-REPORTED ADHERENCE; BARRIERS; REGIMENS; ADULTS; HAART; NAIVE
AB Antiretroviral therapy success is highly dependent on the ability of the patient to fully adhere to the prescribed treatment regimen. We present the results of a cross-sectional study that evaluates the predictive value of a self-administered questionnaire of adherence to antiretroviral (ARV) therapy. Study participants were interviewed using a 36-item Patient Medication Adherence Questionnaire (PMAQ) designed to assess knowledge about ARV therapy, motivation to adhere to treatment, and behavioral skills. Plasma HIV-1 RNA levels were correlated with the results obtained from the PMAQ. Of the 182 study participants, 82 (45%) were receiving their initial ARV regimen. Of the remaining patients, 39 (21%) and 61 (34%) were on a second or additional ARV regimen, respectively. An undetectable viral load was documented in 47/62 (76%) patients on their first regimen who reported missing medication on less than 4 days in the last 3 months. The PMAQ had a higher predictive value of plasma viral suppression for patients in the initial regimen than for patients in salvage therapy. The overall predictive value of the PMAQ to identify adherence was 74%, and 59% for nonadherence, with an overall efficacy of 64%. Of the 74 patients (45%) who did not understand the concept of antiretroviral therapy, 80% were failing or had previously failed the ARV treatment. Of 35 patients with doubts about their HIV status or skeptical of the benefits of ARV therapy, 29 (84%) were nonadherent. Despite the positive predictive value of PMAQ in identifying adherence, self-reported adherence is not a sufficiently precise predictor of treatment success to substitute for viral load monitoring. On the other hand, the use of such an instrument to identify factors associated with nonadherence provides an excellent opportunity to apply early intervention designed to specifically address factors that might be contributing to the lack of adherence prior to regimen failure.
C1 Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil.
   Univ Calif San Diego, La Jolla, CA 92093 USA.
RP Schooley, RT (corresponding author), Stein Clin Res Bldg,9500 Gilman Dr, La Jolla, CA 92093 USA.
EM rschooley@ucsd.edu
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991
CR Arnsten JH, 2001, CLIN INFECT DIS, V33, P1417, DOI 10.1086/323201
   Catz SL, 2002, BEHAV MED, V28, P53, DOI 10.1080/08964280209596398
   Chesney MA, 2000, CLIN INFECT DIS, V30, pS171, DOI 10.1086/313849
   Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891
   Duong M, 2004, HIV CLIN TRIALS, V5, P216, DOI 10.1310/NXJU-9ERQ-ADWW-UC5X
   Duong M, 2001, HIV Clin Trials, V2, P128
   Duong M, 2001, CLIN INFECT DIS, V33, P386, DOI 10.1086/321876
   Ferguson TF, 2002, AIDS CARE, V14, P607, DOI 10.1080/0954012021000005434
   Garcia Rosa, 2003, Braz J Infect Dis, V7, P307, DOI 10.1590/S1413-86702003000500005
   Gifford AL, 2000, J ACQ IMMUN DEF SYND, V23, P386
   Haubrich RH, 1999, AIDS, V13, P1099, DOI 10.1097/00002030-199906180-00014
   Kirkland LR, 2002, CLIN INFECT DIS, V34, P511, DOI 10.1086/338400
   Laniece I, 2003, AIDS, V17, pS103, DOI 10.1097/00002030-200317003-00014
   Loo VS, 2004, AIDS CARE, V16, P834, DOI 10.1080/09540120412331290121
   Moatti JP, 2000, REV EPIDEMIOL SANTE, V48, P182
   Nachega JB, 2004, AIDS RES HUM RETROV, V20, P1053, DOI 10.1089/aid.2004.20.1053
   Nemes MIB, 2004, AIDS, V18, pS15, DOI 10.1097/00002030-200406003-00004
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   Rabkin J G, 1998, GMHC Treat Issues, V12, P8
   Reynolds NR, 2004, AIDS BEHAV, V8, P141, DOI 10.1023/B:AIBE.0000030245.52406.bb
   Smith SR, 2003, PATIENT EDUC COUNS, V50, P187
   Spire B, 2002, SOC SCI MED, V54, P1481, DOI 10.1016/S0277-9536(01)00125-3
   Stout BD, 2004, AIDS PATIENT CARE ST, V18, P297, DOI 10.1089/108729104323076034
   Weiser S, 2003, JAIDS-J ACQ IMM DEF, V34, P281, DOI 10.1097/00126334-200311010-00004
NR 25
TC 14
Z9 16
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD DEC
PY 2006
VL 22
IS 12
BP 1248
EP 1252
DI 10.1089/aid.2006.22.1248
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 124VO
UT WOS:000243398800007
PM 17209767
DA 2020-12-01
ER

PT J
AU Badaro, R
   Lobo, I
   Munos, A
   Netto, EM
   Modabber, F
   Campos-Neto, A
   Coler, RN
   Reed, SG
AF Badaro, Roberto
   Lobo, Iza
   Munos, Alvaro
   Netto, Eduardo M.
   Modabber, Farrokh
   Campos-Neto, Antonio
   Coler, Rhea N.
   Reed, Steven G.
TI Immunotherapy for drug-refractory mucosal leishmaniasis
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 3rd World Congress on Leishmaniasis
CY APR 10-15, 2005
CL Palermo, ITALY
ID COLONY-STIMULATING FACTOR; AMERICAN CUTANEOUS LEISHMANIASIS;
   LINKED-IMMUNOSORBENT-ASSAY; VISCERAL LEISHMANIASIS; IMMUNE-RESPONSES;
   CYTOKINE PROFILE; RHGM-CSF; T-CELL; VACCINE; PROTEIN
AB Background. Pentavalent antimony (Sb-v) the mainstay therapy for mucosal leishmaniasis (ML), but it is toxic, and relapses are common. Immunotherapy using a mixture of killed parasites, with or without bacille Calmette-Guerin, is an alternative but is used sporadically because of inconsistent results.
   Methods. We developed a defined immunotherapeutic antigen preparation for use in an observational, open-label trial to treat 6 patients with ML with a history of Sb-v therapy failure. All patients were treated with the antigens thiol-specific antioxidant, Leishmania major stress inducible protein 1, Leishmania elongation initiation factor, and Leishmania heat shock protein 83, plus granulocyte-macrophage colony-stimulating factor. Patients underwent clinical and pathological evaluations before the initiation of immunotherapy and at 3, 6, 9, 12, 18, 24, and 60 months after.
   Results. One month after the third injection, 1 patient showed complete clinical remission (CC) and remained disease free for the duration of the study. At the 9-month follow-up examination, 5 patients showed CC, and all patients were asymptomatic at a subsequent 5-year follow-up examination.
   Conclusions. These data support the concept that vaccine therapy with a defined antigen combination, used with standard chemotherapy, is a safe and effective approach to treat drug-refractory ML.
C1 Infect Dis Res Inst, Seattle, WA 98104 USA.
   Forsyth Inst, Boston, MA USA.
   Univ Calif San Diego, San Diego, CA 92103 USA.
   Drugs Neglected Dis Initiat, Geneva, Switzerland.
   Univ Fed Bahia, Salvador, BA, Brazil.
RP Reed, SG (corresponding author), Infect Dis Res Inst, 1124 Columbia St,Suite 400, Seattle, WA 98104 USA.
EM sreed@idri.org
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R44AI036810, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R43AI036810, R44AI036810, R01AI025038] Funding Source: NIH
   RePORTER; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [AI25038, AI36810] Funding
   Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [GM08347] Funding Source: Medline
CR Almeida R, 1999, J INFECT DIS, V180, P1735, DOI 10.1086/315082
   Almeida RP, 2005, AM J TROP MED HYG, V73, P79, DOI 10.4269/ajtmh.2005.73.79
   BADARO R, 1994, EUR J CLIN MICROBIOL, V13, pS23, DOI 10.1007/BF01973598
   Badaro R, 2001, Braz J Infect Dis, V5, P223
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BADARO R, 1994, J INFECT DIS, V170, P413, DOI 10.1093/infdis/170.2.413
   Berman JD, 1996, CLIN DERMATOL, V14, P519, DOI 10.1016/0738-081X(96)00048-X
   BOENTE P, 1993, LANCET, V341, P1154, DOI 10.1016/0140-6736(93)93174-Y
   Campos-Neto A, 2002, INFECT IMMUN, V70, P2828, DOI 10.1128/IAI.70.6.2828-2836.2002
   Campos-Neto A, 2001, INFECT IMMUN, V69, P4103, DOI 10.1128/IAI.69.6.4103-4108.2001
   CARONIA G, 1916, PEDIATRIA, V24, P64
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   Coler RN, 2005, TRENDS PARASITOL, V21, P244, DOI 10.1016/j.pt.2005.03.006
   Coler RN, 2002, INFECT IMMUN, V70, P4215, DOI 10.1128/IAI.70.8.4215-4225.2002
   CONVIT J, 1989, J INFECT DIS, V160, P104, DOI 10.1093/infdis/160.1.104
   Convit J, 2003, T ROY SOC TROP MED H, V97, P469, DOI 10.1016/S0035-9203(03)90093-9
   CONVIT J, 1987, LANCET, V1, P401
   Di Giorgio C, 1999, J ANTIMICROB CHEMOTH, V44, P71, DOI 10.1093/jac/44.1.71
   Follador I, 2002, VACCINE, V20, P1365, DOI 10.1016/S0264-410X(01)00469-8
   Genaro O, 1996, CLIN DERMATOL, V14, P503, DOI 10.1016/0738-081X(96)00040-5
   HANDMAN E, 1979, J IMMUNOL, V122, P1134
   JONES T, 1994, EUR J CLIN MICROBIOL, V13, pS47, DOI 10.1007/BF01973602
   KADARO AY, 1993, AM J TROP MED HYG, V48, P44, DOI 10.4269/ajtmh.1993.48.44
   Machado-Pinto J, 2002, INT J DERMATOL, V41, P73, DOI 10.1046/j.1365-4362.2002.01336.x
   MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9
   Mayrink W., 1992, Parassitologia (Rome), V34, P159
   Netto E M, 1989, Rev Soc Bras Med Trop, V22, P105, DOI 10.1590/S0037-86821989000200011
   PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341
   Probst P, 1997, EUR J IMMUNOL, V27, P2634, DOI 10.1002/eji.1830271024
   REED SG, 1993, CURR OPIN IMMUNOL, V5, P524, DOI 10.1016/0952-7915(93)90033-O
   ROBSON M, 1994, EUR J CLIN MICROBIOL, V13, pS41, DOI 10.1007/BF01973601
   ROCHA RAA, 1980, J TROP MED HYG, V83, P131
   Row R, 1912, BRIT MED J, V1912, P540, DOI 10.1136/bmj.1.2671.540
   SAMPAIO RNR, 1985, LANCET, V1, P1096
   SKEIKY YAW, 1995, J EXP MED, V181, P1527, DOI 10.1084/jem.181.4.1527
   SKEIKY YAW, 1995, INFECT IMMUN, V63, P4105, DOI 10.1128/IAI.63.10.4105-4114.1995
   Skeiky YAW, 1998, J IMMUNOL, V161, P6171
   Skeiky YAW, 2002, VACCINE, V20, P3292, DOI 10.1016/S0264-410X(02)00302-X
   Skeiky YAW, 1997, INFECT IMMUN, V65, P5368, DOI 10.1128/IAI.65.12.5368-5370.1997
   Soto J, 2004, CLIN INFECT DIS, V38, P1266, DOI 10.1086/383321
   Tarr PE, 1996, VACCINE, V14, P1199, DOI 10.1016/S0264-410X(96)00031-X
   Webb JR, 1996, J IMMUNOL, V157, P5034
   Webb JR, 1998, INFECT IMMUN, V66, P3279, DOI 10.1128/IAI.66.7.3279-3289.1998
   Webb JR, 1997, MOL BIOCHEM PARASIT, V89, P179, DOI 10.1016/S0166-6851(97)00115-1
   Zijlstra EE, 1998, CLIN DIAGN LAB IMMUN, V5, P717, DOI 10.1128/CDLI.5.5.717-720.1998
NR 45
TC 42
Z9 44
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT 15
PY 2006
VL 194
IS 8
BP 1151
EP 1159
DI 10.1086/507708
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 084QC
UT WOS:000240548500017
PM 16991091
OA Bronze
DA 2020-12-01
ER

PT J
AU Lobo, IMF
   Soares, MBP
   Correia, TM
   de Freitas, LAR
   Oliveira, MI
   Nakatani, M
   Netto, E
   Badaro, R
   David, JR
AF Lobo, Iza M. F.
   Soares, Milena B. P.
   Correia, Tania M.
   de Freitas, Luiz A. R.
   Oliveira, Maria Ines
   Nakatani, Maria
   Netto, Eduardo
   Badaro, Roberto
   David, John R.
TI Heat therapy for cutaneous leishmaniasis elicits a systemic cytokine
   response similar to that of antimonial (Glucantime) therapy
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE leishmaniasis; cutaneous leishmaniasis; heat therapy; cytokine; Brazil
ID MACROPHAGES INVITRO; PATTERNS; BRAZILIENSIS; PROFILE
AB Controlled heat delivered as radio waves has been used successfully in the treatment of cutaneous leishmaniasis (CL). Here we investigated whether local heat therapy has systemic effects, as measured by the modulation of cytokine production following heat therapy of CL lesions compared with antimonial (Glucantime) treatment. Patients with CL were randomly assigned into this study. Heat (50 degrees C for 30s) was applied once. The control group received Glucantime therapy for 20 d. Cytokine production by peripheral blood mononuclear cells was assayed on days 0, 14 and 28 after onset of treatment. At the end of 28 cl, 75% of lesions were heating or heated in the heat therapy group and 90% in the control group (P = 0.1261). There was a decrease in IFN-gamma, IL-5 and TNF-alpha levels comparing day 0 with day 28 in both groups, but no difference between the two therapy groups. In patients with only one of several lesions treated with heat therapy, the untreated lesions also heated. Local heat therapy in CL lesions leads to systemic cytokine responses similar to that induced by systemic Glucantime therapy. (C) 2005 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.
C1 Univ Fed Bahia, Salvador, BA, Brazil.
   Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
RP David, JR (corresponding author), 300 W 23rd St,Apt 13K, New York, NY 10011 USA.
EM jdavid@hsph.harvard.edu
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761; Soares, Milena/0000-0001-7549-2992
CR ARAM H, 1987, CUTIS, V40, P350
   ASHFORD DA, 1993, AM J TROP MED HYG, V48, P1
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   BERMAN JD, 1981, AM J TROP MED HYG, V30, P318, DOI 10.4269/ajtmh.1981.30.318
   Bomfim G, 1996, EXP PARASITOL, V84, P188, DOI 10.1006/expr.1996.0104
   CASTES M, 1988, J CLIN MICROBIOL, V26, P1207, DOI 10.1128/JCM.26.6.1207-1213.1988
   CONVIT J, 1987, LANCET, V1, P401
   Coutinho SG, 1998, BRAZ J MED BIOL RES, V31, P139, DOI 10.1590/S0100-879X1998000100019
   daCosta CA, 1996, MEM I OSWALDO CRUZ, V91, P193, DOI 10.1590/S0074-02761996000200013
   DASILVEIRA MR, 1950, O HOSP RIO DE JANEIR, V37, P637
   Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261
   JONES TC, 1987, J INFECT DIS, V156, P73, DOI 10.1093/infdis/156.1.73
   JUNAID AJN, 1986, INT J DERMATOL, V25, P470
   Marsden P. D., 1985, Revista da Sociedade Brasileira de Medicina Tropical, V18, P187, DOI 10.1590/S0037-86821985000300011
   MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9
   MELBY PC, 1989, J CLIN INVEST, V83, P1868, DOI 10.1172/JCI114093
   NAVIN TR, 1990, AM J TROP MED HYG, V42, P43, DOI 10.4269/ajtmh.1990.42.43
   NEVA FA, 1984, AM J TROP MED HYG, V33, P800, DOI 10.4269/ajtmh.1984.33.800
   Ribeiro-de-Jesus A, 1998, BRAZ J MED BIOL RES, V31, P143, DOI 10.1590/S0100-879X1998000100020
   SACKS DL, 1983, AM J TROP MED HYG, V32, P300, DOI 10.4269/ajtmh.1983.32.300
   Toledo VPCP, 2001, MEM I OSWALDO CRUZ, V96, P89, DOI 10.1590/S0074-02762001000100010
   VelascoCastrejon O, 1997, AM J TROP MED HYG, V57, P309, DOI 10.4269/ajtmh.1997.57.309
NR 22
TC 31
Z9 33
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0035-9203
EI 1878-3503
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD JUL
PY 2006
VL 100
IS 7
BP 642
EP 649
DI 10.1016/j.trstmh.2005.08.011
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 049IZ
UT WOS:000238011000007
PM 16274713
OA Green Published
DA 2020-12-01
ER

PT J
AU Netto, EM
   Takahashi, D
   de Oliveira, MD
   Barbosa, P
   Ferraz, N
   Paixao, A
   Oyafuso, LK
   Bortoletto, C
   Matos, D
   Paixao, M
   da Silva, AOP
   Badaro, R
AF Netto, Eduardo Martins
   Takahashi, Denise
   de Fatima Paim de Oliveira, Maria
   Barbosa, Paulo
   Ferraz, Neide
   Paixao, Ariene
   Oyafuso, Luiza Keiko
   Bortoletto, Cecilia
   Matos, Denise
   Paixao, Mauricio
   Pessoa da Silva, Anete Olivieri
   Badaro, Roberto
TI Phase II randomized, placebo-controlled trial of M-vaccae-derived
   protein (PVAC (R)) for the treatment of psoriasis
SO VACCINE
LA English
DT Article
DE plaque psoriasis; treatment; immunotherapy; PVAC; placebo
ID QUALITY-OF-LIFE; DEGLYCOLIPIDATED MYCOBACTERIUM-VACCAE; REGULATORY
   T-CELLS; IMMUNOTHERAPY; TUBERCULOSIS; LESIONS; BLOOD; PROLIFERATION;
   CHILDREN; CONTACT
AB The treatment effect against psoriasis of an antigen (delipidated, deglycolipidated form of M. vaccae-PVAC) was investigated. One hundred and sixty-five patients were enrolled in three arms (50 or 15 mu g or placebo), each receiving a total of two intradermal injections (days 0 and 21). At week 12, a 75% decrease in psoriasis area and severity index was similar among the studied groups (13, 9 and 18%, p=0.429). The overall incidence of adverse events was significantly higher in the PVAC treated groups when compared to placebo (98.2, 87.3 and 70.9%; p < 0.001) largely due to local reactions that were limited for the most part to grades I and 2 in severity and were self-limiting. Despite its overall safety, PVAC was not clearly indicated to be superior to placebo in the treatment of psoriasis in this study. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil.
   Univ Sao Paulo, Sao Paulo, Brazil.
   Univ Calif San Diego, San Diego, CA 92103 USA.
RP Netto, EM (corresponding author), Hosp Univ Prof Edgard Santos, Rua Joao das Botas,S-N-6o Andar Canela, BR-40110160 Salvador, BA, Brazil.
EM enetto@ufba.br
RI bortoletto, maria/AAE-4347-2020; Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761
CR Abbot NC, 2002, EUR J VASC ENDOVASC, V24, P202, DOI 10.1053/ejvs.2002.1716
   Almeida LMD, 2001, PEDIATR INFECT DIS J, V20, P1061, DOI 10.1097/00006454-200111000-00011
   Asadullah Khusru, 2004, Current Drug Targets - Inflammation and Allergy, V3, P185, DOI 10.2174/1568010043343886
   Austin LM, 1999, J INVEST DERMATOL, V113, P752, DOI 10.1046/j.1523-1747.1999.00749.x
   Balagon MV, 2001, CLIN EXP DERMATOL, V26, P233, DOI 10.1046/j.1365-2230.2001.00804.x
   BJERKE JR, 1978, J INVEST DERMATOL, V71, P340, DOI 10.1111/1523-1747.ep12529841
   Bos JD, 2006, LANCET, V367, P6, DOI 10.1016/S0140-6736(05)67818-X
   Bos JD, 2005, BRIT J DERMATOL, V152, P1098, DOI 10.1111/j.1365-2133.2005.06645.x
   Bos JD, 1999, IMMUNOL TODAY, V20, P40, DOI 10.1016/S0167-5699(98)01381-4
   Carruthers R, 1992, Aust Fam Physician, V21, P1625
   Chiaverini C, 1999, PRESSE MED, V28, P1266
   Choi J, 2003, J AM ACAD DERMATOL, V49, pS57, DOI 10.1016/S0190-9622(03)01136-8
   Dalbeth N, 2004, ANN RHEUM DIS, V63, P718, DOI 10.1136/ard.2003.007104
   de Albuquerque MDPM, 2004, J TROP PEDIATRICS, V50, P32, DOI 10.1093/tropej/50.1.32
   Feldman SR, 2003, J AM ACAD DERMATOL, V49, pS62, DOI 10.1016/S0190-9622(03)01137-X
   GANAPATI R, 1989, INT J LEPROSY, V57, P33
   Gottlieb Alice B, 2003, J Drugs Dermatol, V2, P260
   Gruber Franjor, 2004, Acta Dermatovenerol Croat, V12, P30
   Guilhou Jean-Jacques, 2002, Rev Prat, V52, P1861
   Koo J, 2004, J AM ACAD DERMATOL, V50, P613, DOI 10.1016/j.jaad.2003.11.046
   Koo John Y.M., 1999, Journal of Dermatology (Tokyo), V26, P723
   Langley RGB, 2005, ANN RHEUM DIS, V64, P18, DOI 10.1136/ard.2004.033217
   Lebwohl M, 2003, J AM ACAD DERMATOL, V49, pS118, DOI 10.1016/S0190-9622(03)01144-7
   Lehrer A, 1998, FEMS IMMUNOL MED MIC, V21, P71
   Leopold Claudia S, 2002, Curr Opin Investig Drugs, V3, P1604
   Marikovsky M, 1996, J INVEST DERMATOL, V106, P616, DOI 10.1111/1523-1747.ep12345413
   Menter MA, 2003, J AM ACAD DERMATOL, V49, pS39, DOI 10.1016/mjd.2003.545
   Nickoloff BJ, 2004, J CLIN INVEST, V113, P1664, DOI 10.1172/JCI200422147
   Ortonne JP, 2004, EUR J DERMATOL, V14, P41
   PAUKKONEN K, 1992, ARCH DERMATOL RES, V284, P375, DOI 10.1007/BF00372065
   Pietrzak Aldona, 2003, Ann Univ Mariae Curie Sklodowska Med, V58, P222
   RAMBUKKANA A, 1993, J INVEST DERMATOL, V100, P87, DOI 10.1111/1523-1747.ep12354979
   Rapp SR, 1999, J AM ACAD DERMATOL, V41, P401, DOI 10.1016/S0190-9622(99)70112-X
   Rotsztejn H, 2005, MED SCI MONITOR, V11, pCR594
   Schon MP, 2005, NEW ENGL J MED, V352, P1899, DOI 10.1056/NEJMra041320
   Stanford J, 2004, FRONT BIOSCI-LANDMRK, V9, P1701, DOI 10.2741/1292
   STANFORD JL, 1994, IMMUNOBIOLOGY, V191, P555, DOI 10.1016/S0171-2985(11)80462-6
   Sugiyama H, 2005, J IMMUNOL, V174, P164, DOI 10.4049/jimmunol.174.1.164
   Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040
NR 39
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUN 5
PY 2006
VL 24
IS 23
BP 5056
EP 5063
DI 10.1016/j.vaccine.2006.03.047
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 056XD
UT WOS:000238557500020
PM 16621200
OA Green Published
DA 2020-12-01
ER

PT J
AU Swanson, P
   Huang, SH
   Holzmayer, V
   Bodelle, P
   Yamaguchi, J
   Brennan, C
   Badaro, R
   Brites, C
   Abravaya, K
   Devare, SG
   Hackett, J
AF Swanson, Priscilla
   Huang, Shihai
   Holzmayer, Vera
   Bodelle, Pierre
   Yamaguchi, Julie
   Brennan, Catherine
   Badaro, Roberto
   Brites, Carlos
   Abravaya, Klara
   Devare, Sushil G.
   Hackett, John, Jr.
TI Performance of the automated Abbott RealTime (TM) HIV-1 assay on a
   genetically diverse panel of specimens from Brazil
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE real-time PCR; HIV quantitation; genetic diversity
ID IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL LOAD ASSAYS; REAL-TIME PCR;
   SUBTYPES A-G; GROUP-O; MOLECULAR CHARACTERIZATION; QUANTITATIVE
   DETECTION; SAO-PAULO; RNA; QUANTIFICATION
AB The combination of automated sample preparation and real-time RT-PCR for measurement of HIV-1 viral load has the potential to significantly enhance throughput, reduce operator-associated error, and increase assay sensitivity and dynamic range. In this study, RNA was extracted from the plasma of 91 HIV-1 seropositive Brazilian blood donors using the Abbott m2000sp (TM) automated sample preparation system. Viral loads measured using the RealTime (TM) HIV-1 (RealTime HIV-1) assay and the Abbott m2000rt (TM) instrument were compared to values obtained in the LCx((R)) HIV RNA quantitative assay. Subtype was determined for 89 of 91 specimens by sequence/phylogenetic analysis of three genomic regions: gag p24, pol integrase, and env gp41. The panel included 69 subtype B, I C, 2 F, and 17 recombinant strains. Eighty-seven specimens were quantified by both assays. Two specimens were quantified only in RealTime HIV-1. Two additional specimens below the detection limit of both assays were also negative on PCR amplification. Viral load results were highly correlated, and good agreement was observed between assays with 90% of values within 0.5 log(10) copies/ml. The RealTime HIV-1 assay and m2000 system offer the advantages of automation while providing reliable quantification of diverse HIV strains. (c) 2006 Elsevier B.V. All rights reserved.
C1 Abbott Labs, AIDS Res & Retrovirus Discovery, Abbott Pk, IL 60064 USA.
   Abbott Mol Inc, Des Plaines, IL USA.
   Univ Fed Bahia, Fdn Bahiana Infectol, BR-41170290 Salvador, BA, Brazil.
   Univ Calif San Diego, San Diego, CA 92103 USA.
RP Hackett, J (corresponding author), Abbott Labs, AIDS Res & Retrovirus Discovery, D-9NG,Bldg AP20,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.
EM john.hackett@abbott.com
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
CR Akouamba BS, 2005, EMERG INFECT DIS, V11, P1230, DOI 10.3201/eid1108.040877
   Barlow KL, 1997, J CLIN MICROBIOL, V35, P2846, DOI 10.1128/JCM.35.11.2846-2853.1997
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Brigido LFM, 2005, AIDS RES HUM RETROV, V21, P673, DOI 10.1089/aid.2005.21.673
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169
   Collins ML, 1997, NUCLEIC ACIDS RES, V25, P2979, DOI 10.1093/nar/25.15.2979
   de Mendoza C, 2005, J VIROL METHODS, V127, P54, DOI 10.1016/j.jviromet.2005.03.013
   de Mendoza C, 2002, J CLIN MICROBIOL, V40, P1518, DOI 10.1128/JCM.40.4.1518-1521.2002
   De Sa DJ, 2005, AIDS RES HUM RETROV, V21, P145, DOI 10.1089/aid.2005.21.145
   Dyer JR, 1999, J CLIN MICROBIOL, V37, P447, DOI 10.1128/JCM.37.2.447-449.1999
   Gardner SN, 2003, J CLIN MICROBIOL, V41, P2417, DOI 10.1128/JCM.41.6.2417-2427.2003
   Geelen S, 2003, AIDS, V17, P781, DOI 10.1097/00002030-200303280-00027
   GOTTESMAN B, 2005, C RETR OPP INF, P335
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   Hirigoyen DL, 2005, J CLIN MICROBIOL, V43, P5263, DOI 10.1128/JCM.43.10.5263-5271.2005
   Johanson J, 2001, J VIROL METHODS, V95, P81, DOI 10.1016/S0166-0934(01)00297-X
   Lot F, 2004, Euro Surveill, V9, P34
   Nye MB, 2005, J CLIN MICROBIOL, V43, P4968, DOI 10.1128/JCM.43.10.4968-4971.2005
   Osmanov S, 2002, J ACQ IMMUN DEF SYND, V29, P184, DOI 10.1097/00042560-200202010-00013
   Plantier JC, 2003, JAIDS-J ACQ IMM DEF, V33, P1, DOI 10.1097/00126334-200305010-00001
   Rouet F, 2005, J CLIN MICROBIOL, V43, P2709, DOI 10.1128/JCM.43.6.2709-2717.2005
   Soares EAJM, 2003, JAIDS-J ACQ IMM DEF, V34, P520, DOI 10.1097/00126334-200312150-00012
   Soares MA, 2003, AIDS, V17, P11, DOI 10.1097/00002030-200301030-00004
   Stevens W, 2005, J VIROL METHODS, V124, P105, DOI 10.1016/j.jviromet.2004.11.009
   Sun R, 1998, J CLIN MICROBIOL, V36, P2964, DOI 10.1128/JCM.36.10.2964-2969.1998
   Swanson P, 2000, J VIROL METHODS, V89, P97, DOI 10.1016/S0166-0934(00)00205-6
   Swanson P, 2005, J CLIN MICROBIOL, V43, P3860, DOI 10.1128/JCM.43.8.3860-3868.2005
   Swanson P, 2003, AIDS RES HUM RETROV, V19, P625, DOI 10.1089/088922203322231003
   Swanson P, 2001, J CLIN MICROBIOL, V39, P862, DOI 10.1128/JCM.39.3.862-870.2001
   Troonen H, 2002, CLIN CHEM LAB MED, V40, P698, DOI 10.1515/CCLM.2002.120
   Whiley DA, 2005, J CLIN VIROL, V34, P104, DOI 10.1016/j.jcv.2005.02.010
   Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01
   Yao J, 2005, J VIROL METHODS, V129, P40, DOI 10.1016/j.jviromet.2005.04.017
NR 34
TC 37
Z9 38
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD JUN
PY 2006
VL 134
IS 1-2
BP 237
EP 243
DI 10.1016/j.jviromet.2006.01.012
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 049GZ
UT WOS:000238005500033
PM 16510195
DA 2020-12-01
ER

PT J
AU Moraes-Silva, E
   Antunes, FR
   Rodrigues, MS
   Julido, FD
   Dias-Lima, AG
   Lemos-de-Sousa, V
   de Alcantara, AC
   Reis, EAG
   Nakatani, M
   Badaro, R
   Reis, MG
   Pontes-de-Carvalho, L
   Franke, CR
AF Moraes-Silva, Evandro
   Antunes, Fabiana Rodrigues
   Rodrigues, Marcio Silva
   da Silva Julido, Fred
   Gomes Dias-Lima, Artur
   Lemos-de-Sousa, Valderez
   Costa de Alcantara, Adriano
   Gomes Reis, Eliana Almeida
   Nakatani, Maria
   Badaro, Roberto
   Galvao Reis, Mitermayer
   Pontes-de-Carvalho, Lain
   Franke, Carlos Roberto
TI Domestic swine in a visceral leishmaniasis endemic area produce
   antibodies against multiple Leishmania infantum antigens but apparently
   resist to L-infantum infection
SO ACTA TROPICA
LA English
DT Article
DE visceral leishmaniasis; pig; immune response; experimental infection
ID LUTZOMYIA-LONGIPALPIS; RECOMBINANT ANTIGEN; CHAGASI; BAHIA; DONOVANI;
   CANINE; STATE; FOCUS
AB In order to investigate whether pigs can be infected by Leishmania infantum, a serological and parasitological study was carried out on swine in the Jequie municipality, Northeast of Brazil. Anti-Leishmania infantum antibodies were detected in 37 out of 92 swine (40.2%), by two different assays: an anti-L. infantum lysate and an anti-K39 recombinant protein ELISA. An experimental study was also carried out to verify the susceptibility of domestic pigs to L. infantum infection. Three sows inoculated with 10(8) stationary-phase infective L. infantum promastigotes (26% metacyclic promastigotes) per kilogram of body weight produced anti-Leishmania antibodies until the end of the experiment, 11 months later. No parasites, however, could be visualized through optical microscopy of spleen, liver and bone marrow or by in vitro culture of these organs. Homogenates of these organs were also inoculated in hamsters, without producing infection. No Leishmania DNA was detected by polymerase chain reaction (PCR) in sand flies fed on these animals. The results indicate that domestic pigs bitten by L. infantum-infected vectors in the endemic area do not display a full infection pattern, and the positive association in endemic areas between the presence of swine and infection in canines may not be ascribable to the former acting as a parasite reservoir. (c) 2006 Published by Elsevier B.V.
C1 Univ Fed Bahia, Escola Med Vet, Lab Infectol Vet, BR-40170110 Salvador, BA, Brazil.
   Fundacao Oswaldo Cruz, CPqGM, BR-40295001 Salvador, BA, Brazil.
   Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Lab Doencas Trop, BR-40110160 Salvador, BA, Brazil.
RP Franke, CR (corresponding author), Univ Fed Bahia, Escola Med Vet, Lab Infectol Vet, Av Adhemar Barros 500, BR-40170110 Salvador, BA, Brazil.
EM franke@ufba.br
RI Reis, Mitermayer/AAO-9742-2020; de Alcantara, Adriano Costa/A-6333-2011
OI Reis, Mitermayer/0000-0002-3051-9060; de Alcantara, Adriano
   Costa/0000-0003-0115-4987
CR Ashford DA, 1998, AM J TROP MED HYG, V59, P53, DOI 10.4269/ajtmh.1998.59.53
   Badaro R, 1996, J INFECT DIS, V173, P758, DOI 10.1093/infdis/173.3.758
   BRAZIL R P, 1987, Memorias do Instituto Oswaldo Cruz, V82, P145, DOI 10.1590/S0074-02761987000100025
   BURNS JM, 1993, P NATL ACAD SCI USA, V90, P775, DOI 10.1073/pnas.90.2.775
   CUNHA S, 1995, T ROY SOC TROP MED H, V89, P155, DOI 10.1016/0035-9203(95)90474-3
   DEANE LEONIDaS M., 1962, REV INST MED TROP SAO PAULO, V4, P198
   Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
   Dietze R, 1997, CLIN INFECT DIS, V25, P1240, DOI 10.1086/516096
   Ferro C, 1997, J MED ENTOMOL, V34, P719, DOI 10.1093/jmedent/34.6.719
   Franke CR, 2002, T ROY SOC TROP MED H, V96, P236, DOI 10.1016/S0035-9203(02)90087-8
   Frantz S, 2002, NAT MED, V8, P9, DOI 10.1038/nm0102-9a
   JERONIMO SMB, 1994, T ROY SOC TROP MED H, V88, P386, DOI 10.1016/0035-9203(94)90393-X
   KIRKPATRICK CE, 1984, EXP PARASITOL, V58, P125, DOI 10.1016/0014-4894(84)90027-4
   Lainson R., 1979, P1
   MATHIS A, 1995, J CLIN MICROBIOL, V33, P1145, DOI 10.1128/JCM.33.5.1145-1149.1995
   Mauricio IL, 1999, PARASITOLOGY, V119, P237, DOI 10.1017/S0031182099004710
   Moreira ED, 2003, AM J TROP MED HYG, V69, P393, DOI 10.4269/ajtmh.2003.69.393
   MORRISON AC, 1993, AM J TROP MED HYG, V49, P68, DOI 10.4269/ajtmh.1993.49.68
   Mukhtar MM, 2000, T ROY SOC TROP MED H, V94, P33, DOI 10.1016/S0035-9203(00)90429-2
   Nicolle C., 1908, Bulletin de la Societe de Pathologie Exotique Paris, V1
   Paranhos-Silva M, 2003, VET PARASITOL, V114, P97, DOI 10.1016/S0304-4017(03)00132-8
   Paranhos-Silva M, 1998, ACTA TROP, V69, P75, DOI 10.1016/S0001-706X(97)00116-2
   QU JQ, 1994, T ROY SOC TROP MED H, V88, P543, DOI 10.1016/0035-9203(94)90154-6
   REED SG, 1990, AM J TROP MED HYG, V43, P632, DOI 10.4269/ajtmh.1990.43.632
   Schubach A, 1998, J INFECT DIS, V178, P911, DOI 10.1086/515355
   Sherlock IA, 1996, MEM I OSWALDO CRUZ, V91, P671, DOI 10.1590/S0074-02761996000600003
   Singh S, 1995, J PARASITOL, V81, P1000, DOI 10.2307/3284056
   SOARES NM, 1993, PARASITOL RES, V79, P340, DOI 10.1007/BF00932193
   *WHO, 1992, INT CLASS DIS, P47
NR 29
TC 9
Z9 12
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0001-706X
EI 1873-6254
J9 ACTA TROP
JI Acta Trop.
PD MAY
PY 2006
VL 98
IS 2
BP 176
EP 182
DI 10.1016/j.actatropica.2006.04.002
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 055PB
UT WOS:000238461500009
PM 16730628
OA Green Published
DA 2020-12-01
ER

PT J
AU Mehta, S
   Xing-Quan, Z
   Spina, C
   Day, J
   Schooley, R
   Badaro, R
AF Mehta, Sanjay
   Xing-Quan, Zhang
   Spina, Celsa
   Day, John
   Schooley, Robert
   Badaro, Roberto
TI New tool for in vitro work on HIV and leishmania co-infection
   immunopathogenesis
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
C1 [Mehta, Sanjay; Xing-Quan, Zhang; Spina, Celsa; Day, John; Schooley, Robert] Univ Calif San Diego, San Diego, CA 92103 USA.
   [Badaro, Roberto] Univ Fed Bahia, Salvador, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2005
VL 73
IS 6
SU S
MA 1099
BP 363
EP 363
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA V44GA
UT WOS:000202990001522
DA 2020-12-01
ER

PT J
AU dos-Santos, WLC
   David, J
   Badaro, R
   de-Freitas, LAR
AF dos-Santos, WLC
   David, J
   Badaro, R
   de-Freitas, LAR
TI Association between skin parasitism and a granulomatous inflammatory
   pattern in canine visceral leishmaniosis
SO PARASITOLOGY RESEARCH
LA English
DT Article
ID CUTANEOUS LEISHMANIASIS; IFN-GAMMA; INFECTION; INFANTUM; DOGS; SEROLOGY;
   LESIONS; CHAGASI; BRAZIL; IMMUNE
AB In this work we examined 76 stray dogs from an area of endemic visceral leishmaniosis, in order to determine whether the presence of skin inflammation or a specific inflammatory pattern could be taken as indicative of infection with Leishmania chagasi, and whether the parasite burden in the skin could be associated with the intensity or the nature of the inflammatory process. Inflammatory infiltrates were observed in the skin of 51 out of 55 animals with diagnosis of leishmaniosis, and in 17 out of 21 animals without signs of infection. Amastigotes were identified in the skin of 29 out of the 55 animals with diagnosis of leishmaniosis. Granuloma and a monomorphic macrophage inflammatory infiltrate, and not a mixed focal or mixed diffuse inflammation, were significantly associated with skin parasitism, both in terms of frequency (P=0.015 in the Chi-square test) and intensity (P=0.005 in the Kruskal-Wallis test). A low parasite burden was associated with a multifocal inflammatory pattern.
C1 Fdn Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, BR-40295001 Salvador, BA, Brazil.
   Escola Bahiana Med & Saude Publ, BR-40290000 Salvador, BA, Brazil.
   Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
   Univ Fed Bahia, Fac Med, Salvador, BA, Brazil.
RP dos-Santos, WLC (corresponding author), Fdn Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Rua Valdemar Falcao 121, BR-40295001 Salvador, BA, Brazil.
EM wluis@cpqgm.fiocruz.br
RI DOS-SANTOS, WASHINGTON/B-4173-2009
OI DOS-SANTOS, WASHINGTON/0000-0003-1445-2318
CR Amato VS, 2003, ACTA TROP, V85, P39, DOI 10.1016/S0001-706X(02)00260-7
   Anstead GM, 2001, INFECT IMMUN, V69, P4709, DOI 10.1128/IAI.69.8.4709-4718.2001
   ASHFORD DA, 1993, AM J TROP MED HYG, V48, P1
   ASHFORD DA, 1995, AM J TROP MED HYG, V53, P251, DOI 10.4269/ajtmh.1995.53.251
   BARBOSA AA, 1987, BRAZ J MED BIOL RES, V20, P63
   BARRALNETTO M, 1995, EUR J DERMATOL, V5, P104
   BERTHO AL, 1994, J PARASITOL, V80, P93, DOI 10.2307/3283351
   BITTENCOURT AL, 1995, TROPICAL PATHOLOGY, P597
   CHENSUE SW, 1995, J IMMUNOL, V154, P5969
   de Souza VL, 2000, MICROBES INFECT, V2, P1807, DOI 10.1016/S1286-4579(00)01340-X
   Deane LM, 1955, HOSPITAL, V47, P75
   Dye C, 1996, AM J TROP MED HYG, V55, P125, DOI 10.4269/ajtmh.1996.55.125
   Enserink M, 2000, SCIENCE, V290, P1881, DOI 10.1126/science.290.5498.1881
   FERRER L, 1988, J SMALL ANIM PRACT, V29, P381, DOI 10.1111/j.1748-5827.1988.tb02298.x
   Fondevila D, 1997, VET IMMUNOL IMMUNOP, V56, P319, DOI 10.1016/S0165-2427(96)05755-8
   Glantz S, 1997, PRIMER BIOSTATISTICS, P473
   Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2
   Liarte D B, 2001, Rev Soc Bras Med Trop, V34, P577, DOI 10.1590/S0037-86822001000600013
   Mariano M., 1995, Revista do Instituto de Medicina Tropical de Sao Paulo, V37, P161, DOI 10.1590/S0036-46651995000200012
   MARTINEZMORENO A, 1995, VET IMMUNOL IMMUNOP, V48, P209, DOI 10.1016/0165-2427(95)05434-8
   Mauricio IL, 2000, PARASITOL TODAY, V16, P188, DOI 10.1016/S0169-4758(00)01637-9
   Mozos E, 1999, J COMP PATHOL, V120, P257, DOI 10.1053/jcpa.1998.0273
   OLIVEIRA GGS, 1993, MEM I OSWALDO CRUZ, V88, P243, DOI 10.1590/S0074-02761993000200011
   Pontes-de-Carvalho L, 2002, J AUTOIMMUN, V18, P131, DOI 10.1006/jaut.2001.0574
   Postigo C, 1997, J INFECTION, V35, P265, DOI 10.1016/S0163-4453(97)93080-2
   PRATS N, 1995, VET REC, V134, P103
   Silva ES, 2001, MEM I OSWALDO CRUZ, V96, P285, DOI 10.1590/S0074-02762001000300002
   Solano-Gallego L, 2001, J CLIN MICROBIOL, V39, P560, DOI 10.1128/JCM.39.2.560-563.2001
   SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143
   Sulahian A, 1997, FEMS IMMUNOL MED MIC, V17, P131, DOI 10.1111/j.1574-695X.1997.tb01005.x
   Tafuri WL, 2001, VET PARASITOL, V96, P203, DOI 10.1016/S0304-4017(00)00436-2
   Tarantino C, 2001, VET PARASITOL, V102, P77, DOI 10.1016/S0304-4017(01)00518-0
   Travi BL, 2001, AM J TROP MED HYG, V64, P119, DOI 10.4269/ajtmh.2001.64.119
   Wilson ME, 1996, J IMMUNOL, V156, P2231
NR 34
TC 30
Z9 31
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0932-0113
EI 1432-1955
J9 PARASITOL RES
JI Parasitol. Res.
PD JAN
PY 2004
VL 92
IS 2
BP 89
EP 94
DI 10.1007/s00436-003-1016-1
PG 6
WC Parasitology
SC Parasitology
GA 767FM
UT WOS:000188429600001
PM 14610666
OA Green Published
DA 2020-12-01
ER

PT J
AU Olivier, M
   Badaro, R
   Medrano, FJ
   Moreno, J
AF Olivier, M
   Badaro, R
   Medrano, FJ
   Moreno, J
TI The pathogenesis of Leishmania/HIV co-infection: cellular and
   immunological mechanisms
SO ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; LONG TERMINAL
   REPEAT; NF-KAPPA-B; EXPERIMENTAL VISCERAL LEISHMANIASIS;
   GROWTH-FACTOR-BETA; HUMAN CUTANEOUS LEISHMANIASIS; AZAR DERMAL
   LEISHMANIASIS; HIV-INFECTED INDIVIDUALS; PROTEIN-KINASE-C
AB The intracellular protozoan parasites of the genus Leishmania have been recognized as opportunistic pathogens in immunosuppressed individuals, including those infected with human immunodeficiency virus type-1 (HIV-1). Leishmaniasis and AIDS overlap in several sub-tropical and tropical regions around the world, including the Mediterranean area. In 1994, 3%-7% of HIV-1-infected individuals in southern Europe developed visceral leishmaniasis. In humans, interestingly, both HIV-1 and Leishmania interact with, invade, and multiply within cells of myeloid or lymphoid origin. The combined modulation of Leishmania- and HIV-1-related pathogenesis in the co-infected cases is therefore probably a realistic goal. In the light of the recent demonstration that L. donovani can up-regulate HIV-1 replication, both in monocytoid and lymphoid cells in vitro and in co-infected individuals, it is clear from the epidemiological data available that Leishmania can probably act as a powerful co-factor in the pathogenesis of HIV-1 infection. In those who are co-infected, complex mechanisms involving cytokine secretion and cellular-signalling events play pivotal roles in the Leishmania-mediated activation and pathogenesis of HIV-1. An overview of the recent findings concerning this Leishmania/HIV-1 interaction is presented here.
C1 McGill Univ, Fac Med, Montreal, PQ H3A 2B4, Canada.
   Univ Fed Bahia, Dept Med, BR-40050420 Salvador, BA, Brazil.
   Hosp Univ Virgen del Rocio, Dept Internal Med, Viral Hepatitis & AIDS Study Grp, Seville 41013, Spain.
   Inst Salud Carlos III, WHO Collaborating Ctr Leishmaniasis, Serv Parasitol, Ctr Nacl Microbiol, Madrid 28220, Spain.
RP Olivier, M (corresponding author), McGill Univ, Fac Med, Lyman Duff Med Bldg,3775 Univ St, Montreal, PQ H3A 2B4, Canada.
EM martin.olivier@mcgill.ca
RI Medrano, FJ/V-1091-2019; IBIS, EPIDEMIOLOGIA/O-8791-2015
OI Medrano, FJ/0000-0001-5863-344X; 
CR ABEL PM, 1992, FEMS MICROBIOL IMMUN, V105, P317
   ALVAR J, 1994, PARASITOL TODAY, V10, P160, DOI 10.1016/0169-4758(94)90270-4
   ALVAR J, 1987, EUR J CLIN MICROBIOL, V6, P604, DOI 10.1007/BF02014266
   AUKRUST P, 1994, J INFECT DIS, V169, P420, DOI 10.1093/infdis/169.2.420
   BADARO R, 1986, LANCET, V1, P647
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   BADARO R, 1997, BRAZ J INFECT DIS, V1, P145
   Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968
   BARRAL A, 1993, P NATL ACAD SCI USA, V90, P3442, DOI 10.1073/pnas.90.8.3442
   BARRALNETTO M, 1995, EUR J DERMATOL, V5, P104
   BARRALNETTO M, 1991, J INFECT DIS, V163, P853, DOI 10.1093/infdis/163.4.853
   Bernier R, 1998, J IMMUNOL, V160, P2881
   BERNIER R, 1995, J VIROL, V69, P7282, DOI 10.1128/JVI.69.11.7282-7285.1995
   BIGGAR RJ, 1987, NEW ENGL J MED, V316, P630, DOI 10.1056/NEJM198703053161015
   BORTHWICK NJ, 1994, AIDS, V8, P431, DOI 10.1097/00002030-199404000-00004
   Cacopardo B, 1996, T ROY SOC TROP MED H, V90, P434, DOI 10.1016/S0035-9203(96)90538-6
   CARVALHO EM, 1981, INFECT IMMUN, V33, P498, DOI 10.1128/IAI.33.2.498-500.1981
   CENINI P, 1994, J INFECT DIS, V169, P707, DOI 10.1093/infdis/169.3.707
   CENINI P, 1993, J INFECT DIS, V168, P986, DOI 10.1093/infdis/168.4.986
   CHAMOT E, 1990, AIDS, V4, P1275, DOI 10.1097/00002030-199012000-00016
   CHEHIMI J, 1994, J EXP MED, V179, P1361, DOI 10.1084/jem.179.4.1361
   CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376
   CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294
   Coutinho SG, 1996, MEM I OSWALDO CRUZ, V91, P381, DOI 10.1590/S0074-02761996000300024
   DACRUZ AM, 1994, INFECT IMMUN, V62, P2614, DOI 10.1128/IAI.62.6.2614-2618.1994
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   DEMARTINI RM, 1988, CLIN IMMUNOL IMMUNOP, V46, P258, DOI 10.1016/0090-1229(88)90188-2
   Desjeux P, 2003, ANN TROP MED PARASIT, V97, P3, DOI 10.1179/000349803225002499
   DESOUZA E, 1998, J EUROPEAN ACAD DERM, V10, P214
   DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974
   Dumais N, 1998, J BIOL CHEM, V273, P27306, DOI 10.1074/jbc.273.42.27306
   EASTERBROOK MD, 1995, J ACQ IMMUN DEF SYND, V10, P496, DOI 10.1097/00042560-199510050-00002
   FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274
   Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0
   FAUCI AS, 1988, HUMAN RETROVIRUSES C, P187
   FILLOLA G, 1992, J CLIN MICROBIOL, V30, P3284, DOI 10.1128/JCM.30.12.3284-3285.1992
   FOLEY P, 1992, IMMUNOLOGY, V75, P391
   FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729
   Frank Y, 1998, NEUROLOGY, V51, P915, DOI 10.1212/WNL.51.3.915
   FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x
   GAZZINELLI RT, 1995, J IMMUNOL, V155, P1565
   GRADONI L, 1994, PARASITOL TODAY, V10, P264, DOI 10.1016/0169-4758(94)90142-2
   GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143
   HALDAR JP, 1983, INFECT IMMUN, V42, P702, DOI 10.1128/IAI.42.2.702-707.1983
   HANDMAN E, 1986, J IMMUNOL, V137, P3608
   Haug CJ, 1996, J INFECT DIS, V173, P259, DOI 10.1093/infdis/173.1.259
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   JANOSSY G, 1993, AIDS, V7, P613, DOI 10.1097/00002030-199305000-00002
   JEANNEL D, 1989, LANCET, V2, P804, DOI 10.1016/S0140-6736(89)90868-4
   JERONIMO SMB, 1994, T ROY SOC TROP MED H, V88, P386, DOI 10.1016/0035-9203(94)90393-X
   Jimenez M. I., 1991, Research and Reviews in Parasitology, V51, P95
   Jimenez MI, 1996, LANCET, V347, P264, DOI 10.1016/S0140-6736(96)90441-9
   KEKOW J, 1990, P NATL ACAD SCI USA, V87, P8321, DOI 10.1073/pnas.87.21.8321
   KEMP M, 1993, INFECT IMMUN, V61, P1069, DOI 10.1128/IAI.61.3.1069-1073.1993
   KEMP M, 1994, CLIN EXP IMMUNOL, V96, P410, DOI 10.1111/j.1365-2249.1994.tb06043.x
   KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660
   Klein SA, 1997, AIDS, V11, P1111, DOI 10.1097/00002030-199709000-00005
   Kubar J, 1998, AIDS, V12, P2147, DOI 10.1097/00002030-199816000-00009
   LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993
   LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203
   LIEW FY, 1993, ADV PARASIT, V32, P161, DOI 10.1016/S0065-308X(08)60208-0
   MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142
   Mansfield John M., 2002, P379
   MARTINEZ P, 1993, AIDS, V7, P227, DOI 10.1097/00002030-199302000-00011
   MARTY P, 1994, T ROY SOC TROP MED H, V88, P33, DOI 10.1016/0035-9203(94)90485-5
   MARY C, 1992, AM J TROP MED HYG, V47, P764, DOI 10.4269/ajtmh.1992.47.764
   Matte C, 2001, PARASITE IMMUNOL, V23, P177, DOI 10.1046/j.1365-3024.2001.00372.x
   MCDOUGAL JS, 1986, J IMMUNOL, V137, P2937
   MEDRANO FJ, 1992, AIDS, V6, P1499, DOI 10.1097/00002030-199212000-00013
   Medrano FJ, 1998, AIDS RES HUM RETROV, V14, P835, DOI 10.1089/aid.1998.14.835
   MEDRANO FJ, 1998, CLIN EXPT IMMUNOLOGY, V114, P733
   MELBYE M, 1986, ANN INTERN MED, V104, P496, DOI 10.7326/0003-4819-104-4-496
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   MELLORS JW, 1991, J INFECT DIS, V163, P78, DOI 10.1093/infdis/163.1.78
   Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003
   MELTZER MS, 1990, ANNU REV IMMUNOL, V8, P169, DOI 10.1146/annurev.iy.08.040190.001125
   MIRALLES GD, 1994, INFECT IMMUN, V62, P1058, DOI 10.1128/IAI.62.3.1058-1063.1994
   Moreno-Camacho A, 1998, Enferm Infecc Microbiol Clin, V16 Suppl 1, P52
   MORRIS AC, 1989, MED VET ENTOMOL, V3, P1, DOI 10.1111/j.1365-2915.1989.tb00467.x
   MunozRodriguez FJ, 1997, EUR J CLIN MICROBIOL, V16, P246, DOI 10.1007/BF01709591
   MURRAY HW, 1992, J IMMUNOL, V148, P1858
   MURRAY HW, 1989, J CLIN INVEST, V83, P1253, DOI 10.1172/JCI114009
   Nabors GS, 1996, J INFECT DIS, V173, P979, DOI 10.1093/infdis/173.4.979
   Nigro L, 1999, AM J TROP MED HYG, V60, P142, DOI 10.4269/ajtmh.1999.60.142
   Olivier M, 1996, PARASITOL TODAY, V12, P145, DOI 10.1016/0169-4758(96)10006-5
   Olivier M, 1998, J BIOL CHEM, V273, P13944, DOI 10.1074/jbc.273.22.13944
   OLIVIER M, 1992, P NATL ACAD SCI USA, V89, P7481, DOI 10.1073/pnas.89.16.7481
   OLIVIER M, 1992, J IMMUNOL, V148, P1188
   PANTALEO G, 1994, IMMUNOL REV, V140, P105, DOI 10.1111/j.1600-065X.1994.tb00867.x
   PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341
   POLI G, 1991, J EXP MED, V173, P589, DOI 10.1084/jem.173.3.589
   POMERANTZ RJ, 1990, J EXP MED, V172, P253, DOI 10.1084/jem.172.1.253
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   Preiser W, 1996, INTERVIROLOGY, V39, P285, DOI 10.1159/000150531
   REED SG, 1993, CURR OPIN IMMUNOL, V5, P524, DOI 10.1016/0952-7915(93)90033-O
   REINER NE, 1984, CELL IMMUNOL, V88, P501, DOI 10.1016/0008-8749(84)90181-3
   REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055
   Russo R, 1996, J INFECTION, V32, P133, DOI 10.1016/S0163-4453(96)91343-2
   SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337
   SCOTT P, 1991, J IMMUNOL, V147, P3149
   Sebastian JJ, 1997, J CLIN GASTROENTEROL, V25, P691, DOI 10.1097/00004836-199712000-00029
   Tremblay M, 1996, PARASITOL TODAY, V12, P257, DOI 10.1016/0169-4758(96)10021-1
   Turco SJ, 1999, PARASITE IMMUNOL, V21, P597, DOI 10.1046/j.1365-3024.1999.00266.x
   Vazquez-Pineiro T, 1998, ORAL SURG ORAL MED O, V86, P179, DOI 10.1016/S1079-2104(98)90122-6
   Weissman D, 1997, CLIN MICROBIOL REV, V10, P358, DOI 10.1128/CMR.10.2.358
   *WHO, 1997, WKLY EPIDEMIOL REC, V72, P49
   Wolday D, 1998, SCAND J INFECT DIS, V30, P29, DOI 10.1080/003655498750002268
   Zaitseva MB, 1998, J IMMUNOL, V161, P3103
   ZHANG YH, 1995, J CLIN INVEST, V95, P2324, DOI 10.1172/JCI117924
   ZIJLSTRA EE, 1994, AM J TROP MED HYG, V51, P826, DOI 10.4269/ajtmh.1994.51.826
   ZUMLA A, 1992, PARASITOLOGY, V105, pS93, DOI 10.1017/S0031182000075405
NR 113
TC 39
Z9 41
U1 0
U2 5
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 0003-4983
EI 1364-8594
J9 ANN TROP MED PARASIT
JI Ann. Trop. Med. Parasitol.
PD OCT
PY 2003
VL 97
SU 1
BP 79
EP 98
DI 10.1179/000349803225002561
PG 20
WC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
SC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
GA 751GK
UT WOS:000187044300008
PM 14678636
DA 2020-12-01
ER

PT J
AU Correa, JC
   Badaro, R
   Bumroongkit, C
   Mera, JR
   Dolmann, AL
   Martinez, LGJ
   Mayrinck, LR
   Tamez, R
   Yang, JY
AF Correa, JC
   Badaro, R
   Bumroongkit, C
   Mera, JR
   Dolmann, AL
   Martinez, LGJ
   Mayrinck, LR
   Tamez, R
   Yang, JY
TI Randomized, open-label, parallel-group, multicenter study of the
   efficacy and tolerability of IV gatifloxacin with the option for oral
   stepdown gatifloxacin versus IV ceftriaxone (with or without
   erythromycin or clarithromycin) with the option for oral stepdown
   clarithromycin for treatment of patients with mild to moderate
   community-acquired pneumonia requiring hospitalization
SO CLINICAL THERAPEUTICS
LA English
DT Article
DE gatifloxacin; ceftriaxone; clarithromycin; erythromycin;
   community-acquired pneumonia; tolerability
ID STREPTOCOCCUS-PNEUMONIAE; THERAPY; FLUOROQUINOLONES; GUIDELINES;
   MANAGEMENT; INFECTIONS; FOCUS
AB Background: Empiric therapy for community-acquired pneumonia (CAP) requires the use of antibiotics with activity against a broad spectrum of respiratory pathogens and suitable pharmacokinetic properties to simplify IV-to-oral step-down therapy switches.
   Objective: The aim of this study was to compare the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin with a standard regimen of IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin in patients with mild to moderate CAP requiring hospitalization.
   Methods: In a randomized, open-label, parallel-group, multicenter study, adults with CAP received 7 to 14 days of treatment with either IV gatifloxacin 400 mg QD with the stepdown option or IV ceftriaxone 1 or 2 g QD (with or without erythromycin 0.5 or 1 g QID or clarithromycin 500 mg BID) with the stepdown option.
   Results: One hundred seventy adults with CAP were included in the study IV gatifloxacin was stepped down to oral gatifloxacin in 90.6% (77/85) of patients; IV ceftriaxone was stepped down to oral clarithromycin in 87.1% (74/85) of patients. Among clinically evaluable patients (n = 153), cure rates at 1 to 3 days after treatment were 97.4% in the gatifloxacin group (74/76) and 90.9% in the ceftriaxone group (70/77), with a 95% Cl for the difference (-3.7% to 19.1%) indicating statistical equivalence. In patients in whom pathogens were isolated from pretreatment sputum cultures, bacteriologic eradication rates were 100.0% (29/29) and 90.9% (30/33), respectively. Both regimens were well tolerated; treatment-related adverse events occurred in 27.1% (23/85) and 21.2% (18/85) of patients, respectively
   Conclusions: In the population studied, treatment with IV gatifloxacin with an option for oral stepdown gatifloxacin was as effective for achieving clinical cure as IV ceftriaxone (with or without concomitant IV erythromycin or clarithromycin) with an option for oral stepdown clarithromycin. Both regimens were well tolerated. Copyright (C) 2003 Excerpta Medica, Inc.
C1 Hosp Veneravel Ordem Terceira Sao Francisco Penit, Rio De Janeiro, Brazil.
   Univ Fed Bahia, Edgard Santos Univ Hosp, Salvador, BA, Brazil.
   Chang Mai Univ, Chiang Mai, Thailand.
   Univ Aconcagua, Mendoza, Argentina.
   Hosp Antonio A Cetranglo, Buenos Aires, DF, Argentina.
   Inst Mexicano Seguro Social, Nuevo Leon, Mexico.
   Hosp Servidores Estado Rio Janeiro, Rio De Janeiro, Brazil.
   Bristol Myers Squibb Co, Mexico City, DF, Mexico.
   Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
RP Correa, JC (corresponding author), Rua Toneleros 248-702, BR-22030000 Copacabana, RJ, Brazil.
CR Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
   Bernstein JM, 1999, CHEST, V115, p9S, DOI 10.1378/chest.115.suppl_1.9S
   Coyle EA, 2001, ANTIMICROB AGENTS CH, V45, P1654, DOI 10.1128/AAC.45.6.1654-1659.2001
   Cubbon MD, 2000, J ANTIMICROB CHEMOTH, V46, P869, DOI 10.1093/jac/46.6.869
   Doern GV, 2001, ANTIMICROB AGENTS CH, V45, P1721, DOI 10.1128/AAC.45.6.1721-1729.2001
   Fleiss JL, 1981, STAT METHODS RATES P
   FOGARTY C, 1999, J RESP DIS S, V20, pS60
   Fung-Tomc J, 2000, J ANTIMICROB CHEMOTH, V45, P437, DOI 10.1093/jac/45.4.437
   Lode H, 2002, J ANTIMICROB CHEMOTH, V50, P151, DOI 10.1093/jac/dkf133
   Luna CM, 2001, ARCH BRONCONEUMOL, V37, P340
   MARRIE TJ, 1994, CLIN INFECT DIS, V18, P501, DOI 10.1093/clinids/18.4.501
   Milkovich G, 2001, PHARMACOTHERAPY, V21, p83S, DOI 10.1592/phco.21.10.83S.34533
   NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418
   Perry CM, 2002, DRUGS, V62, P169, DOI 10.2165/00003495-200262010-00007
   Ramirez JA, 2001, PHARMACOTHERAPY, V21, p79S, DOI 10.1592/phco.21.10.79S.34530
   RAMIREZ JA, 1999, J RESP DIS S, V20, pS40
   SULLIVAN JG, 1999, J RESP DIS S, V20, pS49
   Zhanel GG, 2002, DRUGS, V62, P13, DOI 10.2165/00003495-200262010-00002
NR 18
TC 10
Z9 12
U1 0
U2 1
PU EXCERPTA MEDICA INC
PI NEW YORK
PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA
SN 0149-2918
J9 CLIN THER
JI Clin. Ther.
PD MAY
PY 2003
VL 25
IS 5
BP 1453
EP 1468
DI 10.1016/S0149-2918(03)80132-7
PG 16
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 688TQ
UT WOS:000183452700009
PM 12867221
DA 2020-12-01
ER

PT J
AU Houghton, RL
   Lodes, MJ
   Dillon, DC
   Reynolds, LD
   Day, CH
   McNeill, PD
   Hendrickson, RC
   Skeiky, YAW
   Sampaio, DP
   Badaro, R
   Lyashchenko, KP
   Reed, SG
AF Houghton, RL
   Lodes, MJ
   Dillon, DC
   Reynolds, LD
   Day, CH
   McNeill, PD
   Hendrickson, RC
   Skeiky, YAW
   Sampaio, DP
   Badaro, R
   Lyashchenko, KP
   Reed, SG
TI Use of multiepitope polyproteins in serodiagnosis of active tuberculosis
SO CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY
LA English
DT Article
ID LINKED-IMMUNOSORBENT-ASSAY; CULTURE FILTRATE ANTIGENS; POLYMERASE
   CHAIN-REACTION; MYCOBACTERIUM-BOVIS BCG; SEROLOGICAL DIAGNOSIS;
   ANTIBODY-RESPONSES; SECRETED ANTIGEN; EXPRESSION; CLONING; PROTEIN
AB Screening of genomic expression libraries from Mycobacterium tuberculosis with sera from tuberculosis (TB) patients or rabbit antiserum to M. tuberculosis led to the identification of novel antigens capable of detecting specific antibodies to M. tuberculosis. Three antigens, Mtb11 (also known as CTP-10), Mtb8, and Mtb48, were tested together with the previously reported 38-kDa protein, in an enzyme-linked immunosorbent assay (ELISA) to detect antibodies in TB patients. These four proteins were also produced as a genetically fused polyprotein, which was tested with two additional antigens, DPEP (also known as MPT32) and Mtb81. Sera from individuals with pulmonary and extrapulmonary TB, human immunodeficiency virus (HIV)-TB coinfections, and purified protein derivative (PPD) -positive and PPD-negative status with no evidence of disease were tested. In samples from HIV-negative individuals, the ELISA detected antibodies in >80% of smear-positive individuals and >60% smear-negative individuals, with a specificity of similar to98%. For this group, smears detected 81.6% but a combination of smear and ELISA had a sensitivity of similar to93%. The antigen combination detected a significant number of HIV-TB coinfections as well as antibodies in patients with extrapulmonary infections. Improved reactivity in the HIV-TB group was observed by including the antigen Mtb81 that was identified by proteomics, The data indicate that the use of multiple antigens, some of which are in a single polyprotein, can be used to facilitate the development of a highly sensitive test for M. tuberculosis antibody detection.
C1 Corixa Corp, Seattle, WA 98104 USA.
   Chembio Diagnost Syst Inc, Medford, NY USA.
   Univ Fed Bahia, Salvador, BA, Brazil.
   Fundacao Bahiana Infectol, Salvador, BA, Brazil.
RP Houghton, RL (corresponding author), Corixa Corp, 1124 Columbia St,Suite 200, Seattle, WA 98104 USA.
OI Brasil Pedral Sampaio, Diana/0000-0002-2446-5828
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R44AI043781, R44AI039879, R44AI039879, R43AI039879, R43AI043781,
   R44AI043781] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI-39879, AI-43781] Funding Source: Medline
CR ANDERSEN AB, 1989, INFECT IMMUN, V57, P2481, DOI 10.1128/IAI.57.8.2481-2488.1989
   BARNES PF, 1992, J IMMUNOL, V148, P1835
   BENJAMIN RG, 1984, J MED MICROBIOL, V18, P309, DOI 10.1099/00222615-18-3-309
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195
   BOTHAMLEY G, 1988, EUR J CLIN MICROBIOL, V7, P639, DOI 10.1007/BF01964242
   BOTHAMLEY GH, 1994, EUR RESPIR J, V7, P240, DOI 10.1183/09031936.94.07020240
   *CDC, 1993, JAMA-J AM MED ASSOC, V272, P265
   Chan ED, 2000, TUBERCLE LUNG DIS, V80, P131, DOI 10.1054/tuld.2000.0243
   CHANG ZY, 1994, J BIOL CHEM, V269, P1956
   COATES ARM, 1989, BRIT J EXP PATHOL, V70, P215
   COCITO CG, 1991, CHEST, V100, P1687, DOI 10.1378/chest.100.6.1687
   COHEN ML, 1987, J CLIN MICROBIOL, V25, P1176, DOI 10.1128/JCM.25.7.1176-1180.1987
   Colangeli R, 2000, INFECT IMMUN, V68, P990, DOI 10.1128/IAI.68.2.990-993.2000
   COUSINS DV, 1992, J CLIN MICROBIOL, V30, P255, DOI 10.1128/JCM.30.1.255-258.1992
   DANIEL TM, 1987, AM REV RESPIR DIS, V135, P1137
   DEKESEL M, 1993, J CLIN MICROBIOL, V31, P947, DOI 10.1128/JCM.31.4.947-954.1993
   Dillon DC, 2000, J CLIN MICROBIOL, V38, P3285, DOI 10.1128/JCM.38.9.3285-3290.2000
   ESPITIA C, 1989, CLIN EXP IMMUNOL, V77, P373
   ESPITIA C, 1995, INFECT IMMUN, V63, P580, DOI 10.1128/IAI.63.2.580-584.1995
   Foulds J, 1998, INT J TUBERC LUNG D, V2, P778
   Harries AD, 2001, LANCET, V357, P1519, DOI 10.1016/S0140-6736(00)04639-0
   Hendrickson RC, 2000, J CLIN MICROBIOL, V38, P2354
   JACKETT PS, 1988, J CLIN MICROBIOL, V26, P2313, DOI 10.1128/JCM.26.11.2313-2318.1988
   Laal S, 1997, J INFECT DIS, V176, P133, DOI 10.1086/514015
   Laal S, 1997, CLIN DIAGN LAB IMMUN, V4, P49, DOI 10.1128/CDLI.4.1.49-56.1997
   LAQUEYRERIE A, 1995, INFECT IMMUN, V63, P4003, DOI 10.1128/IAI.63.10.4003-4010.1995
   Lodes MJ, 2001, J CLIN MICROBIOL, V39, P2485, DOI 10.1128/JCM.39.7.2485-2493.2001
   Lyashchenko K, 1998, INFECT IMMUN, V66, P3936, DOI 10.1128/IAI.66.8.3936-3940.1998
   Lyashchenko K, 1998, INFECT IMMUN, V66, P3606, DOI 10.1128/IAI.66.8.3606-3610.1998
   Lyashchenko KP, 2000, J IMMUNOL METHODS, V242, P91, DOI 10.1016/S0022-1759(00)00241-6
   Lyashchenko KP, 1998, INFECT IMMUN, V66, P5344, DOI 10.1128/IAI.66.11.5344-5349.1998
   MILLER N, 1994, J CLIN MICROBIOL, V32, P393, DOI 10.1128/JCM.32.2.393-397.1994
   NOORDHOEK GT, 1994, J CLIN MICROBIOL, V32, P277, DOI 10.1128/JCM.32.2.277-284.1994
   Nunn P, 2001, SCAND J INFECT DIS, V33, P329, DOI 10.1080/003655401750173887
   Pottumarthy S, 2000, J CLIN MICROBIOL, V38, P2227
   QADRI SMH, 1992, CAN J MICROBIOL, V38, P804, DOI 10.1139/m92-131
   SADA E, 1992, J CLIN MICROBIOL, V30, P2415, DOI 10.1128/JCM.30.9.2415-2418.1992
   SADA E, 1990, J CLIN MICROBIOL, V28, P2587, DOI 10.1128/JCM.28.12.2587-2590.1990
   Samanich K, 2001, INFECT IMMUN, V69, P4600, DOI 10.1128/IAI.69.7.4600-4609.2001
   Samanich KM, 1998, J INFECT DIS, V178, P1534, DOI 10.1086/314438
   Samanich KM, 2000, CLIN DIAGN LAB IMMUN, V7, P662, DOI 10.1128/CDLI.7.4.662-668.2000
   SHAWAR RM, 1993, J CLIN MICROBIOL, V31, P61, DOI 10.1128/JCM.31.1.61-65.1993
   Skjot RLV, 2000, INFECT IMMUN, V68, P214, DOI 10.1128/IAI.68.1.214-220.2000
   VERACABRERA L, 1994, J IMMUNOL METHODS, V177, P69, DOI 10.1016/0022-1759(94)90144-9
   WADEE AA, 1990, J CLIN MICROBIOL, V28, P2786, DOI 10.1128/JCM.28.12.2786-2791.1990
   Webb JR, 1998, INFECT IMMUN, V66, P4208
   Wilkins E. G. L., 1994, P367
NR 47
TC 84
Z9 99
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1071-412X
J9 CLIN DIAGN LAB IMMUN
JI Clin. Diagn. Lab. Immunol.
PD JUL
PY 2002
VL 9
IS 4
BP 883
EP 891
DI 10.1128/CDLI.9.4.883-891.2002
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 575CW
UT WOS:000176929600024
PM 12093690
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Badaro, R
   Lobo, I
   Campos-Neto, A
   Modabber, F
   Skeiky, YAW
   Reed, SG
AF Badaro, R
   Lobo, I
   Campos-Neto, A
   Modabber, F
   Skeiky, YAW
   Reed, SG
TI Successful treatment of mucosal leishmaniasis with recombinant based
   subunit vaccine
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 Univ Fed Bahia, Salvador, BA, Brazil.
   Infect Dis Res Inst, Tampa, FL USA.
   Corixa Corp, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD OCT 1
PY 2001
VL 33
IS 7
MA 384
BP 1154
EP 1154
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 476KU
UT WOS:000171226900410
DA 2020-12-01
ER

PT J
AU Lodes, MJ
   Dillon, DC
   Mohamath, R
   Day, CH
   Benson, DR
   Reynolds, LD
   McNeill, P
   Sampaio, DP
   Skeiky, YAW
   Badaro, R
   Persing, DH
   Reed, SG
   Houghton, RL
AF Lodes, MJ
   Dillon, DC
   Mohamath, R
   Day, CH
   Benson, DR
   Reynolds, LD
   McNeill, P
   Sampaio, DP
   Skeiky, YAW
   Badaro, R
   Persing, DH
   Reed, SG
   Houghton, RL
TI Serological expression cloning and immunological evaluation of MTB48, a
   novel Mycobacterium tuberculosis antigen
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID NEGATIVE PULMONARY TUBERCULOSIS; HIV-INFECTION; BOVIS BCG; DIAGNOSIS;
   COUNTRIES; PROTEINS; IMPACT
AB Improved diagnostics are needed for the detection of Mycobacterium tuberculosis, especially for patients with smear-negative disease. To address this problem, we have screened M. tuberculosis (H37Rv and Erdman strains) genomic expression libraries with pooled sera from patients with extrapulmonary disease and with sera from patients with elevated reactivity with M. tuberculosis lysate. Both serum pools were reactive,vith clones expressing a recombinant protein referred to here as MTB48. The genomic sequence of the resulting clones was identical to that of the M. tuberculosis H37Rv isolate and showed 99% identity to the Mycobacterium bovis and M. bovis BCG isolate sequences. The genomic location of this sequence is 826 bp upstream of a region containing the esat-6 gene that is deleted in the M. bovis BCG isolate. The mtb48 1,380-bp open reading frame encodes a predicted 47.6-kDa polypeptide with no known function. Southern and Western blot analyses indicate that this sequence is present in a single copy and is conserved in the M. tuberculosis and M. bovis isolates tested but not in other mycobacterial species tested, including Mycobacterium leprae and Mycobacterium avium. In addition, the native protein was detected in the cytoplasm, as was a processed form that was also shed into the medium during culture. Serological analysis of recombinant MTB48 and the M. tuberculosis 38-kDa antigen with a panel of patient and control sera indicates that the inclusion of recombinant MTB48 in a prototype serodiagnostic test increases assay sensitivity for M. tuberculosis infection when it is combined with other known immunodominant antigens, such as the 38-kDa antigen.
C1 Corixa Corp, Seattle, WA 98104 USA.
   Infect Dis Res Inst, Seattle, WA 98104 USA.
   Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA.
   Univ Fed Bahia, Salvador, BA, Brazil.
RP Lodes, MJ (corresponding author), Corixa Corp, 1124 Columbia St,Suite 200, Seattle, WA 98104 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI044373, AI-39879, AI-44373,
   N01-AI-25147] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [N01AI025147, R01AI044373,
   N01AI025147, N01AI025147, N01AI025147, R01AI044373, N01AI025147,
   N01AI025147, N01AI025147, R43AI039879, R44AI039879, N01AI025147,
   R01AI044373, R01AI044373, R01AI044373, R01AI044373, R01AI044373,
   N01AI025147, R01AI044373, R01AI044373, R01AI044373, N01AI025147,
   R44AI039879, N01AI025147] Funding Source: NIH RePORTER
CR ANDERSEN AB, 1989, INFECT IMMUN, V57, P2481, DOI 10.1128/IAI.57.8.2481-2488.1989
   ASHBRIDGE KR, 1990, J IMMUNOL, V144, P3137
   Barry S M, 1999, Curr Opin Pulm Med, V5, P168, DOI 10.1097/00063198-199905000-00008
   Bergmann JS, 1999, J CLIN MICROBIOL, V37, P1419, DOI 10.1128/JCM.37.5.1419-1425.1999
   Chan ED, 2000, TUBERCLE LUNG DIS, V80, P131, DOI 10.1054/tuld.2000.0243
   Chou T, 1999, NURS CLIN N AM, V34, P427
   Colebunders R, 2000, INT J TUBERC LUNG D, V4, P97
   DEMKOW U, 1998, ALERGOL POL, V66, P509
   Dillon DC, 2000, J CLIN MICROBIOL, V38, P3285, DOI 10.1128/JCM.38.9.3285-3290.2000
   Eltringham IJ, 1998, BRIT MED BULL, V54, P569
   Felix R, 1995, Pneumologie, V49 Suppl 3, P657
   Foulds J, 1998, INT J TUBERC LUNG D, V2, P778
   Gillespie S, 1999, Curr Opin Pulm Med, V5, P174, DOI 10.1097/00063198-199905000-00009
   Ginsberg AM, 1998, PUBLIC HEALTH REP, V113, P128
   Glynn JR, 1998, BRIT MED BULL, V54, P579
   Gupta Sunil, 1995, Journal of Communicable Diseases, V27, P208
   Hageman J R, 1998, J Perinatol, V18, P389
   HARBOE M, 1992, J INFECT DIS, V166, P874, DOI 10.1093/infdis/166.4.874
   Harries AD, 1998, B WORLD HEALTH ORGAN, V76, P651
   Hendrickson RC, 2000, J CLIN MICROBIOL, V38, P2354
   Hirsch C S, 1999, Curr Opin Pulm Med, V5, P143, DOI 10.1097/00063198-199905000-00004
   Kamholz S L, 1996, J Assoc Acad Minor Phys, V7, P83
   Lyashchenko K, 1998, INFECT IMMUN, V66, P3936, DOI 10.1128/IAI.66.8.3936-3940.1998
   Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996
   Manca C, 1997, INFECT IMMUN, V65, P4951, DOI 10.1128/IAI.65.12.4951-4957.1997
   MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035
   Migliori G B, 1998, Monaldi Arch Chest Dis, V53, P681
   Netto EM, 1999, INT J TUBERC LUNG D, V3, P310
   Pottumarthy S, 2000, J CLIN MICROBIOL, V38, P2227
   Rattan A, 1998, EMERG INFECT DIS, V4, P195, DOI 10.3201/eid0402.980207
   Samanich KM, 2000, CLIN DIAGN LAB IMMUN, V7, P662, DOI 10.1128/CDLI.7.4.662-668.2000
   VERBON A, 1992, J BACTERIOL, V174, P1352, DOI 10.1128/jb.174.4.1352-1359.1992
   VERBON A, 1994, TROP GEOGR MED, V46, P275
   Wilkinson RJ, 1997, J CLIN MICROBIOL, V35, P553, DOI 10.1128/JCM.35.3.553-557.1997
   Zumla A, 2000, POSTGRAD MED J, V76, P259, DOI 10.1136/pmj.76.895.259
NR 35
TC 35
Z9 44
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUL
PY 2001
VL 39
IS 7
BP 2485
EP 2493
DI 10.1128/JCM.39.7.2485-2493.2001
PG 9
WC Microbiology
SC Microbiology
GA 447RN
UT WOS:000169586400017
PM 11427558
OA Green Published, Other Gold
DA 2020-12-01
ER

PT J
AU Probst, P
   Stromberg, E
   Ghalib, HW
   Mozel, M
   Badaro, R
   Reed, SG
   Webb, JR
AF Probst, P
   Stromberg, E
   Ghalib, HW
   Mozel, M
   Badaro, R
   Reed, SG
   Webb, JR
TI Identification and characterization of T cell-stimulating antigens from
   Leishmania by CD4 T cell expression cloning
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID VISCERAL LEISHMANIASIS; IMMUNE-RESPONSE; MALATE-DEHYDROGENASE; INFECTED
   MACROPHAGES; MOLECULAR-CLONING; PROTEIN; IMMUNIZATION; MEXICANA;
   INFANTUM; GENES
AB Persistent immunity against Leishmania infections in humans is mediated predominantly by CD4(+) T cells of the Th1 phenotype, Herein we report the expression cloning of eight Leishmania Ags using parasite-specific T cell lines derived from an immune donor. The Ags identified by this technique include the flagellar proteins alpha- and beta -tubulin, histone H2b, ribosomal protein S4, malate dehydrogenase, and elongation factor 2, as well as two novel parasite proteins. None of these proteins have been previously reported as T cell-stimulating Ags from Leishmania, beta -tubulin-specific T cell clones generated against Leishmania major amastigotes responded to Leishmania-infected macrophages and dendritic cells, IFN-gamma enzyme-linked immunospot analysis demonstrated the presence of T cells specific for several of these Ags in PBMC from self-healing cutaneous leishmaniasis patients infected with either Leishmania tropica or L. major. The responses elicited by Leishmania histone H2b were particularly striking in terms of frequency of histone-specific T cells in PBMC (1 T cell of 6000 PBMC) as well as the percentage of responding donors (86%, 6 of 7), Ags identified by T cells from immune donors might constitute potential vaccine candidates for leishmaniasis.
C1 Corixa Corp, Seattle, WA 98104 USA.
   King Khalid Univ, Coll Med, Abha, Saudi Arabia.
   Infect Dis Res Inst, Seattle, WA 98104 USA.
   Univ Fed Bahia, Salvador, BA, Brazil.
   Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada.
RP Probst, P (corresponding author), Corixa Corp, 1124 Columbia St,Suite 200, Seattle, WA 98104 USA.
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R44AI036810, R01AI025038, R01AI025038, R01AI025038, R44AI036810,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R43AI036810, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038] Funding Source: NIH
   RePORTER; FIC NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [TW-00428] Funding Source: Medline; NIAID NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-36810, AI-25038] Funding Source: Medline
CR Alderson MR, 2000, J EXP MED, V191, P551, DOI 10.1084/jem.191.3.551
   Alvar J, 1997, CLIN MICROBIOL REV, V10, P298, DOI 10.1128/CMR.10.2.298
   Anderson SA, 1998, MOL BIOCHEM PARASIT, V96, P185, DOI 10.1016/S0166-6851(98)00116-9
   BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   CHAMPSI J, 1988, INFECT IMMUN, V56, P3272, DOI 10.1128/IAI.56.12.3272-3279.1988
   CHANG KP, 1985, LEISHMANIASIS, V1, P1
   Coulson RMR, 1996, MOL BIOCHEM PARASIT, V82, P227, DOI 10.1016/0166-6851(96)02739-9
   Galanti N, 1998, PARASITOL TODAY, V14, P64, DOI 10.1016/S0169-4758(97)01162-9
   GENSKE JE, 1991, MOL CELL BIOL, V11, P240, DOI 10.1128/MCB.11.1.240
   HANDMAN E, 1990, EXP PARASITOL, V70, P427, DOI 10.1016/0014-4894(90)90127-X
   HANDMAN E, 1995, INFECT IMMUN, V63, P4261, DOI 10.1128/IAI.63.11.4261-4267.1995
   Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2
   Ivens AC, 1998, GENOME RES, V8, P135, DOI 10.1101/gr.8.2.135
   Jaffe CL, 1999, CLIN DERMATOL, V17, P339, DOI 10.1016/S0738-081X(99)00052-8
   Kemp M, 1997, APMIS Suppl, V68, P1
   LIEW FY, 1989, IMMUNOL TODAY, V10, P40, DOI 10.1016/0167-5699(89)90302-2
   Locksley RM, 1999, J INFECT DIS, V179, pS305, DOI 10.1086/513843
   MELBY PC, 1991, REV INFECT DIS, V13, P1009
   MODABBER F, 1989, PARASITOLOGY, V98, pS49, DOI 10.1017/S0031182000072243
   MOTTRAM JC, 1985, BIOCHIM BIOPHYS ACTA, V827, P310, DOI 10.1016/0167-4838(85)90216-X
   MOUGNEAU E, 1995, SCIENCE, V268, P563, DOI 10.1126/science.7725103
   Nieto CG, 1999, VET IMMUNOL IMMUNOP, V67, P117, DOI 10.1016/S0165-2427(98)00213-X
   Overath P, 1999, PARASITOL TODAY, V15, P325, DOI 10.1016/S0169-4758(99)01473-8
   Pearson RD, 1996, CLIN INFECT DIS, V22, P1, DOI 10.1093/clinids/22.1.1
   Prina E, 1996, J IMMUNOL, V156, P4318
   PROBST P, 1995, CELL IMMUNOL, V165, P134, DOI 10.1006/cimm.1995.1196
   Probst P, 1997, EUR J IMMUNOL, V27, P2634, DOI 10.1002/eji.1830271024
   REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055
   RUSSELL DG, 1988, J IMMUNOL, V140, P1274
   SACKS DL, 1987, J IMMUNOL, V138, P908
   Seaman J, 1996, ANN INTERN MED, V124, P664, DOI 10.7326/0003-4819-124-7-199604010-00007
   Soto M, 1999, CLIN EXP IMMUNOL, V115, P342, DOI 10.1046/j.1365-2249.1999.00796.x
   Webb JR, 1996, J IMMUNOL, V157, P5034
   Webb JR, 1998, INFECT IMMUN, V66, P3279, DOI 10.1128/IAI.66.7.3279-3289.1998
   Webb JR, 1997, MOL BIOCHEM PARASIT, V89, P179, DOI 10.1016/S0166-6851(97)00115-1
   WOLFRAM M, 1995, EUR J IMMUNOL, V25, P1094, DOI 10.1002/eji.1830250435
   1990, WHO MONOGR SER, V793, P1
NR 38
TC 64
Z9 68
U1 0
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JAN 1
PY 2001
VL 166
IS 1
BP 498
EP 505
DI 10.4049/jimmunol.166.1.498
PG 8
WC Immunology
SC Immunology
GA 385PG
UT WOS:000166012400062
PM 11123329
OA Bronze
DA 2020-12-01
ER

PT J
AU Campos-Neto, A
   Rodrigues-Junior, V
   Pedral-Sampaio, DB
   Netto, EM
   Ovendale, RJ
   Coler, RN
   Skeiky, YAW
   Badaro, R
   Reed, SG
AF Campos-Neto, A
   Rodrigues-Junior, V
   Pedral-Sampaio, DB
   Netto, EM
   Ovendale, RJ
   Coler, RN
   Skeiky, YAW
   Badaro, R
   Reed, SG
TI Evaluation of DPPD, a single recombinant Mycobacterium tuberculosis
   protein as an alternative antigen for the Mantoux test
SO TUBERCULOSIS
LA English
DT Article
ID SITUATION; DIAGNOSIS
AB Although the tuberculin test has aided in the diagnosis of tuberculosis for more than 85 years, its interpretation is difficult particularly because sensitization with non-tuberculous mycobacteria leads to false positive tests. Using the guinea pig model of tuberculosis, we have recently described a recombinant antigen (DPPD) that could circumvent this problem. The DPPD gene is unique to the M. tuberculosis complex organisms and is absent in the organisms representative of all other members of the Mycobacterium genus. Moreover, DPPD induced strong DTH in 100% of the guinea pigs infected with M. tuberculosis and in none of the guinea pigs immunized with nine different species of Mycobacterium, Here we present results of a clinical investigation using DPPD. Mantoux test using both PPD and DPPD was initially performed in 26 patients with confirmed pulmonary tuberculosis and in 25 healthy PPD negative individuals. The results indicated that both PPD and DPPD elicited DTH in 24 out of the 26 patients. No DTH was observed in any of the PPD negative individuals. In addition, a small clinical trial was performed in a population of 270 clinically healthy and randomly selected individuals. DPPD produced a bimodal histogram of skin reaction size and PPD produced a skewed histogram. Because the DPPD gene is not present in non-tuberculous bacilli, these results suggest that this molecule can be an additional tool for a more specific diagnosis of tuberculosis. (C) 2001 Harcourt Publishers Ltd.
C1 Infect Dis Res Inst, Seattle, WA 98104 USA.
   Med Sch Triangulo Mineiro, Mineiro, MG, Brazil.
   Univ Fed Bahia, Salvador, BA, Brazil.
   Corixa Corp, Seattle, WA USA.
   Med Sch Itajuba, Itajuba, MG, Brazil.
RP Campos-Neto, A (corresponding author), Infect Dis Res Inst, 1124 Columbia St,Suite 600, Seattle, WA 98104 USA.
EM acampos@idri.org
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761; Rodrigues Jr,
   Virmondes/0000-0001-8706-4223; Brasil Pedral Sampaio,
   Diana/0000-0002-2446-5828
CR *AM THOR SOC, 1981, AM REV RESPIR DIS, V124, P356
   American Thoracic Society, 1991, AM REV RESPIR DIS, V142, P725
   Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2
   BERTHET FX, 1998, MICROBIOLOGY, V144, P3185
   Coler RN, 2000, J INFECT DIS, V182, P224, DOI 10.1086/315677
   Dillon DC, 2000, J CLIN MICROBIOL, V38, P3285, DOI 10.1128/JCM.38.9.3285-3290.2000
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677
   Elhay MJ, 1998, INFECT IMMUN, V66, P3454, DOI 10.1128/IAI.66.7.3454-3456.1998
   Ginsberg AM, 1998, PUBLIC HEALTH REP, V113, P128
   HAAS F, 1996, TUBERCULOSIS, P3
   HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540
   HOPEWELL PC, 1998, TXB RESP MED, P1094
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968
   KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M
   KROPSHOFER H, 1993, J IMMUNOL, V151, P4732
   LORDI GM, 1999, TUBERCULOSIS NONTUBE, P65
   MANTOUX C, 1912, PRESSE MED, V20, P146
   Netto EM, 1999, INT J TUBERC LUNG D, V3, P310
   OKWERA A, 1994, LANCET, V344, P1323, DOI 10.1016/S0140-6736(94)90693-9
   PELOQUIN CA, 1993, PHARMACOTHERAPY, V13, P634
   RAVIGLIONE MC, 1992, B WORLD HEALTH ORGAN, V70, P515
   RUFFINONETTO A, 1979, REV ASSOC MED BRAS, V25, P257
   SUDRE P, 1992, B WORLD HEALTH ORGAN, V70, P149
   WOLINSKY E, 1992, CLIN INFECT DIS, V15, P1, DOI 10.1093/clinids/15.1.1
   YOUNG DB, 1992, CURR OPIN IMMUNOL, V4, P396, DOI 10.1016/S0952-7915(06)80029-4
   YOUNG DB, 1992, MOL MICROBIOL, V6, P133, DOI 10.1111/j.1365-2958.1992.tb01994.x
   1998, FED REG, V63, P4272
   1994, WKLY EPIDEMIOL REC, V69, P191
NR 28
TC 20
Z9 20
U1 0
U2 3
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1472-9792
J9 TUBERCULOSIS
JI Tuberculosis
PY 2001
VL 81
IS 5-6
BP 353
EP 358
DI 10.1054/tube.2001.0311
PG 6
WC Immunology; Microbiology; Respiratory System
SC Immunology; Microbiology; Respiratory System
GA 508NF
UT WOS:000173094800007
PM 11800586
DA 2020-12-01
ER

PT J
AU Dillon, DC
   Alderson, MR
   Day, CH
   Bement, T
   Campos-Neto, A
   Skeiky, YAW
   Vedvick, T
   Badaro, R
   Reed, SG
   Houghton, R
AF Dillon, DC
   Alderson, MR
   Day, CH
   Bement, T
   Campos-Neto, A
   Skeiky, YAW
   Vedvick, T
   Badaro, R
   Reed, SG
   Houghton, R
TI Molecular and immunological characterization of Mycobacterium
   tuberculosis CFP-10, an immunodiagnostic antigen missing in
   Mycobacterium bovis BCG
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID PROTEIN; ANTIBODIES; RESPONSES; INFECTION
AB In order to identify antigens that may be used in the serodiagnosis of active tuberculosis (TB), we screened a Mycobacterium tuberculosis genomic expression library with a pool of sera from patients diagnosed with active pulmonary TB. The sera used lacked reactivity with a recombinant form of the M. tuberculosis 38-kDa antigen (r38kDa), and the goal was to identify antigens that might complement r38kDa in a serodiagnostic assay, Utilizing this strategy, we identified a gene, previously designated lhp, which encodes a 100-amino-acid protein referred to as culture filtrate protein 10 (CFP-10), The lhp gene is located directly upstream of esat-6, within a region missing in M. bovis BCG, Immunoblot analysis demonstrated that CFP-10 is present in M. tuberculosis CFP, indicating that it is likely a secreted or shed antigen. Purified recombinant CFP-10 (rCFP-10) was shown to be capable of detecting specific antibody in a percentage of TB patients that lack reactivity with r38kDa, most notably in smear-negative cases, where sensitivity was increased from 21% for r38kDa alone to 40% with the inclusion of rCFP-10. In smear-positive patient sera, sensitivity was increased from 49% for r38kDa alone to 58% with the inclusion of rCFP-10, In addition, rCFP-10 was shown to be a potent T-cell antigen, eliciting proliferative responses and gamma interferon production from peripheral blood mononuclear cells in 70% of purified protein derivative-positive individuals without evident disease. The responses to this antigen argue for the inclusion of rCFP-10 in a polyvalent serodiagnostic test for detection of active TB infection. rCFP-10 could also contribute to the development of a recombinant T-cell diagnostic test capable of detecting exposure to M. tuberculosis.
C1 Corixa Corp, Seattle, WA 98104 USA.
   Infect Dis Res Inst, Seattle, WA 98104 USA.
   Univ Fed Bahia, Salvador, BA, Brazil.
RP Dillon, DC (corresponding author), Corixa Corp, 1124 Columbia St, Seattle, WA 98104 USA.
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [N01AI025147, N01AI025147, N01AI025147, N01AI025147, N01AI025147,
   N01AI025147, N01AI025147, N01AI025147, N01AI025147, N01AI025147,
   N01AI025147] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [N01-AI-25147] Funding Source: Medline
CR Alderson MR, 2000, J EXP MED, V191, P551, DOI 10.1084/jem.191.3.551
   Amara RR, 1996, INFECT IMMUN, V64, P3765, DOI 10.1128/IAI.64.9.3765-3771.1996
   ANDERSEN AB, 1989, INFECT IMMUN, V57, P2481, DOI 10.1128/IAI.57.8.2481-2488.1989
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195
   BOTHAMLEY GH, 1994, EUR RESPIR J, V7, P240, DOI 10.1183/09031936.94.07020240
   CHANG ZY, 1994, J BIOL CHEM, V269, P1956
   Colangeli R, 2000, INFECT IMMUN, V68, P990, DOI 10.1128/IAI.68.2.990-993.2000
   Dalovisio JR, 1996, CLIN INFECT DIS, V23, P1099, DOI 10.1093/clinids/23.5.1099
   Dillon DC, 1999, INFECT IMMUN, V67, P2941, DOI 10.1128/IAI.67.6.2941-2950.1999
   ESPITIA C, 1989, CLIN EXP IMMUNOL, V77, P373
   Hendrickson RC, 2000, J CLIN MICROBIOL, V38, P2354
   Hoft DF, 1999, ANN INTERN MED, V131, P32, DOI 10.7326/0003-4819-131-1-199907060-00007
   JACKETT PS, 1988, J CLIN MICROBIOL, V26, P2313, DOI 10.1128/JCM.26.11.2313-2318.1988
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Laal S, 1997, J INFECT DIS, V176, P133, DOI 10.1086/514015
   Lyashchenko K, 1998, INFECT IMMUN, V66, P3936, DOI 10.1128/IAI.66.8.3936-3940.1998
   Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   SADA E, 1992, J CLIN MICROBIOL, V30, P2415, DOI 10.1128/JCM.30.9.2415-2418.1992
   Sambrook J, 1989, MOL CLONING LAB MANU
   SKEIKY YAW, 1995, J EXP MED, V181, P1527, DOI 10.1084/jem.181.4.1527
   Skjot RLV, 2000, INFECT IMMUN, V68, P214, DOI 10.1128/IAI.68.1.214-220.2000
   SORENSEN AL, 1995, INFECT IMMUN, V63, P1710
   Wilkins E. G. L., 1994, P367
   Wilkinson RJ, 1997, J CLIN MICROBIOL, V35, P553, DOI 10.1128/JCM.35.3.553-557.1997
NR 25
TC 97
Z9 124
U1 0
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD SEP
PY 2000
VL 38
IS 9
BP 3285
EP 3290
DI 10.1128/JCM.38.9.3285-3290.2000
PG 6
WC Microbiology
SC Microbiology
GA 350RG
UT WOS:000089114500026
PM 10970372
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Freitas, AC
   Badaro, R
   Santos, A
   Costa, JG
AF Freitas, AC
   Badaro, R
   Santos, A
   Costa, JG
TI Cost minimization by sequential therapy for early discharge in
   hospitalized patients with moderate to severe bacterial infection
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 Univ Fed Bahia, Salvador, BA, Brazil.
   Univ Bahia, Salvador, BA, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 SOUTH WOODLAWN AVE, CHICAGO, IL 60637-1603 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUL
PY 2000
VL 31
IS 1
MA 448
BP 289
EP 289
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 347VY
UT WOS:000088950900498
DA 2020-12-01
ER

PT J
AU Badaro, R
   Nakatani, M
   Houghton, R
   Skeiky, Y
   Bhatia, A
   Ghalib, H
   Brites, C
   Reed, S
AF Badaro, R
   Nakatani, M
   Houghton, R
   Skeiky, Y
   Bhatia, A
   Ghalib, H
   Brites, C
   Reed, S
TI A novel protein K26 of L-chagasi in combination with K39 upgrading the
   sensitivity of the serodiagnosis of Visceral Leishmaniasis
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 Corixa Corp, Seattle, WA USA.
   Univ Fed Bahia, Salvador, BA, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 SOUTH WOODLAWN AVE, CHICAGO, IL 60637-1603 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUL
PY 2000
VL 31
IS 1
MA 471
BP 293
EP 293
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 347VY
UT WOS:000088950900521
DA 2020-12-01
ER

PT J
AU Pedral-Sampaio, DB
   Netto, EM
   Bandeira, AC
   Guerra, C
   Barberino, MG
   Hayes, A
   Badaro, R
   Agosti, J
AF Pedral-Sampaio, DB
   Netto, EM
   Bandeira, AC
   Guerra, C
   Barberino, MG
   Hayes, A
   Badaro, R
   Agosti, J
TI Use of GM-CSF in pulmonary tuberculosis patients: preliminary results of
   a randomized clinical trial
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 Univ Fed Bahia, Salvador, BA, Brazil.
   Hosp Alianca, Salvador, BA, Brazil.
   Immunex Corp, Seattle, WA USA.
   LACEN, Salvador, BA, Brazil.
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761
NR 0
TC 0
Z9 0
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 SOUTH WOODLAWN AVE, CHICAGO, IL 60637-1603 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUL
PY 2000
VL 31
IS 1
MA 574
BP 312
EP 312
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 347VY
UT WOS:000088950900624
DA 2020-12-01
ER

PT J
AU Dillon, DC
   Alderson, MR
   Day, CH
   Lewinsohn, DM
   Coler, R
   Bement, T
   Campos-Neto, A
   Skeiky, YAW
   Orme, IM
   Roberts, A
   Steen, S
   Dalemans, W
   Badaro, R
   Reed, SG
AF Dillon, DC
   Alderson, MR
   Day, CH
   Lewinsohn, DM
   Coler, R
   Bement, T
   Campos-Neto, A
   Skeiky, YAW
   Orme, IM
   Roberts, A
   Steen, S
   Dalemans, W
   Badaro, R
   Reed, SG
TI Molecular characterization and human T-cell responses to a member of a
   novel Mycobacterium tuberculosis mtb39 gene family
SO INFECTION AND IMMUNITY
LA English
DT Article
ID DELAYED-TYPE HYPERSENSITIVITY; BACILLE CALMETTE-GUERIN;
   IMMUNODEFICIENCY-VIRUS-INFECTION; PROTECTIVE IMMUNITY; BOVIS BCG; MICE;
   ANTIGEN; PROTEINS; IMMUNIZATION; VACCINATION
AB We have used expression screening of a genomic Mycobacterium tuberculosis library with tuberculosis (TB) patient sera to identify novel genes that may be used diagnostically or in the development of a TB vaccine. Using this strategy, we have cloned a novel gene, termed mtb39a, that encodes a 39-kDa protein. Molecular characterization revealed that mtb39a is a member of a family of three highly related genes that are conserved among strains of M. tuberculosis and Mycobacterium bovis BCG but not in other mycobacterial species tested. Immunoblot analysis demonstrated the presence of Mtb39A in M; tuberculosis lysate but not in culture filtrate proteins (CFP), indicating that it is not a secreted antigen. This conclusion is strengthened by the observation that a human T-cell clone specific for purified recombinant Mtb39A protein recognized autologous dendritic cells infected with TB or pulsed with purified protein derivative (PPD) but did not respond to M. tuberculosis CFP. Purified recombinant Mtb39A elicited strong T-cell proliferative and gamma interferon responses in peripheral blood mononuclear cells from 9 of 12 PPD-positive individuals tested, and overlapping peptides were used to identify a minimum of 10 distinct T-cell epitopes. Additionally, mice immunized with mtb39a DNA have shown increased protection from M. tuberculosis challenge, as indicated by a reduction of bacterial load. The human T-cell responses and initial animal studies provide support for further evaluation of this antigen as a possible component of a subunit vaccine for M. tuberculosis.
C1 Corixa Corp, Seattle, WA 98104 USA.
   Infect Dis Res Inst, Seattle, WA 98104 USA.
   Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA.
   SmithKline Beecham Biol, Rixensart, Belgium.
   Univ Fed Bahia, Salvador, BA, Brazil.
   Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA.
RP Dillon, DC (corresponding author), Corixa Corp, 1124 Columbia St,Suite 200, Seattle, WA 98104 USA.
RI Lewinsohn, David/I-4936-2013
OI Lewinsohn, David/0000-0001-9906-9494
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-75320] Funding Source: Medline; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [N01AI075320, N01AI075320, N01AI075320, N01AI075320, N01AI075320,
   N01AI075320, N01AI075320] Funding Source: NIH RePORTER
CR ABOUZEID C, 1988, INFECT IMMUN, V56, P3046, DOI 10.1128/IAI.56.12.3046-3051.1988
   Amara RR, 1996, INFECT IMMUN, V64, P3765, DOI 10.1128/IAI.64.9.3765-3771.1996
   ANDERSEN P, 1994, INFECT IMMUN, V62, P2536, DOI 10.1128/IAI.62.6.2536-2544.1994
   ANDERSEN P, 1995, J IMMUNOL, V154, P3359
   Arachi A, 1991, TUBERCLE, V72, P1
   BAILY GV, 1981, LANCET, V1, P309
   BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307
   BARNES PF, 1992, J IMMUNOL, V148, P1835
   BARNES PF, 1993, ANN INTERN MED, V119, P400, DOI 10.7326/0003-4819-119-5-199309010-00009
   BRAUN MM, 1992, PEDIATR INFECT DIS J, V11, P220, DOI 10.1097/00006454-199203000-00010
   CALMETTE A., 1926, ANN INST PASTEUR, V40, P89
   CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570
   COATES ARM, 1981, LANCET, V2, P167
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243
   ENGERS HD, 1986, INFECT IMMUN, V51, P718
   FLYNN JL, 1993, J EXP MED, V178, P2248
   HASLOV K, 1995, INFECT IMMUN, V63, P804
   Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604
   KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   LAUNOIS P, 1994, INFECT IMMUN, V62, P3679, DOI 10.1128/IAI.62.9.3679-3687.1994
   Lewinsohn DM, 1998, J EXP MED, V187, P1633, DOI 10.1084/jem.187.10.1633
   MATSUO K, 1988, J BACTERIOL, V170, P3847, DOI 10.1128/jb.170.9.3847-3854.1988
   MULLER I, 1987, INFECT IMMUN, V55, P2037
   NARRAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   ORME I, 1994, IMMUNOBIOLOGY, V191, P503, DOI 10.1016/S0171-2985(11)80456-0
   ORME IM, 1988, INFECT IMMUN, V56, P3310, DOI 10.1128/IAI.56.12.3310-3312.1988
   ORME IM, 1987, J IMMUNOL, V138, P293
   ORME IM, 1984, CELL IMMUNOL, V84, P113, DOI 10.1016/0008-8749(84)90082-0
   PAL PG, 1992, INFECT IMMUN, V60, P4781, DOI 10.1128/IAI.60.11.4781-4792.1992
   PEDRAZZINI T, 1987, J IMMUNOL, V139, P2032
   ROCHE PW, 1994, J INFECT DIS, V170, P1326, DOI 10.1093/infdis/170.5.1326
   ROMAIN F, 1993, P NATL ACAD SCI USA, V90, P5322, DOI 10.1073/pnas.90.11.5322
   ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83
   Sambrook J, 1989, MOL CLONING LAB MANU
   SANCHEZ FO, 1994, INFECT IMMUN, V62, P5673
   Schaaf HS, 1996, TROP MED INT HEALTH, V1, P718
   SHINNICK TM, 1987, J BACTERIOL, V169, P1080, DOI 10.1128/jb.169.3.1080-1088.1987
   SKEIKY YAW, 1995, J EXP MED, V181, P1527, DOI 10.1084/jem.181.4.1527
   VONREYN CF, 1987, LANCET, V2, P669
   WELTMAN AC, 1993, AIDS, V7, P149, DOI 10.1097/00002030-199302000-00001
NR 44
TC 122
Z9 127
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD JUN
PY 1999
VL 67
IS 6
BP 2941
EP 2950
DI 10.1128/IAI.67.6.2941-2950.1999
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 199GX
UT WOS:000080473600034
PM 10338503
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Ashford, DA
   David, JR
   Freire, M
   David, R
   Sherlock, I
   Eulalio, MD
   Sampaio, DP
   Badaro, R
AF Ashford, DA
   David, JR
   Freire, M
   David, R
   Sherlock, I
   Eulalio, MD
   Sampaio, DP
   Badaro, R
TI Studies on control of visceral leishmaniasis: Impact of dog control on
   canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID ENDEMIC AREA; EPIDEMIOLOGY; COLOMBIA; FRANCE; SOUTH; ISLE; ELBA
AB To assess the effect of removing leishmania-infected dogs on the incidence of visceral leishmaniasis, a controlled intervention study was performed in northeast Brazil. The attempted elimination of seropositive dogs resulted in an initial significant decrease in the annual incidence of seroconversion among dogs from 36% to 6% over the first two years. In the following two ye:ars, the incidence increased to 11% and 14%, respectively. In a control area in which dogs were surveyed but seropositive dogs were not removed, the cumulative incidence did not vary significantly from year to year, ranging from 16% to 27%. In the intervention area, the prevalence of dog seropositivity decreased from 36% before the intervention to 10% and remained stable. These findings suggest that attempting to remove seropositive dogs is insufficient as a measure for eradicating visceral leishmaniasis in dogs. However, the force of transmission of infection among dogs can be reduced by such programs. Also, when the number of human cases before and after the start of the intervention was calculated, a significant decrease in incidence of disease in the intervention area was observed among children less than 15 years of age (P < 0.01). The results of this intervention study suggest that the elimination of the majority of seropositive dogs may affect the cumulative incidence of seroconversion in dogs temporarily and may also diminish the incidence of human cases of visceral leishmaniasis.
C1 Harvard Univ, Sch Publ Hlth, Dept Trop Publ Hlth, Boston, MA 02115 USA.
   Univ Fed Bahia, Salvador, BA, Brazil.
   Fdn Oswaldo Cruz Bahia, Salvador, BA, Brazil.
   Cornell Univ, Coll Med, New York, NY USA.
RP Ashford, DA (corresponding author), Ctr Dis Control & Prevent, Mailstop C-09, Atlanta, GA 30333 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-16305-13] Funding Source: Medline
CR ADLER S., 1929, ANN TROP MED & PARASITOL, V23, P1
   Adler S, 1932, P R SOC LOND B-CONTA, V110, P402, DOI 10.1098/rspb.1932.0035
   Alencar J.E., 1961, REV INST MED TROP, V3, P175
   ASHFORD DA, 1993, AM J TROP MED HYG, V48, P1
   ASHFORD DA, 1995, AM J TROP MED HYG, V53, P251, DOI 10.4269/ajtmh.1995.53.251
   ASHFORD RW, 1987, LEISHMANIASES BIOL M, V1, P291
   BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   BETTINI S, 1986, INSECT SCI APPL, V7, P241, DOI 10.1017/S1742758400009024
   CORREDOR A, 1989, AM J TROP MED HYG, V40, P480, DOI 10.4269/ajtmh.1989.40.480
   CORREDOR A, 1989, T ROY SOC TROP MED H, V83, P195, DOI 10.1016/0035-9203(89)90640-8
   DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS, P154
   DYE C, 1992, PARASITOLOGY, V104, pS7, DOI 10.1017/S0031182000075211
   GRADONI L, 1988, T ROY SOC TROP MED H, V82, P568, DOI 10.1016/0035-9203(88)90511-1
   LANOTTE G, 1978, ANN PARASIT HUM COMP, V53, P33, DOI 10.1051/parasite/1978531033
   LENG YJ, 1982, T ROY SOC TROP MED H, V76, P531, DOI 10.1016/0035-9203(82)90157-2
   MANCIANTI F, 1988, AM J VET RES, V49, P1409
   MANCIANTI F, 1986, TROP MED PARASITOL, V37, P110
   MARTY P, 1992, T ROY SOC TROP MED H, V86, P249, DOI 10.1016/0035-9203(92)90295-N
   MUTINGA MJ, 1980, ANN TROP MED PARASIT, V74, P139, DOI 10.1080/00034983.1980.11687323
   NEOGY AB, 1992, AM J TROP MED HYG, V47, P772, DOI 10.4269/ajtmh.1992.47.772
   Nicole CH, 1908, ARCH I PASTEUR TUNIS, V3, P59
   Shaw JJ, 1987, LEISHMANIASES BIOL M, V1, P365
   Sherlock I.A., 1984, Memorias do Instituto Oswaldo Cruz, V79, P511, DOI 10.1590/S0074-02761984000400020
   SHERLOCK IA, 1969, REV BRAS MAL DOEN TR, V14, P523
   SLAPPENDEL RJ, 1988, VET QUART, V10, P1
NR 25
TC 141
Z9 149
U1 0
U2 9
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUL
PY 1998
VL 59
IS 1
BP 53
EP 57
DI 10.4269/ajtmh.1998.59.53
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA ZZ953
UT WOS:000074786000012
PM 9684628
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Webb, JR
   Campos-Neto, A
   Ovendale, PJ
   Martin, TI
   Stromberg, EJ
   Badaro, R
   Reed, SG
AF Webb, JR
   Campos-Neto, A
   Ovendale, PJ
   Martin, TI
   Stromberg, EJ
   Badaro, R
   Reed, SG
TI Human and murine immune responses to a novel Leishmania major
   recombinant protein encoded by members of a multicopy gene family
SO INFECTION AND IMMUNITY
LA English
DT Article
ID THIOL-SPECIFIC ANTIOXIDANT; T-CELL RESPONSES;
   MYCOBACTERIUM-TUBERCULOSIS; ENTAMOEBA-HISTOLYTICA; PROTECTIVE IMMUNITY;
   HYDROGEN-PEROXIDE; SURFACE-ANTIGEN; CUTANEOUS LEISHMANIASIS;
   EXTRACELLULAR PROTEINS; ACID-PHOSPHATASE
AB Vaccination of BALB/c mice with Leishmania major promastigote culture filtrate proteins plus Corynebacterium parvum confers resistance to infection,vith L. major. To define immunogenic components of this protein mixture, we used sera from vaccinated mice to screen an L. major amastigote cDNA expression library. One of the immunoreactive clones thus obtained encoded a novel protein of L. major with a molecular mass of 22.1 kDa. The predicted amino acid sequence of this clone exhibited significant homology to eukaryotic thiol-specific-antioxidant (TSA) proteins. Therefore, we have designated this protein L. major TSA protein. Southern blot hybridization analyses indicate that there are multiple copies of the TSA gene in all species of Leishmania analyzed. Northern blot analyses demonstrated that the TSA gene is constitutively expressed in L. major promastigotes and amastigotes. Recombinant TSA protein containing an amino-terminal six-histidine tag was expressed in Escherichia coli with the pET17b system and was purified to homogeneity by affinity chromatography. Immunization of BALB/c mice with recombinant TSA protein resulted in the development of strong cellular immune responses and conferred protective immune responses against infection with L. major when the protein was combined,vith interleukin 12. In addition, recombinant TSA protein elicited in vitro proliferative responses from peripheral blood mononuclear cells of human leishmaniasis patients and significant TSA protein-specific antibody titers were detected in sera of both cutaneous-leishmaniasis and visceral-leishmaniasis patients. Together, these data suggest that the TSA protein may be useful as a component of a subunit vaccine against leishmaniasis.
C1 Infect Dis Res Inst, Seattle, WA 98104 USA.
   Corixa Corp, Seattle, WA 98104 USA.
   Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA.
   Univ Fed Bahia, Salvador, BA, Brazil.
RP Reed, SG (corresponding author), Infect Dis Res Inst, 1124 Columbia St,Suite 200, Seattle, WA 98104 USA.
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [TW00428] Funding Source: Medline; NIAID NIH HHSUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [AI25038,
   R01 AI025038] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038] Funding Source: NIH
   RePORTER
CR AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381
   ANDERSEN P, 1994, INFECT IMMUN, V62, P2536, DOI 10.1128/IAI.62.6.2536-2544.1994
   BATES PA, 1987, MOL BIOCHEM PARASIT, V26, P289, DOI 10.1016/0166-6851(87)90081-8
   BATES PA, 1988, EXP PARASITOL, V67, P199, DOI 10.1016/0014-4894(88)90067-7
   Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684
   BLANDER SJ, 1991, J IMMUNOL, V147, P285
   BUCHMULLERROUILLER Y, 1987, INFECT IMMUN, V55, P587
   CAMPOSNETO A, 1995, J EXP MED, V182, P1423, DOI 10.1084/jem.182.5.1423
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   CHAE HZ, 1993, J BIOL CHEM, V268, P16815
   CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017
   CHAE HZ, 1994, J BIOL CHEM, V269, P27670
   CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022
   Chakraborty R, 1996, MOL CELL BIOCHEM, V154, P23, DOI 10.1007/BF00248457
   CONNELL ND, 1993, P NATL ACAD SCI USA, V90, P11473, DOI 10.1073/pnas.90.24.11473
   FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9
   GHALIB HW, 1993, J CLIN INVEST, V92, P324, DOI 10.1172/JCI116570
   Goyal N, 1996, FREE RADICAL BIO MED, V21, P683, DOI 10.1016/0891-5849(96)00130-X
   HANDMAN E, 1995, INFECT IMMUN, V63, P4261, DOI 10.1128/IAI.63.11.4261-4267.1995
   HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530
   HUBBARD RD, 1992, CLIN EXP IMMUNOL, V87, P94
   Ilg T, 1996, J BIOL CHEM, V271, P21583, DOI 10.1074/jbc.271.35.21583
   ISHII T, 1993, J BIOL CHEM, V268, P18633
   JAMES SL, 1993, CURR OPIN IMMUNOL, V5, P518, DOI 10.1016/0952-7915(93)90032-N
   JARDIM A, 1991, J IMMUNOL, V147, P3538
   Klimowski L, 1997, MOL BIOCHEM PARASIT, V90, P297, DOI 10.1016/S0166-6851(97)00167-9
   LIEW FY, 1989, IMMUNOL TODAY, V10, P40, DOI 10.1016/0167-5699(89)90302-2
   LOVELACE JK, 1986, AM J TROP MED HYG, V35, P1121, DOI 10.4269/ajtmh.1986.35.1121
   MCMAHONPRATT D, 1993, INFECT IMMUN, V61, P3351, DOI 10.1128/IAI.61.8.3351-3359.1993
   McSorley SJ, 1997, INFECT IMMUN, V65, P171, DOI 10.1128/IAI.65.1.171-178.1997
   Mehlotra RK, 1996, CRIT REV MICROBIOL, V22, P295, DOI 10.3109/10408419609105484
   MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145
   MOUGNEAU E, 1995, SCIENCE, V268, P563, DOI 10.1126/science.7725103
   MULLER I, 1989, IMMUNOL REV, V112, P95, DOI 10.1111/j.1600-065X.1989.tb00554.x
   MULLER I, 1989, ANNU REV IMMUNOL, V7, P561, DOI 10.1146/annurev.iy.07.040189.003021
   MURRAY PJ, 1991, J BIOL CHEM, V266, P24477
   Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315
   OTOOLE PW, 1991, J BACTERIOL, V173, P505, DOI 10.1128/jb.173.2.505-513.1991
   PAL PG, 1992, INFECT IMMUN, V60, P4781, DOI 10.1128/IAI.60.11.4781-4792.1992
   REED SL, 1992, INFECT IMMUN, V60, P542, DOI 10.1128/IAI.60.2.542-549.1992
   REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055
   RUSSO DM, 1992, J IMMUNOL, V148, P202
   RUSSO DM, 1991, J IMMUNOL, V147, P3575
   SACKS DL, 1987, J IMMUNOL, V138, P908
   SCOTT P, 1990, J IMMUNOL, V144, P1075
   SCOTT P, 1991, J IMMUNOL, V147, P3149
   SEDER R, COMMUNICATION
   SKEIKY YAW, 1995, J EXP MED, V181, P1527, DOI 10.1084/jem.181.4.1527
   SKEIKY YAW, 1995, INFECT IMMUN, V63, P4105, DOI 10.1128/IAI.63.10.4105-4114.1995
   SOONG CJG, 1995, INFECT IMMUN, V63, P472, DOI 10.1128/IAI.63.2.472-477.1995
   SYMONS FM, 1994, MOL BIOCHEM PARASIT, V67, P103, DOI 10.1016/0166-6851(94)90100-7
   TORIAN BE, 1990, P NATL ACAD SCI USA, V87, P6358, DOI 10.1073/pnas.87.16.6358
   Webb JR, 1996, J IMMUNOL, V157, P5034
   WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x
   WILSON K, 1991, NUCLEIC ACIDS RES, V19, P5787, DOI 10.1093/nar/19.20.5787
   WILSON ME, 1995, INFECT IMMUN, V63, P2062, DOI 10.1128/IAI.63.5.2062-2069.1995
   XU D, 1995, IMMUNOLOGY, V85, P1
   ZARLEY JH, 1991, J CLIN INVEST, V88, P1511, DOI 10.1172/JCI115461
NR 58
TC 124
Z9 127
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD JUL
PY 1998
VL 66
IS 7
BP 3279
EP 3289
DI 10.1128/IAI.66.7.3279-3289.1998
PG 11
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA ZW149
UT WOS:000074379900035
PM 9632596
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Berman, JD
   Badaro, R
   Thakur, CP
   Wasunna, KM
   Behbehani, K
   Davidson, R
   Kuzoe, F
   Pang, L
   Weerasuriya, K
   Bryceson, ADM
AF Berman, JD
   Badaro, R
   Thakur, CP
   Wasunna, KM
   Behbehani, K
   Davidson, R
   Kuzoe, F
   Pang, L
   Weerasuriya, K
   Bryceson, ADM
TI Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral
   leishmaniasis in endemic developing countries
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID SODIUM STIBOGLUCONATE; KALA-AZAR; MUCOSAL LEISHMANIASIS; TOXICITY;
   REGIMENS; DRUG
AB Reported are the results of a study to determine the efficacy and safety of liposomal amphotericin B (AmBisome) for treating visceral leishmaniasis (kala-azar) in several developing countries where the disease is endemic (Brazil, India, and Kenya).
   At each study site, sequential cohorts of 10 patients each were treated with AmBisome at a dose of 2 mg.kg(-1).day(-1) (2 MKD). The first cohort received regimen 1:2 MKD on days 1-6 and day 10 (total dose: 14 mg/kg). If the efficacy with this regimen was satisfactory, a second cohort received regimen 2: 2 MKD on days 1-4 and day 10 (total dose: 10 mg/kg); and a third cohort received regimen 3:2 MKD on days 1, 5, and 10 (total dose: 6 mg/kg). In India, regimens 1, 2 and 3 (which were studied concurrently) each cured 100% of 10 patients. In Kenya, regimen 1 cured all 10 patients, regimen 2 cured 90% of 10 patients, but regimen 3 cured only 20% of 5 patients. In Brazil, regimen 1 was only partially curative: 5 of 13 patients (62%). Therefore, 15 patients were administered regimen 4 (2 MKD for 10 consecutive days; total dose, 20 mg/kg) and 13 patients were cured (83%).
   These results suggest that for the treatment of kala-azar the following doses of AmBisome should be administered: in India and Kenya, 2 mg/kg on days 1-4 and day 10; and in Brazil, 2 mg/kg on days 1-10.
C1 WHO, TDR Commun, CH-1211 Geneva 27, Switzerland.
   WHO, Steering Comm Drugs African Trypanosomiasis Chaga, CH-1211 Geneva, Switzerland.
   WHO, UNDP, World Bank, Special Programme Res & Training Trop Dis, CH-1211 Geneva 27, Switzerland.
   US Army Component, Armed Forces Res Inst Med Sci, Dept Bacteriol, Bangkok, Thailand.
   Univ Colombo, Dept Pharmacol, Fac Med, Colombo, Sri Lanka.
   Univ London Kings Coll Hosp, Hosp Trop Dis, London, England.
   Northwick Pk Hosp, Lister Unit Infect & Trop Dis, Harrow HA1 3UJ, Middx, England.
   WHO, Div Control Trop Dis, CH-1211 Geneva, Switzerland.
   Kenya Med Res Inst, Clin Res Ctr, Nairobi, Kenya.
   Balaji Utthan Sanastan, Patna, Bihar, India.
   Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Dept Biol, Washington, DC 20307 USA.
   Univ Fed Bahia, Infect Dis Unit, Hosp Univ Professor Edgard Santos, Salvador, BA, Brazil.
RP Berman, JD (corresponding author), WHO, TDR Commun, CH-1211 Geneva 27, Switzerland.
CR BERMAN JD, 1986, MOL BIOCHEM PARASIT, V20, P85, DOI 10.1016/0166-6851(86)90145-3
   CHULAY JD, 1983, AM J TROP MED HYG, V32, P474
   Davidson RN, 1996, CLIN INFECT DIS, V22, P938, DOI 10.1093/clinids/22.6.938
   DAVIDSON RN, 1994, Q J MED, V87, P75
   DAVIDSON RN, 1991, LANCET, V337, P1061, DOI 10.1016/0140-6736(91)91708-3
   FRANKE ED, 1994, AM J TROP MED HYG, V51, P77, DOI 10.4269/ajtmh.1994.51.77
   FRANKE ED, 1990, ANN INTERN MED, V113, P934, DOI 10.7326/0003-4819-113-12-934
   GASSER RA, 1994, CLIN INFECT DIS, V18, P83, DOI 10.1093/clinids/18.1.83
   HARDIE WD, 1992, J INFECT DIS, V166, P134, DOI 10.1093/infdis/166.1.134
   Hiemenz JW, 1996, CLIN INFECT DIS, V22, pS133, DOI 10.1093/clinids/22.Supplement_2.S133
   LEVINE SJ, 1991, ANN INTERN MED, V114, P664, DOI 10.7326/0003-4819-114-8-664
   MISHRA M, 1994, LANCET, V344, P1599, DOI 10.1016/S0140-6736(94)90406-5
   MISHRA M, 1992, LANCET, V340, P1256, DOI 10.1016/0140-6736(92)92952-C
   Russo R, 1996, J INFECTION, V32, P133, DOI 10.1016/S0163-4453(96)91343-2
   Seaman J, 1996, ANN INTERN MED, V124, P664, DOI 10.7326/0003-4819-124-7-199604010-00007
   Thakur C. P., 1995, National Medical Journal of India, V8, P13
   THAKUR CP, 1994, B WORLD HEALTH ORGAN, V72, P931
   THAKUR CP, 1993, INDIAN J MED RES-A, V97, P170
   Thakur CP, 1996, T ROY SOC TROP MED H, V90, P319, DOI 10.1016/S0035-9203(96)90271-0
NR 19
TC 119
Z9 118
U1 0
U2 2
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA DISTRIBUTION AND SALES, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 1998
VL 76
IS 1
BP 25
EP 32
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA ZQ227
UT WOS:000073836200004
PM 9615494
DA 2020-12-01
ER

PT J
AU Skeiky, YAW
   Benson, DR
   Costa, JLM
   Badaro, R
   Reed, SG
AF Skeiky, YAW
   Benson, DR
   Costa, JLM
   Badaro, R
   Reed, SG
TI Association of Leishmania heat shock protein 83 antigen and
   immunoglobulin G4 antibody titers in Brazilian patients with diffuse
   cutaneous leishmaniasis
SO INFECTION AND IMMUNITY
LA English
DT Article
ID INTERFERON-GAMMA; CYTOKINE PROFILE; IMMUNE-RESPONSES; INTERLEUKIN-4;
   IGE; CELLS; EPIDEMIOLOGY; ALPHA; IGG1
AB Diffuse cutaneous leishmaniasis (DCL) is characterized by the presence of numerous nonulcerated nodules and plaques containing large numbers of Leishmania amazonensis parasites and few lymphoid elements. The immune responses of DCL patients reflect severe antigen-specific T-cell deficiencies, while the antibody response to Leishmania antigens is often accentuated. We report herein on the Leishmania antigen-specific antibody subclass distribution in DCL patients and demonstrate that a dominant antigen contributing to the biased immunoglobulin G4 antibody subclass in sera of DCL patients is Leismania heat shock protein 83.
C1 INFECT DIS RES INST,SEATTLE,WA 98104.
   UNIV FED BAHIA,BR-40140 SALVADOR,BA,BRAZIL.
RP Skeiky, YAW (corresponding author), CORIXA CORP,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI25038] Funding Source: Medline; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038] Funding Source: NIH RePORTER
CR BADARO R, 1993, J INFECT DIS, V167, pS13, DOI 10.1093/infdis/167.Supplement_1.S13
   Badaro Roberto, 1993, P111
   BOGDAN C, 1990, EUR J IMMUNOL, V20, P1131, DOI 10.1002/eji.1830200528
   BRIERE F, 1994, J EXP MED, V179, P757, DOI 10.1084/jem.179.2.757
   BRIERE F, 1970, TREATMENT T R SOC TR, V64, P368
   CACERESDITTMAR G, 1993, CLIN EXP IMMUNOL, V91, P500, DOI 10.1111/j.1365-2249.1993.tb05931.x
   CASTES M, 1983, CLIN IMMUNOL IMMUNOP, V27, P176, DOI 10.1016/0090-1229(83)90068-5
   CONVIT J, 1972, T ROY SOC TROP MED H, V66, P603, DOI 10.1016/0035-9203(72)90306-9
   CONVIT J, 1993, T ROY SOC TROP MED H, V87, P444, DOI 10.1016/0035-9203(93)90030-T
   DILLON DC, 1995, P NATL ACAD SCI USA, V92, P7981, DOI 10.1073/pnas.92.17.7981
   GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747
   GHALIB HW, 1993, J CLIN INVEST, V92, P324, DOI 10.1172/JCI116570
   JONES TC, 1987, J INFECT DIS, V156, P73, DOI 10.1093/infdis/156.1.73
   KARP CL, 1993, J CLIN INVEST, V91, P1644, DOI 10.1172/JCI116372
   KAWANO Y, 1994, J IMMUNOL, V153, P4948
   LAINSON R, 1983, T ROY SOC TROP MED H, V77, P569, DOI 10.1016/0035-9203(83)90185-2
   LEBMAN DA, 1988, J EXP MED, V168, P853, DOI 10.1084/jem.168.3.853
   Marsden P. D., 1985, Leishmaniasis. (Human Parasitic Diseases Vol.1.), P183
   PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880
   PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341
   Rodriguez V, 1996, PARASITE IMMUNOL, V18, P341, DOI 10.1046/j.1365-3024.1996.d01-113.x
   SARFATI M, 1988, J IMMUNOL, V141, P2195
   SIBER GR, 1980, NEW ENGL J MED, V303, P178, DOI 10.1056/NEJM198007243030402
   SKEIKY YAW, 1995, J EXP MED, V181, P1527, DOI 10.1084/jem.181.4.1527
   SKEIKY YAW, 1995, INFECT IMMUN, V63, P4105, DOI 10.1128/IAI.63.10.4105-4114.1995
   SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127
   STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0
   TITUS RG, 1989, J EXP MED, V170, P2097, DOI 10.1084/jem.170.6.2097
NR 28
TC 17
Z9 18
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD DEC
PY 1997
VL 65
IS 12
BP 5368
EP 5370
DI 10.1128/IAI.65.12.5368-5370.1997
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA YJ227
UT WOS:A1997YJ22700071
PM 9393843
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Aaby, P
   Babiker, A
   Darbyshire, J
   Nunn, A
   Barreto, S
   Alonso, P
   Badaro, R
   Barros, F
   Victoria, C
   Binka, F
   Biryahwaho, B
   Byabamazima, C
   Sempala, S
   Tugume, B
   Kalebu, P
   KengeyaKayondo, J
   Whitworth, J
   Paxton, L
   Convit, J
   Corrah, T
   McAdam, K
   Datta, M
   Dowlati, Y
   Fine, P
   Hall, A
   Hayes, R
   Jaffar, S
   Ross, D
   Smith, P
   deFrancisco, A
   Godal, T
   John, J
   Lansang, MA
   TanTorres, T
   Morrow, R
   Nicoll, A
   Peckham, C
   Serwadda, D
   Tanner, M
AF Aaby, P
   Babiker, A
   Darbyshire, J
   Nunn, A
   Barreto, S
   Alonso, P
   Badaro, R
   Barros, F
   Victoria, C
   Binka, F
   Biryahwaho, B
   Byabamazima, C
   Sempala, S
   Tugume, B
   Kalebu, P
   KengeyaKayondo, J
   Whitworth, J
   Paxton, L
   Convit, J
   Corrah, T
   McAdam, K
   Datta, M
   Dowlati, Y
   Fine, P
   Hall, A
   Hayes, R
   Jaffar, S
   Ross, D
   Smith, P
   deFrancisco, A
   Godal, T
   John, J
   Lansang, MA
   TanTorres, T
   Morrow, R
   Nicoll, A
   Peckham, C
   Serwadda, D
   Tanner, M
TI Ethics of HIV trials
SO LANCET
LA English
DT Letter
C1 EPIDEMIOL RES UNIT, COPENHAGEN, DENMARK.
   UCL, SCH MED, MRC, HIV CLIN TRIALS CTR, LONDON W1N 8AA, ENGLAND.
   CTR PESQUISAS RENE RACHOU FIOCRUZ, LAB EPIDEMIOL, BELO HORIZONTE, MG, BRAZIL.
   HOSP CLIN BARCELONA, EPIDEMIOL RES UNIT, BARCELONA, SPAIN.
   UNIV FED BAHIA, BRAZILIAN SOC INFECT DIS, SALVADOR, BA, BRAZIL.
   UNIV FED PELOTAS, DEPT SOCIAL MED, PELOTAS, BRAZIL.
   MINIST HLTH, NAVRONGO HLTH RES CTR, NAVRONGO, GHANA.
   AREA HOSP VARGAS, INST BIOMED, CARACAS, VENEZUELA.
   MRC LABS, BANJUL, GAMBIA.
   INDIAN COUNCIL MED RES, TB RES CTR, MADRAS, TAMIL NADU, INDIA.
   CTR RES & TRAINING SKIN DIS & LEPROSY, TEHRAN, IRAN.
   LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND.
   ICDDR B, PUBL HLTH SCI DIV, DHAKA, BANGLADESH.
   WHO, UNDP, WORLD BANK, SPECIAL PROGRAMME RES & TRAINING TROP DIS, GENEVA, SWITZERLAND.
   CHRISTIAN MED COLL & HOSP, VELLORE, TAMIL NADU, INDIA.
   UNIV PHILIPPINES, COLL MED, CLIN EPIDEMIOL UNIT, MANILA, PHILIPPINES.
   JOHNS HOPKINS UNIV, DEPT INT HLTH, BALTIMORE, MD USA.
   PUBL HLTH LAB SERV, CTR COMMUNICABLE DIS SURVEILLANCE, LONDON NW9 5EQ, ENGLAND.
   INST CHILD HLTH, DEPT EPIDEMIOL & PUBL HLTH, LONDON, ENGLAND.
   MAKERERE UNIV, SCH MED, INST PUBL HLTH, KAMPALA, UGANDA.
   SWISS TROP INST, CH-4002 BASEL, SWITZERLAND.
RI Alonso, Pedro L/AAZ-3645-2020; Barreto, Sandhi Maria M/A-5140-2012;
   Barreto, Sandhi/D-2855-2014; Victora, Cesar/D-4476-2013
OI Alonso, Pedro L/0000-0003-3292-3443; Barreto, Sandhi Maria
   M/0000-0003-4392-5428; Lansang, Mary Ann/0000-0002-6606-0466; Jaffar,
   Shabbar/0000-0002-9615-1588; Barreto, Sandhi/0000-0001-7383-7811; Hayes,
   Richard/0000-0002-1729-9892; Nunn, Andrew/0000-0002-9158-4595; Victora,
   Cesar/0000-0002-2465-2180; Aaby, Peter/0000-0001-8331-1389; Smith,
   Peter/0000-0003-0080-7560
CR Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   1997, LANCET, V350, P897
NR 3
TC 11
Z9 11
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD NOV 22
PY 1997
VL 350
IS 9090
BP 1546
EP 1546
DI 10.1016/S0140-6736(97)26047-2
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA YH115
UT WOS:A1997YH11500043
PM 9388413
DA 2020-12-01
ER

PT J
AU Bittencourt, AL
   Badaro, R
   Costa, J
   Barral, A
   Badaro, F
   Carvalho, EM
AF Bittencourt, AL
   Badaro, R
   Costa, J
   Barral, A
   Badaro, F
   Carvalho, EM
TI Effect of pentavalent antimonial treatment on the histopathological and
   ultrastructural aspects of diffuse cutaneous leishmaniasis due to
   Leishmania amazonensis
SO EUROPEAN JOURNAL OF DERMATOLOGY
LA English
DT Article
DE IFN-gamma therapy; diffuse cutaneous Leishmaniasis; Leishmania
   amazonensis; pathology of tegumentary Leishmaniasis
ID INTERFERON-GAMMA
AB The histopathological and ultrastructural aspects of six patients with diffuse cutaneous leishmaniasis (three with the polar form and three with the sub-polar and borderline forms) during and after treatment with pentavalent antimony associated with IFN-gamma is presented. In most of the biopsies a marked decrease or disappearence of the parasitism and of the macrophagic aspect associated with an increase in the intensity of the lymphoplasmacytic infiltration and appearance of granulomas was observed in two cases. These aspects indicated a cell-mediated immune response that in two cases were enough to produce clearing of parasitism and healing of the lesions demonstrating the effectiveness of the treatment associating pentavalent antimony with IFN-gamma.
C1 FED UNIV MARANHAO,FAC MED,DEPT INFECT & PARASIT DIS,SAO LUIS,BRAZIL.
RP Bittencourt, AL (corresponding author), UNIV FED BAHIA,SCH MED,DEPT PATHOL & INTERNAL MED,SALVADOR,BA,BRAZIL.
RI Barral, Aldina/B-4191-2009
OI Barral, Aldina/0000-0002-7177-464X
CR BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104
   BARRAL A, 1995, INT J DERMATOL, V34, P474, DOI 10.1111/j.1365-4362.1995.tb00613.x
   BITTENCOURT A, 1989, MEM I OSWALDO CRUZ, V84, P585, DOI 10.1590/S0074-02761989000400022
   Bittencourt A L, 1983, Med Cutan Ibero Lat Am, V11, P265
   BITTENCOURT AL, 1990, MEM I OSWALDO CRUZ, V85, P53, DOI 10.1590/S0074-02761990000100008
   BITTENCOURT AL, 1992, INT J DERMATOL, V31, P568, DOI 10.1111/j.1365-4362.1992.tb02721.x
   BITTENCOURT AL, 1995, TROPICAL PATHOLOGY, P597
   CASLES M, 1983, CLIN IMMUNOL IMMUNOP, V27, P176
   CONVIT J, 1974, CIBA F S, V20, P159
   ITOH K, 1985, J IMMUNOL, V134, P3124
   Moriearty P.I., 1978, Revista do Instituto de Medicina Tropical de Sao Paulo, V20, P15
   MURRAY HW, 1983, J CLIN INVEST, V72, P1506, DOI 10.1172/JCI111107
   POMPEU ML, 1992, EXP PARASITOL, V74, P169, DOI 10.1016/0014-4894(92)90044-B
   RIDLEY DS, 1983, J PATHOL, V141, P83, DOI 10.1002/path.1711410109
   VELASCO O, 1989, AM J TROP MED HYG, V41, P280, DOI 10.4269/ajtmh.1989.41.280
NR 15
TC 1
Z9 1
U1 0
U2 0
PU JOHN LIBBEY EUROTEXT LTD
PI MONTROUGE
PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE
SN 1167-1122
J9 EUR J DERMATOL
JI Eur. J. Dermatol.
PD JUN
PY 1996
VL 6
IS 4
BP 264
EP 267
PG 4
WC Dermatology
SC Dermatology
GA UP090
UT WOS:A1996UP09000004
DA 2020-12-01
ER

PT J
AU ASHFORD, DA
   BOZZA, M
   FREIRE, M
   MIRANDA, JC
   SHERLOCK, I
   EULALIO, C
   LOPES, U
   FERNANDES, O
   DEGRAVE, W
   BARKER, RH
   BADARO, R
   DAVID, JR
AF ASHFORD, DA
   BOZZA, M
   FREIRE, M
   MIRANDA, JC
   SHERLOCK, I
   EULALIO, C
   LOPES, U
   FERNANDES, O
   DEGRAVE, W
   BARKER, RH
   BADARO, R
   DAVID, JR
TI COMPARISON OF THE POLYMERASE CHAIN-REACTION AND SEROLOGY FOR THE
   DETECTION OF CANINE VISCERAL LEISHMANIASIS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID DIRECT AGGLUTINATION-TEST; KINETOPLAST DNA; SENSITIVE DETECTION; ENDEMIC
   AREA; AMPLIFICATION; DIAGNOSIS; SERODIAGNOSIS; INFECTION; DISEASE;
   BRAZIL
AB The polymerase chain reaction (PCR) and serology was evaluated for the diagnosis of canine visceral leishmaniasis in Bahia, Brazil in a study of 125 dogs. The PCR was 100% sensitive in 25 dogs that had Leishmania demonstrated by either culture or hamster inoculation. It was 100% specific for 35 dogs from the northeastern United States, all were PCR negative. However, 22 of 54 Brazilian dogs that were culture-hamster inoculation-negative were positive by PCR. The nature of the PCR product was identified by hybridization with specific Leishmania probes. Whereas the sensitivity of serology in relationship to infection, as determined by hamster or culture assay was more than 80%, sensitivity of serology was only 63% when compared with PCR. These results raise questions about the use of serology to detect Leishmania infection in dogs, and suggest that the PCR might serve as a better gold standard to define Leishmania infection than culture or hamster inoculation.
C1 UNIV FED RIO DE JANEIRO,INST BIOFIS CARLOS CHAGAS FILHO,RIO JANEIRO,BRAZIL.
   UNIV FED BAHIA,BAHIA BLANCA,ARGENTINA.
   FDN OSWALDO CRUZ,BAHIA BLANCA,ARGENTINA.
   CORNELL UNIV,COLL MED,NEW YORK,NY.
   FDN OSWALDO CRUZ,RIO JANEIRO,BRAZIL.
RP ASHFORD, DA (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT TROP PUBL HLTH,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.
RI Degrave, Wim/B-4162-2009; Lopes, Ulisses/N-4416-2013; Lopes, Ulisses
   Gazos/T-6634-2019
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-16305-13] Funding Source: Medline
CR ABRANCHES P, 1991, J PARASITOL, V77, P557, DOI 10.2307/3283159
   ASHFORD DA, 1993, AM J TROP MED HYG, V48, P1
   AVILA HA, 1991, MOL BIOCHEM PARASIT, V48, P211, DOI 10.1016/0166-6851(91)90116-N
   BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   BADARO R, 1981, AM J TROP MED HYG, V32, P480
   BADARO R, 1987, P INT WORKSHOP CONTR, pB1
   BARKER DC, 1989, PARASITOLOGY, V99, P129
   BOZZA M, 1995, T ROY SOC TROP MED H, V89, P333, DOI 10.1016/0035-9203(95)90569-3
   BURG JL, 1989, J CLIN MICROBIOL, V27, P1787, DOI 10.1128/JCM.27.8.1787-1792.1989
   DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS, P154
   DYE C, 1993, EPIDEMIOL INFECT, V110, P647, DOI 10.1017/S0950268800051074
   EVANS TG, 1990, AM J TROP MED HYG, V42, P118, DOI 10.4269/ajtmh.1990.42.118
   GRANDONI LM, 1988, T R SOC TROP MED HYG, V82, P568
   HARITH AE, 1986, T ROY SOC TROP MED H, V80, P583, DOI 10.1016/0035-9203(86)90149-5
   HOWARD MK, 1991, MOL BIOCHEM PARASIT, V44, P63, DOI 10.1016/0166-6851(91)90221-Q
   LABORDA J, 1981, NUCLEIC ACIDS RES, V19, P3998
   LANOTTE G, 1979, ANN PARASIT HUM COMP, V54, P277, DOI 10.1051/parasite/1979543277
   LOPES UG, 1986, MOL BIOCHEM PARASIT, V20, P77, DOI 10.1016/0166-6851(86)90144-1
   MANCIANTI F, 1986, TROP MED PARASITOL, V37, P110
   NEOGY AB, 1992, AM J TROP MED HYG, V47, P772, DOI 10.4269/ajtmh.1992.47.772
   PERRIN LH, 1990, BLOOD, V76, P641
   PINELLI E, 1994, INFECT IMMUN, V62, P229, DOI 10.1128/IAI.62.1.229-235.1994
   POZIO E, 1981, ACTA TROP, V38, P383
   REED SG, 1990, AM J TROP MED HYG, V43, P632, DOI 10.4269/ajtmh.1990.43.632
   RODGERS MR, 1990, EXP PARASITOL, V71, P267, DOI 10.1016/0014-4894(90)90031-7
   RODGERS MR, 1987, P NATL ACAD SCI USA, V84, P565
   RUSSELL ME, 1993, P NATL ACAD SCI USA, V90, P6086, DOI 10.1073/pnas.90.13.6086
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   SCHNUR LF, 1987, LEISHMANIASES BIOL M, V1, P499
   SLAPPENDEL RJ, 1988, VET QUART, V10, P1
   SMYTH AJ, 1992, PARASITOLOGY, V105, P183, DOI 10.1017/S0031182000074096
NR 31
TC 107
Z9 114
U1 0
U2 5
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD SEP
PY 1995
VL 53
IS 3
BP 251
EP 255
DI 10.4269/ajtmh.1995.53.251
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA RY073
UT WOS:A1995RY07300009
PM 7573707
DA 2020-12-01
ER

PT J
AU SKEIKY, YAW
   GUDERIAN, JA
   BENSON, DR
   BACELAR, O
   CARVALHO, EM
   KUBIN, M
   BADARO, R
   TRINCHIERI, G
   REED, SG
AF SKEIKY, YAW
   GUDERIAN, JA
   BENSON, DR
   BACELAR, O
   CARVALHO, EM
   KUBIN, M
   BADARO, R
   TRINCHIERI, G
   REED, SG
TI A RECOMBINANT LEISHMANIA ANTIGEN THAT STIMULATES HUMAN PERIPHERAL-BLOOD
   MONONUCLEAR-CELLS TO EXPRESS A TH1-TYPE CYTOKINE PROFILE AND TO PRODUCE
   INTERLEUKIN-12
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID AMERICAN CUTANEOUS LEISHMANIASIS; INTERFERON-GAMMA-PRODUCTION;
   NECROSIS-FACTOR-ALPHA; TRANSLATION INITIATION-FACTOR;
   NATURAL-KILLER-CELLS; T-CELL; BRAZILIENSIS-BRAZILIENSIS;
   MEDIATED-IMMUNITY; INDUCTION; GENES
AB Leishmania braziliensis causes cutaneous and mucosal leishmaniasis in humans. Most patients with cutaneous leishmaniasis heal spontaneously and may therefore have developed protective immunity. There appears to be a mixed cytokine profile associated with active cutaneous or mucosal disease, and a dominant T helper (Th)1-type response associated with healing. Leishmanial antigens that elicit these potent proliferative and cytokine responses from peripheral blood mononuclear cells (PBMC) are now being identified. Herein, we report on the cloning and expression of a L. braziliensis gene homologous to the eukaryotic ribosomal protein eIF4A (LeIF) and patient PBMC responses to rLeIF. Patients with mucosal and self-healing cutaneous disease had significantly higher proliferative responses than those with cutaneous lesions. Whereas the parasite lysate stimulated patient PBMC to produce a mixed Th1/Th2-type cytokine profile, LeIF stimulated the production of interferon gamma (IFN-gamma), interleukin 2 (IL-2), and tumor necrosis factor alpha but not IL-4 or IL-10. Recombinant LeIF (rLeIF) downregulated both IL-10 mRNA in the ''resting'' PBMC of leishmaniasis patients and LPS-induced IL-10 production by patient PBMC, rLeIF also stimulated the production of IL-12 in cultured PBMC from both patients and uninfected individuals. The production of IFN-gamma by patient PBMC stimulated with either rLeIF or parasite lysate was IL-12 dependent, whereas anti-IFN-gamma monoclonal antibody only partially blocked the LeIF-induced production of IL-12. In vitro production of both IFN-gamma and IL-12 was abrogated by exogenous human recombinant IL-10. Therefore, we have identified a recombinant leishmanial antigen that elicits IL-12 production and Th1-type responses in patients as well as IL-12 production in normal human PBMC.
C1 INFECT DIS RES INST,SEATTLE,WA 98104.
   UNIV FED BAHIA,BR-40110160 SALVADOR,BA,BRAZIL.
   WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104.
RI Trinchieri, Giorgio/F-9369-2015
OI Trinchieri, Giorgio/0000-0001-5892-7464
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [TW-00428] Funding Source: Medline; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI-22726, AI-25038] Funding Source: Medline; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI022726, R01AI025038, R01AI025038, R01AI025038,
   R01AI022726, R01AI022726, R01AI025038, R01AI022726, R01AI025038,
   R01AI025038, R01AI025038, R01AI022726, R01AI022726, R01AI025038,
   R01AI022726, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI022726, R01AI022726, R01AI025038, R01AI025038, R01AI025038,
   R01AI022726, R01AI025038, R01AI025038, R01AI025038, R01AI025038] Funding
   Source: NIH RePORTER
CR AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381
   BELOSEVIC M, 1989, J IMMUNOL, V143, P266
   BOGDAN C, 1990, EUR J IMMUNOL, V20, P1131, DOI 10.1002/eji.1830200528
   BURNS JM, 1993, P NATL ACAD SCI USA, V90, P775, DOI 10.1073/pnas.90.2.775
   CACERESDITTMAR G, 1993, CLIN EXP IMMUNOL, V91, P500, DOI 10.1111/j.1365-2249.1993.tb05931.x
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   CASTES M, 1983, CLIN IMMUNOL IMMUNOP, V27, P176, DOI 10.1016/0090-1229(83)90068-5
   CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869
   CHOMARAT P, 1993, J EXP MED, V177, P523, DOI 10.1084/jem.177.2.523
   CONVIT J, 1993, T ROY SOC TROP MED H, V87, P444, DOI 10.1016/0035-9203(93)90030-T
   COSTA JML, 1987, T ROY SOC TROP MED H, V81, P606, DOI 10.1016/0035-9203(87)90424-X
   DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041
   DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387
   EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25
   FINKELMAN FD, 1994, J EXP MED, V179, P1563, DOI 10.1084/jem.179.5.1563
   GAZZINELLI RT, 1993, P NATL ACAD SCI USA, V90, P6115, DOI 10.1073/pnas.90.13.6115
   GHALIB HW, 1993, J CLIN INVEST, V92, P324, DOI 10.1172/JCI116570
   HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505
   HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338
   JONES TC, 1987, J INFECT DIS, V156, P73, DOI 10.1093/infdis/156.1.73
   KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827
   KUBIN M, 1994, BLOOD, V83, P1847
   KUBIN M, 1994, J EXP MED, V180, P211, DOI 10.1084/jem.180.1.211
   LIEW FY, 1989, EUR J IMMUNOL, V9, P1227
   LINDER P, 1988, NUCLEIC ACIDS RES, V16, P10359, DOI 10.1093/nar/16.21.10359
   LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0
   MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199
   Marsden P. D., 1985, Leishmaniasis. (Human Parasitic Diseases Vol.1.), P183
   MURPHY EE, 1994, J EXP MED, V180, P223, DOI 10.1084/jem.180.1.223
   NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x
   OWTTRIM GW, 1991, NUCLEIC ACIDS RES, V19, P5491, DOI 10.1093/nar/19.20.5491
   PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341
   REED SG, 1993, CURR OPIN IMMUNOL, V5, P524, DOI 10.1016/0952-7915(93)90033-O
   REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447
   SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115
   SCOTT P, 1987, J IMMUNOL, V139, P221
   SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337
   SKEIKY YAW, 1992, J EXP MED, V176, P201, DOI 10.1084/jem.176.1.201
   STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808
   SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797
   TITUS RG, 1989, J EXP MED, V170, P2097, DOI 10.1084/jem.170.6.2097
   TRINCHIERI G, 1993, IMMUNOL TODAY, V14, P335, DOI 10.1016/0167-5699(93)90230-I
   TRIPP CS, 1993, P NATL ACAD SCI USA, V90, P3725, DOI 10.1073/pnas.90.8.3725
   VIERA P, 1991, P NATL ACAD SCI USA, V88, P1172
   WANIDWORANUN C, 1993, J IMMUNOL, V151, P6853
   WOLF SF, 1991, J IMMUNOL, V146, P3074
   WYNN TA, 1994, J EXP MED, V179, P1551, DOI 10.1084/jem.179.5.1551
NR 47
TC 144
Z9 148
U1 0
U2 5
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 222 E 70TH STREET, NEW YORK, NY 10021
SN 0022-1007
J9 J EXP MED
JI J. Exp. Med.
PD APR 1
PY 1995
VL 181
IS 4
BP 1527
EP 1537
DI 10.1084/jem.181.4.1527
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA QQ192
UT WOS:A1995QQ19200026
PM 7699334
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU CUNHA, S
   FREIRE, M
   EULALIO, C
   CRITOSVAO, J
   NETTO, E
   JOHNSON, WD
   REED, SG
   BADARO, R
AF CUNHA, S
   FREIRE, M
   EULALIO, C
   CRITOSVAO, J
   NETTO, E
   JOHNSON, WD
   REED, SG
   BADARO, R
TI VISCERAL LEISHMANIASIS IN A NEW ECOLOGICAL NICHE NEAR A MAJOR
   METROPOLITAN-AREA OF BRAZIL
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE LEISHMANIASIS; VISCERAL LEISHMANIASIS; NEW FOCUS; BRAZIL
ID ANTIGEN; SELECTION
AB In 1991, a community cross-sectional study was conducted in a village situated near the beach and close to Salvador, the capital city of Bahia, in Brazil, to determine the prevalence of visceral leishmaniasis since 1989. A serological survey was made of human and canine reservoirs and an intradermal skin test for leishmaniasis was used to assess cellular immune responses. Nearly 30% of the 243 individuals in the study area had positive skin tests and 14% had positive serology, the latter being compatible with recent infection; 29 of 460 dogs examined were seropositive. A possible association was observed between human infection and the presence of dogs in or near residences, but not between human infection and malnutrition. This report describes the evolution of a new focus of visceral leishmaniasis, its expansion toward a metropolitan area, and current measures taken to control the epidemic.
C1 UNIV FED BAHIA,DEPT PREVENT MED,SALVADOR,BA,BRAZIL.
   UNIV BAHIA,UNIV HOSP PROFESSOR EDGARD SANTOS,TROP DIS LAB,SALVADOR,BA,BRAZIL.
   NATL FDN HLTH,REG DIRECTORATE BAHIA,SALVADOR,BA,BRAZIL.
   CORNELL UNIV,COLL MED,DIV INT MED,NEW YORK,NY 10021.
   INFECT DIS RES INST,SEATTLE,WA.
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761; Cunha, Sergio/0000-0002-4926-3827
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P50AI030639, P01AI026506, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P01AI016282, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P01AI016282, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P01AI016282, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P01AI016282, P01AI016282, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P01AI016282,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P01AI016282, P01AI016282, P50AI030639, P01AI026506, P50AI030639,
   P50AI030639, P01AI016282, P50AI030639, P50AI030639, P01AI016282,
   P01AI026506, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P01AI016282,
   P50AI030639, P50AI030639, P01AI026506, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P01AI016282, P50AI030639,
   P01AI026506, P50AI030639, P50AI030639, P01AI016282, P50AI030639,
   P01AI016282, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P01AI016282,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI16282, AI30639,
   AI26506] Funding Source: Medline
CR ASHFORD DA, 1993, AM J TROP MED HYG, V48, P1
   BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BHATTACHARYYA PK, 1981, T ROY SOC TROP MED H, V75, P333, DOI 10.1016/0035-9203(81)90356-4
   BURNS JM, 1993, P NATL ACAD SCI USA, V90, P775, DOI 10.1073/pnas.90.2.775
   CERF BJ, 1987, J INFECT DIS, V156, P1030, DOI 10.1093/infdis/156.6.1030
   COSTA CHN, 1990, REV SAUDE PUBL, V24, P361, DOI 10.1590/S0034-89101990000500003
   LAINSON R, 1983, T ROY SOC TROP MED H, V77, P569, DOI 10.1016/0035-9203(83)90185-2
   Marques A C, 1986, Rev Bras Malariol Doencas Trop, V38, P51
   Mott K. E., 1991, Bulletin of the World Health Organization, V69, P9
   PEREA WA, 1991, T ROY SOC TROP MED H, V85, P48, DOI 10.1016/0035-9203(91)90152-O
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   SAFJANOVA VM, 1971, B WORLD HEALTH ORGAN, V44, P561
   SHERLOCK I A, 1964, Rev Bras Malariol Doencas Trop, V16, P19
   WATERLOW JC, 1977, B WORLD HEALTH ORGAN, V55, P489
   1986, B WORLD HEALTH ORGAN, V64, P929
NR 17
TC 45
Z9 49
U1 0
U2 3
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAR-APR
PY 1995
VL 89
IS 2
BP 155
EP 158
DI 10.1016/0035-9203(95)90474-3
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA RW847
UT WOS:A1995RW84700007
PM 7778139
DA 2020-12-01
ER

PT J
AU BADARO, R
   NASCIMENTO, C
   CARVALHO, JS
   BADARO, F
   RUSSO, D
   HO, JL
   REED, SG
   JOHNSON, WD
   JONES, TC
AF BADARO, R
   NASCIMENTO, C
   CARVALHO, JS
   BADARO, F
   RUSSO, D
   HO, JL
   REED, SG
   JOHNSON, WD
   JONES, TC
TI RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
   REVERSES NEUTROPENIA AND REDUCES SECONDARY INFECTIONS IN VISCERAL
   LEISHMANIASIS
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy
CY OCT   19, 1993
CL NEW ORLEANS, LA
SP AMER SOC MICROBIOL
ID T-CELL CLONES; INTERFERON-GAMMA; DRUG-THERAPY; DONOVANI
AB Twenty-four patients with acute visceral leishmaniasis and leukopenia (<1500 neutrophils/mm(3)) due to Leishmania chagasi were studied, 4 in an open-label pilot study and 20 in a double-blind, placebo-controlled trial. Patients received granulocyte-macrophage colony-stimulating factor (GM-CSF), 5 mu g/kg daily, or placebo for 10 days, plus 10-20 mg/kg pentavalent antimony daily for 20 days. In GM-CSF recipients, neutrophil counts increased threefold and fourfold over baseline at 5 and 10 days, respectively, and were significantly higher than those in placebo recipients (P < .02). Eosinophil and monocyte counts were significantly increased in GM-CSF recipients at 10 days (P less than or equal to .03). Secondary infections occurred in 3 GM-CSF and in 8 placebo recipients (P = .04). All patients had complete resolution of their leishmaniasis at 3 months. Few adverse events were recorded. GM-CSF, 5 mu g/kg daily for 10 days, was safe, rapidly reversed neutropenia, and reduced the number of secondary infections in patients with leishmaniasis.
C1 CORNELL UNIV,COLL MED,DIV INTERNAL MED,NEW YORK,NY 10021.
   UNIV FED BAHIA,BR-40210 SALVADOR,BA,BRAZIL.
   SANDOZ PHARMA LTD,CLIN RES,CH-4002 BASEL,SWITZERLAND.
   SEATTLE BIOMED RES INST,SEATTLE,WA 98109.
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [TW-00018] Funding Source: Medline; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI-16282] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282] Funding Source: NIH RePORTER
CR ADDISON IE, 1989, CLIN EXP IMMUNOL, V76, P149
   ANDRADE TM, 1990, J INFECT DIS, V162, P1354, DOI 10.1093/infdis/162.6.1354
   BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   BADARO R, 1993, J INFECT DIS, V167, pS13, DOI 10.1093/infdis/167.Supplement_1.S13
   BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104
   CARVALHO EM, 1989, J CLIN INVEST, V83, P860, DOI 10.1172/JCI113969
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   CHULAY JD, 1983, AM J TROP MED HYG, V32, P475, DOI 10.4269/ajtmh.1983.32.475
   DEWITTE T, 1992, BLOOD, V79, P1359
   GERHARTZ HH, IN PRESS LEUKEMIA
   GULATI SC, 1992, ANN INTERN MED, V116, P177, DOI 10.7326/0003-4819-116-3-177
   HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296
   HO JL, 1990, J INFECT DIS, V162, P224, DOI 10.1093/infdis/162.1.224
   HO JL, 1992, J INFECT DIS, V165, P344, DOI 10.1093/infdis/165.2.344
   JONES TC, 1993, EUR J CANCER, V29A, pS10, DOI 10.1016/0959-8049(93)90625-P
   KEMP M, 1993, INFECT IMMUN, V61, P1069, DOI 10.1128/IAI.61.3.1069-1073.1993
   LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P99
   LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P28
   PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538
   REED SG, 1987, J EXP MED, V166, P1734, DOI 10.1084/jem.166.6.1734
   SMITH PD, 1990, J INFECT DIS, V161, P999, DOI 10.1093/infdis/161.5.999
   WEISER WY, 1987, J EXP MED, V166, P1436, DOI 10.1084/jem.166.5.1436
   1990, WHO TECH REP SER, V793, P1
NR 24
TC 47
Z9 47
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD AUG
PY 1994
VL 170
IS 2
BP 413
EP 418
DI 10.1093/infdis/170.2.413
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA NZ467
UT WOS:A1994NZ46700026
PM 8035028
DA 2020-12-01
ER

PT J
AU SKEIKY, YAW
   BENSON, DR
   ELWASILA, M
   BADARO, R
   BURNS, JM
   REED, SG
AF SKEIKY, YAW
   BENSON, DR
   ELWASILA, M
   BADARO, R
   BURNS, JM
   REED, SG
TI ANTIGENS SHARED BY LEISHMANIA SPECIES AND TRYPANOSOMA-CRUZI -
   IMMUNOLOGICAL COMPARISON OF THE ACIDIC RIBOSOMAL P0 PROTEINS
SO INFECTION AND IMMUNITY
LA English
DT Article
ID AMERICAN VISCERAL LEISHMANIASIS; CIRCULATING IMMUNE-COMPLEXES; SYSTEMIC
   LUPUS-ERYTHEMATOSUS; CASEIN KINASE-II; CHAGAS-DISEASE;
   SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; EUKARYOTIC RIBOSOMES;
   DONOVANI-CHAGASI; IDENTIFICATION
AB Patients with visceral leishmaniasis produce high levels of immunoglobulin, but the specificities of antibodies produced are not well characterized. In an effort to identify leishmania antigens that are specific to Leishmania species or are cross-reactive with other parasitic protozoa, we have cloned and characterized full-length genomic and cDNA clones encoding a Leishmania chagasi acidic ribosomal antigen, LcP0, recognized during human infections. The protein is homologous to the Trypanosoma cruzi and human ribosomal proteins TcP0 and HuP0, respectively. Unlike most higher eukaryotes, but similar to TcP0, LcP0 has a C-terminal heptapeptide sequence resembling those of the archaebacterial acidic (P-like) proteins. The highly charged C-terminal acidic domain of LcP0 contains a serine residue typically found in most eukaryotes but lacking in all T. cruzi P proteins we have characterized thus far. L. chagasi-infected individuals as well as those with T. cruzi infections have antibodies cross-reactive,vith recombinant LcP0 and TcP0 as well as HuP0. However, the properties of anti-P0 antibodies in T. cruzi and L. chagasi infection sera are quite different. Through the use of synthetic peptides, we showed that while T. cruzi infection anti-TcP0 antibodies are exclusively directed against the C-terminal domain of TcP0, L. chagasi infection sera contain antibodies reactive with epitopes other than the C-terminal sequence of LcP0. Thus, anti-LcP0 antibodies in L. chagasi infection sera represent the first characterized deviation from the restricted immunodominant C-terminal epitope involved in the generation of anti-P0 antibodies following infection or autoimmune diseases.
C1 INFECT DIS RES INST,SEATTLE,WA 98109.
   FAC SCI ELAIN,DEPT BIOL,ELAIN,U ARAB EMIRATES.
   UNIV KHARTOUM,FAC SCI,DEPT ZOOL,KHARTOUM,SUDAN.
   UNIV FED BAHIA,BR-40140 SALVADOR,BA,BRAZIL.
   MEHARRY MED COLL,NASHVILLE,TN 37208.
   CORNELL UNIV,COLL MED,NEW YORK,NY 10021.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-25038, AI-22726, AI-30639] Funding
   Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P50AI030639, R01AI022726, P50AI030639,
   P50AI030639, P50AI030639, R01AI022726, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, P50AI030639, P50AI030639, P50AI030639, R01AI025038,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, R01AI025038, P50AI030639, R01AI025038, P50AI030639,
   R01AI025038, R01AI022726, R01AI025038, P50AI030639, R01AI025038,
   P50AI030639, P50AI030639, P50AI030639, R01AI025038, R01AI025038,
   R01AI025038, R01AI022726, P50AI030639, R01AI025038, P50AI030639,
   P50AI030639, P50AI030639, R01AI025038, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R01AI025038, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R01AI025038, P50AI030639, R01AI025038,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, R01AI025038, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, R01AI022726, P50AI030639, P50AI030639, P50AI030639,
   R01AI022726, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R01AI022726, R01AI025038, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, R01AI025038, P50AI030639,
   R01AI022726, R01AI025038, R01AI022726, P50AI030639, P50AI030639,
   R01AI025038, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R01AI025038, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, R01AI025038, R01AI025038, P50AI030639,
   R01AI022726, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639] Funding Source: NIH RePORTER
CR ARAUJO FG, 1986, INFECT IMMUN, V53, P179, DOI 10.1128/IAI.53.1.179-185.1986
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BURNS JM, 1991, J IMMUNOL, V146, P742
   BURNS JM, 1993, P NATL ACAD SCI USA, V90, P775, DOI 10.1073/pnas.90.2.775
   BURNS JM, 1992, P NATL ACAD SCI USA, V89, P1239, DOI 10.1073/pnas.89.4.1239
   CAMARGO ME, 1969, AM J TROP MED HYG, V18, P500, DOI 10.4269/ajtmh.1969.18.500
   CAMPOSNETO N, 1982, INFECT IMMUN, V38, P871
   CARVALHO EM, 1983, AM J TROP MED HYG, V32, P61, DOI 10.4269/ajtmh.1983.32.61
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   CHILLER TM, 1990, AM J TROP MED HYG, V43, P650, DOI 10.4269/ajtmh.1990.43.650
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   ELKON K, 1988, P NATL ACAD SCI USA, V85, P5186, DOI 10.1073/pnas.85.14.5186
   ELKON K, 1986, P NATL ACAD SCI USA, V83, P7419, DOI 10.1073/pnas.83.19.7419
   ELKON KB, 1985, J EXP MED, V162, P459, DOI 10.1084/jem.162.2.459
   FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266
   FRANCOEUR AM, 1985, J IMMUNOL, V135, P2378
   GALVAOCASTRO B, 1984, CLIN EXP IMMUNOL, V56, P58
   HASLER P, 1991, J BIOL CHEM, V266, P13815
   HEINKOFF S, 1984, GENE, V28, P351
   HINES JJ, 1991, J IMMUNOL, V146, P3386
   KUENZEL EA, 1987, J BIOL CHEM, V262, P9136
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   MACCONNELL WP, 1982, J BIOL CHEM, V257, P5359
   MARCHIORI F, 1988, BIOCHIM BIOPHYS ACTA, V971, P332
   MILHAUSEN M, 1984, CELL, V38, P721, DOI 10.1016/0092-8674(84)90267-8
   MITSUI K, 1989, J BIOCHEM-TOKYO, V106, P223, DOI 10.1093/oxfordjournals.jbchem.a122836
   MOLLER W, 1985, STRUCTURE FUNCTION G, P310
   NAFZIGER DA, 1991, MOL BIOCHEM PARASIT, V49, P325, DOI 10.1016/0166-6851(91)90076-I
   NAIRN AC, 1982, NATURE, V299, P734, DOI 10.1038/299734a0
   REED SG, 1987, J IMMUNOL, V138, P1596
   REED SG, 1990, AM J TROP MED HYG, V43, P632, DOI 10.4269/ajtmh.1990.43.632
   REED SG, 1990, J CLIN INVEST, V85, P690, DOI 10.1172/JCI114493
   RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065
   RICHTER D, 1973, J BIOL CHEM, V248, P2853
   Sambrook J, 1989, MOL CLONING LABORATO
   SANCHEZMADRID F, 1979, EUR J BIOCHEM, V98, P409, DOI 10.1111/j.1432-1033.1979.tb13200.x
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SCHIJMAN AG, 1992, IMMUNOL LETT, V33, P15, DOI 10.1016/0165-2478(92)90087-5
   SKEIKY YAW, 1992, J EXP MED, V176, P201, DOI 10.1084/jem.176.1.201
   SKEIKY YAW, 1993, J IMMUNOL, V151, P5504
   SKEIKY YAW, UNPUB
   SOTO M, 1993, MOL BIOCHEM PARASIT, V61, P265, DOI 10.1016/0166-6851(93)90072-6
   STACEY DW, 1988, ARCH BIOCHEM BIOPHYS, V267, P398
   TACHIBANA H, 1988, PARASITOL RES, V74, P409, DOI 10.1007/BF00535139
   TOWBIN H, 1982, J BIOL CHEM, V257, P2709
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   TSURUGI K, 1978, J BIOL CHEM, V253, P946
   UCHIUMI T, 1990, J BIOL CHEM, V265, P89
   UCHIUMI T, 1987, P NATL ACAD SCI USA, V84, P5580, DOI 10.1073/pnas.84.16.5580
   VIDALES FJ, 1984, BIOCHEMISTRY-US, V23, P390, DOI 10.1021/bi00297a032
   WEINTRAUB J, 1982, EXP PARASITOL, V53, P87, DOI 10.1016/0014-4894(82)90095-9
NR 51
TC 38
Z9 41
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD MAY
PY 1994
VL 62
IS 5
BP 1643
EP 1651
DI 10.1128/IAI.62.5.1643-1651.1994
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA NH313
UT WOS:A1994NH31300019
PM 7513304
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU BRITES, C
   HARRINGTON, W
   NETTO, EM
   PEDROSO, C
   BADARO, R
AF BRITES, C
   HARRINGTON, W
   NETTO, EM
   PEDROSO, C
   BADARO, R
TI INCREASED RISK OF AIDS IN HIV-1-INFECTED WOMEN CO-INFECTED WITH HTLV-I
   OR HTLV-II IN BRAZIL
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD APR
PY 1994
VL 10
IS 4
BP 488
EP 488
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA NK470
UT WOS:A1994NK47000184
DA 2020-12-01
ER

PT J
AU BRITES, C
   HARRINGTON, W
   NETTO, EM
   PEDROSO, C
   BADARO, R
AF BRITES, C
   HARRINGTON, W
   NETTO, EM
   PEDROSO, C
   BADARO, R
TI HIV-I AND HTLV-I/II COINFECTION IN BRAZIL - IV DRUG-USE IS THE MAJOR
   ROUTE OF TRANSMISSION
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
C1 HOSP CENT ROBERTOS SANTOS,DEPT PUBL HLTH,SALVADOR,BRAZIL.
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD APR
PY 1994
VL 10
IS 4
BP 490
EP 490
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA NK470
UT WOS:A1994NK47000193
DA 2020-12-01
ER

PT J
AU HO, JL
   BADARO, R
   HATZIGEORGIOU, D
   REED, SG
   JOHNSON, WD
AF HO, JL
   BADARO, R
   HATZIGEORGIOU, D
   REED, SG
   JOHNSON, WD
TI CYTOKINES IN THE TREATMENT OF LEISHMANIASIS - FROM STUDIES OF
   IMMUNOPATHOLOGY TO PATIENT THERAPY
SO BIOTHERAPY
LA English
DT Review
ID TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; GROWTH-FACTOR-BETA;
   AMERICAN CUTANEOUS LEISHMANIASIS; RECOMBINANT INTERFERON-GAMMA;
   BONE-MARROW MACROPHAGES; CELL-MEDIATED-IMMUNITY; PROTEIN-KINASE-C; CD4+
   T-CELLS; VISCERAL LEISHMANIASIS
AB The genus Leishmania, an obligate intramacrophage parasite, causes a wide spectrum of clinical diseases. It is worldwide in distribution and causes 20 million new cases annually with an at risk population of approximately 1.5 billion persons. The most severe forms are associated with high morbidity, mortality and relapses with conventional therapy. The therapeutic issues and responses to standard and alternative therapies are reviewed. Recent developments in molecular biology and immunology methods employed in the study of leishmaniasis have defined an intricate interaction of the parasite with host immune system. Perturbation of the host immune responses may be part of the survival mechanisms of Leishmania. In murine model, the finding of T helper cells that differ by their panel of cytokines has allowed a more precise definition of immunopathogenesis of leishmaniasis. Preliminary data from leishmaniasis patients lend support to this concept of altered immunomodulation. Furthermore, the enhancement of therapeutic response by interferon-gamma has provided a new approach for treatment of patients using recombinant cytokines and for the study of the disease. Current research for early diagnosis, alternative therapies and need for vaccines are reviewed in the context of the immunopathology of leishmaniasis.
C1 SEATTLE BIOMED RES INST, SEATTLE, WA 98109 USA.
RP HO, JL (corresponding author), CORNELL UNIV, COLL MED,DEPT MED,DIV INTERNAL MED,ROOM A431, 1300 YORK AVE, NEW YORK, NY 10021 USA.
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [TW-00018] Funding Source: Medline; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI-16282] Funding Source: Medline; PHS HHSUnited States Public Health
   Service [R37-22624] Funding Source: Medline; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282] Funding Source: NIH
   RePORTER
CR ALWAN WH, 1993, J IMMUNOL, V150, P5211
   ANDRADE TM, 1990, J INFECT DIS, V162, P1354, DOI 10.1093/infdis/162.6.1354
   APONSO LCC, IN PRESS INFECT IMMU
   ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   BADARO R, 1993, J INFECT DIS, V167, pS13, DOI 10.1093/infdis/167.Supplement_1.S13
   BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104
   BADARO R, UNPUB RHGM CSF REVER
   Badaro Roberto, 1993, P111
   BARRAL A, 1991, AM J TROP MED HYG, V44, P536, DOI 10.4269/ajtmh.1991.44.536
   BARRAL A, 1993, P NATL ACAD SCI USA, V90, P3442, DOI 10.1073/pnas.90.8.3442
   BARRALNETTO M, 1992, SCIENCE, V257, P545, DOI 10.1126/science.1636092
   BELOSEVIC M, 1992, CLIN EXP IMMUNOL, V87, P304, DOI 10.1111/j.1365-2249.1992.tb02992.x
   BERMAN JD, 1986, MOL BIOCHEM PARASIT, V20, P85, DOI 10.1016/0166-6851(86)90145-3
   BERMUDEZ LE, 1987, CLIN RES, V35, pA612
   BERMUDEZ LE, 1993, CLIN EXP IMMUNOL, V91, P277
   BLASI E, 1990, INFECT IMMUN, V58, P1073, DOI 10.1128/IAI.58.4.1073-1077.1990
   BOGDAN C, 1990, EUR J IMMUNOL, V20, P2533, DOI 10.1002/eji.1830201202
   BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090
   BRUMMER E, 1988, J IMMUNOL, V140, P2786
   BRYCESON AD, 1970, T ROY SOC TROP MED H, V64, P369, DOI 10.1016/0035-9203(70)90173-2
   BRYCESON ADM, 1985, T ROY SOC TROP MED H, V79, P705, DOI 10.1016/0035-9203(85)90199-3
   BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7404, DOI 10.1073/pnas.82.21.7404
   BYRD TF, 1989, J CLIN INVEST, V83, P1457, DOI 10.1172/JCI114038
   CACERESDITTMAR G, 1993, CLIN EXP IMMUNOL, V91, P500, DOI 10.1111/j.1365-2249.1993.tb05931.x
   CARVALHO EM, 1992, J INFECT DIS, V165, P535, DOI 10.1093/infdis/165.3.535
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   CASSATELLA MA, 1990, J BIOL CHEM, V265, P20241
   CHANG HR, 1990, IMMUNOLOGY, V69, P33
   CHATELAIN R, 1992, J IMMUNOL, V148, P1182
   CHEN WX, 1992, J EXP MED, V176, P713, DOI 10.1084/jem.176.3.713
   CHOMARAT P, 1993, J EXP MED, V177, P523, DOI 10.1084/jem.177.2.523
   CONRAD DH, 1990, J EXP MED, V171, P1497, DOI 10.1084/jem.171.5.1497
   CONVIT J, 1987, LANCET, V1, P401
   DEGORGOLAS M, 1993, CLIN INFECT DIS, V17, P56, DOI 10.1093/clinids/17.1.56
   DENIS M, 1991, J LEUKOCYTE BIOL, V49, P380
   DENIS M, 1991, J LEUKOCYTE BIOL, V49, P65
   DENIS M, 1990, CAN J MICROBIOL, V36, P671, DOI 10.1139/m90-114
   DENIS M, 1990, INT J IMMUNOPHARMACO, V12, P721, DOI 10.1016/0192-0561(90)90034-K
   DESCOTEAUX A, 1989, MOL CELL BIOL, V9, P5223, DOI 10.1128/MCB.9.11.5223
   DESCOTEAUX A, 1991, J IMMUNOL, V146, P2747
   DESJEUX P, 1991, WHOLEISH9130
   DING A, 1990, J IMMUNOL, V145, P940
   EDWARDS CK, 1992, INFECT IMMUN, V60, P2514, DOI 10.1128/IAI.60.6.2514-2521.1992
   EDWARDS CK, 1986, J IMMUNOL, V136, P1820
   ERARD F, 1993, SCIENCE, V260, P1802, DOI 10.1126/science.8511588
   EZEKOWITZ RAB, 1991, NEW ENGL J MED, V324, P509, DOI 10.1056/NEJM199102213240801
   FLESCH I, 1987, J IMMUNOL, V138, P4408
   FLESCH IEA, 1988, INFECT IMMUN, V56, P1464, DOI 10.1128/IAI.56.6.1464-1469.1988
   FRUTH U, 1993, J IMMUNOL, V150, P1857
   GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245
   GHALIB HG, IN PRESS J CLIN INVE
   GLADUE R, 1988, AGENTS ACTIONS, V24, P130, DOI 10.1007/BF01968091
   GROGL M, 1992, AM J TROP MED HYG, V47, P117, DOI 10.4269/ajtmh.1992.47.117
   GROGL M, 1989, EXP PARASITOL, V69, P78, DOI 10.1016/0014-4894(89)90173-2
   GUSTAFSON TL, 1985, AM J TROP MED HYG, V34, P58, DOI 10.4269/ajtmh.1985.34.58
   HANDMAN E, 1979, J IMMUNOL, V122, P1134
   HATZIGEORGIOU DE, 1993, J IMMUNOL, V151, P3682
   HATZIGEORGIOU DH, 1993, CLIN RES, V41, pA322
   HAVELL EA, 1987, J IMMUNOL, V139, P4225
   HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505
   HEINZEL FP, 1993, J IMMUNOL, V150, P3924
   HO JL, 1992, J INFECT DIS, V165, P1094, DOI 10.1093/infdis/165.6.1094
   HO JL, 1992, INFECT IMMUN, V60, P1984, DOI 10.1128/IAI.60.5.1984-1993.1992
   HO JL, 1992, J INFECT DIS, V165, P344, DOI 10.1093/infdis/165.2.344
   HO JL, 1988, J INFECT DIS, V157, P925, DOI 10.1093/infdis/157.5.925
   HO JL, 1989, PHAGOCYTES DISEASE, P59
   HOLADAY BJ, 1993, J INFECT DIS, V167, P411, DOI 10.1093/infdis/167.2.411
   HOLTMANN H, 1990, INFECT IMMUN, V58, P3168, DOI 10.1128/IAI.58.10.3168-3172.1990
   HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338
   JENSEN WA, 1988, CELL IMMUNOL, V117, P369, DOI 10.1016/0008-8749(88)90126-8
   JHA TK, 1983, T ROY SOC TROP MED H, V77, P204, DOI 10.1016/0035-9203(83)90071-8
   JHA TK, 1983, T ROY SOC TROP MED H, V77, P167, DOI 10.1016/0035-9203(83)90058-5
   JONES TC, 1987, J INFECT DIS, V156, P73, DOI 10.1093/infdis/156.1.73
   KAGAYA K, 1989, INFECT IMMUN, V57, P609, DOI 10.1128/IAI.57.2.609-615.1989
   KAGER PA, 1981, T ROY SOC TROP MED H, V75, P556, DOI 10.1016/0035-9203(81)90198-X
   KARP CL, 1993, J CLIN INVEST, V91, P1644, DOI 10.1172/JCI116372
   KAYE PM, 1992, INFECT IMMUN, V60, P4335, DOI 10.1128/IAI.60.10.4335-4342.1992
   KAYE PM, 1991, J IMMUNOL, V146, P2763
   KIDERLEN AF, 1984, EUR J IMMUNOL, V14, P964, DOI 10.1002/eji.1830141019
   KULLBERG BJ, 1993, J INFECT DIS, V168, P436, DOI 10.1093/infdis/168.2.436
   KULLBERG BJ, 1990, INFECT IMMUN, V58, P3319, DOI 10.1128/IAI.58.10.3319-3324.1990
   LAINSON R, 1978, NATURE, V273, P595, DOI 10.1038/273595a0
   LANGERMANS JAM, 1992, J IMMUNOL, V148, P568
   LEAL LMCC, 1993, EUR J IMMUNOL, V23, P566, DOI 10.1002/eji.1830230241
   LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921
   LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P99
   LIEW FY, 1990, J IMMUNOL, V145, P4306
   LOCKSLEY RM, 1991, IMMUNOPARASITOL TOD, pA58, DOI 10.1016/S0167-5699(05)80017-9
   MAGGI E, 1992, J IMMUNOL, V148, P2142
   MAGILL AJ, 1993, NEW ENGL J MED, V328, P1383, DOI 10.1056/NEJM199305133281904
   MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199
   MARSDEN PD, 1984, REV INFECT DIS, V6, P736
   MARSDEN PD, 1985, T ROY SOC TROP MED H, V79, P424, DOI 10.1016/0035-9203(85)90405-5
   MARSDEN PD, 1986, LEISHMANIASIS
   MARTINEZ S, 1992, NEW ENGL J MED, V326, P741, DOI 10.1056/NEJM199203123261105
   MCCABE RE, 1991, J INFECT DIS, V163, P912, DOI 10.1093/infdis/163.4.912
   MCNEELY TB, 1990, J IMMUNOL, V144, P2745
   MCNEELY TB, 1987, BIOCHEM BIOPH RES CO, V148, P653, DOI 10.1016/0006-291X(87)90926-0
   METCALF D, 1987, IMMUNOL CELL BIOL, V65, P35, DOI 10.1038/icb.1987.4
   MONTENEGRO J, 1926, ANN FAC MED SAO PAUL, V1, P1
   MORRIS L, 1992, J IMMUNOL, V149, P2715
   MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145
   MUNOZFERNANDEZ MA, 1992, EUR J IMMUNOL, V22, P301, DOI 10.1002/eji.1830220203
   MURRAY HW, 1985, J IMMUNOL, V135, P2374
   MURRAY HW, 1984, J IMMUNOL, V133, P2250
   MURRAY HW, 1983, J CLIN INVEST, V72, P1506, DOI 10.1172/JCI111107
   NASH TW, 1984, J CLIN INVEST, V74, P771, DOI 10.1172/JCI111493
   NATHAN C, 1992, FASEB J, V6, P3051
   NATHAN CF, 1984, J EXP MED, V160, P600, DOI 10.1084/jem.160.2.600
   NATHAN CF, 1986, NEW ENGL J MED, V315, P6, DOI 10.1056/NEJM198607033150102
   NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670
   NATHAN CF, 1985, P NATL ACAD SCI USA, V82, P8686, DOI 10.1073/pnas.82.24.8686
   NATHAN CF, 1986, NEW ENGL J MED, V324, P509
   NELSON BJ, 1991, J IMMUNOL, V146, P1849
   OLIVIER M, 1992, P NATL ACAD SCI USA, V89, P7481, DOI 10.1073/pnas.89.16.7481
   PARRONCHI P, 1992, J IMMUNOL, V149, P2977
   Pearson R. D., 1985, Principles and practice of infectious diseases., P1522
   PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908
   PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341
   RACHAMIM N, 1993, J IMMUNOL, V150, P2322
   RALPH P, 1983, CELL IMMUNOL, V76, P10, DOI 10.1016/0008-8749(83)90343-X
   REED SG, 1987, J EXP MED, V166, P1734, DOI 10.1084/jem.166.6.1734
   REED SG, 1988, J IMMUNOL, V140, P4342
   REED SG, IN PRESS CUR OP IMMU
   REINER NE, 1990, J CLIN INVEST, V85, P1914, DOI 10.1172/JCI114654
   REINER NE, 1987, J IMMUNOL, V138, P1919
   ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3
   ROGERS HW, 1992, P NATL ACAD SCI USA, V89, P1011, DOI 10.1073/pnas.89.3.1011
   ROMANI L, 1992, INFECT IMMUN, V60, P4950, DOI 10.1128/IAI.60.11.4950-4952.1992
   SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115
   SAENZ RE, 1990, AM J MED, V89, P147, DOI 10.1016/0002-9343(90)90292-L
   SCHARTON TM, IN PRESS J EXP MED
   SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337
   SCOTT P, 1991, J IMMUNOL, V147, P3149
   SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x
   SQUIRES KE, IN PRESS J INFECT DI
   SUNDAR S, 1993, CLIN RES, V41, P381
   SUZUKI Y, 1988, SCIENCE, V240, P516, DOI 10.1126/science.3128869
   SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797
   THAKUR CP, 1991, AM J TROP MED HYG, V45, P435, DOI 10.4269/ajtmh.1991.45.435
   TOBIN JF, IN PRESS J IMMUNOL
   TRINCHIERI G, IN PRESS PROG GROWTH
   TRIPP CS, 1993, P NATL ACAD SCI USA, V90, P3725, DOI 10.1073/pnas.90.8.3725
   VARKILA K, 1993, EUR J IMMUNOL, V23, P262, DOI 10.1002/eji.1830230141
   VECCHIARELLI A, 1991, AM REV RESPIR DIS, V143, P1049, DOI 10.1164/ajrccm/143.5_Pt_1.1049
   VOGELS MTE, 1992, ANTIMICROB AGENTS CH, V36, P1
   WAHL SM, 1992, J CLIN IMMUNOL, V12, P61, DOI 10.1007/BF00918135
   WAHL SM, 1988, J EXP MED, V168, P1403, DOI 10.1084/jem.168.4.1403
   WEISER WY, 1987, J EXP MED, V166, P1436, DOI 10.1084/jem.166.5.1436
   WYLER DJ, 1987, J IMMUNOL, V138, P1246
   YANG X, 1993, J EXP MED, V178, P349, DOI 10.1084/jem.178.1.349
   ZHAN YF, 1991, INFECT IMMUN, V59, P1790, DOI 10.1128/IAI.59.5.1790-1794.1991
   1991, TDR NEWS, V37, P1
NR 155
TC 13
Z9 13
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0921-299X
J9 BIOTHERAPY
JI Biotherapy
PY 1994
VL 7
IS 3-4
BP 223
EP 235
DI 10.1007/BF01878488
PG 13
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA PQ405
UT WOS:A1994PQ40500009
PM 7865353
DA 2020-12-01
ER

PT J
AU BADARO, R
   NASCIMENTO, C
   CARVALHO, JS
   BADARO, F
   RUSSO, D
   HO, JL
   REED, SG
   JOHNSON, WD
   JONES, TC
AF BADARO, R
   NASCIMENTO, C
   CARVALHO, JS
   BADARO, F
   RUSSO, D
   HO, JL
   REED, SG
   JOHNSON, WD
   JONES, TC
TI GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN COMBINATION WITH
   PENTAVALENT ANTIMONY FOR THE TREATMENT OF VISCERAL LEISHMANIASIS
SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT Symposium on Granulocyte-Macrophage Colony-Stimulating Factor: Current
   Use and Future Applications
CY 1993
CL LUZERN, SWITZERLAND
ID T-CELL CLONES; INTERFERON-GAMMA; DRUG-THERAPY; DONOVANI; ADJUNCT
AB The efficacy of GM-CSF was investigated in 20 neutropenic patients (< 1500 neutrophils/mu l) with acute visceral leishmaniasis due to Leishmania chagasi. Patients were randomized to receive either GM-CSF, 5 mu g/kg daily (intravenously or subcutaneously), or placebo for ten days, in combination with pentavalent antimony, 10-20 mg/kg daily for 20 days. Neutrophil counts mere significantly greater on days 5 and 10 of treatment in the GM-CSF group compared with the placebo group (p < 0.02). Eosinophil and monocyte counts were also significantly increased in the GM-CSF group at day 10 (p less than or equal to 0.03). Interestingly, at day 30, platelet counts were significantly higher in the GM-CSF treated group (p = 0.007). Haemoglobin levels were significantly increased in the GM-CSF group on days 5 and 10 (p = 0.04 and 0.02, respectively). Patients in the GM-CSF group experienced fewer secondary bacterial or viral infections than placebo patients. Infections occurred in only three patients given GMCSF compared with eight patients given placebo (p < 0.04). All patients had complete resolution of disease symptoms at three months. Few adverse events were recorded. GM-CSF given subcutaneously at a dose of 5 mu g/kg daily for ten days was well tolerated, reversed neutropenia rapidly and reduced the number of secondary infections in patients with leishmaniasis.
C1 CORNELL UNIV MED COLL,DIV INTERNAL MED,ITHACA,NY.
   SEATTLE BIOMED RES INST,SEATTLE,WA 98109.
   SANDOZ PHARMA LTD,CLIN RES,CH-4002 BASEL,SWITZERLAND.
RP BADARO, R (corresponding author), UNIV FED BAHIA,BR-40210 SALVADOR,BA,BRAZIL.
CR ANDRADE TM, 1990, J INFECT DIS, V162, P1354, DOI 10.1093/infdis/162.6.1354
   BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104
   BADARO R, 1994, J INFECT DIS, V170, P413, DOI 10.1093/infdis/170.2.413
   BADARO R, 1993, J INFECT DIS, V167, P513
   BRYCESON ADM, 1985, T ROY SOC TROP MED H, V79, P705, DOI 10.1016/0035-9203(85)90199-3
   CARVALHO EM, 1989, J CLIN INVEST, V83, P860, DOI 10.1172/JCI113969
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   CHULAY JD, 1982, AM J TROP MED HYG, V32, P475
   DEWITTE T, 1992, BLOOD, V79, P1359
   EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25
   GERHARTZ HH, 1993, BLOOD, V82, P2329
   GULATI SC, 1992, ANN INTERN MED, V116, P177, DOI 10.7326/0003-4819-116-3-177
   HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296
   HO JL, 1990, J INFECT DIS, V162, P224, DOI 10.1093/infdis/162.1.224
   HO JL, 1992, J INFECT DIS, V165, P344, DOI 10.1093/infdis/165.2.344
   JONES TC, 1993, EUR J CANCER, V29A, pS10, DOI 10.1016/0959-8049(93)90625-P
   KEMP M, 1993, INFECT IMMUN, V61, P1069, DOI 10.1128/IAI.61.3.1069-1073.1993
   LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P99
   LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P28
   MALEFYT RD, 1991, J EXP MED, V174, P1209
   MARSDEN PD, 1985, HUMAN PARASITIC DISE, P183
   PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538
   REED SG, 1987, J EXP MED, V166, P1734, DOI 10.1084/jem.166.6.1734
   SMITH PD, 1990, J INFECT DIS, V161, P999, DOI 10.1093/infdis/161.5.999
   WEISER WY, 1987, J EXP MED, V166, P1436, DOI 10.1084/jem.166.5.1436
   1990, WHO TECHNICAL REPORT, V793, P1
NR 28
TC 9
Z9 10
U1 0
U2 1
PU FRIEDR VIEWEG SOHN VERLAG GMBH
PI WIESBADEN 1
PA PO BOX 5829, W-6200 WIESBADEN 1, GERMANY
SN 0934-9723
J9 EUR J CLIN MICROBIOL
JI Eur. J. Clin. Microbiol. Infect. Dis.
PY 1994
VL 13
SU 2
BP S23
EP S28
DI 10.1007/BF01973598
PG 6
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA PW284
UT WOS:A1994PW28400005
PM 7875148
DA 2020-12-01
ER

PT J
AU BADARO, R
   JOHNSON, WD
AF BADARO, R
   JOHNSON, WD
TI THE ROLE OF INTERFERON-GAMMA IN THE TREATMENT OF VISCERAL AND DIFFUSE
   CUTANEOUS LEISHMANIASIS (VOL 167, PG S 13, 1993)
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Correction, Addition
CR BADARO R, 1993, J INFECT DIS, V167, pS13, DOI 10.1093/infdis/167.Supplement_1.S13
NR 1
TC 0
Z9 0
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN
PY 1994
VL 169
IS 1
BP 233
EP 233
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA MP527
UT WOS:A1994MP52700046
DA 2020-12-01
ER

PT J
AU MOREIRA, ED
   SILVA, N
   BRITES, C
   CARVALHO, EM
   BINA, JC
   BADARO, R
   JOHNSON, WD
AF MOREIRA, ED
   SILVA, N
   BRITES, C
   CARVALHO, EM
   BINA, JC
   BADARO, R
   JOHNSON, WD
TI CHARACTERISTICS OF THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME IN BRAZIL
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID TROPICAL DISEASES; HIV INFECTION; AIDS; LEISHMANIASIS
AB The clinical and epidemiologic characteristics of the acquired immunodeficiency syndrome (AIDS) were studied in a tropical area of Brazil. During an 18-month period (July 1989-January 1991), 111 consecutive AIDS patients (102 men and nine women) were evaluated. Patients reported homosexual/bisexual activities (60%), intravenous drug use (19%), or both (6%), heterosexual activities (11%), blood transfusions (2%), and 2% belonged to an undetermined category. Weight loss, fever, oral thrush, and diarrhea were present in greater-than-or-equal-to 70% of the patients at presentation. An unexpected high frequency of hepatomegaly (49%) was detected, and found to be significantly associated with tuberculosis (P < 0.0001). Although the epidemiologic features of human immunodeficiency virus transmission were comparable to the United States/European pattern, the clinical spectrum of opportunistic infections more closely resembled that reported in Africa and Haiti, with a greater frequency of fungal and mycobacterial infections than Pneumocystis carinii pneumonia and viral infections.
C1 FED UNIV BAHIA,SALVADOR,BRAZIL.
   HOSP CENT ROBERTO SANTOS,SALVADOR,BRAZIL.
   CORNELL UNIV,MED CTR,DIV INT MED,NEW YORK,NY 10021.
RI Moreira, Edson/W-7437-2019; Moreira, Edson D/J-1758-2012; Brites,
   Carlos/D-1353-2013
OI Moreira, Edson/0000-0002-7081-8348; Moreira, Edson
   D/0000-0002-7081-8348; Brites, Carlos/0000-0002-4673-6991
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [TW-00018] Funding Source: Medline; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI-26506] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P01AI026506, P01AI026506,
   P01AI026506, P01AI026506, P01AI026506] Funding Source: NIH RePORTER
CR BADARO R, 1986, AM J TROP MED HYG, V35, P79
   BERENGUER J, 1989, ANN INTERN MED, V111, P129, DOI 10.7326/0003-4819-111-2-129
   CHAISSON RE, 1990, PRINCIPLES PRACTICE, P1059
   CHAMBERLAND ME, 1990, PRINCIPLES PRACTICES, P1029
   COLTON T, 1974, STATISTICS MED
   DEHOVITZ JA, 1986, NEW YORK STATE J MED, V86, P117
   GARRIS I, 1991, J ACQ IMMUN DEF SYND, V4, P1173
   GLUCKSTEIN D, 1992, AM J MED, V92, P429, DOI 10.1016/0002-9343(92)90275-G
   Ho M, 1990, PRINCIPLES PRACTICES, P1159
   JACOBSON MA, 1988, ANN INTERN MED, V108, P585, DOI 10.7326/0003-4819-108-4-585
   KOSHIBA L, 1987, HIST BRASIL, P28
   LENNETTE E, 1980, MANUAL CLIN MICROBIO
   MAAYAN S, 1987, AM J MED, V83, P945, DOI 10.1016/0002-9343(87)90656-5
   Pape JW, 1988, BAILLIERE CLIN TROP, V3, P31
   QUINN TC, 1986, SCIENCE, V234, P955, DOI 10.1126/science.3022379
   SATO PA, 1989, AIDS, V3, pS301, DOI 10.1097/00002030-198901001-00043
   SCAGLIA M, 1989, T ROY SOC TROP MED H, V83, P338, DOI 10.1016/0035-9203(89)90494-X
   SMITH PG, 1988, INT J EPIDEMIOL, V17, P705, DOI 10.1093/ije/17.4.705
   SMITH PG, 1988, T ROY SOC TROP MED H, V82, P753, DOI 10.1016/0035-9203(88)90226-X
   1981, MMWR MORBID MORTAL W, V30, P250
   1987, 1987 INF CONS HELD K
   1990, B EPIDEMIOLOGICO AID
   1991, B EPIDEMIOLOGICO DOE
   1987, MMWR MORBID MORTAL W, V36, pS3
   1991, UPDATE AIDS CASES
NR 25
TC 15
Z9 15
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAY
PY 1993
VL 48
IS 5
BP 687
EP 692
DI 10.4269/ajtmh.1993.48.687
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA LJ653
UT WOS:A1993LJ65300014
PM 8517487
DA 2020-12-01
ER

PT J
AU BOENTE, P
   SAMPAIO, C
   BRANDAO, MA
   MOREIRA, ED
   BADARO, R
   JONES, TC
AF BOENTE, P
   SAMPAIO, C
   BRANDAO, MA
   MOREIRA, ED
   BADARO, R
   JONES, TC
TI LOCAL PERI-LESIONAL THERAPY WITH RHGM-CSF FOR KAPOSIS-SARCOMA
SO LANCET
LA English
DT Letter
ID ACQUIRED IMMUNODEFICIENCY SYNDROME
C1 INFECT DIS CLIN HOSP, SALVADOR, BRAZIL.
   SANDOZ PHARMA, CH-4002 BASEL, SWITZERLAND.
   CORNELL UNIV, MED CTR, COLL MED, DIV INT MED, NEW YORK, NY 10021 USA.
RP BOENTE, P (corresponding author), ONCOL CLIN HOSP, SALVADOR, BRAZIL.
RI Moreira, Edson/W-7437-2019; Moreira, Edson D/J-1758-2012
OI Moreira, Edson/0000-0002-7081-8348; Moreira, Edson D/0000-0002-7081-8348
CR Harris J W, 1985, Front Radiat Ther Oncol, V19, P126
   KAPLAN L, 1986, CANCER TREAT REP, V70, P1121
   MUZYKA BC, 1993, NEW ENGL J MED, V328, P210, DOI 10.1056/NEJM199301213280312
   VADHANRAJ S, 1986, CANCER RES, V46, P417
   YAU JC, 1991, ROY SOC MED INT CONG, V182, P13
NR 5
TC 46
Z9 46
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD MAY 1
PY 1993
VL 341
IS 8853
BP 1154
EP 1155
DI 10.1016/0140-6736(93)93174-Y
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA KZ687
UT WOS:A1993KZ68700042
PM 8097837
DA 2020-12-01
ER

PT J
AU BADARO, R
   JOHNSON, WD
AF BADARO, R
   JOHNSON, WD
TI THE ROLE OF INTERFERON-GAMMA IN THE TREATMENT OF VISCERAL AND DIFFUSE
   CUTANEOUS LEISHMANIASIS
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID PENTAVALENT ANTIMONY; T-CELLS; DONOVANI; INFECTION; DIFFERENTIATION;
   HETEROGENEITY; MACROPHAGES; INVITRO; INVIVO; MICE
AB Traditionally, the mainstay of visceral and diffuse cutaneous leishmaniasis therapy has been pentavalent antimony, with pentamidine and amphotericin B reserved for refractory cases. Interferon-gamma (IFN-gamma) in combination with pentavalent antimony has been used successfully in treating patients refractory to pentavalent antimony and in patients with previously untreated visceral leishmaniasis (39 total). In addition, 6 patients with diffuse cutaneous leishmaniasis have been treated with combination IFN-gamma and antimony therapy. Preliminary experience with these patients indicates that IFN-gamma is a useful adjunct therapy for severe or refractory cases of visceral leishmaniasis; however, the potential of IFN-gamma in treating diffuse cutaneous leishmaniasis cannot be assessed as current clinical experience is too limited.
C1 CORNELL UNIV, MED CTR, COLL MED, DIV INT MED, NEW YORK, NY 10021 USA.
RP BADARO, R (corresponding author), FED UNIV BAHIA, HOSP PROFESSOR EDGARD SANTOS, SALVADOR, BRAZIL.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-30639, AI-16282] Funding Source:
   Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P01AI016282, P50AI030639,
   P01AI016282, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P01AI016282,
   P01AI016282, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P01AI016282,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P01AI016282, P01AI016282, P50AI030639, P01AI016282,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P01AI016282, P01AI016282, P50AI030639, P01AI016282,
   P50AI030639, P01AI016282, P50AI030639, P01AI016282, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P01AI016282, P50AI030639, P50AI030639,
   P50AI030639, P01AI016282, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639] Funding Source: NIH RePORTER
CR ANDRADE TM, 1982, REV INST MED TROP, V24, P298
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104
   BARRAL A, 1986, AM J TROP MED HYG, V35, P735, DOI 10.4269/ajtmh.1986.35.735
   BELOSEVIC M, 1989, J IMMUNOL, V143, P266
   BRYCESON AD, 1969, T ROY SOC TROP MED H, V63, P708, DOI 10.1016/0035-9203(69)90116-3
   CARVALHO EM, 1989, J CLIN INVEST, V83, P860, DOI 10.1172/JCI113969
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   CHULAY JD, 1983, AM J TROP MED HYG, V32, P475, DOI 10.4269/ajtmh.1983.32.475
   COFFMAN RL, 1991, IMMUNOL REV, V123, P189, DOI 10.1111/j.1600-065X.1991.tb00611.x
   COFFMAN RL, 1991, RES IMMUNOL, V142, P36, DOI 10.1016/0923-2494(91)90009-8
   CRAWFORD GD, 1985, J INFECT DIS, V152, P315, DOI 10.1093/infdis/152.2.315
   EZEKOWITZ RAB, 1988, NEW ENGL J MED, V319, P146, DOI 10.1056/NEJM198807213190305
   FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081
   LIEW FY, 1989, IMMUNOL TODAY, V10, P40, DOI 10.1016/0167-5699(89)90302-2
   MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9
   MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5
   MOSMANN TR, 1987, IMMUNOL TODAY, V8, P223, DOI 10.1016/0167-5699(87)90171-X
   MURRAY HW, 1983, J CLIN INVEST, V72, P1506, DOI 10.1172/JCI111107
   MURRAY HW, 1988, J INFECT DIS, V157, P973, DOI 10.1093/infdis/157.5.973
   NATHAN CF, 1986, NEW ENGL J MED, V315, P6, DOI 10.1056/NEJM198607033150102
   REINER NE, 1988, P NATL ACAD SCI USA, V85, P4330, DOI 10.1073/pnas.85.12.4330
   REINER NE, 1985, J IMMUNOL, V134, P556
   REINER NE, 1987, J IMMUNOL, V138, P1926
NR 24
TC 70
Z9 71
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR
PY 1993
VL 167
SU 1
BP S13
EP S17
DI 10.1093/infdis/167.Supplement_1.S13
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA KN475
UT WOS:A1993KN47500004
PM 8433014
DA 2020-12-01
ER

PT J
AU SHREFFLER, WG
   BURNS, JM
   BADARO, R
   GHALIB, HW
   BUTTON, LL
   MCMASTER, WR
   REED, SG
AF SHREFFLER, WG
   BURNS, JM
   BADARO, R
   GHALIB, HW
   BUTTON, LL
   MCMASTER, WR
   REED, SG
TI ANTIBODY-RESPONSES OF VISCERAL LEISHMANIASIS PATIENTS TO GP63, A MAJOR
   SURFACE GLYCOPROTEIN OF LEISHMANIA SPECIES
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID CUTANEOUS LEISHMANIASIS; MEMBRANE GLYCOPROTEIN; DONOVANI-CHAGASI;
   PROMASTIGOTES; ANTIGENS; MACROPHAGES; PROTEASE; IDENTIFICATION;
   PURIFICATION; IMMUNIZATION
AB A major surface glycoprotein of Leishmania parasites, gp63, is highly conserved among species and is expressed in both infective and intracellular stages. Although much is known about its role in entry and survival in host macrophages, patient antibody responses to this glycoprotein have not been well characterized. The prevalence of anti-gp63 antibody in sera of leishmaniasis patients was evaluated by ELISA. Sera from most acute visceral leishmaniasis patients (84%) from Brazil and Sudan had notably high levels of antibody to recombinant (r) gp63. Sera from other forms of leishmaniasis and from other diseases did not contain significantly elevated levels of anti-gp63 antibody. These results indicate that rgp63 might be a useful constituent of a defined serologic test for visceral leishmaniasis.
C1 SEATTLE BIOMED RES INST,4 NICKERSON ST,SEATTLE,WA 98109.
   FED UNIV BAHIA,HOSP PROFESSOR EDGARD SANTOS,SALVADOR,BRAZIL.
   UNIV JUBA,COLL MED,DEPT,JUBA,SUDAN.
   UNIV BRITISH COLUMBIA,VANCOUVER V6T 1W5,BC,CANADA.
   CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021.
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, R01AI025038, R01AI025038, R01AI025038, P01AI016282,
   P01AI016282, R01AI025038, P01AI016282, R01AI025038, P01AI016282,
   P01AI016282, P01AI016282, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, P01AI016282, R01AI025038, P01AI016282, R01AI025038,
   P01AI016282, P01AI016282, P01AI016282, R01AI025038, P01AI016282,
   P01AI016282, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R01AI025038, R01AI025038, P01AI016282,
   R01AI025038] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI-25038, AI-16282] Funding Source: Medline
CR BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BOUVIER J, 1989, MOL BIOCHEM PARASIT, V37, P235, DOI 10.1016/0166-6851(89)90155-2
   BOUVIER J, 1985, J BIOL CHEM, V260, P5504
   BURNS JM, 1992, P NATL ACAD SCI USA, V89, P1239, DOI 10.1073/pnas.89.4.1239
   BUTTON LL, 1991, MOL BIOCHEM PARASIT, V44, P213, DOI 10.1016/0166-6851(91)90007-S
   BUTTON LL, 1988, J EXP MED, V167, P724, DOI 10.1084/jem.167.2.724
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100
   CHAUDHURI G, 1988, MOL BIOCHEM PARASIT, V27, P43, DOI 10.1016/0166-6851(88)90023-0
   CHAUDHURI G, 1989, J BIOL CHEM, V264, P7483
   COLOMERGOULD V, 1985, J EXP MED, V162, P902, DOI 10.1084/jem.162.3.902
   ETGES R, 1986, J BIOL CHEM, V261, P9098
   FROMMEL TO, 1990, MOL BIOCHEM PARASIT, V38, P25, DOI 10.1016/0166-6851(90)90201-V
   GALVAOCASTRO B, 1984, CLIN EXP IMMUNOL, V56, P58
   HANDMAN E, 1990, EXP PARASITOL, V70, P427, DOI 10.1016/0014-4894(90)90127-X
   HANDMAN E, 1985, P NATL ACAD SCI USA, V82, P5910, DOI 10.1073/pnas.82.17.5910
   JAFFE CL, 1990, CLIN EXP IMMUNOL, V80, P77, DOI 10.1111/j.1365-2249.1990.tb06444.x
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAINSON R, 1987, LEISHMANIASES BIOL M, V1, P1
   LEPAY DA, 1983, J EXP MED, V157, P1562, DOI 10.1084/jem.157.5.1562
   MARSDEN PD, 1984, REV INFECT DIS, V6, P736
   MEDINAACOSTA E, 1989, MOL BIOCHEM PARASIT, V37, P263, DOI 10.1016/0166-6851(89)90158-8
   MILLER RA, 1990, MOL BIOCHEM PARASIT, V39, P267, DOI 10.1016/0166-6851(90)90065-T
   MOSSER DM, 1985, J IMMUNOL, V135, P2785
   REED SG, 1987, J IMMUNOL, V138, P1596
   REED SG, 1990, AM J TROP MED HYG, V43, P632, DOI 10.4269/ajtmh.1990.43.632
   REED SG, 1990, J CLIN INVEST, V85, P690, DOI 10.1172/JCI114493
   RUSSELL DG, 1988, J IMMUNOL, V140, P1274
   RUSSELL DG, 1986, J IMMUNOL, V136, P2613
   RUSSO DM, 1991, J IMMUNOL, V147, P3575
   SCOTT JM, 1991, AM J TROP MED HYG, V44, P272, DOI 10.4269/ajtmh.1991.44.272
   WILSON ME, 1988, J IMMUNOL, V141, P265
   YANG DM, 1990, J IMMUNOL, V145, P2281
NR 34
TC 46
Z9 48
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD FEB
PY 1993
VL 167
IS 2
BP 426
EP 430
DI 10.1093/infdis/167.2.426
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA KJ487
UT WOS:A1993KJ48700023
PM 7678428
DA 2020-12-01
ER

PT J
AU BURNS, JM
   SHREFFLER, WG
   BENSON, DR
   GHALIB, HW
   BADARO, R
   REED, SG
AF BURNS, JM
   SHREFFLER, WG
   BENSON, DR
   GHALIB, HW
   BADARO, R
   REED, SG
TI MOLECULAR CHARACTERIZATION OF A KINESIN-RELATED ANTIGEN OF
   LEISHMANIA-CHAGASI THAT DETECTS SPECIFIC ANTIBODY IN AFRICAN AND
   AMERICAN VISCERAL LEISHMANIASIS
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE REPETITIVE EPITOPE; MOTOR PROTEIN; PARASITE; DIAGNOSIS
ID AMINO-ACID-SEQUENCE; LINKED IMMUNOSORBENT-ASSAY; SECONDARY-STRUCTURE;
   PROTEINS; DONOVANI; GENES; SERODIAGNOSIS; IDENTIFICATION; EXPRESSION;
   RESPONSES
AB We report the cloning of a Leishmania chagasi antigen gene and an evaluation of leishmaniasis patient antibody responses to the recombinant protein, rK39. rK39 contains a 39-amino acid repeat that is part of a 230-kDa protein predominant in L. chagasi tissue amastigotes. Sequence analyses showed this protein, LcKin, to be related to the kinesin superfamily of motor proteins. Southern blot analyses demonstrated LcKin-related sequences in seven species of Leishmania, with conservation of the repeat between L. chagasi and Leishmania donovani. Serological evaluation revealed that 98% (56 of 57) of Brazilian and 100% (52 of 52) of Sudanese visceral leishmaniasis patients have high antibody levels to the rK39 repeat. Detectable anti-K39 antibody was virtually absent in cutaneous and mucosal leishmaniasis patients and in individuals infected with Trypanosoma cruzi. The data show that rK39 may replace crude parasite antigens as a basis for serological diagnosis of visceral leishmaniasis.
C1 SEATTLE BIOMED RES INST, 4 NICKERSON ST, SEATTLE, WA 98109 USA.
   UNIV JUBA, KHARTOUM, SUDAN.
   FED UNIV BAHIA, HOSP PROFESSOR EDGARD SANTOS, BR-40140 SALVADOR, BA, BRAZIL.
   CORNELL UNIV, MED CTR, COLL MED, DEPT MED, DIV INT MED, NEW YORK, NY 10021 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-25038, AI-16282] Funding Source:
   Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI025038, R01AI025038, P01AI016282, R01AI025038,
   P01AI016282, P01AI016282, R01AI025038, P01AI016282, R01AI025038,
   P01AI016282, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, P01AI016282, R01AI025038, P01AI016282, P01AI016282,
   P01AI016282, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, P01AI016282, R01AI025038, R01AI025038,
   P01AI016282, R01AI025038, P01AI016282, R01AI025038, R01AI025038,
   P01AI016282, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   P01AI016282, P01AI016282] Funding Source: NIH RePORTER
CR BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BEVERLEY SM, 1987, P NATL ACAD SCI USA, V84, P484, DOI 10.1073/pnas.84.2.484
   BLAXTER ML, 1988, MOL BIOCHEM PARASIT, V30, P259, DOI 10.1016/0166-6851(88)90095-3
   BLOOM G S, 1992, Current Opinion in Cell Biology, V4, P66, DOI 10.1016/0955-0674(92)90060-P
   BURNS JM, 1991, J IMMUNOL, V146, P742
   BURNS JM, 1992, P NATL ACAD SCI USA, V89, P1239, DOI 10.1073/pnas.89.4.1239
   Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45
   Dwyer D. M., 1985, Leishmaniasis. (Human Parasitic Diseases Vol.1.), P31
   ELSAFI SH, 1989, T ROY SOC TROP MED H, V83, P334, DOI 10.1016/0035-9203(89)90493-8
   GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8
   GHOSE AC, 1980, CLIN EXP IMMUNOL, V40, P318
   HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7
   HOFT DF, 1989, INFECT IMMUN, V57, P1959, DOI 10.1128/IAI.57.7.1959-1967.1989
   HOMMEL M, 1978, ANN TROP MED PARASIT, V72, P213, DOI 10.1080/00034983.1978.11719308
   IBANEZ CF, 1988, MOL BIOCHEM PARASIT, V30, P27, DOI 10.1016/0166-6851(88)90129-6
   JAFFE CL, 1988, J INFECT DIS, V157, P1212, DOI 10.1093/infdis/157.6.1212
   KEMP DJ, 1987, ANNU REV MICROBIOL, V41, P181, DOI 10.1146/annurev.mi.41.100187.001145
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAFAILLE JJ, 1989, MOL BIOCHEM PARASIT, V35, P127, DOI 10.1016/0166-6851(89)90115-1
   MCCUTCHAN TF, 1988, PROG ALLERGY, V41, P173
   NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4
   OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K
   PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444
   REED SG, 1987, J IMMUNOL, V138, P1596
   REED SG, 1990, AM J TROP MED HYG, V43, P632, DOI 10.4269/ajtmh.1990.43.632
   Sambrook J, 1989, MOL CLONING LABORATO
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SCHOLLER JK, 1986, MOL BIOCHEM PARASIT, V20, P279, DOI 10.1016/0166-6851(86)90108-8
   SHEPPARD HW, 1986, MOL BIOCHEM PARASIT, V19, P35, DOI 10.1016/0166-6851(86)90063-0
   SKEIKY YAW, 1992, J EXP MED, V176, P201, DOI 10.1084/jem.176.1.201
   VALE RD, 1992, TRENDS BIOCHEM SCI, V17, P300, DOI 10.1016/0968-0004(92)90440-K
   WALLIS AE, 1987, J EXP MED, V166, P1814, DOI 10.1084/jem.166.6.1814
   YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2
   1991, TROPICAL DISEASES PR, P79
   1991, TDR NEWS, V37, P1
NR 36
TC 304
Z9 319
U1 0
U2 15
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 15
PY 1993
VL 90
IS 2
BP 775
EP 779
DI 10.1073/pnas.90.2.775
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA KH516
UT WOS:A1993KH51600087
PM 8421715
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU ASHFORD, DA
   BADARO, R
   EULALIO, C
   FREIRE, M
   MIRANDA, C
   ZALIS, MG
   DAVID, JR
AF ASHFORD, DA
   BADARO, R
   EULALIO, C
   FREIRE, M
   MIRANDA, C
   ZALIS, MG
   DAVID, JR
TI STUDIES ON THE CONTROL OF VISCERAL LEISHMANIASIS - VALIDATION OF THE
   FALCON ASSAY SCREENING-TEST - ENZYME-LINKED-IMMUNOSORBENT-ASSAY
   (FAST-ELISA(TM)) FOR FIELD DIAGNOSIS OF CANINE VISCERAL LEISHMANIASIS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID FAST-ELISA; ANTIBODIES; MANSONI
AB The Falcon assay screening test-enzyme-linked immunosorbent assay (FAST-ELISA(TM)), the latest version of the enzyme-linked immunosorbent assay, uses antigen-coated beads. A 96-well plate can be run in 20 min without electricity or expensive equipment. We compared the FAST-ELISA, a standard ELISA, and an indirect immunofluorescent assay (IFA) for evaluation of canine leishmaniasis under field conditions using samples from 161 dogs from our longitudinal study in the endemic area of Jacobina, Bahia, Brazil. Organisms were isolated by culture (NNN medium) or by inoculation of hamsters with samples from 59 of the dogs. When plasma were tested, we found a sensitivity of 88% and a specificity of 90% using the FAST-ELISA with a spectrophotometer. Using the same plasma samples, the IFA had a sensitivity of 75% and a specificity of 93%. The standard ELISA had a sensitivity of 90% and a specificity of 85%. When whole blood was tested with the FAST-ELISA, we found a sensitivity of 85%. There was no significant difference between visual and spectrophotometric results with plasma or whole blood. The FAST-ELISA system provides a sensitive, specific, and field-adaptable test for canine visceral leishmaniasis, which can be evaluated quickly without the use of a microscope or spectro photometer.
C1 CORNELL UNIV, MED CTR, COLL MED, DIV INT MED, NEW YORK, NY 10021 USA.
   UNIV FED BAHIA, SALVADOR, BA, BRAZIL.
   FDN OSWALDO CRUZ BAHIA, SALVADOR, BA, BRAZIL.
RP ASHFORD, DA (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT TROP PUBL HLTH, BOSTON, MA 02115 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-16305-13] Funding Source: Medline
CR Adler S, 1935, PROC R SOC SER B-BIO, V116, P494, DOI 10.1098/rspb.1935.0005
   ANTHONY RL, 1980, AM J TROP MED HYG, V29, P190, DOI 10.4269/ajtmh.1980.29.190
   BADARO R, 1983, AM J TROP MED HYG, V32, P480, DOI 10.4269/ajtmh.1983.32.480
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BADARO R, 1987, P INT WORKSHOP CONTR, pB1
   CAMPBELL GH, 1987, AM J TROP MED HYG, V37, P428, DOI 10.4269/ajtmh.1987.37.428
   DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS, P154
   DUXBURY RE, 1964, AM J TROP MED HYG, V13, P525, DOI 10.4269/ajtmh.1964.13.525
   ENGVALL E, 1972, J IMMUNOL, V109, P129
   EVANS TG, 1990, AM J TROP MED HYG, V42, P118, DOI 10.4269/ajtmh.1990.42.118
   HANCOCK K, 1986, J IMMUNOL METHODS, V92, P167, DOI 10.1016/0022-1759(86)90162-6
   HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708
   HARITH AE, 1989, J CLIN MICROBIOL, V27, P2252
   HILLYER GV, 1991, J PARASITOL, V77, P362, DOI 10.2307/3283120
   HOMMEL M, 1978, ANN TROP MED PARASIT, V72, P213, DOI 10.1080/00034983.1978.11719308
   IANCONESCU M, 1985, J IMMUNOL METHODS, V76, P307, DOI 10.1016/0022-1759(85)90308-4
   KRONVALL G, 1970, J IMMUNOL, V104, P140
   MANCIANTI F, 1988, AM J VET RES, V49, P1409
   PAPPAS MG, 1983, J IMMUNOL METHODS, V64, P205, DOI 10.1016/0022-1759(83)90399-X
   PELLIGRINO J, 1958, REV BRAS MALARIOL DO, V10, P40
   POZIO E, 1981, ACTA TROP, V38, P383
   RICHARDS FO, 1989, TROP MED PARASITOL, V40, P332
   RIOUX J-A, 1972, Annales de Parasitologie Humaine et Comparee, V47, P413
   SCHEINBERG DA, 1983, J IMMUNOL METHODS, V58, P285, DOI 10.1016/0022-1759(83)90356-3
   SCHNUR LF, 1987, LEISHMANIASES BIOL M, V1, P499
   SHAW JJ, 1987, LEISHMANIASES BIOL M, V1, P291
   YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
   ZALIS MG, 1990, MEM I O CRUZ, V83, P130
NR 28
TC 43
Z9 44
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JAN
PY 1993
VL 48
IS 1
BP 1
EP 8
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA KL730
UT WOS:A1993KL73000001
PM 8427377
DA 2020-12-01
ER

PT J
AU HO, JL
   BADARO, R
   SCHWARTZ, A
   DINARELLO, CA
   GELFAND, JA
   SOBEL, J
   BARRAL, A
   NETTO, MB
   CARVALHO, EM
   REED, SG
   JOHNSON, WD
AF HO, JL
   BADARO, R
   SCHWARTZ, A
   DINARELLO, CA
   GELFAND, JA
   SOBEL, J
   BARRAL, A
   NETTO, MB
   CARVALHO, EM
   REED, SG
   JOHNSON, WD
TI DIMINISHED INVITRO PRODUCTION OF INTERLEUKIN-1 AND
   TUMOR-NECROSIS-FACTOR-ALPHA DURING ACUTE VISCERAL LEISHMANIASIS AND
   RECOVERY AFTER THERAPY
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID ACCESSORY CELL-INTERACTIONS; INTERFERON-GAMMA; MURINE LEISHMANIASIS;
   MONONUCLEAR-CELLS; GENE-EXPRESSION; DONOVANI; IMMUNOSUPPRESSION;
   MONOCYTES; IL-1; MACROPHAGES
AB Disturbance of T cell-mediated immunity has been reported in acute visceral leishmaniasis (AVL). In a study of 16 patients with AVL, defective production of interleukin-1 (IL-1) by peripheral blood mononuclear cells was demonstrated in response to leishmania antigens, heat-killed Listeria organisms, and lipopolysaccharide when compared to posttherapy values or controls. This global defect in IL-1 production was corrected after successful therapy. Twelve of 16 patients responded with a greater-than-or-equal-to 2.5-fold increase in IL-1 production that correlated with clinical cure, P < .01. Depressed production of tumor necrosis factor (TNF) was leishmania antigen-specific and similarly recovered after therapy. In vitro TNF production during the follow-up period did not correlate with clinical status but high serum levels were associated with AVL. Since T cells are activated by processed antigens presented on class 11 major histocompatibility molecules and by newly synthesized IL-1, defective IL-1 production may contribute to the immunosuppression observed in AVL.
C1 FED UNIV BAHIA,IMMUNOL & INFECT DIS LABS,SALVADOR,BRAZIL.
   SEATTLE BIOMED RES INST,SEATTLE,WA.
   TUFTS UNIV,NEW ENGLAND MED CTR,DIV GEOG MED & INFECT DIS,BOSTON,MA 02111.
RP HO, JL (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT MED,DIV INT MED,A431,1300 YORK AVE,NEW YORK,NY 10021, USA.
RI Barral, Aldina/B-4191-2009; Gelfand, Jeffrey A/G-1885-2018
OI Barral, Aldina/0000-0002-7177-464X; Gelfand, Jeffrey
   A/0000-0002-4118-5676
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-16282, AI-15614, AI-25038] Funding
   Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R37AI015614, R01AI025038, R01AI015614,
   R01AI025038, R01AI015614, R01AI025038, P01AI016282, P01AI016282,
   R01AI015614, R56AI015614, R01AI015614, P01AI016282, R01AI025038,
   P01AI016282, P01AI016282, R01AI025038, R01AI015614, R01AI025038,
   R37AI015614, R37AI015614, P01AI016282, R01AI015614, R01AI015614,
   P01AI016282, R01AI015614, R01AI015614, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R37AI015614, R01AI015614, P01AI016282,
   R37AI015614, R01AI025038, R01AI025038, R01AI025038, R01AI025038,
   R01AI025038, R01AI025038, R37AI015614, R01AI015614, R01AI025038,
   R01AI025038, R01AI025038, R01AI015614, R01AI015614, R37AI015614,
   R01AI015614, P01AI016282, P01AI016282, R01AI025038, R01AI015614,
   R01AI015614, R01AI025038, R01AI025038, R37AI015614, R01AI015614,
   R01AI015614, R37AI015614, R01AI015614, R01AI015614, P01AI016282,
   R01AI015614, R37AI015614, R01AI015614, P01AI016282, R01AI025038,
   R01AI025038, R01AI025038, P01AI016282, P01AI016282, R37AI015614,
   R01AI025038, P01AI016282] Funding Source: NIH RePORTER
CR BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104
   BARRAL A, 1989, AM J TROP MED HYG, P35735
   BARRALNETTO M, 1991, J IMMUNOL, V147, P281
   BARRALNETTO M, 1991, J INFECT DIS, V163, P853, DOI 10.1093/infdis/163.4.853
   BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549
   BRANTSCHEN S, 1989, EUR J IMMUNOL, V19, P2017, DOI 10.1002/eji.1830191108
   BRYCESON ADM, 1985, T ROY SOC TROP MED H, V79, P705, DOI 10.1016/0035-9203(85)90199-3
   CARVALHO EM, 1981, INFECT IMMUN, V33, P498, DOI 10.1128/IAI.33.2.498-500.1981
   CARVALHO EM, 1989, J CLIN INVEST, V83, P860, DOI 10.1172/JCI113969
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   COLTON T, 1974, STATISTICS MED
   CRAWFORD GD, 1985, J INFECT DIS, V152, P315, DOI 10.1093/infdis/152.2.315
   EICKHOFF TC, 1982, J INFECT DIS, V145, P407, DOI 10.1093/infdis/145.3.407
   ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501
   ESSNER R, 1989, J IMMUNOL, V142, P3857
   FIORENTINO DF, 1991, J IMMUNOL, V146, P3444
   FIORENTINO DF, 1989, J EXP MED, V170, P1495
   HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59
   HO JL, 1992, J INFECT DIS, V165, P344, DOI 10.1093/infdis/165.2.344
   HO M, 1983, CLIN EXP IMMUNOL, V51, P207
   KNUDSEN PJ, 1986, J IMMUNOL, V137, P3189
   LEHN M, 1989, J IMMUNOL, V143, P3020
   LISI PJ, 1987, LYMPHOKINE RES, V6, P229
   LONNEMANN G, 1988, J LEUKOCYTE BIOL, V43, P216
   MALEFYT RD, 1991, J EXP MED, V174, P1209
   Marsden P. D., 1985, Leishmaniasis. (Human Parasitic Diseases Vol.1.), P183
   MARSDEN PD, 1984, REV INFECT DIS, V6, P736
   MITSUYAMA M, 1990, INFECT IMMUN, V58, P1254, DOI 10.1128/IAI.58.5.1254-1260.1990
   MIZEL SB, 1980, CELL IMMUNOL, V54, P382, DOI 10.1016/0008-8749(80)90218-X
   MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559
   MOSSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145
   OPPENHEIM JJ, 1982, FED PROC, V41, P257
   REED SG, 1989, J IMMUNOL, V142, P2067
   REED SG, 1989, J IMMUNOL, V142, P3129
   REED SG, 1989, J CLIN INVEST, V86, P690
   REINER NE, 1988, P NATL ACAD SCI USA, V85, P4330, DOI 10.1073/pnas.85.12.4330
   REINER NE, 1985, J IMMUNOL, V134, P556
   REINER NE, 1990, J CLIN INVEST, V85, P1914, DOI 10.1172/JCI114654
   REINER NE, 1987, J IMMUNOL, V138, P1926
   REINER NE, 1987, J IMMUNOL, V138, P1919
   SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115
   SCHINDLER R, 1990, BIOTECHNIQUES, V8, P408
   SCUDERI P, 1986, LANCET, V2, P1364
   STREET NE, 1991, FASEB J, V5, P171
   TARTAKOVSKY B, 1988, J IMMUNOL, V141, P3863
   TITUS RG, 1989, J EXP MED, V170, P2097, DOI 10.1084/jem.170.6.2097
   TITUS RG, 1991, IMMUNO PARASITOL TOD, V12
   ZWINGENBERGER K, 1990, CLIN IMMUNOL IMMUNOP, V57, P242, DOI 10.1016/0090-1229(90)90038-R
NR 49
TC 30
Z9 30
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN
PY 1992
VL 165
IS 6
BP 1094
EP 1102
DI 10.1093/infdis/165.6.1094
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA HV960
UT WOS:A1992HV96000017
PM 1583328
DA 2020-12-01
ER

PT J
AU CARVALHO, EM
   BARRAL, A
   PEDRALSAMPAIO, D
   BARRALNETTO, M
   BADARO, R
   ROCHA, H
   JOHNSON, WD
AF CARVALHO, EM
   BARRAL, A
   PEDRALSAMPAIO, D
   BARRALNETTO, M
   BADARO, R
   ROCHA, H
   JOHNSON, WD
TI IMMUNOLOGICAL MARKERS OF CLINICAL EVOLUTION IN CHILDREN RECENTLY
   INFECTED WITH LEISHMANIA-DONOVANI-CHAGASI
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID AMERICAN VISCERAL LEISHMANIASIS; CUTANEOUS LEISHMANIASIS;
   GAMMA-INTERFERON; KALA-AZAR; RESPONSES; IMMUNOSUPPRESSION; LYMPHOCYTES;
   MACROPHAGES; ANTIBODIES; IMMUNITY
AB The study attempted to identify immunologic markers for progression of Leishmania donovani chagasi infection to disease in children in an area endemic for visceral leishmaniasis (VL). [H-3]thymidine uptake of lymphocytes stimulated with L. donovani chagasi antigen from children with asymptomatic infection (25,286 +/- 11,648) and from children with self-healing subclinical infection (15,511 +/- 4681) was greater (P = .001) than that observed with lymphocytes from children who progressed to classic VL (4811 +/- 2984). The interferon-gamma (IFN-gamma) levels from asymptomatic and subclinically infected children (74 +/- 90 units/ml) were higher (P = .02) than those observed in children who progressed to VL (7 +/- 8 units/ml). Absence of lymphocyte blastogenesis and IFN-gamma-production were associated with progression of infection to classic VL. In the presence of these markers, children should be closely followed to identify signs and symptoms that would permit early initiation of therapy.
C1 UNIV FED BAHIA,FAC MED,SERV IMUNOL,SALVADOR,BA,BRAZIL.
   CORNELL UNIV,MED CTR,NEW YORK,NY 10021.
RI Barral, Aldina/B-4191-2009; Barral-Netto, Manoel/B-3904-2009
OI Barral, Aldina/0000-0002-7177-464X; Barral-Netto,
   Manoel/0000-0002-5823-7903; Brasil Pedral Sampaio,
   Diana/0000-0002-2446-5828
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282] Funding
   Source: NIH RePORTER; FIC NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [TW-00018] Funding Source: Medline; NIAID NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-16282] Funding Source: Medline
CR Badaro R., 1985, Revista da Sociedade Brasileira de Medicina Tropical, V18, P77, DOI 10.1590/S0037-86821985000200003
   BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BADARO R, 1986, LANCET, V1, P746
   BARRAL A, 1986, AM J TROP MED HYG, V35, P735, DOI 10.4269/ajtmh.1986.35.735
   CARVALHO EM, 1988, BRAZ J MED BIOL RES, V21, P85
   CARVALHO EM, 1981, INFECT IMMUN, V33, P498, DOI 10.1128/IAI.33.2.498-500.1981
   CARVALHO EM, 1989, J CLIN INVEST, V83, P860, DOI 10.1172/JCI113969
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   CARVALHO EM, 1983, BRAZ J MED BIOL RES, V16, P35
   CERF BJ, 1987, J INFECT DIS, V156, P1030, DOI 10.1093/infdis/156.6.1030
   CHANG TW, 1984, P NATL ACAD SCI-BIOL, V81, P5219, DOI 10.1073/pnas.81.16.5219
   FERNANDEZGUERRERO ML, 1987, AM J MED, V83, P1098, DOI 10.1016/0002-9343(87)90948-X
   HORWITZ DA, 1987, J IMMUNOL, V118, P1712
   HUIID L, 1990, INFECT IMMUN, V56, P3163
   KOECH DK, 1987, AM J TROP MED HYG, V36, P497, DOI 10.4269/ajtmh.1987.36.497
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MA DDF, 1979, LANCET, V2, P311
   MURRAY HW, 1982, J IMMUNOL, V131, P1487
   MUSUMECI S, 1980, T R SOC TROP MED HYG, V75, P304
   REED SG, 1986, AM J TROP MED HYG, V35, P77
   REINER NE, 1988, P NATL ACAD SCI USA, V85, P4330, DOI 10.1073/pnas.85.12.4330
   REINER NE, 1990, J CLIN INVEST, V85, P1914, DOI 10.1172/JCI114654
   REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061
   REZAI HR, 1978, AM J TROP MED HYG, V27, P1079, DOI 10.4269/ajtmh.1978.27.1079
   SACKS DL, 1987, J IMMUNOL, V138, P908
   SADICK MD, 1986, J IMMUNOL, V136, P655
   SCOTT P, 1987, J IMMUNOL, V139, P3118
   SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675
NR 30
TC 127
Z9 129
U1 0
U2 3
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR
PY 1992
VL 165
IS 3
BP 535
EP 540
DI 10.1093/infdis/165.3.535
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA HE466
UT WOS:A1992HE46600019
PM 1347057
DA 2020-12-01
ER

PT J
AU BARRALNETTO, M
   BARRAL, A
   SANTOS, SB
   CARVALHO, EM
   BADARO, R
   ROCHA, H
   REED, SG
   JOHNSON, WD
AF BARRALNETTO, M
   BARRAL, A
   SANTOS, SB
   CARVALHO, EM
   BADARO, R
   ROCHA, H
   REED, SG
   JOHNSON, WD
TI SOLUBLE IL-2 RECEPTOR AS AN AGENT OF SERUM-MEDIATED SUPPRESSION IN HUMAN
   VISCERAL LEISHMANIASIS
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID INTERLEUKIN-2 RECEPTORS; B-CELLS; RESPONSES; IMMUNOSUPPRESSION;
   INTERFERON; LYMPHOKINE; EXPRESSION; DONOVANI; GAMMA; AIDS
AB In visceral leishmaniasis (VL), patient's lymphocytes are not activated by leishmania Ag stimulation , and their sera exhibit a potent nonspecific suppressive effect on the responses of normal lymphocytes . Sera were obtained from 33 VL patients, eight patients with subclinical VL, and from 27 normal volunteers. Only sera from VL patients markedly reduced Con A-induced lymphocyte proliferative responses, as well as IL-2 or IFN-gamma production by normal lymphocytes. Addition of exogenous human rIL-2 to cultures containing VL patient sera partially reversed the normal lymphocyte proliferative capacity and restored IFN-gamma production. This phenomenon was consistent with the presence of greatly elevated levels of soluble IL-2R (slL-2R) in VL patients' sera (4299 +/- 2351 U/ml), well above those of normal sera (180 +/- 94 U/ml), or of sera from patients with subclinical leishmania infection without immunosuppression (1002 +/- 281 U/ml). Furthermore, the removal of slL-2R reduced VL serum suppressive activity as evaluated by effects on IL-2 and on IFN-gamma production. These data suggest the participation of high levels of sIL-2R in the serum-mediated suppression in VL.
C1 UNIV FED BAHIA,HOSP PROFESSOR EDGARD SANTOS,SERV IMUNOL,SALVADOR,BA,BRAZIL.
   CORNELL UNIV,MED CTR,COLL MED,DEPT INT MED,NEW YORK,NY 10021.
RI Barral-Netto, Manoel/B-3904-2009; Barral, Aldina/B-4191-2009
OI Barral-Netto, Manoel/0000-0002-5823-7903; Barral,
   Aldina/0000-0002-7177-464X
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI-16282-11] Funding
   Source: Medline
CR ANDRADE TM, 1982, REV INST MED TROP, V24, P298
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BARRAL A, 1986, AM J TROP MED HYG, V35, P735, DOI 10.4269/ajtmh.1986.35.735
   BARRAL-NETTO M, 1986, Memorias do Instituto Oswaldo Cruz, V81, P343, DOI 10.1590/S0074-02761986000300012
   CARVALHO EM, 1989, J CLIN INVEST, V83, P860, DOI 10.1172/JCI113969
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   CARVALHO EM, 1983, BRAZ J MED BIOL RES, V16, P35
   CARVALHO EM, 1981, INFECT IMMUN, V22, P649
   CHULAY JD, 1983, AM J TROP MED HYG, V32, P475, DOI 10.4269/ajtmh.1983.32.475
   COLLEY DG, 1977, AM J TROP MED HYG, V26, P917, DOI 10.4269/ajtmh.1977.26.917
   COX RA, 1987, INFECT IMMUN, V55, P1058, DOI 10.1128/IAI.55.5.1058-1062.1987
   HANCOCK WW, 1987, J IMMUNOL, V138, P185
   HO M, 1983, CLIN EXP IMMUNOL, V51, P207
   HONDA M, 1989, J IMMUNOL, V142, P4248
   KLEINHENZ ME, 1981, J CLIN INVEST, V68, P153, DOI 10.1172/JCI110231
   KOECH DK, 1987, AM J TROP MED HYG, V36, P501, DOI 10.4269/ajtmh.1987.36.501
   LAMMIE PJ, 1984, CLIN EXP IMMUNOL, V55, P602
   LOUGHNAN MS, 1989, NATURE, V340, P76, DOI 10.1038/340076a0
   MANSON-BAHR P. E. C., 1959, TRANS ROY SOC TROP MED AND HYG, V53, P380, DOI 10.1016/0035-9203(59)90038-0
   MEHRA VL, 1972, CLIN EXP IMMUNOL, V12, P205
   MURRAY HW, 1983, J CLIN INVEST, V72, P1506, DOI 10.1172/JCI111107
   NICHOLAS NS, 1984, CLIN EXP IMMUNOL, V58, P578
   RUBIN LA, 1986, J IMMUNOL, V137, P3841
   RUBIN LA, 1985, J IMMUNOL, V135, P3172
   SIEGEL JP, 1984, CLIN RES, V32, pA358
   SMITH KA, 1988, ADV IMMUNOL, V42, P165, DOI 10.1016/S0065-2776(08)60844-5
   SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319
   VIRGIN HW, 1985, INFECT IMMUN, V50, P343, DOI 10.1128/IAI.50.2.343-353.1985
   WALDMANN TA, 1984, J EXP MED, V160, P1450, DOI 10.1084/jem.160.5.1450
   WYLER DJ, 1982, T ROY SOC TROP MED H, V76, P304, DOI 10.1016/0035-9203(82)90174-2
NR 31
TC 56
Z9 56
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JUL 1
PY 1991
VL 147
IS 1
BP 281
EP 284
PG 4
WC Immunology
SC Immunology
GA FT763
UT WOS:A1991FT76300042
PM 1904902
DA 2020-12-01
ER

PT J
AU BARRAL, A
   PEDRALSAMPAIO, D
   GRIMALDI, G
   MOMEN, H
   MCMAHONPRATT, D
   DEJESUS, AR
   ALMEIDA, R
   BADARO, R
   BARRALNETTO, M
   CARVALHO, EM
   JOHNSON, WD
AF BARRAL, A
   PEDRALSAMPAIO, D
   GRIMALDI, G
   MOMEN, H
   MCMAHONPRATT, D
   DEJESUS, AR
   ALMEIDA, R
   BADARO, R
   BARRALNETTO, M
   CARVALHO, EM
   JOHNSON, WD
TI LEISHMANIASIS IN BAHIA, BRAZIL - EVIDENCE THAT LEISHMANIA-AMAZONENSIS
   PRODUCES A WIDE SPECTRUM OF CLINICAL-DISEASE
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID AMERICAN VISCERAL LEISHMANIASIS; CUTANEOUS LEISHMANIASIS;
   MONOCLONAL-ANTIBODIES; IDENTIFICATION; EPIDEMIOLOGY; AMASTIGOTES;
   SELECTION; ANTIGENS; WORLD
AB One hundred fourteen Leishmania isolates from patients with different clinical forms of leishmaniasis in the State of Bahia, Brazil, were characterized by indirect radioimmune binding assay using specific monoclonal antibodies (serodeme analysis). Seventy-five of these isolates were also analyzed by enzyme electrophoresis, based on 11 enzyme loci; parasite species were compared, according to their characteristic zymodemes, to those of WHO Leishmania reference strains. All isolates could be classified into one of three species: Leishmania amazonensis (n = 40), L. braziliensis (n = 39) or L. chagasi (n = 35). The most interesting information obtained from this study is the realization that L. amazonensis is capable of producing a wide spectrum of disease in humans. Infection with this parasite was associated with many different clinical presentations, including cutaneous leishmaniasis [CL] (20/49 cases), mucocutaneous leishmaniasis [MCL] (5/13 cases) and, of special note, visceral leishmaniasis [VL] (I 1/46 cases), as well as four cases of post kala-azar dermal leishmaniasis [PKDL]. In situ tissue parasite characterization, by immunoperoxidase assay and employing anti-L. amazonensis amastigote monoclonal antibodies, confirmed the infection with this species in two cases of CL, one case of DCL, one case of MCL and one case of PKDL. Our results also demonstrate the difficulty of parasite differentiation based on clinical grounds, since at least L. amazonensis infection can be associated with all types of leishmanial diseases, and different Leishmania species may be associated with indistinguishable clinical presentations. Since leishmanial parasites may vary in their biological behavior or in their response to treatment, it is important that their identification be made by reliable methods.
C1 CORNELL UNIV, MED CTR, COLL MED, DIV INT MED, NEW YORK, NY 10021 USA.
   INST OSWALDO CRUZ, RIO DE JANEIRO, BRAZIL.
   YALE UNIV, SCH MED, NEW HAVEN, CT 06510 USA.
RI Momen, Hooman/A-1850-2008; Barral-Netto, Manoel/B-3904-2009; Barral,
   Aldina/B-4191-2009; almeida, roque/F-5609-2012
OI Momen, Hooman/0000-0002-2324-1515; Barral-Netto,
   Manoel/0000-0002-5823-7903; Barral, Aldina/0000-0002-7177-464X; 
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 16282, AI 23004] Funding Source:
   Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [P01AI016282, R01AI023004, R01AI023004, R01AI023004,
   R01AI023004, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   R01AI023004, P01AI016282, R01AI023004, P01AI016282, R01AI023004,
   R01AI023004, R01AI023004, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, R01AI023004, P01AI016282, R01AI023004,
   P01AI016282, R01AI023004, R01AI023004, P01AI016282] Funding Source: NIH
   RePORTER
CR ABDALLA RE, 1982, ANN TROP MED PARASIT, V76, P299, DOI 10.1080/00034983.1982.11687545
   ALTAQI M, 1978, T ROY SOC TROP MED H, V72, P56, DOI 10.1016/0035-9203(78)90302-4
   ANTHONY RL, 1987, AM J TROP MED HYG, V37, P271, DOI 10.4269/ajtmh.1987.37.271
   BADARO R, 1983, AM J TROP MED HYG, V32, P480, DOI 10.4269/ajtmh.1983.32.480
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BARRAL A, 1983, AM J TROP MED HYG, V32, P277, DOI 10.4269/ajtmh.1983.32.277
   BARRAL A, 1986, AM J TROP MED HYG, V35, P732, DOI 10.4269/ajtmh.1986.35.732
   BELAZZOUG S, 1985, ANN PARASIT HUM COMP, V60, P1
   BITTENCOURT A, 1989, MEM I OSWALDO CRUZ, V84, P585, DOI 10.1590/S0074-02761989000400022
   CHULAY JD, IN PRESS REV SOC BRA
   Cuba C. C., 1984, Revista da Sociedade Brasileira de Medicina Tropical, V17, P161, DOI 10.1590/S0037-86821984000400002
   GRIMALDI G, 1987, AM J TROP MED HYG, V36, P270, DOI 10.4269/ajtmh.1987.36.270
   GRIMALDI G, 1989, AM J TROP MED HYG, V41, P687, DOI 10.4269/ajtmh.1989.41.687
   Grimaldi G Jr, 1991, Prog Clin Parasitol, V2, P73
   HOOGSTRAAL H, 1969, AM J TROP MED HYG, V18, P1091, DOI 10.4269/ajtmh.1969.18.1091
   JAFFE CL, 1984, J IMMUNOL, V133, P440
   JONES TC, 1987, J INFECT DIS, V156, P73, DOI 10.1093/infdis/156.1.73
   LAINSON R, 1983, T ROY SOC TROP MED H, V77, P569, DOI 10.1016/0035-9203(83)90185-2
   LAINSON R, 1987, LEISHMANIASES BIOL M, V1, P1
   LEON LL, 1990, T ROY SOC TROP MED H, V84, P678, DOI 10.1016/0035-9203(90)90144-4
   LYNCH NR, 1986, T ROY SOC TROP MED H, V80, P6, DOI 10.1016/0035-9203(86)90183-5
   MARSDEN PD, 1975, REV SOC BRASILEIRA M, V9, P309
   MOMEN H, 1985, AM J TROP MED HYG, V34, P1076, DOI 10.4269/ajtmh.1985.34.1076
   NETO MPO, 1986, ANN TROP MED PARASIT, V80, P587, DOI 10.1080/00034983.1986.11812072
   Oliveira Neto M P, 1986, Mem Inst Oswaldo Cruz, V81, P303, DOI 10.1590/S0074-02761986000300006
   PACHECO RS, 1984, 4 P JAP BRAZ S SCI T, V2, P58
   PAN AA, 1988, J IMMUNOL, V140, P2406
   PRATT DM, 1985, J IMMUNOL, V134, P1935
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   RIOUX JA, 1986, T ROY SOC TROP MED H, V80, P1004, DOI 10.1016/0035-9203(86)90300-7
   Sampaio R. N., 1985, Revista da Sociedade Brasileira de Medicina Tropical, V18, P273, DOI 10.1590/S0037-86821985000400015
   SCHILIRO G, 1978, T ROY SOC TROP MED H, V72, P656, DOI 10.1016/0035-9203(78)90027-5
   SCHNUR LF, 1985, T ROY SOC TROP MED H, V79, P134, DOI 10.1016/0035-9203(85)90259-7
   SCHNUR LF, 1981, ANN TROP MED PARASIT, V75, P131, DOI 10.1080/00034983.1981.11687421
   SELLS PG, 1981, T ROY SOC TROP MED H, V75, P461, DOI 10.1016/0035-9203(81)90121-8
   SILVEIRA FT, 1984, REV INST MED TROP SP, V26, P272, DOI 10.1590/S0036-46651984000500008
   WALTON BC, 1977, AM J TROP MED HYG, V26, P850, DOI 10.4269/ajtmh.1977.26.850
NR 37
TC 253
Z9 256
U1 0
U2 7
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAY
PY 1991
VL 44
IS 5
BP 536
EP 546
DI 10.4269/ajtmh.1991.44.536
PG 11
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FW270
UT WOS:A1991FW27000011
PM 2063957
DA 2020-12-01
ER

PT J
AU BARRALNETTO, M
   BADARO, R
   BARRAL, A
   ALMEIDA, RP
   SANTOS, SB
   BADARO, F
   PEDRALSAMPAIO, D
   CARVALHO, EM
   FALCOFF, E
   FALCOFF, R
AF BARRALNETTO, M
   BADARO, R
   BARRAL, A
   ALMEIDA, RP
   SANTOS, SB
   BADARO, F
   PEDRALSAMPAIO, D
   CARVALHO, EM
   FALCOFF, E
   FALCOFF, R
TI TUMOR-NECROSIS-FACTOR (CACHECTIN) IN HUMAN VISCERAL LEISHMANIASIS
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID B-CELL ACTIVATION; INTERFERON-GAMMA; FACTOR-ALPHA; FALCIPARUM-MALARIA;
   PROTECTS MICE; SERUM LEVELS; INDUCE; MACROPHAGES; INFECTION; CACHEXIA
AB High tumor necrosis factor-alpha (TNF-alpha) levels were present in the serum of 24 of 28 active visceral leishmaniasis (VL) patients (142.9 +/- 113.9 pg/ml, mean +/- SD), whereas levels were not elevated in 26 of 30 patients with cryptic leishmanial infection (16 asymptomatic, 4 with self-healing subclinical infection, and 10 posttreatment VL cases).  Serum TNF-alpha levels were also not elevated in 15 normal volunteers (11.3 +/- 15.6 pg/ml) and in 10 patients with tegumentary leishmaniasis (19.1 +/- 10.8 pg/ml).  Leishmanial infection of human monocyte-derived macrophages enhanced the basal TNF-alpha production by these cells, and this effect was further potentiated by treatment with recombinant interferon-gamma.  After effective treatment of VL patients, serum TNF-alpha levels dropped rapidly (129 +/- 112 vs. 9 +/- 13 pg/ml in 10 days), even before clinical parameters such as spleen size or parasitism, white blood cell count, or levels of hemoglobin returned to normal values.  On the other hand, patients unresponsive to treatment remained with elevated levels (276 +/- 69 vs. 155 +/- 71 pg/ml in 10 days).  Thus, serum TNF-alpha levels in VL patients are a good parameter to monitor in determining host response to therapy.
C1 INST CURIE,INSERM,U196,F-75231 PARIS 05,FRANCE.
RP BARRALNETTO, M (corresponding author), UNIV FED BAHIA,HOSP UNIV PROF EDGARD SANTOS,SERV IMMUNOL,R JOAO DAS BOTAS S-N,BR-40140 SALVADOR,BA,BRAZIL.
RI Barral-Netto, Manoel/B-3904-2009; Barral, Aldina/B-4191-2009
OI Barral-Netto, Manoel/0000-0002-5823-7903; Barral,
   Aldina/0000-0002-7177-464X
CR ANDRADE TM, 1982, REV INST MED TROP, V24, P298
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104
   BARRAL A, 1986, AM J TROP MED HYG, V35, P735, DOI 10.4269/ajtmh.1986.35.735
   BATE CAW, 1988, IMMUNOLOGY, V64, P227
   BATE CAW, 1989, IMMUNOLOGY, V66, P600
   BEUTLER B, 1985, J EXP MED, V161, P984, DOI 10.1084/jem.161.5.984
   BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437
   BEUTLER B, 1982, LANCET, V2, P504
   BOHME MWJ, 1986, IMMUNOLOGY, V59, P583
   BROUCKAERT P, 1989, J EXP MED, V169, P2257, DOI 10.1084/jem.169.6.2257
   CARVALHO EM, 1988, BRAZ J MED BIOL RES, V21, P85
   CARVALHO EM, 1983, BRAZ J MED BIOL RES, V16, P35
   CARVALHO EM, 1981, INFECT IMMUN, V22, P649
   CERF BJ, 1987, J INFECT DIS, V156, P1030, DOI 10.1093/infdis/156.6.1030
   CHULAY JD, 1983, AM J TROP MED HYG, V32, P475, DOI 10.4269/ajtmh.1983.32.475
   CROSS AS, 1989, J EXP MED, V169, P2021, DOI 10.1084/jem.169.6.2021
   DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018
   ESPARZA I, 1987, J EXP MED, V166, P589, DOI 10.1084/jem.166.2.589
   FIERS W, 1986, BIOL INTERFERON SYST
   GALVAOCASTRO B, 1984, CLIN EXP IMMUNOL, V56, P58
   GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404
   GRAU GE, 1987, SCIENCE, V237, P1210, DOI 10.1126/science.3306918
   KERN P, 1989, AM J MED, V87, P139, DOI 10.1016/S0002-9343(89)80688-6
   LIEW FY, 1990, IMMUNOLOGY, V69, P570
   LIN Y, 1988, INFECT IMMUN, V56, P3072, DOI 10.1128/IAI.56.12.3072-3075.1988
   MURRAY HW, 1988, J INFECT DIS, V157, P973, DOI 10.1093/infdis/157.5.973
   NAKANE A, 1988, INFECT IMMUN, V56, P2563, DOI 10.1128/IAI.56.10.2563-2569.1988
   NEDWIN GE, 1985, J IMMUNOL, V135, P2492
   OLIFF A, 1987, CELL, V50, P555, DOI 10.1016/0092-8674(87)90028-6
   PICOT S, 1990, INFECT IMMUN, V58, P214, DOI 10.1128/IAI.58.1.214-216.1990
   RAMPART M, 1989, J EXP MED, V169, P2227, DOI 10.1084/jem.169.6.2227
   SCUDERI P, 1986, LANCET, V2, P1364
   TEPPO AM, 1987, CLIN CHEM, V33, P2024
   TITUS RG, 1989, J EXP MED, V170, P2097, DOI 10.1084/jem.170.6.2097
   TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597
   TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421
   TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211
   VALONE SE, 1988, INFECT IMMUN, V56, P3313, DOI 10.1128/IAI.56.12.3313-3315.1988
   VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727
   WEI H, 1987, FED PROC, V46, P1338
NR 41
TC 97
Z9 97
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD APR
PY 1991
VL 163
IS 4
BP 853
EP 857
DI 10.1093/infdis/163.4.853
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA FD939
UT WOS:A1991FD93900029
PM 1901333
DA 2020-12-01
ER

PT J
AU SCOTT, JM
   SHREFFLER, WG
   GHALIB, HW
   ELASAD, A
   SIDDIG, M
   BADARO, R
   REED, SG
AF SCOTT, JM
   SHREFFLER, WG
   GHALIB, HW
   ELASAD, A
   SIDDIG, M
   BADARO, R
   REED, SG
TI A RAPID AND SIMPLE DIAGNOSTIC-TEST FOR ACTIVE VISCERAL LEISHMANIASIS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID LINKED IMMUNOSORBENT-ASSAY; DIRECT AGGLUTINATION-TEST; PROTEIN-A;
   ANTIBODIES; ELISA; HEMAGGLUTINATION; SERODIAGNOSIS; RESPONSES; ANTIGENS;
   DISEASE
AB We have developed an immunodot assay for the serodiagnosis of active visceral leishmaniasis (AVL) which utilizes protein A colloidal gold as the visualizing agent.  The test is simple, requires few reagents, and can be completed in two hours.  It is sensitive and specific for active visceral leishmaniasis, and generally correlates with the ELISA.  Either whole blood or sera in minute quantities may be used as test antibody.  In addition, the use of the protein A gold immunodot is shown to detect anti-leishmania antibodies in infected dogs.
C1 FED UNIV BAHIA,HOSP PROF EDGARD SANTOS,SALVADOR,BRAZIL.
   UNIV KHARTOUM,FAC MED,DEPT MED,KHARTOUM,SUDAN.
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016312, P01AI016312, P01AI016312, P01AI016312,
   P01AI016312, P01AI016312, P01AI016312, P01AI016312, P01AI016312,
   R01AI025038, P01AI016312, P01AI016312, R01AI025038, P01AI016312,
   P01AI016312, P01AI016312, P01AI016312, P01AI016282, P01AI016282,
   P01AI016282, P01AI016312, P01AI016312, P01AI016282, P01AI016312,
   P01AI016282, R01AI025038, P01AI016312, R01AI025038, P01AI016282,
   P01AI016282, P01AI016312, R01AI025038, R01AI025038, R01AI025038,
   P01AI016312, P01AI016312, P01AI016282, P01AI016312, P01AI016282,
   P01AI016312, P01AI016312, R01AI025038, P01AI016312, P01AI016312,
   R01AI025038, R01AI025038, P01AI016312, R01AI025038, R01AI025038,
   P01AI016282, P01AI016312, P01AI016312, R01AI025038, R01AI025038,
   P01AI016312, P01AI016312, R01AI025038, R01AI025038, R01AI025038,
   P01AI016312, R01AI025038, P01AI016312, P01AI016282, P01AI016312,
   P01AI016312, P01AI016312, P01AI016312, R01AI025038, P01AI016312,
   P01AI016312, R01AI025038, R01AI025038, R01AI025038, P01AI016312,
   P01AI016312, R01AI025038, P01AI016312, P01AI016312, R01AI025038,
   P01AI016312, R01AI025038, P01AI016312, R01AI025038, P01AI016282,
   P01AI016282, P01AI016312, P01AI016282, P01AI016312, P01AI016312,
   P01AI016312] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI25038, AI16312, AI16282] Funding Source: Medline
CR BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BRADA D, 1984, ANAL BIOCHEM, V142, P79, DOI 10.1016/0003-2697(84)90518-9
   CAMARGO ME, 1969, AM J TROP MED HYG, V18, P500, DOI 10.4269/ajtmh.1969.18.500
   EDRISSIAN GH, 1979, T ROY SOC TROP MED H, V73, P289, DOI 10.1016/0035-9203(79)90084-1
   ELSAFI SH, 1989, T ROY SOC TROP MED H, V83, P334, DOI 10.1016/0035-9203(89)90493-8
   EVANS TG, 1990, AM J TROP MED HYG, V42, P118, DOI 10.4269/ajtmh.1990.42.118
   GODING JW, 1978, J IMMUNOL METHODS, V20, P241, DOI 10.1016/0022-1759(78)90259-4
   GUSS B, 1986, EMBO J, V5, P1576
   HARITH AE, 1987, T ROY SOC TROP MED H, V81, P603, DOI 10.1016/0035-9203(87)90423-8
   HARITH AE, 1989, J CLIN MICROBIOL, V27, P2252
   LINDMARK R, 1983, J IMMUNOL METHODS, V62, P1, DOI 10.1016/0022-1759(83)90104-7
   MANSONBAHR PEC, 1987, LEISHMANIASIS BIOL M, V2, P704
   MOHAMMED EAE, 1986, T ROY SOC TROP MED H, V80, P271, DOI 10.1016/0035-9203(86)90033-7
   PAPPAS MG, 1984, VET PARISITOL, V14, P39
   PENNEY CL, 1989, J IMMUNOL METHODS, V123, P185, DOI 10.1016/0022-1759(89)90222-6
   RASSAM MB, 1980, ANN TROP MED PARASIT, V74, P283, DOI 10.1080/00034983.1980.11687346
   REED SG, 1990, AM J TROP MED HYG, V43, P632, DOI 10.4269/ajtmh.1990.43.632
   REED SG, 1990, J CLIN INVEST, V85, P690, DOI 10.1172/JCI114493
   REED SG, 1987, J IMMUNOL, V126, P1614
   Rees PH, 1987, LEISHMANIASES BIOL M, V2, P583
   SIDDIG M, 1988, T ROY SOC TROP MED H, V82, P66, DOI 10.1016/0035-9203(88)90265-9
   STOCKER JW, 1981, IMMUNOLOGICAL METHOD, V2, P299
   THAYER SG, 1987, AVIAN DIS, V31, P459, DOI 10.2307/1590724
NR 23
TC 28
Z9 31
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAR
PY 1991
VL 44
IS 3
BP 272
EP 277
DI 10.4269/ajtmh.1991.44.272
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FN791
UT WOS:A1991FN79100005
PM 2035748
DA 2020-12-01
ER

PT J
AU MARSDEN, PD
   BADARO, R
   NETTO, EM
   CASLER, JD
AF MARSDEN, PD
   BADARO, R
   NETTO, EM
   CASLER, JD
TI SPONTANEOUS CLINICAL RESOLUTION WITHOUT SPECIFIC TREATMENT IN MUCOSAL
   LEISHMANIASIS
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Note
C1 WALTER REED ARMY MED CTR,DEPT OTOLARYNGEAL,WASHINGTON,DC.
   UNIV BAHIA,IMMUNOL LAB,SALVADOR,BRAZIL.
RP MARSDEN, PD (corresponding author), UNIV BRASILIA,BR-70910 BRASILIA,DF,BRAZIL.
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761
CR Marsden P. D., 1984, Revista da Sociedade Brasileira de Medicina Tropical, V17, P179, DOI 10.1590/S0037-86821984000400004
   MARSDEN PD, 1984, T ROY SOC TROP MED H, V78, P561, DOI 10.1016/0035-9203(84)90087-7
   ZAJTCHUK JT, 1989, LARYNGOSCOPE, V99, P925, DOI 10.1288/00005537-198909000-00006
NR 3
TC 7
Z9 7
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAR-APR
PY 1991
VL 85
IS 2
BP 221
EP 221
DI 10.1016/0035-9203(91)90030-3
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FN691
UT WOS:A1991FN69100022
PM 1887476
DA 2020-12-01
ER

PT J
AU BACELLAR, O
   BARRALNETTO, M
   BADARO, R
   CARVALHO, EM
AF BACELLAR, O
   BARRALNETTO, M
   BADARO, R
   CARVALHO, EM
TI GAMMA-INTERFERON PRODUCTION BY LYMPHOCYTES FROM CHILDREN INFECTED WITH
   L-CHAGASI
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article; Proceedings Paper
CT 6TH ANNUAL MEETING OF THE
   FEDERACAO-DE-SOCIEDADES-DE-BIOLOGIA-EXPERIMENTAL
CY AUG 21-25, 1991
CL CAXAMBU, BRAZIL
SP FEDERAC SOC BIOL EXPTL
DE VISCERAL LEISHMANIASIS; LEISHMANIASIS; LEISHMANIA-CHAGASI; GAMMA-IFN;
   KALA-AZAR
ID VISCERAL LEISHMANIASIS; SUBSETS; RESPOND
AB The present study was performed to evaluate the ability of lymphocytes from 18 children living in an endemic area of visceral leishmaniasis (VL) to produce gamma-interferon.  These children had no previous history of VL and were considered to be infected with Leishmania chagasi based on leishmanial seroconversion.  The gamma IFN levels were determined by radioimmunoassay on supernatants of lymphocyte cultures (3 x 10(6)/ml) stimulated with PHA (final dilution 1:10) and Leishmania chagasi antigen (10-mu-g/ml).  The gamma-IFN production by lymphocytes from seroconverting children stimulated with PHA (178 +/- 151 U/ml) and Leishmania chagasi (47 +/- 77 U/ml) was significantly higher than that observed in visceral leishmaniasis.  For clinical follow-up, these 18 seroconverting children were divided into three groups:  asymptomatic infection (N = 4); self-healing subclinical illness (N = 9), and subclinical infection progressing to VL (N = 5).  Gamma IFN levels in children with either asymptomatic or subclinical infection (65 +/- 85 U/ml) were significantly higher (P < 0.003) than those observed in children progressing to VL (9 +/- 6 U/ml).  The data demonstrate that there is an association between gamma IFN levels and the clinical course of Leishmania infection.
C1 UNIV FED BAHIA,HOSP UNIV PROF EDGARD SANTOS,SERV IMUNOL,RUA JOAO BOTAS S-N,BR-40140 SALVADOR,BA,BRAZIL.
RI Barral-Netto, Manoel/B-3904-2009
OI Barral-Netto, Manoel/0000-0002-5823-7903
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 16282] Funding Source: Medline; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282] Funding
   Source: NIH RePORTER
CR BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   BARRALNETTO M, 1989, BRAZ J MED BIOL RES, V22, P1485
   CARVALHO EM, 1988, BRAZ J MED BIOL RES, V21, P85
   CARVALHO EM, 1989, J CLIN INVEST, V83, P860, DOI 10.1172/JCI113969
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59
   REINER NE, 1990, J CLIN INVEST, V85, P1914, DOI 10.1172/JCI114654
   REINER NE, 1990, P NATIONAL ACADEMY S, V85, P4330
   SACKS DL, 1987, J IMMUNOL, V138, P908
   SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675
NR 11
TC 13
Z9 13
U1 0
U2 0
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PY 1991
VL 24
IS 8
BP 791
EP 795
PG 5
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA GK418
UT WOS:A1991GK41800006
PM 1797267
DA 2020-12-01
ER

PT J
AU REED, SG
   SHREFFLER, WG
   BURNS, JM
   SCOTT, JM
   ORGE, MD
   GHALIB, HW
   SIDDIG, M
   BADARO, R
AF REED, SG
   SHREFFLER, WG
   BURNS, JM
   SCOTT, JM
   ORGE, MD
   GHALIB, HW
   SIDDIG, M
   BADARO, R
TI AN IMPROVED SERODIAGNOSTIC PROCEDURE FOR VISCERAL LEISHMANIASIS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID DIRECT AGGLUTINATION-TEST; LINKED IMMUNOSORBENT-ASSAY; MAJOR
   SURFACE-ANTIGEN; SERO-DIAGNOSIS; ANTIBODY-TEST; PROTEIN-A; BINDING;
   ELISA; PROMASTIGOTES
AB The enzyme-linked immunosorbent assay (ELISA) is a sensitive and specific serodiagnostic method for leishmaniasis.  In this report, we describe how this versatile assay can be improved by the use of protein A or protein G conjugates for the specific detection of Leishmania antibody in the sera of patients with visceral leishmaniasis.  In direct comparisons with anti-immunoglobulin conjugate, enzyme-linked protein A gave significantly higher absorbance values for positive sera without a corresponding increase in absorbance values for sera from normal individuals or from patients with other diseases known to cross-react with leishmaniasis.  The effect was to increase the distance between positive and negative values, which aided in the interpretation of the results.  This also permitted visual distinction between positive sera and negative or weakly reactive sera.  The assay was effective using either blood or serum as the source of primary antibody.  A further advantage of protein A over anti-Ig conjugate was its ability to detect specific antibody in dog as well as human sera.  Finally, we demonstrated the usefulness of the protein A ELISA with a recombinant leishmania antigen, gp63.
C1 FED UNIV BAHIA,HOSP PROF EDGARD SANTOS,SALVADOR,BRAZIL.
   NIH,SUDAN MRC,KHARTOUM,SUDAN.
   UNIV KHARTOUM,FAC MED,DEPT MED,KHARTOUM,SUDAN.
   CORNELL UNIV,MED CTR,COLL MED,DEPT INT MED,NEW YORK,NY 10021.
RP REED, SG (corresponding author), SEATTLE BIOMED RES INST,4 NICKERSON ST,SEATTLE,WA 98109, USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI16282, AI16312, AI25038] Funding Source:
   Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [P01AI016312, P01AI016312, P01AI016312, R01AI025038,
   R01AI025038, R01AI025038, P01AI016282, P01AI016282, P01AI016312,
   P01AI016312, R01AI025038, P01AI016312, P01AI016312, P01AI016312,
   R01AI025038, P01AI016312, P01AI016312, P01AI016312, P01AI016282,
   P01AI016312, P01AI016312, R01AI025038, P01AI016282, P01AI016282,
   R01AI025038, R01AI025038, P01AI016312, P01AI016282, P01AI016312,
   P01AI016312, P01AI016312, P01AI016282, R01AI025038, P01AI016312,
   P01AI016312, R01AI025038, P01AI016312, R01AI025038, R01AI025038,
   P01AI016312, P01AI016312, P01AI016282, P01AI016312, P01AI016282,
   R01AI025038, P01AI016312, P01AI016312, R01AI025038, P01AI016282,
   R01AI025038, R01AI025038, P01AI016312, R01AI025038, R01AI025038,
   P01AI016312, P01AI016312, P01AI016312, P01AI016282, R01AI025038,
   P01AI016312, P01AI016312, P01AI016312, P01AI016312, P01AI016312,
   P01AI016312, P01AI016312, P01AI016312, P01AI016312, P01AI016312,
   P01AI016312, P01AI016312, P01AI016282, R01AI025038, P01AI016312,
   P01AI016312, P01AI016312, R01AI025038, P01AI016312, P01AI016312,
   P01AI016282, P01AI016282, P01AI016312, R01AI025038, R01AI025038,
   P01AI016312, P01AI016282, R01AI025038, P01AI016312, R01AI025038,
   R01AI025038, P01AI016312] Funding Source: NIH RePORTER
CR ALLAIN DS, 1975, AM J TROP MED HYG, V24, P232, DOI 10.4269/ajtmh.1975.24.232
   BADARO R, 1983, AM J TROP MED HYG, V32, P480, DOI 10.4269/ajtmh.1983.32.480
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BUTTON LL, 1988, J EXP MED, V167, P724, DOI 10.1084/jem.167.2.724
   CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100
   COLOMERGOULD V, 1985, J EXP MED, V162, P902, DOI 10.1084/jem.162.3.902
   EDRISSIAN GH, 1979, T ROY SOC TROP MED H, V73, P289, DOI 10.1016/0035-9203(79)90084-1
   el Amin E R, 1986, Trans R Soc Trop Med Hyg, V80, P271, DOI 10.1016/0035-9203(86)90033-7
   ELHARITH A, 1989, J CLIN MICROBIOL, V27, P2252, DOI 10.1128/JCM.27.10.2252-2257.1989
   ELSAFI SH, 1989, T ROY SOC TROP MED H, V83, P334, DOI 10.1016/0035-9203(89)90493-8
   EVANS TG, 1990, AM J TROP MED HYG, V42, P118, DOI 10.4269/ajtmh.1990.42.118
   GODING JW, 1978, J IMMUNOL METHODS, V20, P241, DOI 10.1016/0022-1759(78)90259-4
   GUSS B, 1986, EMBO J, V5, P1567, DOI 10.1002/j.1460-2075.1986.tb04398.x
   HARITH AE, 1987, T ROY SOC TROP MED H, V81, P603, DOI 10.1016/0035-9203(87)90423-8
   HOMMEL M, 1978, ANN TROP MED PARASIT, V72, P213, DOI 10.1080/00034983.1978.11719308
   JONES TC, 1987, J INFECT DIS, V156, P73, DOI 10.1093/infdis/156.1.73
   LEPAY DA, 1983, J EXP MED, V157, P1562, DOI 10.1084/jem.157.5.1562
   LINDMARK R, 1983, J IMMUNOL METHODS, V62, P1, DOI 10.1016/0022-1759(83)90104-7
   MILLER RA, 1990, MOL BIOCHEM PARASIT, V39, P267, DOI 10.1016/0166-6851(90)90065-T
   RASSAM MB, 1980, ANN TROP MED PARASIT, V74, P283, DOI 10.1080/00034983.1980.11687346
   REED SG, 1987, J IMMUNOL, V138, P1596
   REED SG, 1990, J CLIN INVEST, V85, P690, DOI 10.1172/JCI114493
   ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X
   STOCKER JW, 1979, IMMUNOLOGICAL METHOD, V2, P299
NR 24
TC 57
Z9 58
U1 0
U2 5
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 1990
VL 43
IS 6
BP 632
EP 639
DI 10.4269/ajtmh.1990.43.632
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA ET983
UT WOS:A1990ET98300010
PM 2267968
DA 2020-12-01
ER

PT J
AU NETTO, EM
   MARSDEN, PD
   LLANOSCUENTAS, EA
   COSTA, JML
   CUBA, CC
   BARRETO, AC
   BADARO, R
   JOHNSON, WD
   JONES, TC
AF NETTO, EM
   MARSDEN, PD
   LLANOSCUENTAS, EA
   COSTA, JML
   CUBA, CC
   BARRETO, AC
   BADARO, R
   JOHNSON, WD
   JONES, TC
TI LONG-TERM FOLLOW-UP OF PATIENTS WITH LEISHMANIA-(VIANNIA)-BRAZILIENSIS
   INFECTION AND TREATED WITH GLUCANTIME
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
C1 CORNELL UNIV,MED CTR,COLL MED,DIV INT MED,NEW YORK,NY 10021.
   UNIV FED BAHIA,SALVADOR,BA,BRAZIL.
RP NETTO, EM (corresponding author), UNIV BRASILIA,NUCL MED TROP & NUTR,BR-70910 BRASILIA,DF,BRAZIL.
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761; Llanos-Cuentas,
   Alejandro/0000-0002-7567-5534
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 16282] Funding Source: Medline; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282] Funding
   Source: NIH RePORTER
CR Cuba Cuba C.A., 1981, Bulletin of the Pan American Health Organization, V15, P249
   Llanos-Cuentas E. A., 1984, Revista da Sociedade Brasileira de Medicina Tropical, V17, P169, DOI 10.1590/S0037-86821984000400003
   LLANOSCUENTAS EA, 1984, THESIS U BRASILIA
   Marsden P. D., 1984, Revista da Sociedade Brasileira de Medicina Tropical, V17, P179, DOI 10.1590/S0037-86821984000400004
   MARSDEN PD, 1979, T ROY SOC TROP MED H, V73, P391, DOI 10.1016/0035-9203(79)90161-5
   MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9
   NETTO EM, 1986, LANCET, V1, P501
   NETTO EM, 1990, IN PRESS REV SOC BRA
   ROSA AC, 1988, T ROY SOC TROP MED H, V82, P409, DOI 10.1016/0035-9203(88)90138-1
   SAMPAIO RN, 1986, LANCET, V1, P1097
   WALTON BC, 1980, AM J TROP MED HYG, V29, P747, DOI 10.4269/ajtmh.1980.29.747
   WEIGLE KA, 1985, LANCET, V2, P557
NR 12
TC 41
Z9 42
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAY-JUN
PY 1990
VL 84
IS 3
BP 367
EP 370
DI 10.1016/0035-9203(90)90321-5
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA DQ323
UT WOS:A1990DQ32300017
PM 2260171
DA 2020-12-01
ER

PT J
AU BADARO, R
   PEDRALSAMPAIO, D
   JOHNSON, WD
   REED, SG
AF BADARO, R
   PEDRALSAMPAIO, D
   JOHNSON, WD
   REED, SG
TI EVALUATION OF THE STABILITY OF A SOLUBLE INTRADERMAL SKIN-TEST ANTIGEN
   PREPARATION IN AMERICAN VISCERAL LEISHMANIASIS
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Note
C1 SEATTLE BIOMED RES INST,4 NICKERSON ST,SEATTLE,WA 98109.
   UNIV BAHIA,DEPT MED,SALVADOR,BRAZIL.
   CORNELL UNIV,MED CTR,COLL MED,DEPT MED,NEW YORK,NY 10021.
CR MANSON-BAHR P. E. C., 1959, TRANS ROY SOC TROP MED AND HYG, V53, P380, DOI 10.1016/0035-9203(59)90038-0
   MANSONBAHR PEC, 1987, LEISHMANIASES BIOL M, V2, P709
   REED SG, 1987, J IMMUNOL, V138, P1596
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
NR 4
TC 11
Z9 12
U1 0
U2 0
PU ROYAL SOC TROPICAL MEDICINE
PI LONDON
PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAR-APR
PY 1990
VL 84
IS 2
BP 226
EP 227
DI 10.1016/0035-9203(90)90264-F
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA DE872
UT WOS:A1990DE87200015
PM 2389311
DA 2020-12-01
ER

PT J
AU BADARO, R
   FALCOFF, E
   BADARO, FS
   CARVALHO, EM
   PEDRALSAMPAIO, D
   BARRAL, A
   CARVALHO, JS
   BARRALNETTO, M
   BRANDELY, M
   SILVA, L
   BINA, JC
   TEIXEIRA, R
   FALCOFF, R
   ROCHA, H
   HO, JL
   JOHNSON, WD
AF BADARO, R
   FALCOFF, E
   BADARO, FS
   CARVALHO, EM
   PEDRALSAMPAIO, D
   BARRAL, A
   CARVALHO, JS
   BARRALNETTO, M
   BRANDELY, M
   SILVA, L
   BINA, JC
   TEIXEIRA, R
   FALCOFF, R
   ROCHA, H
   HO, JL
   JOHNSON, WD
TI TREATMENT OF VISCERAL LEISHMANIASIS WITH PENTAVALENT ANTIMONY AND
   INTERFERON-GAMMA
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
C1 UNIV FED BAHIA,SALVADOR,BA,BRAZIL.
   INST CURIE,F-75231 PARIS 05,FRANCE.
   ROUSSEL UCLAF,ROMAINVILLE,FRANCE.
RP BADARO, R (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DIV INT MED,1300 YORK AVE,NEW YORK,NY 10021, USA.
RI Barral, Aldina/B-4191-2009; Barral-Netto, Manoel/B-3904-2009
OI Barral, Aldina/0000-0002-7177-464X; Barral-Netto,
   Manoel/0000-0002-5823-7903
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI-16282] Funding
   Source: Medline
CR BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   BRYCESON ADM, 1985, T ROY SOC TROP MED H, V79, P705, DOI 10.1016/0035-9203(85)90199-3
   CARVALHO EM, 1981, INFECT IMMUN, V33, P498, DOI 10.1128/IAI.33.2.498-500.1981
   CARVALHO EM, 1989, J CLIN INVEST, V83, P860, DOI 10.1172/JCI113969
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   CHULAY JD, 1983, AM J TROP MED HYG, V32, P475, DOI 10.4269/ajtmh.1983.32.475
   CRAWFORD GD, 1985, J INFECT DIS, V152, P315, DOI 10.1093/infdis/152.2.315
   DURUM SK, 1985, ANNU REV IMMUNOL, V3, P263
   EICKHOFF TC, 1982, J INFECT DIS, V145, P407, DOI 10.1093/infdis/145.3.407
   EZEKOWITZ RAB, 1988, NEW ENGL J MED, V319, P146, DOI 10.1056/NEJM198807213190305
   GERRARD TL, 1988, J IMMUNOL, V140, P3450
   HO M, 1983, CLIN EXP IMMUNOL, V51, P207
   HOOVER DL, 1985, CELL IMMUNOL, V94, P500, DOI 10.1016/0008-8749(85)90274-6
   KAPLAN EH, 1988, P AN M AM SOC CLIN, V7, P226
   LEE SH, 1984, J IMMUNOL, V133, P1083
   Marsden P.D., 1985, HUMAN PARASITIC DISE, V1, P183
   MARSDEN PD, 1984, REV INFECT DIS, V6, P736
   MIZEL SB, 1982, IMMUNOL REV, V63, P51, DOI 10.1111/j.1600-065X.1982.tb00411.x
   MURPHY PM, 1988, ANN INTERN MED, V108, P36, DOI 10.7326/0003-4819-108-1-36
   MURRAY HW, 1985, J IMMUNOL, V134, P1619
   MURRAY HW, 1983, J CLIN INVEST, V72, P1506, DOI 10.1172/JCI111107
   MURRAY HW, 1988, J INFECT DIS, V157, P973, DOI 10.1093/infdis/157.5.973
   NATHAN C, 1988, INFLAMMATION BASIC P, P229
   NATHAN CF, 1986, NEW ENGL J MED, V315, P6, DOI 10.1056/NEJM198607033150102
   NATHAN CF, 1985, P NATL ACAD SCI USA, V82, P8686, DOI 10.1073/pnas.82.24.8686
   REINER NE, 1988, P NATL ACAD SCI USA, V85, P4330, DOI 10.1073/pnas.85.12.4330
   REINER NE, 1985, J IMMUNOL, V134, P556
   REINER NE, 1987, J IMMUNOL, V138, P1926
   REINER NE, 1987, J IMMUNOL, V138, P1919
   SPITALNY GL, 1984, J EXP MED, V159, P1560, DOI 10.1084/jem.159.5.1560
   STEEG PS, 1982, J EXP MED, V156, P1780, DOI 10.1084/jem.156.6.1780
   TALPAZ M, 1988, SEMIN HEMATOL, V25, P62
   TRINCHIERI G, 1984, J EXP MED, V160, P1147, DOI 10.1084/jem.160.4.1147
NR 33
TC 268
Z9 272
U1 0
U2 7
PU MASS MEDICAL SOC
PI BOSTON
PA 10 SHATTUCK, BOSTON, MA 02115
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JAN 4
PY 1990
VL 322
IS 1
BP 16
EP 21
DI 10.1056/NEJM199001043220104
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA CG234
UT WOS:A1990CG23400004
PM 2104665
DA 2020-12-01
ER

PT J
AU CARVALHO, EM
   BACELLAR, O
   BARRAL, A
   BADARO, R
   JOHNSON, WD
AF CARVALHO, EM
   BACELLAR, O
   BARRAL, A
   BADARO, R
   JOHNSON, WD
TI ANTIGEN-SPECIFIC IMMUNOSUPPRESSION IN VISCERAL LEISHMANIASIS IS
   CELL-MEDIATED
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
C1 UNIV BAHIA,DEPT MED,DIV IMMUNOL,SALVADOR,BRAZIL.
   CORNELL UNIV,MED CTR,COLL MED,DEPT MED,DIV INT MED,NEW YORK,NY 10021.
RI Barral, Aldina/B-4191-2009
OI Barral, Aldina/0000-0002-7177-464X
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI-16282] Funding
   Source: Medline
CR ANDRADE TM, 1982, REV INST MED TROP, V24, P298
   BADARO R, 1983, AM J TROP MED HYG, V32, P480, DOI 10.4269/ajtmh.1983.32.480
   BARRAL A, 1986, AM J TROP MED HYG, V35, P735, DOI 10.4269/ajtmh.1986.35.735
   BIRKELAND SA, 1980, J IMMUNOL METHODS, V35, P57, DOI 10.1016/0022-1759(80)90150-7
   Carvalho E. M., 1985, Revista da Sociedade Brasileira de Medicina Tropical, V18, P109, DOI 10.1590/S0037-86821985000200007
   CARVALHO EM, 1981, INFECT IMMUN, V33, P498, DOI 10.1128/IAI.33.2.498-500.1981
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   CARVALHO EM, 1983, BRAZ J MED BIOL RES, V16, P35
   CARVALHO EM, 1980, J IMMUNOL, V124, P565
   ELLNER JJ, 1978, J IMMUNOL, V121, P2573
   HALDAR JP, 1983, INFECT IMMUN, V42, P702, DOI 10.1128/IAI.42.2.702-707.1983
   HO M, 1983, CLIN EXP IMMUNOL, V51, P207
   HOPNER E, 1981, ALLERGOL IMMUNOL PAT, V9, P109
   HORWITZ DA, 1977, J IMMUNOL, V118, P1712
   LI CY, 1971, J HISTOCHEM CYTOCHEM, V21, P1
   LOBO PI, 1976, J IMMUNOL, V117, P939
   MANSON-BAHR P. E. C., 1961, TRANS ROY SOC TROP MED AND HYG, V55, P550, DOI 10.1016/0035-9203(61)90078-5
   MUSUMECI S, 1980, T R SOC TROP MED HYG, V75, P304
   OTTENHOFF THM, 1986, NATURE, V322, P462, DOI 10.1038/322462a0
   PETERSEN EA, 1984, J IMMUNOL, V132, P2603
   PETERSEN EA, 1982, NEW ENGL J MED, V306, P387, DOI 10.1056/NEJM198202183060702
   REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061
   REZAI HR, 1978, AM J TROP MED HYG, V27, P1079, DOI 10.4269/ajtmh.1978.27.1079
   RYAN JL, 1976, J EXP MED, V144, P768, DOI 10.1084/jem.144.3.768
   SACKS DL, 1987, J IMMUNOL, V138, P908
   TRIZIO D, 1974, J IMMUNOL, V113, P1093
   VERESS B, 1977, IMMUNOLOGY, V33, P605
   WEST WH, 1977, J IMMUNOL, V119, P548
   1974, SCAND J IMMUNOL, V3, P521
NR 29
TC 93
Z9 96
U1 0
U2 0
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAR
PY 1989
VL 83
IS 3
BP 860
EP 864
DI 10.1172/JCI113969
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA T5183
UT WOS:A1989T518300018
PM 2522103
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU BARRALNETTO, M
   DIEZ, R
   BADARO, R
   SAMPAIO, D
   BARRAL, A
   CARVALHO, EM
   FALCOFF, E
AF BARRALNETTO, M
   DIEZ, R
   BADARO, R
   SAMPAIO, D
   BARRAL, A
   CARVALHO, EM
   FALCOFF, E
TI SERUM INTERFERON ACTIVITY OF PATIENTS WITH LEISHMANIASIS
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Note
C1 INST CURIE,INSERM,U196,F-75231 PARIS 05,FRANCE.
RP BARRALNETTO, M (corresponding author), UNIV FED BAHIA,HOSP PROF EDGARD SANTOS,SERV IMUNOL,R JOAO BOTAS S-N,BR-40140 SALVADOR,BA,BRAZIL.
RI Barral, Aldina/B-4191-2009; Barral-Netto, Manoel/B-3904-2009
OI Barral, Aldina/0000-0002-7177-464X; Barral-Netto,
   Manoel/0000-0002-5823-7903
CR CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   HUANG KY, 1968, SCIENCE, V162, P123, DOI 10.1126/science.162.3849.123
   KIERSZENBAUM F, 1982, J PARASITOL, V68, P194, DOI 10.2307/3281173
   MURRAY HW, 1983, J CLIN INVEST, V72, P1506, DOI 10.1172/JCI111107
   PASSWELL JH, 1986, J IMMUNOL, V136, P3062
   PREBLE OT, 1982, SCIENCE, V216, P429, DOI 10.1126/science.6176024
   RHODESFEUILLETTE A, 1981, CR ACAD SCI III-VIE, V293, P635
   WIETZERBIN J, 1984, J INTERFERON RES, V4, P141, DOI 10.1089/jir.1984.4.141
NR 8
TC 6
Z9 6
U1 0
U2 0
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PY 1989
VL 22
IS 12
BP 1485
EP 1487
PG 3
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA CE943
UT WOS:A1989CE94300005
PM 2484290
DA 2020-12-01
ER

PT J
AU CERF, BJ
   JONES, TC
   BADARO, R
   SAMPAIO, D
   TEIXEIRA, R
   JOHNSON, WD
AF CERF, BJ
   JONES, TC
   BADARO, R
   SAMPAIO, D
   TEIXEIRA, R
   JOHNSON, WD
TI MALNUTRITION AS A RISK FACTOR FOR SEVERE VISCERAL LEISHMANIASIS
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Note
C1 UNIV FED BAHIA, FAC MED, SALVADOR, BA, BRAZIL.
RP CERF, BJ (corresponding author), CORNELL UNIV, MED CTR,COLL MED,DEPT MED,DIV INT MED, 1300 YORK AVE, NEW YORK, NY 10021 USA.
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI-16282] Funding
   Source: Medline
CR ACTOR PAUL, 1960, EXPTL PARASITOL, V10, P1, DOI 10.1016/0014-4894(60)90078-3
   BADARO R, 1986, LANCET, V1, P647
   BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   CHANDRA RK, 1980, FED PROC, V39, P3086
   FENDALL N R E, 1952, J Trop Med Hyg, V55, P245
   HARRISON LH, 1986, REV INFECT DIS, V8, P447
   JELLIFFE DB, 1966, WHO MONOGRAPH SERIES, V53
   Martorell R, 1984, POPUL DEV REV, V10, P49, DOI 10.2307/2807955
   Monson R., 1980, OCCUPATIONAL EPIDEMI
   MORLEY D, 1969, BMJ-BRIT MED J, V1, P297, DOI 10.1136/bmj.1.5639.297
   PEREZ H, 1979, CLIN EXP IMMUNOL, V38, P453
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   1976, HRA761120 US DHEW PU
NR 15
TC 113
Z9 114
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC
PY 1987
VL 156
IS 6
BP 1030
EP 1033
DI 10.1093/infdis/156.6.1030
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA K8571
UT WOS:A1987K857100031
PM 3680989
DA 2020-12-01
ER

PT J
AU JONES, TC
   JOHNSON, WD
   BARRETTO, AC
   LAGO, E
   BADARO, R
   CERF, B
   REED, SG
   NETTO, EM
   TADA, MS
   FRANCA, F
   WIESE, K
   GOLIGHTLY, L
   FIKRIG, E
   COSTA, JML
   CUBA, CC
   MARSDEN, PD
AF JONES, TC
   JOHNSON, WD
   BARRETTO, AC
   LAGO, E
   BADARO, R
   CERF, B
   REED, SG
   NETTO, EM
   TADA, MS
   FRANCA, F
   WIESE, K
   GOLIGHTLY, L
   FIKRIG, E
   COSTA, JML
   CUBA, CC
   MARSDEN, PD
TI EPIDEMIOLOGY OF AMERICAN CUTANEOUS LEISHMANIASIS DUE TO
   LEISHMANIA-BRAZILIENSIS-BRAZILIENSIS
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
C1 CORNELL UNIV,MED CTR,COLL MED,DEPT MED,DIV INT MED,1300 YORK AVE,NEW YORK,NY 10021.
   UNIV BRASILIA,BR-70910 BRASILIA,DF,BRAZIL.
   UNIV BAHIA,BAHIA,EL SALVADOR.
   BRAZILIAN MINIST HLTH,SUPERINTENDENCIA CAMPAGNA,BRASILIA,BRAZIL.
RI Franca, Flavio/E-1101-2012; de Siqueira Franca, Francisco
   Oscar/AAE-6314-2019; Netto, Eduardo/D-1432-2013
OI de Siqueira Franca, Francisco Oscar/0000-0001-8510-7939; Netto,
   Eduardo/0000-0003-1691-6761
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI-16282] Funding
   Source: Medline
CR BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BARKER DC, 1983, T ROY SOC TROP MED H, V77, P285, DOI 10.1016/0035-9203(83)90146-3
   Barreto AC, 1984, REV SOC BRAS MED TRO, V17, P59
   BARRETTO A C, 1981, Boletin de la Oficina Sanitaria Panamericana, V90, P415
   CUBA CAC, 1985, T ROY SOC TROP MED H, V79, P500, DOI 10.1016/0035-9203(85)90077-X
   CUBA CAC, 1983, THESIS U FEDERAL MIN
   CUBA CAC, 1984, REV SOC BRAS MED TRO, V17, P115
   FALQUETO A, 1986, Memorias do Instituto Oswaldo Cruz, V81, P155, DOI 10.1590/S0074-02761986000200004
   LAINSON R, 1978, NATURE, V273, P595, DOI 10.1038/273595a0
   LAINSON R, 1983, T ROY SOC TROP MED H, V77, P569, DOI 10.1016/0035-9203(83)90185-2
   Llanos-Cuentas E. A., 1984, Revista da Sociedade Brasileira de Medicina Tropical, V17, P169, DOI 10.1590/S0037-86821984000400003
   Marsden P. D., 1984, Revista da Sociedade Brasileira de Medicina Tropical, V17, P179, DOI 10.1590/S0037-86821984000400004
   MARZOCHI M C D, 1980, Revista do Instituto de Medicina Tropical de Sao Paulo, V22, P149
   McDermott W, 1969, Harvey Lect, V63, P1
   MCMAHONPRATT D, 1982, J IMMUNOL, V129, P926
   PESSOA SB, 1940, ARQ HIGIENE SAUDE PU, V8, P35
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   VEXENAT J A, 1986, Memorias do Instituto Oswaldo Cruz, V81, P293, DOI 10.1590/S0074-02761986000300005
   WALTON BC, 1980, AM J TROP MED HYG, V29, P747, DOI 10.4269/ajtmh.1980.29.747
   1984, WHO TECH REP SERIES, V407, P701
NR 20
TC 184
Z9 189
U1 1
U2 3
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL
PY 1987
VL 156
IS 1
BP 73
EP 83
DI 10.1093/infdis/156.1.73
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA H7729
UT WOS:A1987H772900011
PM 3598227
DA 2020-12-01
ER

PT J
AU BARRAL, A
   JESUS, AR
   ALMEIDA, RP
   CARVALHO, EM
   BARRALNETTO, M
   COSTA, JML
   BADARO, R
   ROCHA, H
   JOHNSON, WD
AF BARRAL, A
   JESUS, AR
   ALMEIDA, RP
   CARVALHO, EM
   BARRALNETTO, M
   COSTA, JML
   BADARO, R
   ROCHA, H
   JOHNSON, WD
TI EVALUATION OF T-CELL SUBSETS IN THE LESION INFILTRATES OF HUMAN
   CUTANEOUS AND MUCOCUTANEOUS LEISHMANIASIS
SO PARASITE IMMUNOLOGY
LA English
DT Article
C1 UNIV FED BRASILIA, FAC CIENCIAS SAUDE, SALVADOR, BA, BRAZIL.
   CORNELL UNIV, MED CTR, COLL MED, NEW YORK, NY 10021 USA.
RP BARRAL, A (corresponding author), UNIV FED BAHIA, HOSP PROF EDGARD SANTOS, FAC MED, IMUNOL LAB, 5 ANDAR RUA JOAO BOTAS S-N CANELA, BR-40000 SALVADOR, BA, BRAZIL.
RI Barral-Netto, Manoel/B-3904-2009; almeida, roque/F-5609-2012; Barral,
   Aldina/B-4191-2009
OI Barral-Netto, Manoel/0000-0002-5823-7903; Barral,
   Aldina/0000-0002-7177-464X
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-16282] Funding Source: Medline; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282] Funding
   Source: NIH RePORTER
CR BADARO R, 1983, AM J TROP MED HYG, V32, P480, DOI 10.4269/ajtmh.1983.32.480
   BARRAL A, 1983, AM J TROP MED HYG, V32, P277, DOI 10.4269/ajtmh.1983.32.277
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   CASTES M, 1984, CLIN EXP IMMUNOL, V57, P279
   CASTES M, 1983, CLIN IMMUNOL IMMUNOP, V27, P176, DOI 10.1016/0090-1229(83)90068-5
   CONVIT J, 1985, ARCH DERMATOL, V91, P439
   DHALIWAL JS, 1985, INFECT IMMUN, V49, P417, DOI 10.1128/IAI.49.2.417-423.1985
   KANAM MW, 1975, BRIT J DERMATOL, V92, P4758
   Llanos-Cuentas E. A., 1984, Revista da Sociedade Brasileira de Medicina Tropical, V17, P169, DOI 10.1590/S0037-86821984000400003
   Marsden P. D., 1984, Revista da Sociedade Brasileira de Medicina Tropical, V17, P179, DOI 10.1590/S0037-86821984000400004
   MODLIN RL, 1984, J IMMUNOL, V132, P3085
   MODLIN RL, 1985, CLIN EXP IMMUNOL, V60, P241
   Montenegro J, 1926, ARCH DERMATOL SYPH, V13, P187, DOI 10.1001/archderm.1926.02370140053003
   PEREZ H, 1979, INT J PARASITOL, V9, P27, DOI 10.1016/0020-7519(79)90062-6
   PETERSEN EA, 1984, J IMMUNOL, V132, P2603
   PETERSEN EA, 1982, NEW ENGL J MED, V306, P387, DOI 10.1056/NEJM198202183060702
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   REINHERZ EL, 1979, J EXP MED, V150, P1472, DOI 10.1084/jem.150.6.1472
   ROCHA RAA, 1980, J TROP MED HYG, V83, P131
   SCOTT P, 1986, UNPUB IMMUNOLOGIC RE
   TITUS RG, 1984, J IMMUNOL, V133, P1594
   VANVOORHIS WC, 1982, NEW ENGL J MED, V307, P1593, DOI 10.1056/NEJM198212233072601
   WALTON BC, 1979, ANN TROP MED PARASIT, V73, P23, DOI 10.1080/00034983.1979.11687222
   WYLER DJ, 1979, J INFECT DIS, V140, P215, DOI 10.1093/infdis/140.2.215
NR 24
TC 29
Z9 30
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0141-9838
EI 1365-3024
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD JUL
PY 1987
VL 9
IS 4
BP 487
EP 497
DI 10.1111/j.1365-3024.1987.tb00525.x
PG 11
WC Immunology; Parasitology
SC Immunology; Parasitology
GA J3602
UT WOS:A1987J360200007
PM 2957642
DA 2020-12-01
ER

PT J
AU REED, SG
   BADARO, R
   LLOYD, RMC
AF REED, SG
   BADARO, R
   LLOYD, RMC
TI IDENTIFICATION OF SPECIFIC AND CROSS-REACTIVE ANTIGENS OF
   LEISHMANIA-DONOVANI-CHAGASI BY HUMAN INFECTION SERA
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
C1 HOSP PROFESSOR EDGARD SANTOS, IMMUNOL LAB, BR-40000 SALVADOR, BA, BRAZIL.
   CORNELL UNIV, MED CTR, COLL MED, DEPT MED, DIV INT MED, NEW YORK, NY 10021 USA.
RP REED, SG (corresponding author), SEATTLE BIOMED RES INST, SEATTLE, WA 98109 USA.
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   R01AI022726, P01AI016282, R01AI022726, P01AI016282, R01AI022726,
   R01AI022726, P01AI016282, R01AI022726, P01AI016282, P01AI016282,
   R01AI022726, P01AI016282, R01AI022726, R01AI022726, R01AI022726,
   P01AI016282, P01AI016282, R01AI022726, P01AI016282, P01AI016282] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI16282, AI22726]
   Funding Source: Medline
CR BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BARRAL A, 1986, AM J TROP MED HYG, V35, P735, DOI 10.4269/ajtmh.1986.35.735
   BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8
   CARMARGO ME, 1969, AM J TROP MED HYG, V18, P500
   CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100
   CHANG CS, 1986, MOL BIOCHEM PARASIT, V18, P197, DOI 10.1016/0166-6851(86)90038-1
   COLOMERGOULD V, 1985, J EXP MED, V162, P902, DOI 10.1084/jem.162.3.902
   DWYER DM, 1985, HUMAN PARASITIC DISE, V1, P36
   ETGES R, 1986, EMBO J, V5, P597, DOI 10.1002/j.1460-2075.1986.tb04252.x
   ETGES RJ, 1985, MOL BIOCHEM PARASIT, V14, P141, DOI 10.1016/0166-6851(85)90033-7
   FAYLE L, 1985, ANAL BIOCHEM, V149, P218
   FONG D, 1982, P NATL ACAD SCI-BIOL, V79, P7366, DOI 10.1073/pnas.79.23.7366
   HANDMAN E, 1982, INFECT IMMUN, V37, P28, DOI 10.1128/IAI.37.1.28-33.1982
   JAFFE CL, 1984, J IMMUNOL, V133, P440
   KHALEQUE K. A., 1965, Pakistan Journal of Medical Research, V4, P234
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEPAY DA, 1983, J EXP MED, V157, P1562, DOI 10.1084/jem.157.5.1562
   NUSSENZWEIG V., 1957, Hospital (Rio de Janeiro, Brazil), V51, P217
   PRATT DM, 1981, NATURE, V291, P581, DOI 10.1038/291581a0
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   RUSSELL DG, 1986, J IMMUNOL, V136, P2613
   SMRKOVSKI LL, 1977, INFECT IMMUN, V18, P561, DOI 10.1128/IAI.18.2.561-562.1977
   SMRKOVSKI LL, 1977, INFECT IMMUN, V16, P249, DOI 10.1128/IAI.16.1.249-257.1977
   TORREALBA JOSE WITREMUNDO, 1964, REV INST MED TROP SAO PAULO, V6, P252
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   WEINTRAUB J, 1977, J IMMUNOL, V118, P2288
   ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2
   ZUCKERMAN A, 1977, PARASITIC PROTOZOA, V1, P98
NR 28
TC 69
Z9 70
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAR 1
PY 1987
VL 138
IS 5
BP 1596
EP 1601
PG 6
WC Immunology
SC Immunology
GA G2687
UT WOS:A1987G268700045
PM 3543131
DA 2020-12-01
ER

PT J
AU BADARO, R
   CARVALHO, EM
   SANTOS, RB
   GAM, AA
   GENTA, RM
AF BADARO, R
   CARVALHO, EM
   SANTOS, RB
   GAM, AA
   GENTA, RM
TI PARASITE-SPECIFIC HUMORAL RESPONSES IN DIFFERENT CLINICAL FORMS OF
   STRONGYLOIDIASIS
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
C1 UNIV CINCINNATI, VET ADM HOSP, COLL MED, DEPT PATHOL & LAB MED, CINCINNATI, OH 45267 USA.
   NIH, PARASIT DIS LAB, BETHESDA, MD 20205 USA.
   UNIV BAHIA, HOSP PROFESSOR EDGARD SANTOS, SALVADOR, BA, BRAZIL.
CR BEZJAK B, 1975, AM J TROP MED HYG, V24, P945, DOI 10.4269/ajtmh.1975.24.945
   BUTTERWORTH AE, 1974, NATURE, V252, P503, DOI 10.1038/252503a0
   CARNEIROLEAO R, 1980, ALLERGOL IMMUNOPATH, V8, P31
   CARROLL SM, 1981, T ROY SOC TROP MED H, V75, P706, DOI 10.1016/0035-9203(81)90156-5
   CARVALHO EM, 1983, T ROY SOC TROP MED H, V77, P346, DOI 10.1016/0035-9203(83)90162-1
   DEOLIVEIRA RB, 1981, PARASITE IMMUNOL, V3, P165, DOI 10.1111/j.1365-3024.1981.tb00395.x
   GENTA RM, 1984, AM J TROP MED HYG, V33, P444, DOI 10.4269/ajtmh.1984.33.444
   GENTA RM, 1983, LAB INVEST, V48, P633
   GENTA RM, 1982, LAB INVEST, V47, P87
   GENTA RM, 1986, T ROY SOC TROP MED H, V80, P34, DOI 10.1016/0035-9203(86)90190-2
   HILL DR, 1984, J IMMUNOL, V132, P2046
   IGRASIEGMAN Y, 1981, REV INFECT DIS, V3, P397
   NEVA FA, 1981, J INFECT DIS, V144, P427, DOI 10.1093/infdis/144.5.427
   SHELHAMER JH, 1982, AM J TROP MED HYG, V31, P746, DOI 10.4269/ajtmh.1982.31.746
NR 14
TC 9
Z9 9
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0035-9203
EI 1878-3503
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PY 1987
VL 81
IS 1
BP 149
EP 150
DI 10.1016/0035-9203(87)90309-9
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA G2245
UT WOS:A1987G224500038
PM 3445303
DA 2020-12-01
ER

PT J
AU BADARO, R
   JONES, TC
   CARVALHO, EM
   SAMPAIO, D
   REED, SG
   BARRAL, A
   TEIXEIRA, R
   JOHNSON, WD
AF BADARO, R
   JONES, TC
   CARVALHO, EM
   SAMPAIO, D
   REED, SG
   BARRAL, A
   TEIXEIRA, R
   JOHNSON, WD
TI NEW PERSPECTIVES ON A SUBCLINICAL FORM OF VISCERAL LEISHMANIASIS
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
C1 UNIV BAHIA,DEPT MED,SALVADOR,BRAZIL.
   CORNELL UNIV,MED CTR,COLL MED,DEPT MED,DIV INT MED,NEW YORK,NY 10021.
RI Barral, Aldina/B-4191-2009
OI Barral, Aldina/0000-0002-7177-464X
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI-16282] Funding
   Source: Medline
CR BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   CARVALHO EM, 1981, INFECT IMMUN, V33, P498, DOI 10.1128/IAI.33.2.498-500.1981
   CHULAY JD, 1983, J INFECT DIS, V148, P148, DOI 10.1093/infdis/148.1.148
   CHULAY JD, 1985, AM J TROP MED HYG, V34, P702, DOI 10.4269/ajtmh.1985.34.702
   HO A, 1948, T R SOC TROP MED HYG, V41, P629
   HO M, 1983, AM J TROP MED HYG, V32, P943, DOI 10.4269/ajtmh.1983.32.943
   HO M, 1982, T ROY SOC TROP MED H, V76, P741, DOI 10.1016/0035-9203(82)90095-5
   HORWITZ DA, 1977, J IMMUNOL, V118, P1712
   LAINSON R, 1983, T ROY SOC TROP MED H, V77, P569, DOI 10.1016/0035-9203(83)90185-2
   LEISHMAN WB, 1906, HDB TROPENKRANKHEITE
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Napier L E, 1924, Ind Med Gaz, V59, P492
   PAMPIGLIONE S, 1974, T ROY SOC TROP MED H, V68, P447, DOI 10.1016/0035-9203(74)90067-4
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   THAKUR CP, 1984, T ROY SOC TROP MED H, V78, P391, DOI 10.1016/0035-9203(84)90131-7
   TOLEDO LM, 1983, 19 C SOC BRAS MED TR, P60
   WATERLOW JC, 1977, B WORLD HEALTH ORGAN, V55, P489
   YANJIA L, 1982, T R SOC TROP MED HYG, V76, P531
   1976, HRA761120 US DHEW PU
NR 20
TC 368
Z9 381
U1 0
U2 11
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC
PY 1986
VL 154
IS 6
BP 1003
EP 1011
DI 10.1093/infdis/154.6.1003
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA E9418
UT WOS:A1986E941800012
PM 3782864
DA 2020-12-01
ER

PT J
AU BADARO, R
   JONES, TC
   LORENCO, R
   CERF, BJ
   SAMPAIO, D
   CARVALHO, EM
   ROCHA, H
   TEIXEIRA, R
   JOHNSON, WD
AF BADARO, R
   JONES, TC
   LORENCO, R
   CERF, BJ
   SAMPAIO, D
   CARVALHO, EM
   ROCHA, H
   TEIXEIRA, R
   JOHNSON, WD
TI A PROSPECTIVE-STUDY OF VISCERAL LEISHMANIASIS IN AN ENDEMIC AREA OF
   BRAZIL
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
C1 UNIV BAHIA,DEPT MED,SALVADOR,BRAZIL.
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI-16282] Funding
   Source: Medline
CR ACTOR PAUL, 1960, EXPTL PARASITOL, V10, P1, DOI 10.1016/0014-4894(60)90078-3
   BADARO R, 1983, AM J TROP MED HYG, V32, P480, DOI 10.4269/ajtmh.1983.32.480
   BADARO R, 1986, LANCET, V1, P647
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BEISEL WR, 1982, AM J CLIN NUTR, V35, P417, DOI 10.1093/ajcn/35.2.417
   DEALENCAR JE, 1976, DOENCAS INFECCIOSAS, P712
   FENDALL NRE, 1952, J TROP MED, V55, P256
   GUERREIRO J, 1985, Memorias do Instituto Oswaldo Cruz, V80, P447, DOI 10.1590/S0074-02761985000400011
   HASHEMINASAB A, 1980, J TROP MED HYG, V83, P119
   HO M, 1983, AM J TROP MED HYG, V32, P943, DOI 10.4269/ajtmh.1983.32.943
   HO M, 1983, CLIN EXP IMMUNOL, V51, P207
   HO M, 1982, T ROY SOC TROP MED H, V76, P741, DOI 10.1016/0035-9203(82)90095-5
   HOMMEL M, 1978, ANN TROP MED PARASIT, V72, P213, DOI 10.1080/00034983.1978.11719308
   JAFFE CL, 1984, J IMMUNOL, V133, P440
   LAINSON R, 1983, T ROY SOC TROP MED H, V77, P569, DOI 10.1016/0035-9203(83)90185-2
   LEISHMAN WB, 1906, HDB TROPENKRANKHEITE
   LINDTJORN B, 1984, T ROY SOC TROP MED H, V78, P790, DOI 10.1016/0035-9203(84)90022-1
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MA DDF, 1979, LANCET, V2, P311
   MARTINS J M, 1965, Rev Inst Med Trop Sao Paulo, V7, P47
   NADIM A, 1984, T ROY SOC TROP MED H, V78, P848, DOI 10.1016/0035-9203(84)90046-4
   Napier L E, 1924, Ind Med Gaz, V59, P492
   PAMPIGLIONE S, 1974, T ROY SOC TROP MED H, V68, P447, DOI 10.1016/0035-9203(74)90067-4
   PELLEY RP, 1976, INFECT IMMUN, V13, P1176, DOI 10.1128/IAI.13.4.1176-1183.1976
   PRATA A, 1957, THESIS SALVADOR U FE
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   Sherlock I. A, 1970, Revta bras. Malar. Doenc. trop., V22, P175
   SOUTHGATE B. A., 1964, TRANS ROY SOC TROP MED HYG, V58, P377, DOI 10.1016/0035-9203(64)90082-3
   THAKUR CP, 1984, T ROY SOC TROP MED H, V78, P391, DOI 10.1016/0035-9203(84)90131-7
   WATERLOW JC, 1977, B WORLD HEALTH ORGAN, V55, P489
   YANJIA L, 1982, T R SOC TROP MED HYG, V76, P531
   1976, HRA761120 US DHEW PU
NR 32
TC 263
Z9 272
U1 0
U2 12
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT
PY 1986
VL 154
IS 4
BP 639
EP 649
DI 10.1093/infdis/154.4.639
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA E1134
UT WOS:A1986E113400013
PM 3745974
DA 2020-12-01
ER

PT J
AU BARRAL, A
   BADARO, R
   BARRALNETTO, M
   GRIMALDI, G
   MOMEM, H
   CARVALHO, EM
AF BARRAL, A
   BADARO, R
   BARRALNETTO, M
   GRIMALDI, G
   MOMEM, H
   CARVALHO, EM
TI ISOLATION OF LEISHMANIA-MEXICANA-AMAZONENSIS FROM THE BONE-MARROW IN A
   CASE OF AMERICAN VISCERAL LEISHMANIASIS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
C1 UNIV FED BAHIA,FIOCRUZ,CTR PESQUISAS GONCALO MONIZ,SALVADOR,BA,BRAZIL.
   INST OSWALDO CRUZ,RIO DE JANEIRO,BRAZIL.
RP BARRAL, A (corresponding author), UNIV FED BAHIA,HOSP PROFESOR EDGARD SANTOS,IMUNOL LAB,SALVADOR,BA,BRAZIL.
RI Barral, Aldina/B-4191-2009; Barral-Netto, Manoel/B-3904-2009; Momen,
   Hooman/A-1850-2008
OI Barral, Aldina/0000-0002-7177-464X; Barral-Netto,
   Manoel/0000-0002-5823-7903; Momen, Hooman/0000-0002-2324-1515
FU PHS HHSUnited States Public Health Service [16282] Funding Source:
   Medline
CR ABDALLA RE, 1982, ANN TROP MED PARASIT, V76, P299, DOI 10.1080/00034983.1982.11687545
   BADARO R, 1983, AM J TROP MED HYG, V32, P480, DOI 10.4269/ajtmh.1983.32.480
   BELLAZZOUG S, 1985, ANN PARASITOLOGIE HU, V60, P1
   GRIMALDI G, 1982, 9 REUN AN PESQ BAS D, P1
   HOOGSTRAAL H, 1969, AM J TROP MED HYG, V18, P1087
   LAINSON R, 1983, T ROY SOC TROP MED H, V77, P569, DOI 10.1016/0035-9203(83)90185-2
   LOPES UG, 1984, J PARASITOL, V70, P89, DOI 10.2307/3281930
   MCMAHONPRATT D, 1984, GENES ANTIGENS PARAS, P47
   SCHNUR LF, 1985, T ROY SOC TROP MED H, V79, P134, DOI 10.1016/0035-9203(85)90259-7
   SCHNUR LF, 1981, ANN TROP MED PARASIT, V75, P131, DOI 10.1080/00034983.1981.11687421
NR 10
TC 64
Z9 68
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUL
PY 1986
VL 35
IS 4
BP 732
EP 734
DI 10.4269/ajtmh.1986.35.732
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA D3690
UT WOS:A1986D369000010
PM 3728794
DA 2020-12-01
ER

PT J
AU BARRAL, A
   CARVALHO, EM
   BADARO, R
   BARRALNETTO, M
AF BARRAL, A
   CARVALHO, EM
   BADARO, R
   BARRALNETTO, M
TI SUPPRESSION OF LYMPHOCYTE PROLIFERATIVE RESPONSES BY SERA FROM PATIENTS
   WITH AMERICAN VISCERAL LEISHMANIASIS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
C1 CTR PESQUISAS GONCALO MONIZ FIOCRUZ,SALVADOR,BA,BRAZIL.
RP BARRAL, A (corresponding author), UNIV FED BAHIA,HOSP PROFESOR EDGARD SANTOS,IMUNOL LAB,SALVADOR,BA,BRAZIL.
RI Barral, Aldina/B-4191-2009; Barral-Netto, Manoel/B-3904-2009
OI Barral, Aldina/0000-0002-7177-464X; Barral-Netto,
   Manoel/0000-0002-5823-7903
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI-16282] Funding
   Source: Medline
CR BADARO R, 1983, AM J TROP MED HYG, V32, P480, DOI 10.4269/ajtmh.1983.32.480
   BJUNE G, 1979, CLIN EXP IMMUNOL, V36, P479
   CARVALHO EM, 1983, AM J TROP MED HYG, V32, P61, DOI 10.4269/ajtmh.1983.32.61
   CARVALHO EM, 1983, BRAZ J MED BIOL RES, V16, P35
   CARVALHO EM, 1981, INFECT IMMUN, V22, P649
   CHISARI FV, 1977, J IMMUNOL, V119, P2129
   COTTRELL BJ, 1980, IMMUNOLOGY, V39, P589
   CURTISS LK, 1976, J IMMUNOL, V116, P1452
   CURTISS LK, 1981, J IMMUNOL, V126, P1008
   de Andrade T M, 1982, Rev Inst Med Trop Sao Paulo, V24, P298
   ELLNER JJ, 1979, CLIN EXP IMMUNOL, V35, P250
   FISHER A, 1978, J CLIN INVEST, V62, P1005
   GALVAOCASTRO B, 1984, CLIN EXP IMMUNOL, V56, P58
   GHOSE AC, 1979, T ROY SOC TROP MED H, V73, P725, DOI 10.1016/0035-9203(79)90032-4
   GUERREIRO J, 1985, MEM I OSWALDO CRUZ, V80, P471
   KLEINHENZ ME, 1981, J CLIN INVEST, V68, P153, DOI 10.1172/JCI110231
   LADISCH S, 1978, LANCET, V1, P581
   Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2
   MEHRA V, 1979, J IMMUNOL, V123, P1813
   MOTASANTOS TA, 1977, AM J TROP MED HYG, V26, P727, DOI 10.4269/ajtmh.1977.26.727
   PEARSON RD, 1983, REV INFECT DIS, V5, P907
   PETERSEN EA, 1984, J IMMUNOL, V132, P2603
   PETERSEN EA, 1982, NEW ENGL J MED, V306, P387, DOI 10.1056/NEJM198202183060702
   ROCKLIN RE, 1980, J IMMUNOL, V125, P1916
   TSUYUGUCHI I, 1980, AM REV RESPIR DIS, V121, P951
   WINFIELD JB, 1976, ROLE IMMUNOLOGICAL F, V1, pCH13
   WOLFE L, 1983, CLIN EXP IMMUNOL, V54, P801
   WYLER DJ, 1982, T ROY SOC TROP MED H, V76, P304, DOI 10.1016/0035-9203(82)90174-2
NR 28
TC 32
Z9 32
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUL
PY 1986
VL 35
IS 4
BP 735
EP 742
DI 10.4269/ajtmh.1986.35.735
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA D3690
UT WOS:A1986D369000011
PM 3728795
DA 2020-12-01
ER

PT J
AU BADARO, R
   ROCHA, H
   CARVALHO, EM
   QUEIROZ, AC
   JONES, TC
AF BADARO, R
   ROCHA, H
   CARVALHO, EM
   QUEIROZ, AC
   JONES, TC
TI LEISHMANIA-DONOVANI - AN OPPORTUNISTIC MICROBE ASSOCIATED WITH
   PROGRESSIVE DISEASE IN 3 IMMUNOCOMPROMISED PATIENTS
SO LANCET
LA English
DT Article
C1 FED UNIV BAHIA, DIV IMMUNOL, SALVADOR, BA, BRAZIL.
   CORNELL UNIV, MED CTR, COLL MED, DIV INT MED, NEW YORK, NY 10021 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 16282] Funding Source: Medline; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282] Funding
   Source: NIH RePORTER
CR ANDRADE TM, 1982, REV INST MED TROP, V24, P298
   BADARO R, 1983, AM J TROP MED HYG, V32, P480, DOI 10.4269/ajtmh.1983.32.480
   Badaro R., 1985, Revista da Sociedade Brasileira de Medicina Tropical, V18, P77, DOI 10.1590/S0037-86821985000200003
   BADARO R, 1986, AM J TROP MED HYG, V35, P72, DOI 10.4269/ajtmh.1986.35.72
   BADARO R, 1983, 19 AN C SOC BRAS MED, P59
   CARVALHO EM, 1983, AM J TROP MED HYG, V32, P61, DOI 10.4269/ajtmh.1983.32.61
   CARVALHO EM, 1981, INFECT IMMUN, V33, P498, DOI 10.1128/IAI.33.2.498-500.1981
   CARVALHO EM, 1983, BRAZ J MED BIOL RES, V16, P35
   CARVALHO EM, 1984, 11 REUN PESQ BAS DOE, P111
   CARVALHO JS, 1958, ARQ BRAS MED NAVAL, V68, P65
   CHULAY JD, 1983, J INFECT DIS, V148, P148, DOI 10.1093/infdis/148.1.148
   CURRENT WL, 1983, NEW ENGL J MED, V308, P1252, DOI 10.1056/NEJM198305263082102
   GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401
   GREENWOOD BM, 1984, T ROY SOC TROP MED H, V78, P407, DOI 10.1016/0035-9203(84)90135-4
   HO M, 1982, T ROY SOC TROP MED H, V76, P741, DOI 10.1016/0035-9203(82)90095-5
   LIPSKY JJ, 1976, CELL IMMUNOL, V23, P278, DOI 10.1016/0008-8749(76)90193-3
   MA DDF, 1979, LANCET, V2, P311
   MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402
   MASUR H, 1982, ANN INTERN MED, V97, P533, DOI 10.7326/0003-4819-97-4-533
   PAMPIGLIONE S, 1974, T ROY SOC TROP MED H, V68, P447, DOI 10.1016/0035-9203(74)90067-4
   PAPE JW, 1983, NEW ENGL J MED, V309, P945, DOI 10.1056/NEJM198310203091603
   PESSOA SB, 1956, B FUND G MUNIZ, V7, P1
   PETERSON PK, 1985, PRINCIPLES PRACTICE, P1676
   REED SG, 1986, AM J TROP MED HYG, V35, P79, DOI 10.4269/ajtmh.1986.35.79
   REZAI HR, 1978, AM J TROP MED HYG, V27, P1079, DOI 10.4269/ajtmh.1978.27.1079
   ROCHA H, 1971, ARCH INTERN MED, V128, P254, DOI [10.1001/archinte.128.2.254, 10.1001/archinte.1971.00310200090009]
   SOAVE R, 1985, ARCH INTERN MED, V145, P70, DOI 10.1001/archinte.145.1.70
   TEIXEIRA R, 1959, REV INT MED TROP SAO, V2, P65
   THAKUR CP, 1984, T ROY SOC TROP MED H, V78, P391, DOI 10.1016/0035-9203(84)90131-7
   WONG B, 1984, ANN INTERN MED, V100, P36, DOI 10.7326/0003-4819-100-1-36
NR 30
TC 138
Z9 142
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD MAR 22
PY 1986
VL 1
IS 8482
BP 647
EP 649
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA A4883
UT WOS:A1986A488300005
PM 2869348
DA 2020-12-01
ER

PT J
AU BADARO, R
   REED, SG
   BARRAL, A
   ORGE, G
   JONES, TC
AF BADARO, R
   REED, SG
   BARRAL, A
   ORGE, G
   JONES, TC
TI EVALUATION OF THE MICRO ENZYME-LINKED-IMMUNOSORBENT-ASSAY (ELISA) FOR
   ANTIBODIES IN AMERICAN VISCERAL LEISHMANIASIS - ANTIGEN SELECTION FOR
   DETECTION OF INFECTION-SPECIFIC RESPONSES
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
C1 CORNELL UNIV, MED CTR,COLL MED,DIV INT MED,1300 YORK AVE, ROOM A-431, NEW YORK, NY 10021 USA.
   UNIV BAHIA, SALVADOR, BA, BRAZIL.
RI Barral, Aldina/B-4191-2009
OI Barral, Aldina/0000-0002-7177-464X
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 16282] Funding Source: Medline; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282] Funding
   Source: NIH RePORTER
CR ANTHONY RL, 1980, AM J TROP MED HYG, V29, P190, DOI 10.4269/ajtmh.1980.29.190
   BADARO R, 1983, AM J TROP MED HYG, V32, P480, DOI 10.4269/ajtmh.1983.32.480
   BULLOCK SL, 1977, J INFECT DIS, V136, pS279, DOI 10.1093/infdis/136.Supplement_2.S279
   CAMARGO ME, 1969, AM J TROP MED HYG, V18, P500, DOI 10.4269/ajtmh.1969.18.500
   DUXBURY RE, 1964, AM J TROP MED HYG, V13, P525, DOI 10.4269/ajtmh.1964.13.525
   DWYER DM, 1980, J PROTOZOOL, V27, P176, DOI 10.1111/j.1550-7408.1980.tb04676.x
   ENGVALL E, 1972, J IMMUNOL, V109, P129
   GARDINER PR, 1984, INFECT IMMUN, V43, P637, DOI 10.1128/IAI.43.2.637-643.1984
   GRIMALDI G, 1982, INT J PARASITOL, V12, P185, DOI 10.1016/0020-7519(82)90015-7
   GUIMARAES MCS, 1981, AM J TROP MED HYG, V30, P942, DOI 10.4269/ajtmh.1981.30.942
   HALDAR JP, 1981, T ROY SOC TROP MED H, V75, P514, DOI 10.1016/0035-9203(81)90188-7
   HANDMAN E, 1982, INFECT IMMUN, V37, P28, DOI 10.1128/IAI.37.1.28-33.1982
   HO M, 1983, AM J TROP MED HYG, V32, P943, DOI 10.4269/ajtmh.1983.32.943
   HOMMEL M, 1978, ANN TROP MED PARASIT, V72, P213, DOI 10.1080/00034983.1978.11719308
   JACKSON PR, 1984, AM J TROP MED HYG, V33, P808, DOI 10.4269/ajtmh.1984.33.808
   JAFFE CL, 1984, J IMMUNOL, V133, P440
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MCMAHONPRATT D, 1982, J IMMUNOL, V129, P926
   ROFFI J, 1980, AM J TROP MED HYG, V29, P183, DOI 10.4269/ajtmh.1980.29.183
   RUITENBERG EJ, 1980, J CLIN MICROBIOL, V11, P132, DOI 10.1128/JCM.11.2.132-134.1980
   SHAW JJ, 1964, T R SOC TROP MED HYG, V58, P342
   VOLLER A, 1977, T ROY SOC TROP MED H, V71, P431, DOI 10.1016/0035-9203(77)90046-3
NR 22
TC 106
Z9 111
U1 0
U2 5
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JAN
PY 1986
VL 35
IS 1
BP 72
EP 78
DI 10.4269/ajtmh.1986.35.72
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AYY37
UT WOS:A1986AYY3700012
PM 3080918
DA 2020-12-01
ER

PT J
AU REED, SG
   BADARO, R
   MASUR, H
   CARVALHO, EM
   LORENCO, R
   LISBOA, A
   TEIXEIRA, R
   JOHNSON, WD
   JONES, TC
AF REED, SG
   BADARO, R
   MASUR, H
   CARVALHO, EM
   LORENCO, R
   LISBOA, A
   TEIXEIRA, R
   JOHNSON, WD
   JONES, TC
TI SELECTION OF A SKIN-TEST ANTIGEN FOR AMERICAN VISCERAL LEISHMANIASIS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
C1 FED UNIV BAHIA, SALVADOR, BA, BRAZIL.
RP REED, SG (corresponding author), CORNELL UNIV, MED CTR,COLL MED,DIV INT MED,1300 YORK AVE, ROOM A-431, NEW YORK, NY 10021 USA.
FU PHS HHSUnited States Public Health Service [16282] Funding Source:
   Medline
CR ADLER S, 1948, ANN TROP MED PARASIT, V42, P178, DOI 10.1080/00034983.1948.11685360
   BARRETTO A C, 1981, Boletin de la Oficina Sanitaria Panamericana, V90, P415
   BUSS G., 1929, ARCH SCHIFFS U TROPEN HYG, V33, P65
   CARMARGO ME, 1969, AM J TROP MED HYG, V18, P500
   FULLER GK, 1979, ANN TROP MED PARASIT, V73, P417, DOI 10.1080/00034983.1979.11687281
   FURTADO TA, 1956, J INVEST DERMATOL, V27, P53, DOI 10.1038/jid.1956.77
   HO M, 1982, T ROY SOC TROP MED H, V76, P741, DOI 10.1016/0035-9203(82)90095-5
   LANDI S, 1971, AM REV RESPIR DIS, V104, P385, DOI 10.1164/arrd.1971.104.3.385
   LAPLACA M, 1975, T ROY SOC TROP MED H, V69, P396, DOI 10.1016/0035-9203(75)90195-9
   MANSON-BAHR P E, 1961, East Afr Med J, V38, P165
   MANSON-BAHR P. E. C., 1959, TRANS ROY SOC TROP MED AND HYG, V53, P380, DOI 10.1016/0035-9203(59)90038-0
   MANSON-BAHR P. E. C., 1961, TRANS ROY SOC TROP MED AND HYG, V55, P550, DOI 10.1016/0035-9203(61)90078-5
   MAYRINK W, 1971, Revista do Instituto de Medicina Tropical de Sao Paulo, V13, P268
   Melo M N, 1977, Rev Inst Med Trop Sao Paulo, V19, P161
   Montenegro J., 1926, ANN FAC MED SAO PAUL, V1, P323
   NUSSENZWEIG V., 1957, Hospital (Rio de Janeiro, Brazil), V51, P217
   PAMPIGLIONE S, 1974, T ROY SOC TROP MED H, V68, P447, DOI 10.1016/0035-9203(74)90067-4
   PAMPIGLIONE S, 1975, T ROY SOC TROP MED H, V69, P60, DOI 10.1016/0035-9203(75)90012-7
   Pellegrino J, 1977, Rev Inst Med Trop Sao Paulo, V19, P393
   PESSOA SAMUEL B., 1963, REV INST MED TROP SAO PAULO, V5, P170
   PUPKIS MF, 1984, J GEN MICROBIOL, V130, P2375
   ROSENFELD G, 1945, REV PAUL MED, V26, P9
   SHAW JJ, 1975, T ROY SOC TROP MED H, V69, P323, DOI 10.1016/0035-9203(75)90127-3
   SOUTHGAT.BA, 1967, J TROP MED HYG, V70, P29
   VANPEENEN PFD, 1963, J TROP MED HYG, V66, P171
   WAGNER EH, 1923, U CALIF PUBL ZOOL, V20, P473
   1982, 4TH M SCI WORK GROUP
NR 27
TC 115
Z9 120
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JAN
PY 1986
VL 35
IS 1
BP 79
EP 85
DI 10.4269/ajtmh.1986.35.79
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AYY37
UT WOS:A1986AYY3700013
PM 3946739
DA 2020-12-01
ER

PT J
AU CARVALHO, EM
   BADARO, R
   REED, SG
   JONES, TC
   JOHNSON, WD
AF CARVALHO, EM
   BADARO, R
   REED, SG
   JONES, TC
   JOHNSON, WD
TI ABSENCE OF GAMMA-INTERFERON AND INTERLEUKIN-2 PRODUCTION DURING ACTIVE
   VISCERAL LEISHMANIASIS
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
C1 FED UNIV BAHIA HOSP,DIV IMMUNOL,SALVADOR,BA,BRAZIL.
   CORNELL UNIV,MED CTR,COLL MED,DIV INT MED,NEW YORK,NY 10021.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 16282] Funding Source: Medline; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282] Funding
   Source: NIH RePORTER
CR ANDRADE TM, 1982, REV INST MED TROP, V24, P298
   BADARO R, 1985, AM J TROP MED HYG
   CARVALHO EM, 1983, AM J TROP MED HYG, V32, P61, DOI 10.4269/ajtmh.1983.32.61
   CARVALHO EM, 1981, INFECT IMMUN, V33, P498, DOI 10.1128/IAI.33.2.498-500.1981
   CARVALHO EM, 1983, BRAZ J MED BIOL RES, V16, P35
   CASTES M, 1983, CLIN IMMUNOL IMMUNOP, V27, P176, DOI 10.1016/0090-1229(83)90068-5
   FARRAR JJ, 1980, J IMMUNOL, V125, P2555
   GALVAOCASTRO B, 1984, CLIN EXP IMMUNOL, V56, P58
   GILLIS S, 1978, J IMMUNOL, V120, P2027
   GUERREIRO J, 1985, MEM I O CRUZ RIO J
   HALDAR JP, 1983, INFECT IMMUN, V42, P702, DOI 10.1128/IAI.42.2.702-707.1983
   HO M, 1983, AM J TROP MED HYG, V32, P943, DOI 10.4269/ajtmh.1983.32.943
   HO M, 1983, CLIN EXP IMMUNOL, V51, P207
   LAWRENCE J, 1983, J CLIN INVEST, V72, P2072
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MANSON-BAHR P. E. C., 1961, TRANS ROY SOC TROP MED AND HYG, V55, P550, DOI 10.1016/0035-9203(61)90078-5
   MURRAY HW, 1984, J IMMUNOL, V133, P2250
   MURRAY HW, 1984, NEW ENGL J MED, V310, P883, DOI 10.1056/NEJM198404053101404
   MURRAY HW, 1983, J CLIN INVEST, V72, P1506, DOI 10.1172/JCI111107
   NOGUEIRA N, 1983, J EXP MED, V158, P2165, DOI 10.1084/jem.158.6.2165
   REED SG, 1984, J IMMUNOL, V133, P3333
   REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061
   RUBIN BY, 1983, J IMMUNOL, V130, P1019
   SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319
   STEWART WE, 1981, INTERFERON SYSTEM, P13
   VERESS B, 1977, IMMUNOLOGY, V33, P605
   1974, SCAND J IMMUNOL, V3, P521
NR 27
TC 313
Z9 316
U1 0
U2 2
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD DEC
PY 1985
VL 76
IS 6
BP 2066
EP 2069
DI 10.1172/JCI112209
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AWY85
UT WOS:A1985AWY8500004
PM 3935667
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU BADARO, R
   REED, SG
   CARVALHO, EM
AF BADARO, R
   REED, SG
   CARVALHO, EM
TI IMMUNOFLUORESCENT ANTIBODY-TEST IN AMERICAN VISCERAL LEISHMANIASIS -
   SENSITIVITY AND SPECIFICITY OF DIFFERENT MORPHOLOGICAL FORMS OF 2
   LEISHMANIA SPECIES
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
C1 CORNELL UNIV, MED CTR, COLL MED, DIV INT MED, NEW YORK, NY 10021 USA.
   UNIV BAHIA, BAHIA, BRAZIL.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 16282] Funding Source: Medline; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282,
   P01AI016282, P01AI016282, P01AI016282, P01AI016282, P01AI016282] Funding
   Source: NIH RePORTER
CR ALALOUSI TI, 1980, ANN TROP MED PARASIT, V74, P503, DOI 10.1080/00034983.1980.11687375
   ALENCAR JE, 1974, REV BRAS MALARIOL, V25, P27
   ALVAREZ M, 1968, Boletin Chileno de Parasitologia, V23, P4
   BEHROFOUZ N, 1976, ANN TROP MED PARASIT, V70, P293
   BIAGI F, 1964, B OFIC SANIT PANAM, V57, P234
   CAMARGO MARIO E., 1966, REV INST MED TROP SAO PAULO, V8, P227
   CAMARGO ME, 1969, AM J TROP MED HYG, V18, P500, DOI 10.4269/ajtmh.1969.18.500
   CERISOLA J A, 1971, Revista do Instituto de Medicina Tropical de Sao Paulo, V13, P162
   CHANG KP, 1980, SCIENCE, V209, P1240, DOI 10.1126/science.7403880
   DUXBURY RE, 1964, AM J TROP MED HYG, V13, P525, DOI 10.4269/ajtmh.1964.13.525
   DWYER DM, 1976, J IMMUNOL, V117, P2081
   EDRISSIAN GH, 1981, ANN TROP MED PARASIT, V75, P19, DOI 10.1080/00034983.1981.11687403
   FIFE EH, 1959, P SOC EXP BIOL MED, V101, P540
   MOTT KE, 1976, AM J TROP MED HYG, V25, P552, DOI 10.4269/ajtmh.1976.25.552
   PESSOA SAMUEL B., 1963, REV INST MED TROP SAO PAULO, V5, P170
   SHAW JJ, 1977, J PARASITOL, V63, P384, DOI 10.2307/3280085
   SHAW JJ, 1964, T R SOC TROP MED HYG, V58, P342
   TRUONG TK, 1969, B SOC PATHOL EXOT, V62, P1077
   WALTON BC, 1972, AM J TROP MED HYG, V21, P296, DOI 10.4269/ajtmh.1972.21.296
NR 19
TC 95
Z9 100
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 1983
VL 32
IS 3
BP 480
EP 484
DI 10.4269/ajtmh.1983.32.480
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA QS886
UT WOS:A1983QS88600009
PM 6407345
DA 2020-12-01
ER

EF